06-22-00 A

BAKER BOTTS L.L.P.

30 ROCKEFELLER PLAZA
44TH FLOOR
NEW YORK, NEW YORK
10112-4498
212.705.5000
FAX 212.705.5020

AUSTIN
BAKU
DALLAS
HOUSTON
LONDON
MOSCOW
NEW YORK
WASHINGTON

Appln. Trans.
PATENT

UTILITY PATENT APPLICATION TRANSMITTAL
(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. AP32556-071838

First Named Inventor CHRISTOPHER JOHN WRAIGHT

Express Mail Label No. EJ339573215US

Total Pages ___

June 21, 2000

BY EXPRESS MAIL - **Label No.** EJ339573215US

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

Sir:

Enclosed herewith for filing is a patent application of CHRISTOPHER JOHN WRAIGHT, 6 Maple Street, Blackburn, Victoria, 3130, Australia, GEORGE ARTHUR WERTHER 65 Bellett Street, Camberwell, Victoria, 3124, Australia and STEPHANIE RUTH EDMONDSON, 2 Koonalda Avenue Glen Waverley, Victoria, 3150, Australia entitled A METHOD FOR THE PROPHYLAXIS AND/OR TREATMENT OF MEDICAL DISORDERS

which includes:

[X] Specification	124 Total Pages
[X] Claims	7 Total Pages
[X] Abstract	1 Total Pages
[X] Drawing(s)	65 Total Sheets
_ formal	
X informal	

[] Combined Declaration and Power of Attorney __ Total Pages
- [] Newly executed (original or copy)
- [] Copy from a prior application
  (for continuation/divisional only - **must be filed to avoid surcharge for late filing**)

If a continuing application, check appropriate box:
[] Continuation [] Divisional [] Continuation-In-Part (CIP)
of prior application No. __

[] Amend the specification by inserting, before the first line, the following sentence:

"This is a [] continuation [] divisional [] continuation-in-part of copending application Serial No. _ filed _."

Appln. Trans.
PATENT

Attorney Docket No. AP32556-071838

[X] An Assignment of the invention to MURDOCH CHILDREN'S RESEARCH INSTITUTE.
  [] is attached. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
  [X] will follow.
  [] has been filed in the prior application

[] Small Entity Statement(s) **ENCLOSED**.
[] Small Entity Statement filed in prior application. Status still proper and desired.

[] Information Disclosure Statement (IDS) PTO-1449
  [] Copies of IDS Citations.

[] Preliminary Amendment

[X] Return Receipt Postcard

[X] Other SEQUENCE LISTING (16) Pages

[] Cancel in this application original claims _ of the prior application before calculating the filing fee.

The filing fee has been calculated as shown below:

FOR	(Col. 1) No.Filed			(Col. 2) No. Extra	Small Entity Rate	Fee	OR	Other Than A Small Entity Rate	Fee
Basic Fee									$690.00
Total Claims	44	-20	=	24	x 9 =	$0.00		x 18 =	$432.00
Ind. Claims	7	-3	=	4	x 39 =	$0.00		x 78 =	$312.00
Multiple Dependent Claim					+ 230 =			+ 260 =	$0.00
					Total	$0.00			$1,434.00

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

Fee Payment Being Made:

[X] Enclosed

[X]	Basic filing fee	$1,434.00
[]	Recording Assignment [$40.00; 37 CFR 1.21(h)]	$0.00
	Total Fees Enclosed	$1,434.00

[X] A check in the amount of $1,434.00 to cover filing fee is enclosed.

Appln. Trans.
PATENT

Attorney Docket No. AP32556-071838

Priority

[X] Priority of application Country United States, Appln. No. 60/140,345 filed June 21, 1999 is claimed under 35 U.S.C. 119.

[] Certified Copy of Priority Document(s) Country _, Appln No. _, filed _.

[] is/are attached [] will follow [] has been filed in the parent application S/N _.

[X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR 1.16, 1.17, and 1.21(h) associated with this communication or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

BAKER BOTTS L.L.P.

By: Janet M. MacLeod

Janet M. MacLeod
PTO Registration No. 35,263

Enclosures

A METHOD FOR THE PROPHYLAXIS AND/OR TREATMENT OF MEDICAL DISORDERS

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U. S. Application Ser. No. 60/140,345, the disclosure of which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to a method for the prophylaxis and/or treatment of medical disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on cells such as epidermal keratinocytes to inhibit, reduce or otherwise decrease stimulation of this layer of cells. The present invention contemplates, in a particularly preferred embodiment, a method for the prophylaxis and/or treatment of psoriasis or neovascularization conditions such as neovascularization of the retina. The present invention is further directed to the subject genetic molecules in adjunctive therapy for epidermal hyperplasia, such as in combination with UV treatment, and to facilitate apoptosis of cancer cells and in particular cancer cells comprising keratinocytes.

BACKGROUND OF THE INVENTION

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia or any other country.

Psoriasis and other similar conditions are common and often distressing proliferative and/or inflammatory skin disorders affecting or having the potential to affect a significant proportion

of the population. The condition arises from over proliferation of basal keratinocytes in the epidermal layer of the skin associated with inflammation in the underlying dermis. Whilst a range of treatments have been developed, none is completely effective and free of adverse side effects. Although the underlying cause of psoriasis remains elusive, there is some consensus of opinion that the condition arises at least in part from over expression of local growth factors and their interaction with their receptors supporting keratinocyte proliferation *via* keratinocyte receptors which appear to be more abundant during psoriasis.

One important group of growth factors are the dermally-derived insulin-like growth factors (IGFs) which support keratinocyte proliferation. In particular, IGF-I and IGF-II are ubiquitous peptides each with potent mitogenic effects on a broad range of cells. Molecules of the IGF type are also known as "progression factors" promoting "competent" cells through DNA synthesis. The IGFs act through a common receptor known as the Type I or IGF-I receptor, which is tyrosine kinase linked. They are synthesised in mesenchymal tissues, including the dermis, and act on adjacent cells of mesodermal, endodermal or ectodermal origin. The regulation of their synthesis involves growth hormone (GH) in the liver, but is poorly defined in most tissues [1].

Particular proteins, referred to as IGF binding proteins (IGFBPs), appear to be involved in autocrine/paracrine regulation of tissue IGF availability [2]. Six IGFBPs have so far been identified. The exact effects of the IGFBPs is not clear and observed effects *in vitro* have been inhibitory or stimulatory depending on the experimental method employed [3]. There is some evidence, however, that certain IGFBPs are involved in targeting IGF-I to its cell surface receptor.

Skin, comprising epidermis and underlying dermis, has GH receptors on dermal fibroblasts [4]. Fibroblasts synthesize IGF-I as well as IGFBPs-3, -4, -5 and -6 [5] which may be involved in targeting IGF-I to adjacent cells as well as to the overlaying epidermis. The major epidermal

cell type, the keratinocyte, does not synthesize IGF-I, but possesses IGF-I receptors and is responsive to IGF-I [6].

It is apparent, therefore, that IGF-I and other growth promoting molecules, are responsible for or at least participate in a range of skin cell activities. In accordance with the present invention, the inventors have established that aberrations in the normal functioning of these molecules or aberrations in their interaction with their receptors is an important factor in a variety of medical disorders such as proliferative and/or inflammatory skin disorders. It is proposed, therefore, to target these molecules or other molecules which facilitate their functioning or interaction with their receptors to thereby ameliorate the effects of aberrant activity during or leading to skin disease conditions and other medical conditions such as those involving neovascularization. Furthermore, these molecules may also be used to facilitate apoptosis of target cells and may be useful as adjunctive therapy for epidermal hyperplasia.

SUMMARY OF THE INVENTION

Nucleotide and amino acid sequences are referred to by a sequence identifier, i.e. (<400>1), (<400>2), etc. A sequence listing is provided after the claims.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Accordingly, one aspect of the present invention contemplates a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved in the said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof

capable of inhibiting or otherwise reducing a growth factor mediated cell proliferation and/or inflammation and/or other medical disorder.

According to this preferred embodiment, there is provided a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved with said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation and/or other medical disorder.

According to this embodiment, there is provided a method for ameliorating the effects of a proliferative and/or inflammatory skin disorder such as psoriasis said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation with effective amounts of UV treatment and a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation.

According to this embodiment, there is provided in a particularly preferred aspect a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence transcribed from a genomic gene corresponding to <400>1 or <400>2 wherein said catalytic domain is capable of cleaving said target mRNA sequence to reduce or inhibit IGF-I mediated cell proliferation and/or inflammation and/or other medical disorders.

Yet another aspect of the present invention contemplates co-suppression to reduce expression or to inhibit translation of an endogenous gene encoding, for example, IGF-I, its receptor, or IGFBPs such as IGFBP-2 and/or -3. In co-suppression, a second copy of an endogenous gene or a substantially similar copy or analogue of an endogenous gene is introduced into a cell

following topical administration. As with antisense molecules, nucleic acid molecules defining a ribozyme or nucleic acid molecules useful in co-suppression may first be protected such as by using a nonionic backbone.

Another aspect of the present invention contemplates a pharmaceutical composition for topical administration which comprises a nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation such as psoriasis and one or more pharmaceutically acceptable carriers and/or diluents.

Yet another aspect of the present invention contemplates the use of a nucleic acid molecule in the manufacture of a medicament for the treatment of proliferative and/or inflammatory skin disorders or other medical disorders mediated by a growth factor.

Still a further aspect of the present invention contemplates an agent comprising a nucleic acid molecule as hereinbefore defined useful in the treatment of proliferative and/or inflammatory skin disorders, such as psoriasis or other medical disorder..

The present invention further contemplates the use of the genetic molecules and in particular the antisense molecules to inhibit the anti-apoptotic activity of IGF-I receptor.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a representation of the nucleotide sequence of IGFBP-2.

```
LOCUS       HSIGFBP2     1433 bp    RNA             PRI       31-JAN-1990
DEFINITION  Human mRNA for insulin-like growth factor binding protein (IGFBP-2)
ACCESSION   X16302
KEYWORDS    insulin-like growth factor binding protein.
SOURCE      human
  ORGANISM  Homo sapiens
            Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
            Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
REFERENCE   1  (bases 1 to 1433)
  AUTHORS   Binkert,C., Landwehr,J., Mary,J.L., Schwander,J. and Heinrich,G.
  TITLE     Cloning, sequence analysis and expression of a cDNA encoding a
            novel insulin-like growth factor binding protein (IGFBP-2)
  JOURNAL   EMBO J. 8, 2497-2502 (1989)
  STANDARD  full automatic
COMMENT     NCBI gi: 33009
FEATURES             Location/Qualifiers
     source          1. .1433
                     /organism="Homo sapiens"
                     /dev_stage="fetal"
                     /tissue_type="liver"
     misc_feature    1416. .1420
                     /note="pot. polyadenylation signal"
     polyA_site      1433
                     /note="polyadenylation site"
     CDS             118. .1104
                     /note="precursor polypeptide;  (AA -39 to 289);  NCBI gi:
                     33010."
                     /codon_start=1
                     /translation="MLPRVGCPALPLPPPPLLPLLPLLLLLLGASGGGGGARAEVLFR
                     CPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACG
                     VYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAEYGASPEQVADNGDDHSEGG
                     LVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEP
                     KKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCK
                     MSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNEQQEACGVHTQRMQ"
                     (<400>21)
     CDS             118. .234
                     /note="signal peptide;  (AA -39 to -1);  NCBI gi: 33011."
                     /codon_start=1
                     /translation="MLPRVGCPALPLPPPPLLPLLPLLLLLLGASGGGGGARA"
                     (<400>22)
     CDS             235. .1101
                     /note="mature IGFBP-2;  (AA 1 to 289);  NCBI gi: 33012."
                     /codon_start=1
                     /translation="EVLFRCPPCTPERLAACGPPPVAPPAAVAAVAGGARMPCAELVR
```

```
                     EPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGSELPLQALVMGEGTCEKRRDAE
                     YGASPEQVADNGDDHSEGGLVENHVDSTMNMLGGGGSAGRKPLKSGMKELAVFREKVT
                     EQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQELDQVLERISTMRLPDERGPLEHLY
                     SLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNTGKLIQGAPTIRGDPECHLFYNE
                     QQEACGVHTQRMQ" (<400>23)
BASE COUNT      239 a    466 c    501 g    227 t
ORIGIN

 HSIGFBP2  Length: 1433  May 11, 1994  10:06  Type: N  Check: 6232  ..
```

Figure 2 is a representation of the nucleotide sequence of IGFBP-3.

```
LOCUS       HUMGFIBPA    2474 bp ss-mRNA            PRI       15-JUN-1990
DEFINITION  Human growth hormone-dependent insulin-like growth factor-binding
            protein mRNA, complete cds.
ACCESSION   M31159
KEYWORDS    insulin-like growth factor binding protein.
SOURCE      Human plasma, cDNA to mRNA, clone BP-53.
  ORGANISM  Homo sapiens
            Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
            Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
REFERENCE   1  (bases 1 to 2474)
  AUTHORS   Wood,W.I., Cachianes,G., Henzel,W.J., Winslow,G.A., Spencer,S.A.,
            Hellmiss,R., Martin,J.L. and Baxter,R.C.
  TITLE     Cloning and expression of the growth hormone-dependent insulin-like
            growth factor-binding protein
  JOURNAL   Mol. Endocrinol. 2, 1176-1185 (1988)
  STANDARD  full automatic
COMMENT     NCBI gi: 183115
FEATURES             Location/Qualifiers
     mRNA            <1. .2474
                     /note="GFIBP mRNA"
     CDS             110. .985
                     /gene="IGFBP1"
                     /note="insulin-like growth factor-binding protein;  NCBI
                     gi: 183116."
                     /codon_start=1
                     /translation="MQRARPTLWAAALTLLVLLRGPPVARAGASSGGLGPVVRCEPCD
                     ARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEAR
                     PLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRV
                     SDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREME
                     DTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYT
                     TKGKEDVHCYSMQSK" (<400>24>)
     source          1. .2474
                     /organism="Homo sapiens"
BASE COUNT      597 a    646 c    651 g    580 t
ORIGIN
```

```
HUMGFIBPA  Length: 2474  May 11, 1994  10:00  Type: N  Check: 9946  ..
```

Figure 3 is a representation of the nucleotide sequence of IGF-1-receptor.

```
LOCUS       HSIGFIRR     4989 bp    RNA             PRI       28-MAR-1991
DEFINITION  Human mRNA for insulin-like growth factor I receptor
ACCESSION   X04434 M24599
KEYWORDS    glycoprotein; insulin receptor;
            insulin-like growth factor I receptor; membrane glycoprotein;
            receptor; tyrosine kinase.
SOURCE      human
  ORGANISM  Homo sapiens
            Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
            Theria; Eutheria; Primates; Haplorhini; Catarrhini; Hominidae.
REFERENCE   1  (bases 1 to 4989)
  AUTHORS   Ullrich,A., Gray,A., Tam,A.W., Yang-Feng,T., Tsubokawa,M.,
            Collins,C., Henzel,W., Bon,T.L., Kathuria,S., Chen,E., Jakobs,S.,
            Francke,U., Ramachandran,J. and Fujita-Yamaguchi,Y.
  TITLE     Insulin-like growth factor I receptor primary structure: comparison
            with insulin receptor suggests structural dererminants that define
            functional specificity
  JOURNAL   EMBO J. 5, 2503-2512 (1986)
  STANDARD  full automatic
COMMENT     NCBI gi: 33058
FEATURES             Location/Qualifiers
     source          1. .4989
                     /organism="Homo sapiens"
                     /tissue_type="placenta"
                     /clone_lib="(lamda)gt10"
                     /clone="(lambda)IGF-1-R.85, (lambda)IGF-1-R.76"
     sig_peptide     32. .121
     mat_peptide     122. .4132
                     /note="IGF-I receptor"
     misc_feature    122. .2251
                     /note="alpha-subunit (AA 1 - 710)"
     misc_feature    182. .190
                     /note="pot.N-linked glycosylation site (AA 21 - 23)"
     misc_feature    335. .343
                     /note="pot.N-linked glycostlation site (AA 72 - 74)"
     misc_feature    434. .442
                     /note="pot.N-linked glycostlation site (AA 105 - 107)"
     misc_feature    761. .769
                     /note="pot.N-linked glycostlation site (AA 214 - 216)"
     misc_feature    971. .979
                     /note="pot.N-linked glycostlation site (AA 284 - 286)"
     misc_feature    1280. .1288
                     /note="pot.N-linked glycostlation site (AA 387 - 389)"
```

```
     misc_feature    1343. .1351
                     /note="pot.N-linked glycosylation site (AA 408 - 410)"
     misc_feature    1631. .1639
                     /note="pot.N-linked glycostlation site (AA 504 - 506)"
     misc_feature    1850. .1858
                     /note="pot.N-linked glycosylation site (AA 577 - 579)"
     misc_feature    1895. .1903
                     /note="pot.N-linked glycosylation site (AA 592 - 594)"
     misc_feature    1949. .1957
                     /note="pot.N-linked glycosylation site (AA 610 - 612)"
     misc_feature    2240. .2251
                     /note="putative proreceptor processing site (AA 707 -
                     710)"
     misc_feature    2252. .4132
                     /note="beta-subunit (AA 711 - 1337)"
     misc_feature    2270. .2278
                     /note="pot.N-linked glycosylation site (AA 717 - 719]"
     misc_feature    2297. .2305
                     /note="pot.N-linked glycosylation site (AA 726 - 728)"
     misc_feature    2321. .2329
                     /note="pot.N-linked glycosylation site (AA 734 - 736)"
     misc_feature    2729. .2737
                     /note="pot.N-linked glycosylation site (AA 870 - 872)"
     misc_feature    2768. .2776
                     /note="pot.N-linked glycosylation site (AA 883 - 885)"
     misc_feature    2837. .2908
                     /note="transmembrane region (AA 906 - 929)"
     misc_feature    2918. .2926
                     /note="pot.N-linked glycosylation site (AA 933 - 935)"
     misc_feature    3047. .3049
                     /note="pot.ATP binding site (AA 976)"
     misc_feature    3053. .3055
                     /note="pot.ATP binding site (AA 978)"
     misc_feature    3062. .3064
                     /note="pot.ATP binding site (AA 981)"
     misc_feature    3128. .3130
                     /note="pot.ATP binding site (AA 1003)"
     CDS             32. .4132
                     /product="IGF-I receptor"
                     /note="50 stops when translation attempted, frame 1, code
                     0"
BASE COUNT     1216 a   1371 c   1320 g   1082 t
ORIGIN

  HSIGFIRR  Length: 4989  May 11, 1994  12:10  Type: N  Check: 133  ..
```

Figure 4A is a photographic representation of a Western ligand blot of HaCaT conditioned medium showing IGFBP-3 secreted in 24 hours after 7 day treatment with phosphorothioate oligonucleotides (BP3AS2, BP3AS3 and BP3S) at 0.5μM and 5μM;
* no oligonucleotide added.

Figure 4B is a graphical representation of a scanning imaging desitometry of Western ligand blot (Figure 4A), showing relative band intensities of IGFBP-3 and the 24kDa IGFBP-4 after treatment with phosphorothioate oligonucleotides;
* no oligonucleotide added.

Figure 5A is a photographic representation of a Western ligand blot of HaCaT conditioned medium showing IGFBP-3 secreted in 24 hours after 7 day treatment with phosophorothioate oligonucleotide BP3AS2 at 0.5μM compared with several control oligonucleotides at 0.5μM. (a) oligonucleotide BP3AS2NS; (b) oligonucleotide BP3AS4; (c) oligonucleotide BP3AS4NS; and (untreated), no oligonucleotide added.

Figure 5B is a graphical representation of a scanning imaging densitometry of Western ligand blot (Figure 5A), showing relative band intensities of IGFBP-3 after treatment with phosphorothioate oligonucleotides as in Figure 5A, showing IGFBP-3 band intensities expressed as a percentage of the average band intensity from conditioned medium of cells not treated with oligonucleotide.

Figure 6 is a graphical representation showing inhibition of IGF-I binding by antisense oligonucleotides to IGF-I receptor. IGFR.AS: antisense; IGFR.S: sense.

Figure 7 is a graphical representation showing inhibition of IGFBP-3 production in culture medium following initial treatment with antisense oligonucleotides once daily over a 2 day period.

Figure 8 is a graphical representation showing optimization of IGFBP-3 antisense oligonucleotide concentration as determined by relative IGFBP-3 concentration in culture medium.

Figure 9 is a diagramatic representation of a map of IGF-1 Receptor mRNA and position of target ODNs.

Figure 10 is a photographical representation showing Lipid-mediated uptake of oligonucleotide in keratinocytes. HaCaT keratinocytes were incubated for 24 hours in medium (DMEM plus 10% v/v FCS) containing fluorescently labelled ODN (R451, 30 nM) and cytofectin GSV (2 μg/ml). The cells were then transferred to ODN-free medium and fluorescence microscopy (a) and phase contrast (b) images of the cells were obtained.

Figure 11 is a graphical representation of uptake (A) and toxicity (B) of ODN/lipid complexes in keratinocytes. Confluence HaCaT keratinocytes were incubated in DMEM containing fluoresently labelled ODN (R451) plus liposome over 120 hours, viewed using fluorescene microscopy and trypan blue stained and counted.

Figure 12 is a graphical representation of an IGF-1 Receptor mRNA in ODN treated (30nM) HaCaT cells (2μg/ml GSV). HaCaT keratinocytes were treated for 96 hours with C-5 propynyl, dU, dC ODNs complexed with cytofectin GSV. Cells were treated with ODNs complementary to the human IGF-I receptor mRNA (27, 32, 74 and 78), 2 randomised sequence ODNs (R451) and R766), liposome alone (GSV) or were left untreated (UT). Total RNA was isolated then analysed for IGF-I receptor mRNA and GAPDH mRNA levels by RNase Protection and PhosphorImager quantitiation.

(A) Electrophoretic analysis of IGF-I receptor and GAPDH mRNA fragments after RNase Protection. Molecular weight markers are shown on the right hand side. Full length probe

is shown on the left hand side (G-probe and I-probe). GAPDH protected fragments (G) are seen at 316 bases and IGF-I receptor protected fragments (I) are seen at 276 bases.

(B) Relative level of IGF-I receptor mRNA following each treatment is shown.

Figure 13 is a graphical representation of an IGF-1 receptor mRNA in ODN treated (30nM) HaCaT cells (2μg/ml GSV). Summary of IGF-I receptor ODN screening data. HaCaT keratinocytes were treated for 96 hours with C-5 propynyl, dU, dC ODNs complexed with cytofectin GSV. Total RNA was isolated then analysed for IGF-I receptor mRNA and GAPDH mRNA levels by RNase protection and phosphorImager quantitiation. Relative level of IGF-I receptor mRNA is shown after treatment with ODNs complementary to the human IGF-I receptor mRNA, 4 randomised sequence ODNs and liposome alone. (26-86=IGF-I receptor ODNs; R1, R4, R7 and R9 = randomised ODNs (R1=R121, R4=R451, R7=R766, R9=R961); GSV=liposome alone; UT=untreated). *indicates a significant difference in relative IGF-I receptor mRNA from GSV treated cells (n=4-10, $p<0.05$).

Figure 14 is a graphical representation of the effect of antisense oligonucleotides on IGF-1 receptor levels on the surface of keratinocytes. HaCaT cells were grown to confluence in 24-well plates in DMEM containing 10% v/v FCS. Oligodeoxynucleotide (ODN) and Cytofectin GSV (GSV, Glen Research) were mixed together in serum-free DMEM, incubated at room temperature for 10 minutes before being diluted ten-fold in medium and placed on the cells. Cells were incubated for 72 hours with 30 nM random sequence or antisense ODN and 2 μg/ml GSV or with GSV alone in DMEM containing 10% v/v FCS with solutions replaced every 24 hours. This was followed by incubation with ODN/GSV in serum-free DMEM for 48 hours. All incubations were performed at 37°C. Wells were washed twice with 1 ml cold PBS. Serum-free DMEM containing 10^{-10}M ^{125}I-IGF-I was added with or without the IGF-I analogue, des (1-3) IGF-I, at 10^{-10}M to 10^{-7}M. Cells were incubated at 4°C for 17 hours with gentle shaking then washed three times with 1 ml cold PBS and lysed in 250 μl 0.5M

NaOH/0.1% v/v Triton X-100 at room temperature for 4 hours. Specific binding of the solubilised cell extract was measured using a γ counter.

Figure 15 is a graphical representation of the effect of antisense oligonucleotides on IGF-1 receptor levels on the surface of keratinocytes.

Figure 16 is a photographical representation of H & E stained sections of (A) psoriatic skin biopsy prior to grafting and (B) 49 day old psoriatic skin graft using skin from the same donor.

Figure 17 is a photographical representation of uptake of oligonucleotide after intradermal injection into psoriatic skin graft on a nude mouse. Psoriatic skin graft was intradermally injected with ODN (R451, 50 μl, 10 μM). The graft was removed and sectioned after 24 hours, then viewed using confocal microscopy.

Figure 18(a) is a photographical representation of Pregraft, Donor JH, Donor JH, PBS treated, 50μl, Donor JH, #50 treated, 50μl, 10μM.

Figure 18(b) is a photographical representation of Donor LB, pregraft, Donor LB, PBS treated (50μl), Donor LB, #74 treated (50μl, 10μM).

Figure 18(c) is a photographical representation of Donor PW, pregraft, Donor PW, R451 treated (50μl, 10μM), Donor LB, #74 treated (50μl, 10μM).

Figure 18(d) is a photographical representation of Donor GM, pregraft, Donor GB, R451 treated (50μl, 10μM), Donor GM, #27 treated (50μl, 10μM).

Figure 19(a) is a photographical representation showing Donor JH pregraft, Donor JH PBS treated 50μl, Donor JH #50 treated 50μl, 10μM.

Figure 19(b) is a photographical representation Donor LB pregraft, Donor LB PBS treated 50μl, Donor LB #74 treated 50μl, 10μM.

Figure 19(c) is a photographical representational showing Donor PW pregraft, Donor PW r451 treated 50μl, 10μM, Donor PW #74 treated 50μl, 10μM.

Figure 19(d) is a photographical representation showing Donor GM pregraft, Donor GM R451 treated 50μl, 10μM, Donor #27 treated 50μl, 10μM.

Figure 20 is a graphical representation showing suppression of psoriasis after treatment with oligonucleotide (quantification). Oligonucleotide (50 μl, 10μM) was injected every two days for 20 days, as were control treatments. Skin thickness was measured by removing the skin and using computer software (MCID analysis) to measure the exact thickness of each graft. N=3-4 for each treatment. *indicates a significant difference from the pregraft value (ANOVA, $P<0.05$)

Figure 21 is a photographic representation of αhKi-67 imunobiological binding.

Figure 22 is a photographical representation showing penetration of oligonucleotide into human skin after topical treatment. Fluorescently labelled oligonucleotide (10 μM R451) was applied topically after formulation with cytofectin GSV (10 μg/ml) and viewed using confocal microscopy.

Figure 23 is a photographical representation showing penetration of oligonucleotide into human skin after application of topical gel formation. Fluorescently labelled oligonucleotide

(10 μM R451) was applied topically after complexing with cytofectin GSV (10 μg/ml) and formulation into 3% methylcellulose gel. Image was obtained using confocal microscopy.

Figure 24 is a graphical representation showing IGFBP-3 mRNA.

Figure 25(a) is a graphical representation showing IGFBP-3 mRNA in AON treated (100nM) HaCaT cells (2μg/ml GSV).

Figure 25(b) is a graphical representation showing IGFBP-3 mRNA levels of AON treated (100nm) HaCaT cells (2μg/ml GSV).

Figure 25(c) is a graphical representation showing IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2μg/ml GSV).

Figure 25(d) is a graphical representation showing IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2μg/ml GSV).

Figure 26(a) is a graphical representation showing IGFBP-3 mRNA in ODN treated (30nM) HaCaT cells (2μg/ml). HaCaT keratinocytes were treated for 51 hours with C-5 propynl, dU, dC ODNs complexed with cytofectin GSV. Total RNA was isolated then analysed for IGFBP-3 mRNA and GAPDH mRNA levels by Northern analysis and phosphorimager quantitation. Relative level of IGFBP-3 mRNA is shown after treatment with ODNs complementary to the human IGFBP-3 mRNA, 4 randomised sequence ODNs and lipsome alone. (1-24=IGFBP-3 ODNs; R1, R4, R7 and R9=randomised ODNs (R1=R121, R4=R451, R7=R766, R9 R961); GS=liposome alone; UT=untreated). *indicates a significant different in relative IGFBP-3 mRNA from GSV treated cells (n- 5-8, $p<0.01$), **indicates a significant difference in relative IGFBP-3 mRNA from GSV treated cells (n= 5-8, $p<0.05$).

Figure 26(b) is a graphical representation showing IGFBP-3 mRNA in ODN treated (100nM) HaCaT cells (2μg/ml GSV). HaCaT keratinocytes were treated for 51 hours with C-5 propynl, dU, dC ODNs complexed with cytofectin GSV. Total RNA was isolated then analysed for IGFBP-3 mRNA and GAPDH mRNA levels by Northern analysis and phosphorimager quantitation. Relative level of IGFBP-3 mRNA is shown after treatment with ODNs complementary to the human IGFBP-3 mRNA, 4 randomised sequence ODNs and liposome alone. (1-24=IGFBP-3 ODNs; R1, R4, R7 and R9 = randomised ODNs (R1-R121, R4=R451, R7=R766, R9-R961), GS=lipsome alone; UT=untreated). *indicates a significant difference in relative IGFBP-3 mRNA from GSV treated cells (n- 6-8, $p<0.01$).

Figure 27 is a representation showing a reduction in IGF-I receptor mRNA in HaCaT cells following treatment with antisense oligonucleotides. Confluent HaCaT cells were treated every 24 h for 4 days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific oligonucleotides *(#26 to #86)* or random sequence oligonucleotides (R121, R451 and R766). Total RNA was isolated and analysed for IGF-I receptor and GAPDH mRNA by RNase protection assay. **(a)**. Representative RNase protection assay gel showing IGF-I receptor *(IGF*R) and GAPDH mRNA in untreated or treated HaCaT cells. In this example, a reduction in IGFR band intensity relative to GAPDH can be seen with AON #27 and #78, but not with #32, #74 or the controls *(R*4, *R*7, random oligonucleotides R451 and R766, respectively; G, GSV lipid; *U*T, untreated).

(b) Densitometric quantitation of IGF-I receptor mRNA (normalised to GAPDH mRNA) in HaCaT cells following treatment with IGF-I receptor specific oligonucleotides (solid black), random sequence oligonucleotides (horizontal striped bar) or GSV alone (shaded bar) compared to untreated cells *(U*T, vertical striped bar). Each oligonucleotide was assayed in duplicate in at least two separate experiments.

Results are presented as mean $\pm$ SEM. A one-way ANOVA followed by Tukey's (▲) test was performed; ▲ indicates a significant difference between cells treated with IGF-I receptor

specific AONs and all of the control treatments ($p<0.05$). n=4 except for #27 and #32 (n=6), #28 and #68 (n=3), R766 (n=9), and R451, GSV and untreated (n=10).

Figure 28 is a representation showing a reduction in total cellular IGF-I receptor protein following antisense oligonucleotide treatment. Confluent HaCaT cells were treated every 24 h for 4 days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific AONs (#27, #50 and #64) or the random sequence oligonucleotide, R451. Total cellular protein was isolated and analysed for IGF-I receptor by SDS PAGE followed by western blotting with an antibody specific for the human IGF-I receptor. **(a)** Duplicate treated cellular extracts showing the IGF-I receptor at the predicted size of 110 kD

(b) Densitometric quantitation of IGF-I receptor protein. Results are presented as mean ± SEM of four different experiments each performed in duplicate. A one-way ANOVA followed by a Dunnett's test was performed; * indicates a significant difference from GSV treated cells ($p<0.01$). *GSV*, GSV lipid alone; *UT*, untreated; R451, random sequence oligonucleotide; *64*, *50*, *27*, IGF-I receptor-specific AONs.

Figure 29 is a representation showing a reduction in IGF-I receptor numbers on the keratinocyte cell surface after antisense oligonucleotide treatment. HaCaT cells were transfected with IGF-I receptor specific AONs #27 (—▲—), #50 (—x—), #64 (---■---), a random sequence oligonucleotide R451 (—o—), or treated with GSV lipid alone (--□--) every 24 h for four days (untreated cells, --✳--). Competition binding assays using ^{125}I-IGF-I and the receptor-specific analogue, des(1-3)IGF-I, were performed (inset); plotted values are means ± standard error. The mean values were then subjected to Scatchard analysis.

Figure 30 is a representation showing a reduction in keratinocyte cell number following antisense oligonucleotide treatment. HaCaT cells, initially at 40% confluence, were transfected with the IGF-I receptor specific AON #64, control sequences R451 and 6416, or treated with GSV lipid alone every 24 h for 2 days (UT, untreated cells). Cell number was

measured in the culture wells using a dye binding assay (Experimental protocol). Results are presented as mean ± SD. A one-way ANOVA was performed, followed by a Tukey's multiple comparison test. ▲ indicates a significant difference between cells treated with AON #64 and all of the control treatments ($p < 0.001$).

Figure 31 is a representation showing a reversal of epidermal hyperplasia in psoriatic human skin grafts on nude mice following intradermal injection with antisense oligonucleotides

Grafted psoriasis lesions were injected with IGF-I receptor specific AONs, a random sequence oligonucleotide in PBS, or with PBS alone, every 2 days for 20 days, then analysed histologically. **(a)** Donor A graft treated with AON #50 showing epidermal thinning compared
with pregraft and control *(PBS)* treated graft, and Donor B graft treated with AON #27 showing epidermal thinning compared with pregraft and control (R451) treated graft. E, epidermis; *Scale bar*, 400 mm; all pictures are at the same magnification. **(b)** Mean epidermal cross-sectional area over the full width of grafts was determined by digital image analysis. Results are presented as mean ± SEM. *Shaded bars*, control treatments: R451, random oligonucleotide sequence; *solid bars*, treatments with oligonucleotides that inhibited IGF-I receptor expression in vitro. * indicates a significant difference from the vehicle treated graft ($p < 0.01$, $n = 5\text{-}7$), ++ indicates a significant difference from the random sequence (R451) treated graft ($p < 0.01$, $n = 5\text{-}7$). **(c)** Parakeratosis *(arrow)* was absent in grafts treated with IGF-I receptor AONs *(AON #50)* but persisted in pregraft and control *(PBS)* treated graft. *Scale bar, 100 mm.*

Figure 32 is a representation showing a reversal of epidermal hyperplasia correlates with reduced IGF-I receptor mRNA in grafted psoriasis lesions treated with antisense oligonucleotides (a) A psoriasis lesion prior to grafting, and after grafting and treatment with IGF-I receptor specific oligonucleotide #27 *(AON #27)* or random sequence *(R451)* was immunostained with antibodies to Ki67 to identify proliferating cells. Proliferating cells are

indicated by a dark brown nucleus (arrows). *Scale bar, 250 m*m; all pictures are at the same magnification. **(b)** The same lesion prior to grafting and after oligonucleotide treatment as in (a) was subjected to in situ hybridisation with a ^{35}S-labeled cRNA probe complementary to the human IGF-I receptor mRNA. The presence of IGF-I receptor mRNA is indicated by silver grains (tiny black speckles), which are almost eliminated in the epidermis of the lesion treated with the IGF-I receptor-specific oligonucleotide #27 (AON #27). Arrows indicate the basal layer of the epidermis with dermis underneath. *Scale bar, 50* μm.

Figure 33 is a representation showing a reduction in IGF-I receptor mRNA in HaCaT keratinocytes following treatment with oligonucleotides. HaCaT cell monolayers grown to 90% confluence in DMEM contianing 10% v/v fetal calf serum were treated with 24 h for two days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Total RNA was isolated and analysed for IGF-I receptor and GAPDH mRNA using a commercially availble ribonuclease protection assay kit (RPAII, Ambicon Inc, Austin, Texas). Band intensity was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, California).

Figure 34 is a representation showing a reduction in IGF-I receptor protein in HaCaT keratinocytes following treatment with oligonucleotides. HaCaT cell monolayers grown to 90% confluence in DMEM containing 10% v/v fetal calf serum were treated every 24 h for four days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Cells were lysed in a buffer containing 50 mM HEPES, 150 mM NaCl, 10% v/v gycerol, 1% v/v Triton X-100 and 100 μg/ml aprotinin on ice for 30 mins, then 30 μg of lysate was loaded onto a denaturing 7% w/v polyacrylamide gel followed by transfer onto an Immobilon-P membrane (Millipore, Bedford, Massachusetts). Membranes were incubated with the anti-IGF-I receptor antibody C20 (Sanra Cruz Biotechnology Inc., Santa Cruz, California, 25 ng/ml in 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 0.1% v/v Tween 20) for 1 h at room temperature and developed using the Vistra ECF western blotting kit (Amersham,

Buckinghamshire, England). Band intensity was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, California).

Figure 35 is a representation showing a reduction in HaCaT keratinocyte cell number following treatment with oligonucleotides. HaCaT cell monolayers grown to 40% confluence in DMEM containing 10% fetal calf serum were treated every 24 h for three days with 2 μg/ml GSV lipid alone (GSV) or complexed with 15 nM oligonucleotide. Cell number was measured every 24 h using the amido black dye binding assay [32].

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the use of molecules and in particular genetic molecules and more particularly antisense molecules to down-regulate a growth factor, its receptor and/or growth factor expression facilitating sequences.

Accordingly, one aspect of the present invention contemplates a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved in the said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing a growth factor mediated cell proliferation and/or inflammation and/or other medical disorder.

Growth factor mediated cell proliferation and inflammation are also referred to as epidermal hyperplasias and these and other medical disorders may be mediated by any number of molecules such as but not limited to IGF-I, keratinocyte growth factor (KGF), transforming growth factor-α (TGFα), tumour necrosis factor-α (TNFα), interleukin-1, -4, -6 and 8 (IL-1, IL-4, IL-6 and IL-8, respectively), basic fibroblast growth factor (bFGF) or a combination of one or more of the above. The present invention is particularly described and exemplified with reference to IGF-I and its receptor (IGF-I receptor) and to IGF-I facilitating molecules, IGFBPs, since targeting these molecules according to the methods contemplated herein provides the best results to date. This is done, however, with the understanding that the present invention extends to any growth factor or cytokine-like molecule, a receptor thereof or a facilitating molecule like the IGFBPs involved in skin cell proliferation such as those molecules contemplated above and/or their receptors and/or facilitating molecules therefor.

According to this preferred embodiment, there is provided a method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a

mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved with said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation and/or other medical disorder.

The present invention is particularly described by psoriasis as the proliferative skin disorder. However, the subject invention extends to a range of proliferative and/or inflammatory skin disorders or epidermal hyperplasias such as but not limited to psoriasis, ichthyosis, pityriasis rubra pilaris ("PRP"), seborrhoea, keloids, keratoses, neoplasias and scleroderma, warts, benign growths and cancers of the skin. The present invention extends to a range of other disorders such as neovascularization conditions such as but not limited to hyperneovasularization such as neovascularization of the retina, lining of the brain, skin, hyperproliferation of the inside of blood vessels, kidney disease, atherosclerotic disease, hyperplasias of the gut epithelium or growth factor mediated malignancies such as IGF1-mediated malignancies.

Furthermore, down-regulation of IGF-I receptor is useful as adjunctive therapy for epidermal hyperplasia. In accordance with this aspect of the present invention it is known that IGF-I receptor elicits separate intracellular signals which prevent apoptosis [19]. In keratinocytes, IGF-I receptor activation has been shown to protect UV-irradiated cells from apoptosis [20]. In another cell type, a number of IGF-I receptors expressed by the cells correlated with tumorigenicity and apoptotic resistance [21]. Consequently, in accordance with the present invention, by inactivating IGF-I receptor on cells such as epidermal keratinocytes will achieve three important outcomes:

(i) Acute epidermal hyperplasia following UV has been suggested to increase the risk of keratinocyte carcinogenic transformation [22]. By reducing IGF-I receptor expression in the epidermis, the incidence of epidermal hyperplasia following UV exposure is

likely to be reduced leading to an overall acceleration in normalization of the lesion and reduced carcinogenic risk.

(ii) Inhibition of anti-apoptotic action of IGF-I receptor will enhance the reversal of epidermal thickening and accelerate normalization of differentiation. Topical or injected IGF-I receptor antisense as adjunctive treatment will increase apoptosis in the epidermal layer thereby enhancing the reduction in acanthosis observed in UV treatments.

(iii) Survival of keratinocytes, ie. those which evade apoptosis is likely to occur when cells have damaged DNA. Such mutations may be in the tumor suppressor region. Consequently, the use of antisense therapy will result in less frequent selection of mutated keratinocytes and therefore reduced incidence of basal cell carcinomas and squamous.

According to this embodiment, there is provided a method for ameliorating the effects of a proliferative and/or inflammatory skin disorder such as psoriasis said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation with effective amounts of UV treatment and a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation.

The UV treatment and nucleic acid molecule or its chemical analogue may be administered in any order or may be done simultaneously. This method is particularly useful in treating psoriasis by combination of UV and antisense therapy. Preferably the antisense therapy is directed to the IGF-I receptor.

In a preferred embodiment, the present invention is directed to a method for ameliorating the effects of psoriasis or other medical disorder, said method comprising contacting proliferating

skin or skin capable of proliferation or cells associated with said disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or ameliorating the medical disorder.

The present invention extends to any mammal such as but not limited to humans, livestock animals (e.g. horses, sheep, cows, goats, pigs, donkeys), laboratory test animals (e.g. rabbits, mice, guinea pigs), companion animals (e.g. cats, dogs) and captive wild animals. However, the instant invention is particularly directed to proliferative and/or inflammatory skin disorders such as psoriasis in humans as well as medical disorders contemplated above.

The aspects of the subject invention instantly contemplated are particularly directed to the topical application of one or more suitable nucleic molecules capable of inhibiting, reducing or otherwise interfering with IGF-mediated cell proliferation and/or inflammation. More particularly, the nucleic acid molecule targets IGF-I interaction with its receptor. Conveniently, therefore, the nucleic acid molecule is an antagonist of IGF-I interaction with its receptor. Most conveniently, the nucleic acid molecule antagonist is an antisense molecule to the IGF-I receptor, to IGF-I itself or to a molecule capable of facilitating IGF-I interaction with its receptor such as but not limited to an IGFBP.

Insofar as the invention relates to IGFBPs, the preferred molecules are IGFBP-2, -3, -4, -5 and -6. The most preferred molecules are IGFBP-2 and IGFBP-3.

The nucleotide sequences of IGFBP-2 and IGFBP-3 are set forth in Figures 1 (<400>1) and 2 (<400>2), respectively. According to a particularly preferred aspect of the present invention, there is provided a nucleic acid molecule comprising at least about ten nucleotides capable of hybridising to, forming a heteroduplex or otherwise interacting with an mRNA molecule directed from a gene corresponding to a genomic form of <400>1 and/or <400>2 and which thereby reduces or inhibits translation of said mRNA molecule. Preferably, the nucleic acid molecule is at least about 15 nucleotides in length and more

preferably at least about 20-25 nucleotides in length. However, the instant invention extends to any length nucleic acid molecule including a molecule of 100-200 nucleotides in length to correspond to the full length of or near full length of the subject genes.

The nucleotide sequence of the antisense molecules may correspond exactly to a region or portion of <400>1 or <400>2 or may differ by one or more nucleotide substitutions, deletions and/or additions. It is a requirement, however, that the nucleic acid molecule interact with an mRNA molecule to thereby reduce its translation into active protein.

Examples of potential antisense molecules for IGFBP-2 and IGFBP-3 are those capable of interacting with sequences selected from the lists in Examples 6 and 7, respectively.

The nucleic acid molecules in the form of an antisense molecule may be linear or covalently closed circular and single stranded or partially double stranded. A double stranded molecule may form a triplex with target mRNA or a target gene. The molecule may also be protected from, for example, nucleases, by any number of means such as using a nonionic backbone or a phosphorothioate linkage. A convenient nonionic backbone contemplated herein is ethylphosphotriester linkage or a 2′-O-methylribosyl derivative. A particularly useful modification modifies the DNA backbone by introducing phosphorothioate internucleotide linkages. Alternatively or in addition to the pyrimidine bases are modified by inclusion of a C-5 propyne substitution which modification is proposed to enhance duplex stability [23]. The present invention extends to any chemical modification to the bases and/or RNA or DNA backbone. Reference to a "chemical analogue" of a nucleic acid molecule includes reference to a modified base, nucleotide, nucleoside or phosphate backbone.

Examples of suitable oligonucleotide analogues are conveniently described in Ts'O *et al* [7]. Further suitable examples of oligonucleotide analogues and chemical modifications are described in references 25 to 31.

Alternatively, the antisense molecules of the present invention may target the IGF-I gene itself or its receptor or a multivalent antisense molecule may be constructed or separate molecules administered which target at least two or an IGFBP, IGF-I and/or IGF-I-receptor. Examples of suitable antisense molecules capable of targetting the IGF-I receptor are those capable of interacting with sequences selected from the list in Example 8. One particularly useful antisense molecule is 5′- ATCTCTCCGCTTCCTTTC -3′ (<400>10).

Other particularly useful antisense molecules are:

#27 UCCGGAGCCAGACUU

#64 CACAGUUGCUGCAAG

#78 UCUCCGCUUCCUUUC

#28 AGCCCCCACAGCGAG

#32 GCCUUGGAGAUGAGC

#40 UAACAGAGGUCAGCA

#42 GGAUCAGGGACCAGU

#46 CGGCAAGCUACACAG

#50 GGCAGGCAGGCACAC

Particularly useful molecules are selected from #27, #64 and #78. In a preferred embodiment these molecules comprise a C-5 propynyl dU, dC phosphorothioate modification.

A particularly preferred embodiment of the present invention contemplates a method of ameliorating the effects of psoriasis or other medical disorder, said method comprising contacting proliferating skin or skin capable of proliferation or cells associated with said medical disorder with an effective amount of one or more nucleic acid molecules or chemical analogues thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or ameliorating the medical disorder wherein said one or more molecules comprises a polynucleotide capable of interacting with mRNA directed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an IGFBP such as IGFBP-2 and/or IGFBP-3.

Preferably, the nucleic acid molecule are antisense molecules. Particularly useful antisense molecules are:

#27 UCCGGAGCCAGACUU

#64 CACAGUUGCUGCAAG

#78 UCUCCGCUUCCUUUC

#28 AGCCCCCACAGCGAG

#32 GCCUUGGAGAUGAGC

#40 UAACAGAGGUCAGCA

#42 GGAUCAGGGACCAGU

#46 CGGCAAGCUACACAG

#50 GGCAGGCAGGCACAC

Even more particularly useful molecules are selected from #27, #64 and #78.

In accordance with one aspect of the present invention the nucleic acid molecule is topically applied in aqueous solution or in conjunction with a cream, ointment, oil or other suitable carrier and/or diluent. A single application may be sufficient depending on the severity or exigencies of the condition although more commonly, multiple applications are required ranging from hourly, multi-hourly, daily, multi-daily, weekly or monthly, or in some other suitable time interval. The treatment might comprise solely the application of the nucleic acid molecule or this may be applied in conjunction with other treatments for the skin proliferation and/or inflammatory disorder being treated or for other associated conditions including microbial infection, bleeding and the formation of a variety of rashes.

As an alternative to or in conjunction with antisense therapy, the subject invention extends to the nucleic acid molecule as, or incorporating, a ribozyme including a minizyme to, for example, IGF-I, its receptor or to molecules such as IGFBPs and in particular IGFBP-2 and -3. Ribozymes are synthetic nucleic acid molecules which possess highly specific endoribonuclease activity. In particular, they comprise a hybridising region which is complementary in nucleotide

sequence to at least part of a target RNA. Ribozymes are well described by Haseloff and Gerlach [8] and in International Patent Application No. WO 89/05852. The present invention extends to ribozymes which target mRNA specified by genes encoding IGF-I, its receptor or one or more IGFBPs such as IGFBP-2 and/or IGFBP-3.

According to this embodiment, there is provided in a particularly preferred aspect a ribozyme comprising a hybridising region and a catalytic region wherein the hybridising region is capable of hybridising to at least part of a target mRNA sequence transcribed from a genomic gene corresponding to (<400>1) or (<400>2) wherein said catalytic domain is capable of cleaving said target mRNA sequence to reduce or inhibit IGF-I mediated cell proliferation and/or inflammation and/or other medical disorders.

Yet another aspect of the present invention contemplates co-suppression to reduce expression or to inhibit translation of an endogenous gene encoding, for example, IGF-I, its receptor, or IGFBPs such as IGFBP-2 and/or -3. In co-suppression, a second copy of an endogenous gene or a substantially similar copy or analogue of an endogenous gene is introduced into a cell following topical administration. As with antisense molecules, nucleic acid molecules defining a ribozyme or nucleic acid molecules useful in co-suppression may first be protected such as by using a nonionic backbone.

The efficacy of the nucleic acid molecules of the present invention can be conveniently tested and screened using an *in vitro* system comprising a basal keratinocyte cell line. A particularly useful system comprises the HaCaT cell line described by Boukamp *et al* [9]. In one assay, IGF-I is added to an oligonucleotide treated HaCaT cell line. Alternatively, growth of oligonucleotide treated HaCaT cells is observed on a feeder layer of irradiated 3T3 fibroblasts. Using such *in vitro* assays, it is observed that antisense oligonucleotides to IGFBP-3, for example, inhibit production of IGFBP-3 by HaCaT cells. Other suitable animal models include the nude mouse/human skin graft model (15; 16) and the "flaky skin" mouse model (17; 18). In the nude mouse model, microdermatome biopsies of psoriasis lesions are taken under

local anaesthetic from volunteers then transplanted to congenital athymic (nude) mice. These transplanted human skin grafts maintain the characteristic hyperproliferating epidermis for 6-8 weeks. They are an established model for testing the efficacy of topically applied therapies for psoriasis. In the "flaky skin" mouse model, the fsn/fsn mutation produces mice with skin resembling human psoriasis. This mouse, or another mutant mouse with a similar phenotype is a further *in vivo* model to test the efficacy of topically applied therapies for psoriasis.

Another aspect of the present invention contemplates a pharmaceutical composition for topical administration which comprises a nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation such as psoriasis and one or more pharmaceutically acceptable carriers and/or diluents. Preferably, the nucleic acid molecule is an antisense molecule to IGF-I, the IGF-I receptor or an IGFBP such as IGFBP-2 and/or IGFBP-3 or comprises a ribozyme to one or more of these targets or is a molecule suitable for co-suppression of one or more of these targets. The composition may comprise a single species of a nucleic acid molecule capable of targeting one of IGF-I, its receptor or an IGFBP, such as IGFBP-2 or IGFBP-3 or may be a multi-valent molecule capable of targeting two or more of IGF-I, its receptor or an IGFBP, such as IGFBP-2 and/or IGFBP-3.

The nucleic acid molecules may be administered in dispersions prepared in creams, ointments, oil or other suitable carrier and/or diluent such as glycerol, liquid polyethylene glycols and/or mixtures thereof. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for topical use include sterile aqueous solutions (where water soluble) or dispersions and powders for the extemporaneous preparation of topical solutions or dispersions. In all cases, the form is preferably sterile although this is not an absolute requirement and is stable under the conditions of manufacture and storage. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures

thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants. The prevention of the action of microorganism can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

Topical solutions are prepared by incorporating the nucleic acid molecule compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by where necessary filter sterilization.

The active agent may alternatively be administered by intravenous, subcutaneous, nasal drip, suppository, implant means amongst other suitable routes of administration including intraperitoneal, intramuscular, absorption through epithelial or mucocutaneous linings for example via nasal, oral, vaginal, rectal or gastrointestinal administration. Reference may conveniently be made to reference 24.

As used herein "pharmaceutically acceptable carriers and/or diluents" include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the pharmaceutical compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. Conveniently, the nucleic acid molecules of the present invention are stored in freeze-dried form and are reconstituted prior to use.

Yet another aspect of the present invention contemplates the use of a nucleic acid molecule in the manufacture of a medicament for the treatment of proliferative and/or inflammatory skin disorders or other medical disorders mediated by a growth factor. The proliferative and/or

inflammatory skin disorder is generally psoriasis or other medical disorders as described above and the nucleic acid molecule targets IGF-I, the IGF-I receptor and/or an IGFBP such as IGFBP-2 and/or IGFBP-3.

Still a further aspect of the present invention contemplates an agent comprising a nucleic acid molecule as hereinbefore defined useful in the treatment of proliferative and/or inflammatory skin disorders, such as psoriasis or other medical disorder..

The present invention further contemplates the use of the genetic molecules and in particular the antisense molecules to inhibit the anti-apoptotic activity of IGF-I receptor. Such a use is appropriate for the treatment of certain cancers and as adjunct therapy for epidermal hyperplasia such as in combination with UV treatment.

The present invention is further described by the following non-limiting Examples.

EXAMPLE 1

The differentiated human keratinocyte cell line, HaCaT [9] was used in the *in vitro* assay. Cells at passage numbers 33 to 36 were maintained as monolayer cultures in 5% v/v CO_2 at 37°C in Keratinocyte-SFM (Gibco) containing EGF and bovine pituitary extract as supplied. Media containing foetal calf serum were avoided because of the high content of IGF-I binding proteins in serum.

Feeder layer plates of lethally irradiated 3T3 fibroblasts were prepared exactly as described by Rheinwald and Green [10].

EXAMPLE 2

Cells were grown to 4 days post confluence in $2cm^2$ wells with daily medium changes of Keratinocyte-SFM, then the medium was changed to DMEM (Cytosystems, Australia), with the following additions: 25mM Hepes, 0.19% w/v, sodium bicarbonate, 0.03% w/v glutamine (Sigma Chemical Co, USA), 50IU/ml penicillin and 50µg/ml streptomycin (Flow Laboratories). After 24 hours, IGF-I or tIGF-I was added to triplicate wells, at the concentrations indicated, in 0.5ml fresh DMEM containing 0.02% v/v bovine serum albumin (Sigma molecular biology grade) and incubated for a further 21 hours. [^{3}H]-Thymidine (0.1µCi/well) was then added and the cells incubated for a further 3 hours. The medium was then aspirated and the cells washed once with ice-cold PBS and twice with ice-cold 10% v/v TCA. The TCA-precipitated monolayers were then solubilized with 0.25M NaOH (200µl/well), transferred to scintillation vials and radioactivity determined by liquid scintillation counting (Pharmacia Wallac 1410 liquid scintillation counter).

EXAMPLE 3

HaCaT conditioned medium (250µl) was concentrated by adding 750µl cold ethanol, incubating at -20°C for 2 hours and centrifuging at 16,000g for 20 min at 4°C. The resulting pellet was air dried, resuspended thoroughly in non-reducing Laemmli sample buffer, heated to 90°C for 5 minutes and separated on 12% w/v SDS-PAGE according to the method of Laemmli (1970).

Separated proteins were electrophoretically transferred to nitrocellulose membrane (0.45mm, Schleicher and Schuell, Dassel, Germany) in a buffer containing 25mM Tris, 192mM glycine and 20% v/v methanol. IGFBPs were then visualised by the procedure of Hossenlopp *et al* [11], using [^{125}I]-IGF-I, followed by autoradiography. Autoradiographs were scanned in a BioRad Model GS-670 Imaging Densitometer and band densities were determined using the Molecular Analyst program.

EXAMPLE 4

Phosphorothioate oligodeoxynucleotides were synthesised by Bresatec, Adelaide, South Australia, Australia. The following antisense sequences were used: BP3AS2, 5′- GCG CCC GCT GCA TGA CGC CTG CAA C -3′ (<400>4), a 25mer complementary to the start codon region of the human IGFBP-3 mRNA; BP3AS3, 5′- CGG GCG GCT CAC CTG GAG CTG GCG -3′ (<400>5), a 24mer complementary to the exon 1/intron 1 splice site; BP3AS4, 5′- AGG CGG CTG ACG GCA CTA -3′(<400>6), an 18mer complementary to a region of the coding sequence lacking RNA secondary structure and oligonucleotide-dimer formation (using the computer software "OLIGO for PC"). Since BP3AS4 was found to be ineffective at inhibiting IGFBP-3 synthesis, it was used as a control. The following additional control oligonucleotide sequences were used: BP3S, 5′- CAG GCG TCA TGC AGC GGG C -3′ (<400>7), an 18mer sense control sequence equivalent to the start codon region; BP3AS2NS, 5′- CGG AGA TGC CGC ATG CCA GCG CAG G -3′ (<400>8), a 25mer randomised sequence with the same GC content as BP3AS2; BP3AS4NS, 5′- GAC AGC GTC GGA GCG ATC -3′ (<400>9), an 18mer randomised sequence with the same GC content as BP3AS4NS. Design of the oligonucleotides was based on the human IGFBP-3 cDNA sequence of Spratt *et al* [12].

Cells were grown to one day post confluence in 2cm^2 wells with daily medium changes of 0.5ml Keratinocyte-SFM, then subjected to daily medium changes of Keratinocyte-SFM for a further 4 days. Daily additions of 0.5ml fresh Keratinocyte-SFM were then continued for a further 7 days, except that at the time of medium addition, 5µl oligonucleotide in PBS was added to give

the final concentrations indicated, then the wells were shaken to mix the oligonucleotide. After the final addition, cells were incubated for 24 hours and the medium collected for assay of IGFBPs. Cells were then counted after trypsinisation in a Coulter Industrial D Counter, Coulter Bedfordshire, UK. Cell numbers after oligonucleotide treatment differed by less than 10%.

EXAMPLE 5

HaCaT cells secrete mainly IGFBP-3 (>95%), with the only other IGFBP detectable in HaCaT conditioned medium being IGFBP-4 (<5%). The effect on IGFBP-3 and IGFBP-4 synthesis of antisense oligonucleotides at two concentrations, 5μM and 0.5μM, was tested. Two oligonucleotides were used, BP3AS2 and BP3AS3, directed against the start site and the intron 1/exon 1 splice site, respectively of the IGFBP-3 mRNA. As a control, a sense oligonucleotide corresponding to the start site was used. As shown in Figures 4A and 4B, all oligonucleotides at 5μM caused a significant reduction of IGFBP-3 synthesis compared with untreated cells, however, the two antisense oligonucleotides inhibited IGFBP-3 synthesis of approximately 50% compared to the sense control (Figure 4B). The antisense oligonucleotide directed to the start codon appeared to be more effective of the two, the difference being more apparent at the lower concentration of 0.5μM. The cells of IGFBP-4 secreted by the HaCaT cells make photographic reproduction of the bands on Western ligand blots difficult, however densitometry measurements provide adequate relative quantitation. This resulted in the significant observation that IGFBP-4 levels were unaffected by oligonucleotide addition to the cells, suggesting that the observed inhibitory effects on IGFBP-3 are specific.

To further investigate the inhibitory effects of the more effective of the two antisense oligonucleotides, BP3AS2, inhibition by this oligonucleotide at 0.5μM was compared with a number of control oligonucleotides, including one antisense oligonucleotide to IGFBP-3 that had proved to be ineffective at 0.5μM. As shown in Figures 5A and 5B, BP3AS2 was again inhibitory, resulting in levels of IGFBP-3 of approximately 50% of the most non-specifically inhibitory control oligonucleotide, the randomised equivalent of BP3AS2. The other control oligonucleotides caused no reduction in IGFBP-3 levels at 0.5μM, compared to untreated cells.

Of possible significance is the fact that this control oligonucleotide, BP3AS2NS, like BP3AS2 itself, has the highest potential T_m of the three control oligonucleotides used in this experiment, enhancing the probability of non-specific base pairing with non-target mRNAs. However, the lack of inhibition of IGFBP-4 secretion by BP3AS2 suggests that this oligonucleotide is selective even compared with the most closely related protein likely to be present in this cell line.

EXAMPLE 6

Antisense oligonucleotides to IGFBP2 may be selected from molecules capable of interacting with one or more of the following sense oligonucleotides:

ATTCGGGGCGAGGGA	AGGAGGCGGCTCCCG	CACCTGCCCGCCCGC
TTCGGGGCGAGGGAG	GGAGGCGGCTCCCGC	ACCTGCCCGCCCGCC
TCGGGGCGAGGGAGG	GAGGCGGCTCCCGCT	CCTGCCCGCCCGCCC
CGGGGCGAGGGAGGA	AGGCGGCTCCCGCTC	CTGCCCGCCCGCCCG
GGGGCGAGGGAGGAG	GGCGGCTCCCGCTCG	TGCCCGCCCGCCCGC
GGGCGAGGGAGGAGG	GCGGCTCCCGCTCGC	GCCCGCCCGCCCGCT
GGCGAGGGAGGAGGA	CGGCTCCCGCTCGCA	CCCGCCCGCCCGCTC
GCGAGGGAGGAGGAA	GGCTCCCGCTCGCAG	CCGCCCGCCCGCTCG
CGAGGGAGGAGGAAG	GCTCCCGCTCGCAGG	CGCCCGCCCGCTCGC
GAGGGAGGAGGAAGA	CTCCCGCTCGCAGGG	GCCCGCCCGCTCGCT
AGGGAGGAGGAAGAA	TCCCGCTCGCAGGGC	CCCGCCCGCTCGCTC
GGGAGGAGGAAGAAG	CCCGCTCGCAGGGCC	CCGCCCGCTCGCTCG
GGAGGAGGAAGAAGC	CCGCTCGCAGGGCCG	CGCCCGCTCGCTCGC
GAGGAGGAAGAAGCG	CGCTCGCAGGGCCGT	GCCCGCTCGCTCGCT
AGGAGGAAGAAGCGG	GCTCGCAGGGCCGTG	CCCGCTCGCTCGCTC
GGAGGAAGAAGCGGA	CTCGCAGGGCCGTGC	CCGCTCGCTCGCTCG
GAGGAAGAAGCGGAG	TCGCAGGGCCGTGCA	CGCTCGCTCGCTCGC
AGGAAGAAGCGGAGG	CGCAGGGCCGTGCAC	GCTCGCTCGCTCGCC
GGAAGAAGCGGAGGA	GCAGGGCCGTGCACC	CTCGCTCGCTCGCCC
GAAGAAGCGGAGGAG	CAGGGCCGTGCACCT	TCGCTCGCTCGCCCG
AAGAAGCGGAGGAGG	AGGGCCGTGCACCTG	CGCTCGCTCGCCCGC
AGAAGCGGAGGAGGC	GGGCCGTGCACCTGC	GCTCGCTCGCCCGCC
GAAGCGGAGGAGGCG	GGCCGTGCACCTGCC	CTCGCTCGCCCGCCG
AAGCGGAGGAGGCGG	GCCGTGCACCTGCCC	TCGCTCGCCCGCCGC
AGCGGAGGAGGCGGC	CCGTGCACCTGCCCG	CGCTCGCCCGCCGCG
GCGGAGGAGGCGGCT	CGTGCACCTGCCCGC	GCTCGCCCGCCGCGC
CGGAGGAGGCGGCTC	GTGCACCTGCCCGCC	CTCGCCCGCCGCGCC
GGAGGAGGCGGCTCC	TGCACCTGCCCGCCC	TCGCCCGCCGCGCCG
GAGGAGGCGGCTCCC	GCACCTGCCCGCCCG	CGCCCGCCGCGCCGC

GCCCGCCGCGCCGCG
CCCGCCGCGCCGCGC
CCGCCGCGCCGCGCT
CGCCGCGCCGCGCTG
GCCGCGCCGCGCTGC
CCGCGCCGCGCTGCC
CGCGCCGCGCTGCCG
GCGCCGCGCTGCCGA
CGCCGCGCTGCCGAC
GCCGCGCTGCCGACC
CCGCGCTGCCGACCG
CGCGCTGCCGACCGC
GCGCTGCCGACCGCC
CGCTGCCGACCGCCA
GCTGCCGACCGCCAG
CTGCCGACCGCCAGC
TGCCGACCGCCAGCA
GCCGACCGCCAGCAT
CCGACCGCCAGCATG
CGACCGCCAGCATGC
GACCGCCAGCATGCT
ACCGCCAGCATGCTG
CCGCCAGCATGCTGC
CGCCAGCATGCTGCC
GCCAGCATGCTGCCG
CCAGCATGCTGCCGA
CAGCATGCTGCCGAG
AGCATGCTGCCGAGA
GCATGCTGCCGAGAG
CATGCTGCCGAGAGT
ATGCTGCCGAGAGTG
TGCTGCCGAGAGTGG
GCTGCCGAGAGTGGG
CTGCCGAGAGTGGGC
TGCCGAGAGTGGGCT
GCCGAGAGTGGGCTG
CCGAGAGTGGGCTGC
CGAGAGTGGGCTGCC
GAGAGTGGGCTGCCC
AGAGTGGGCTGCCCC
GAGTGGGCTGCCCCG
AGTGGGCTGCCCCGC
GTGGGCTGCCCCGCG
TGGGCTGCCCCGCGC

GGGCTGCCCCGCGCT
GGCTGCCCCGCGCTG
GCTGCCCCGCGCTGC
CTGCCCCGCGCTGCC
TGCCCCGCGCTGCCG
GCCCCGCGCTGCCGC
CCCCGCGCTGCCGCT
CCCGCGCTGCCGCTG
CCGCGCTGCCGCTGC
CGCGCTGCCGCTGCC
GCGCTGCCGCTGCCG
CGCTGCCGCTGCCGC
GCTGCCGCTGCCGCC
CTGCCGCTGCCGCCG
TGCCGCTGCCGCCGC
GCCGCTGCCGCCGCC
CCGCTGCCGCCGCCG
CGCTGCCGCCGCCGC
GCTGCCGCCGCCGCC
CTGCCGCCGCCGCCG
TGCCGCCGCCGCCGC
GCCGCCGCCGCCGCT
CCGCCGCCGCCGCTG
CGCCGCCGCTGCTGC
GCCGCCGCTGCTGCC
CCGCCGCTGCTGCCG
CGCCGCTGCTGCCGC
GCCGCTGCTGCCGCT
CCGCTGCTGCCGCTG
CGCTGCTGCCGCTGC
GCTGCTGCCGCTGCT
CTGCTGCCGCTGCTG
TGCTGCCGCTGCTGC
GCTGCCGCTGCTGCC
CTGCCGCTGCTGCCG
TGCCGCTGCTGCCGC
GCCGCTGCTGCCGCT
CCGCTGCTGCCGCTG
CGCTGCTGCCGCTGC
GCTGCTGCCGCTGCT
CTGCTGCCGCTGCTG

TGCTGCCGCTGCTGC
GCTGCCGCTGCTGCT
CTGCCGCTGCTGCTG
TGCCGCTGCTGCTGC
GCCGCTGCTGCTGCT
CCGCTGCTGCTGCTG
CGCTGCTGCTGCTGC
GCTGCTGCTGCTGCT
CTGCTGCTGCTGCTA
TGCTGCTGCTGCTAC
GCTGCTGCTGCTACT
CTGCTGCTGCTACTG
TGCTGCTGCTACTGG
GCTGCTGCTACTGGG
CTGCTGCTACTGGGC
TGCTGCTACTGGGCG
GCTGCTACTGGGCGC
CTGCTACTGGGCGCG
TGCTACTGGGCGCGA
GCTACTGGGCGCGAG
CTACTGGGCGCGAGT
TACTGGGCGCGAGTG
ACTGGGCGCGAGTGG
CTGGGCGCGAGTGGC
TGGGCGCGAGTGGCG
GGGCGCGAGTGGCGG
GGCGCGAGTGGCGGC
GCGCGAGTGGCGGCG
CGCGAGTGGCGGCGG
GCGAGTGGCGGCGGC
CGAGTGGCGGCGGCG
GAGTGGCGGCGGCGG
AGTGGCGGCGGCGGC
GTGGCGGCGGCGGCG
TGGCGGCGGCGGCGG
GGCGGCGGCGGCGGG
GCGGCGGCGGCGGGG
CGGCGGCGGCGGGGC
GGCGGCGGCGGGGCG
GCGGCGGCGGGGCGC
CGGCGGCGGGGCGCG
GGCGGCGGGGCGCGC
GCGGCGGGGCGCGCG
CGGCGGGGCGCGCGC

	GGCGGGGCGCGCGCG	ACCCGAGCGCCTGGC	CCGCCGCGGTGGCCG
	GCGGGGCGCGCGCGG	CCCGAGCGCCTGGCC	CGCCGCGGTGGCCGC
	CGGGGCGCGCGCGGA	CCGAGCGCCTGGCCG	GCCGCGGTGGCCGCA
	GGGGCGCGCGCGGAG	CGAGCGCCTGGCCGC	CCGCGGTGGCCGCAG
5	GGGCGCGCGCGGAGG	GAGCGCCTGGCCGCC	CGCGGTGGCCGCAGT
	GGCGCGCGCGGAGGT	AGCGCCTGGCCGCCT	GCGGTGGCCGCAGTG
	GCGCGCGCGGAGGTG	GCGCCTGGCCGCCTG	CGGTGGCCGCAGTGG
	CGCGCGCGGAGGTGC	CGCCTGGCCGCCTGC	GGTGGCCGCAGTGGC
	GCGCGCGGAGGTGCT	GCCTGGCCGCCTGCG	GTGGCCGCAGTGGCC
10	CGCGCGGAGGTGCTG	CCTGGCCGCCTGCGG	TGGCCGCAGTGGCCG
	GCGCGGAGGTGCTGT	CTGGCCGCCTGCGGG	GGCCGCAGTGGCCGG
	CGCGGAGGTGCTGTT	TGGCCGCCTGCGGGC	GCCGCAGTGGCCGGA
	GCGGAGGTGCTGTTC	GGCCGCCTGCGGGCC	CCGCAGTGGCCGGAG
	CGGAGGTGCTGTTCC	GCCGCCTGCGGGCCC	CGCAGTGGCCGGAGG
15	GGAGGTGCTGTTCCG	CCGCCTGCGGGCCCC	GCAGTGGCCGGAGGC
	GAGGTGCTGTTCCGC	CGCCTGCGGGCCCCC	CAGTGGCCGGAGGCG
	AGGTGCTGTTCCGCT	GCCTGCGGGCCCCCG	AGTGGCCGGAGGCGC
	GGTGCTGTTCCGCTG	CCTGCGGGCCCCCGC	GTGGCCGGAGGCGCC
	GTGCTGTTCCGCTGC	CTGCGGGCCCCCGCC	TGGCCGGAGGCGCCC
20	TGCTGTTCCGCTGCC	TGCGGGCCCCCGCCG	GGCCGGAGGCGCCCG
	GCTGTTCCGCTGCCC	GCGGGCCCCCGCCGG	GCCGGAGGCGCCCGC
	CTGTTCCGCTGCCCG	CGGGCCCCCGCCGGT	CCGGAGGCGCCCGCA
	TGTTCCGCTGCCCGC	GGGCCCCCGCCGGTT	CGGAGGCGCCCGCAT
	GTTCCGCTGCCCGCC	GGCCCCCGCCGGTTG	GGAGGCGCCCGCATG
25	TTCCGCTGCCCGCCC	GCCCCCGCCGGTTGC	GAGGCGCCCGCATGC
	TCCGCTGCCCGCCCT	CCCCCGCCGGTTGCG	AGGCGCCCGCATGCC
	CCGCTGCCCGCCCTG	CCCCGCCGGTTGCGC	GGCGCCCGCATGCCA
	CGCTGCCCGCCCTGC	CCCGCCGGTTGCGCC	GCGCCCGCATGCCAT
	GCTGCCCGCCCTGCA	CCGCCGGTTGCGCCG	CGCCCGCATGCCATG
30	CTGCCCGCCCTGCAC	CGCCGGTTGCGCCGC	GCCCGCATGCCATGC
	TGCCCGCCCTGCACA	GCCGGTTGCGCCGCC	CCCGCATGCCATGCG
	GCCCGCCCTGCACAC	CCGGTTGCGCCGCCC	CCGCATGCCATGCGC
	CCCGCCCTGCACACC	CGGTTGCGCCGCCCG	CGCATGCCATGCGCG
	CCGCCCTGCACACCC	GGTTGCGCCGCCCGC	GCATGCCATGCGCGG
35	CGCCCTGCACACCCG	GTTGCGCCGCCCGCC	CATGCCATGCGCGGA
	GCCCTGCACACCCGA	TTGCGCCGCCCGCCG	ATGCCATGCGCGGAG
	CCCTGCACACCCGAG	TGCGCCGCCCGCCGC	TGCCATGCGCGGAGC
	CCTGCACACCCGAGC	GCGCCGCCCGCCGCG	GCCATGCGCGGAGCT
	CTGCACACCCGAGCG	CGCCGCCCGCCGCGG	CCATGCGCGGAGCTC
40	TGCACACCCGAGCGC	GCCGCCCGCCGCGGT	CATGCGCGGAGCTCG
	GCACACCCGAGCGCC	CCGCCCGCCGCGGTG	ATGCGCGGAGCTCGT
	CACACCCGAGCGCCT	CGCCCGCCGCGGTGG	TGCGCGGAGCTCGTC
	ACACCCGAGCGCCTG	GCCCGCCGCGGTGGC	GCGCGGAGCTCGTCC
	CACCCGAGCGCCTGG	CCCGCCGCGGTGGCC	CGCGGAGCTCGTCCG

GCGGAGCTCGTCCGG
CGGAGCTCGTCCGGG
GGAGCTCGTCCGGGA
GAGCTCGTCCGGGAG
AGCTCGTCCGGGAGC
GCTCGTCCGGGAGCC
CTCGTCCGGGAGCCG
TCGTCCGGGAGCCGG
CGTCCGGGAGCCGGG
GTCCGGGAGCCGGGC
TCCGGGAGCCGGGCT
CCGGGAGCCGGGCTG
CGGGAGCCGGGCTGC
GGGAGCCGGGCTGCG
GGAGCCGGGCTGCGG
GAGCCGGGCTGCGGC
AGCCGGGCTGCGGCT
GCCGGGCTGCGGCTG
CCGGGCTGCGGCTGC
CGGGCTGCGGCTGCT
GGGCTGCGGCTGCTG
GGCTGCGGCTGCTGC
GCTGCGGCTGCTGCT
CTGCGGCTGCTGCTC
TGCGGCTGCTGCTCG
GCGGCTGCTGCTCGG
CGGCTGCTGCTCGGT
GGCTGCTGCTCGGTG
GCTGCTGCTCGGTGT
CTGCTGCTCGGTGTG
TGCTGCTCGGTGTGC
GCTGCTCGGTGTGCG
CTGCTCGGTGTGCGC
TGCTCGGTGTGCGCC
GCTCGGTGTGCGCCC
CTCGGTGTGCGCCCG
TCGGTGTGCGCCCGG
CGGTGTGCGCCCGGC
GGTGTGCGCCCGGCT
GTGTGCGCCCGGCTG
TGTGCGCCCGGCTGG
GTGCGCCCGGCTGGA
TGCGCCCGGCTGGAG
GCGCCCGGCTGGAGG

CGCCCGGCTGGAGGG
GCCCGGCTGGAGGGC
CCCGGCTGGAGGGCG
CCGGCTGGAGGGCGA
CGGCTGGAGGGCGAG
GGCTGGAGGGCGAGG
GCTGGAGGGCGAGGC
CTGGAGGGCGAGGCG
TGGAGGGCGAGGCGT
GGAGGGCGAGGCGTG
GAGGGCGAGGCGTGC
AGGGCGAGGCGTGCG
GGGCGAGGCGTGCGG
GGCGAGGCGTGCGGC
GCGAGGCGTGCGGCG
CGAGGCGTGCGGCGT
GAGGCGTGCGGCGTC
AGGCGTGCGGCGTCT
GGCGTGCGGCGTCTA
GCGTGCGGCGTCTAC
CGTGCGGCGTCTACA
GTGCGGCGTCTACAC
TGCGGCGTCTACACC
GCGGCGTCTACACCC
CGGCGTCTACACCCC
GGCGTCTACACCCCG
GCGTCTACACCCCGC
CGTCTACACCCCGCG
GTCTACACCCCGCGC
TCTACACCCCGCGCT
CTACACCCCGCGCTG
TACACCCCGCGCTGC
ACACCCCGCGCTGCG
CACCCCGCGCTGCGG
ACCCCGCGCTGCGGC
CCCCGCGCTGCGGCC
CCCGCGCTGCGGCCA
CCGCGCTGCGGCCAG
CGCGCTGCGGCCAGG
GCGCTGCGGCCAGGG
CGCTGCGGCCAGGGG
GCTGCGGCCAGGGGC
CTGCGGCCAGGGGCT
TGCGGCCAGGGGCTG

GCGGCCAGGGGCTGC
CGGCCAGGGGCTGCG
GGCCAGGGGCTGCGC
GCCAGGGGCTGCGCT
CCAGGGGCTGCGCTG
CAGGGGCTGCGCTGC
AGGGGCTGCGCTGCT
GGGGCTGCGCTGCTA
GGGCTGCGCTGCTAT
GGCTGCGCTGCTATC
GCTGCGCTGCTATCC
CTGCGCTGCTATCCC
TGCGCTGCTATCCCC
GCGCTGCTATCCCCA
CGCTGCTATCCCCAC
GCTGCTATCCCCACC
CTGCTATCCCCACCC
TGCTATCCCCACCCG
GCTATCCCCACCCGG
CTATCCCCACCCGGG
TATCCCCACCCGGGC
ATCCCCACCCGGGCT
TCCCCACCCGGGCTC
CCCCACCCGGGCTCC
CCCACCCGGGCTCCG
CCACCCGGGCTCCGA
CACCCGGGCTCCGAG
ACCCGGGCTCCGAGC
CCCGGGCTCCGAGCT
CCGGGCTCCGAGCTG
CGGGCTCCGAGCTGC
GGGCTCCGAGCTGCC
GGCTCCGAGCTGCCC
GCTCCGAGCTGCCCC
CTCCGAGCTGCCCCT
TCCGAGCTGCCCCTG
CCGAGCTGCCCCTGC
CGAGCTGCCCCTGCA
GAGCTGCCCCTGCAG
AGCTGCCCCTGCAGG
GCTGCCCCTGCAGGC
CTGCCCCTGCAGGCG
TGCCCCTGCAGGCGC
GCCCCTGCAGGCGCT

	CCCCTGCAGGCGCTG	CCGGGACGCCGAGTA	ATGGCGATGACCACT
	CCCTGCAGGCGCTGG	CGGGACGCCGAGTAT	TGGCGATGACCACTC
	CCTGCAGGCGCTGGT	GGGACGCCGAGTATG	GGCGATGACCACTCA
	CTGCAGGCGCTGGTC	GGACGCCGAGTATGG	GCGATGACCACTCAG
5	TGCAGGCGCTGGTCA	GACGCCGAGTATGGC	CGATGACCACTCAGA
	GCAGGCGCTGGTCAT	ACGCCGAGTATGGCG	GATGACCACTCAGAA
	CAGGCGCTGGTCATG	CGCCGAGTATGGCGC	ATGACCACTCAGAAG
	AGGCGCTGGTCATGG	GCCGAGTATGGCGCC	TGACCACTCAGAAGG
	GGCGCTGGTCATGGG	CCGAGTATGGCGCCA	GACCACTCAGAAGGA
10	GCGCTGGTCATGGGC	CGAGTATGGCGCCAG	ACCACTCAGAAGGAG
	CGCTGGTCATGGGCG	GAGTATGGCGCCAGC	CCACTCAGAAGGAGG
	GCTGGTCATGGGCGA	AGTATGGCGCCAGCC	CACTCAGAAGGAGGC
	CTGGTCATGGGCGAG	GTATGGCGCCAGCCC	ACTCAGAAGGAGGCC
	TGGTCATGGGCGAGG	TATGGCGCCAGCCCG	CTCAGAAGGAGGCCT
15	GGTCATGGGCGAGGG	ATGGCGCCAGCCCGG	TCAGAAGGAGGCCTG
	GTCATGGGCGAGGGC	TGGCGCCAGCCCGGA	CAGAAGGAGGCCTGG
	TCATGGGCGAGGGCA	GGCGCCAGCCCGGAG	AGAAGGAGGCCTGGT
	CATGGGCGAGGGCAC	GCGCCAGCCCGGAGC	GAAGGAGGCCTGGTG
	ATGGGCGAGGGCACT	CGCCAGCCCGGAGCA	AAGGAGGCCTGGTGG
20	TGGGCGAGGGCACTT	GCCAGCCCGGAGCAG	AGGAGGCCTGGTGGA
	GGGCGAGGGCACTTG	CCAGCCCGGAGCAGG	GGAGGCCTGGTGGAG
	GCGAGGGCACTTGTG	AGCCCGGAGCAGGTT	AGGCCTGGTGGAGAA
	CGAGGGCACTTGTGA	GCCCGGAGCAGGTTG	GGCCTGGTGGAGAAC
25	GAGGGCACTTGTGAG	CCCGGAGCAGGTTGC	GCCTGGTGGAGAACC
	AGGGCACTTGTGAGA	CCGGAGCAGGTTGCA	CCTGGTGGAGAACCA
	GGGCACTTGTGAGAA	CGGAGCAGGTTGCAG	CTGGTGGAGAACCAC
	GGCACTTGTGAGAAG	GGAGCAGGTTGCAGA	TGGTGGAGAACCACG
	GCACTTGTGAGAAGC	GAGCAGGTTGCAGAC	GGTGGAGAACCACGT
30	CACTTGTGAGAAGCG	AGCAGGTTGCAGACA	GTGGAGAACCACGTG
	ACTTGTGAGAAGCGC	GCAGGTTGCAGACAA	TGGAGAACCACGTGG
	CTTGTGAGAAGCGCC	CAGGTTGCAGACAAT	GGAGAACCACGTGGA
	TTGTGAGAAGCGCCG	AGGTTGCAGACAATG	GAGAACCACGTGGAC
	TGTGAGAAGCGCCGG	GGTTGCAGACAATGG	AGAACCACGTGGACA
35	GTGAGAAGCGCCGGG	GTTGCAGACAATGGC	GAACCACGTGGACAG
	TGAGAAGCGCCGGGA	TTGCAGACAATGGCG	AACCACGTGGACAGC
	GAGAAGCGCCGGGAC	TGCAGACAATGGCGA	ACCACGTGGACAGCA
	AGAAGCGCCGGGACG	GCAGACAATGGCGAT	CCACGTGGACAGCAC
	GAAGCGCCGGGACGC	CAGACAATGGCGATG	CACGTGGACAGCACC
40	AAGCGCCGGGACGCC	AGACAATGGCGATGA	ACGTGGACAGCACCA
	AGCGCCGGGACGCCG	GACAATGGCGATGAC	CGTGGACAGCACCAT
	GCGCCGGGACGCCGA	ACAATGGCGATGACC	GTGGACAGCACCATG
	CGCCGGGACGCCGAG	CAATGGCGATGACCA	TGGACAGCACCATGA
	GCCGGGACGCCGAGT	AATGGCGATGACCAC	GGACAGCACCATGAA

	GACAGCACCATGAAC	GAAGCCCCTCAAGTC	AGAAGGTCACTGAGC
	ACAGCACCATGAACA	AAGCCCCTCAAGTCG	GAAGGTCACTGAGCA
	CAGCACCATGAACAT	AGCCCCTCAAGTCGG	AAGGTCACTGAGCAG
	AGCACCATGAACATG	GCCCCTCAAGTCGGG	AGGTCACTGAGCAGC
5	GCACCATGAACATGT	CCCCTCAAGTCGGGT	GGTCACTGAGCAGCA
	CACCATGAACATGTT	CCCTCAAGTCGGGTA	GTCACTGAGCAGCAC
	ACCATGAACATGTTG	CCTCAAGTCGGGTAT	TCACTGAGCAGCACC
	CCATGAACATGTTGG	CTCAAGTCGGGTATG	CACTGAGCAGCACCG
	CATGAACATGTTGGG	TCAAGTCGGGTATGA	ACTGAGCAGCACCGG
10	ATGAACATGTTGGGC	CAAGTCGGGTATGAA	CTGAGCAGCACCGGC
	TGAACATGTTGGGCG	AAGTCGGGTATGAAG	TGAGCAGCACCGGCA
	GAACATGTTGGGCGG	AGTCGGGTATGAAGG	GAGCAGCACCGGCAG
	AACATGTTGGGCGGG	GTCGGGTATGAAGGA	AGCAGCACCGGCAGA
	ACATGTTGGGCGGGG	TCGGGTATGAAGGAG	GCAGCACCGGCAGAT
15	CATGTTGGGCGGGGG	CGGGTATGAAGGAGC	CAGCACCGGCAGATG
	ATGTTGGGCGGGGGA	GGGTATGAAGGAGCT	AGCACCGGCAGATGG
	TGTTGGGCGGGGGAG	GGTATGAAGGAGCTG	GCACCGGCAGATGGG
	GTTGGGCGGGGGAGG	GTATGAAGGAGCTGG	CACCGGCAGATGGGC
	TTGGGCGGGGGAGGC	TATGAAGGAGCTGGC	ACCGGCAGATGGGCA
20	TGGGCGGGGGAGGCA	ATGAAGGAGCTGGCC	CCGGCAGATGGGCAA
	GGGCGGGGGAGGCAG	TGAAGGAGCTGGCCG	CGGCAGATGGGCAAG
	GGCGGGGGAGGCAGT	GAAGGAGCTGGCCGT	GGCAGATGGGCAAGG
	GCGGGGGAGGCAGTG	AAGGAGCTGGCCGTG	GCAGATGGGCAAGGG
	CGGGGGAGGCAGTGC	AGGAGCTGGCCGTGT	CAGATGGGCAAGGGT
25	GGGGGAGGCAGTGCT	GGAGCTGGCCGTGTT	AGATGGGCAAGGGTG
	GGGGAGGCAGTGCTG	GAGCTGGCCGTGTTC	GATGGGCAAGGGTGG
	GGGAGGCAGTGCTGG	AGCTGGCCGTGTTCC	ATGGGCAAGGGTGGC
	GGAGGCAGTGCTGGC	GCTGGCCGTGTTCCG	TGGGCAAGGGTGGCA
	GAGGCAGTGCTGGCC	CTGGCCGTGTTCCGG	GGGCAAGGGTGGCAA
30	AGGCAGTGCTGGCCG	TGGCCGTGTTCCGGG	GGCAAGGGTGGCAAG
	GGCAGTGCTGGCCGG	GGCCGTGTTCCGGGA	GCAAGGGTGGCAAGC
	GCAGTGCTGGCCGGA	GCCGTGTTCCGGGAG	CAAGGGTGGCAAGCA
	CAGTGCTGGCCGGAA	CCGTGTTCCGGGAGA	AAGGGTGGCAAGCAT
	AGTGCTGGCCGGAAG	CGTGTTCCGGGAGAA	AGGGTGGCAAGCATC
35	GTGCTGGCCGGAAGC	GTGTTCCGGGAGAAG	GGGTGGCAAGCATCA
	TGCTGGCCGGAAGCC	TGTTCCGGGAGAAGG	GGTGGCAAGCATCAC
	GCTGGCCGGAAGCCC	GTTCCGGGAGAAGGT	GTGGCAAGCATCACC
	CTGGCCGGAAGCCCC	TTCCGGGAGAAGGTC	TGGCAAGCATCACCT
	TGGCCGGAAGCCCCT	TCCGGGAGAAGGTCA	GGCAAGCATCACCTT
40	GGCCGGAAGCCCCTC	CCGGGAGAAGGTCAC	GCAAGCATCACCTTG
	GCCGGAAGCCCCTCA	CGGGAGAAGGTCACT	CAAGCATCACCTTGG
	CCGGAAGCCCCTCAA	GGGAGAAGGTCACTG	AAGCATCACCTTGGC
	CGGAAGCCCCTCAAG	GGAGAAGGTCACTGA	AGCATCACCTTGGCC
	GGAAGCCCCTCAAGT	GAGAAGGTCACTGAG	GCATCACCTTGGCCT

CATCACCTTGGCCTG
ATCACCTTGGCCTGG
TCACCTTGGCCTGGA
CACCTTGGCCTGGAG
ACCTTGGCCTGGAGG
CCTTGGCCTGGAGGA
CTTGGCCTGGAGGAG
TTGGCCTGGAGGAGC
TGGCCTGGAGGAGCC
GGCCTGGAGGAGCCC
GCCTGGAGGAGCCCA
CCTGGAGGAGCCCAA
CTGGAGGAGCCCAAG
TGGAGGAGCCCAAGA
GGAGGAGCCCAAGAA
GAGGAGCCCAAGAAG
AGGAGCCCAAGAAGC
GGAGCCCAAGAAGCT
GAGCCCAAGAAGCTG
AGCCCAAGAAGCTGC
GCCCAAGAAGCTGCG
CCCAAGAAGCTGCGA
CCAAGAAGCTGCGAC
CAAGAAGCTGCGACC
AAGAAGCTGCGACCA
AGAAGCTGCGACCAC
GAAGCTGCGACCACC
AAGCTGCGACCACCC
AGCTGCGACCACCCC
GCTGCGACCACCCCC
CTGCGACCACCCCCT
TGCGACCACCCCCTG
GCGACCACCCCCTGC
CGACCACCCCCTGCC
GACCACCCCCTGCCA
ACCACCCCCTGCCAG
CCACCCCCTGCCAGG
CACCCCCTGCCAGGA
ACCCCCTGCCAGGAC
CCCCCTGCCAGGACT
CCCCTGCCAGGACTC
CCCTGCCAGGACTCC
CCTGCCAGGACTCCC
CTGCCAGGACTCCCT

TGCCAGGACTCCCTG
GCCAGGACTCCCTGC
CCAGGACTCCCTGCC
CAGGACTCCCTGCCA
AGGACTCCCTGCCAA
GGACTCCCTGCCAAC
GACTCCCTGCCAACA
ACTCCCTGCCAACAG
CTCCCTGCCAACAGG
TCCCTGCCAACAGGA
CCCTGCCAACAGGAA
CCTGCCAACAGGAAC
CTGCCAACAGGAACT
TGCCAACAGGAACTG
GCCAACAGGAACTGG
CCAACAGGAACTGGA
CAACAGGAACTGGAC
AACAGGAACTGGACC
ACAGGAACTGGACCA
CAGGAACTGGACCAG
AGGAACTGGACCAGG
GGAACTGGACCAGGT
GAACTGGACCAGGTC
AACTGGACCAGGTCC
ACTGGACCAGGTCCT
CTGGACCAGGTCCTG
TGGACCAGGTCCTGG
GGACCAGGTCCTGGA
GACCAGGTCCTGGAG
ACCAGGTCCTGGAGC
CCAGGTCCTGGAGCG
CAGGTCCTGGAGCGG
AGGTCCTGGAGCGGA
GGTCCTGGAGCGGAT
GTCCTGGAGCGGATC
TCCTGGAGCGGATCT
CCTGGAGCGGATCTC
CTGGAGCGGATCTCC
TGGAGCGGATCTCCA
GGAGCGGATCTCCAC
GAGCGGATCTCCACC
AGCGGATCTCCACCA
GCGGATCTCCACCAT
CGGATCTCCACCATG

GGATCTCCACCATGC
GATCTCCACCATGCG
ATCTCCACCATGCGC
TCTCCACCATGCGCC
CTCCACCATGCGCCT
TCCACCATGCGCCTT
CCACCATGCGCCTTC
CACCATGCGCCTTCC
ACCATGCGCCTTCCG
CCATGCGCCTTCCGG
CATGCGCCTTCCGGA
ATGCGCCTTCCGGAT
TGCGCCTTCCGGATG
GCGCCTTCCGGATGA
CGCCTTCCGGATGAG
GCCTTCCGGATGAGC
CCTTCCGGATGAGCG
CTTCCGGATGAGCGG
TTCCGGATGAGCGGG
TCCGGATGAGCGGGG
CCGGATGAGCGGGGC
CGGATGAGCGGGGCC
GGATGAGCGGGGCCC
GATGAGCGGGGCCCT
ATGAGCGGGGCCCTC
TGAGCGGGGCCCTCT
GAGCGGGGCCCTCTG
AGCGGGGCCCTCTGG
GCGGGGCCCTCTGGA
CGGGGCCCTCTGGAG
GGGGCCCTCTGGAGC
GGGCCCTCTGGAGCA
GGCCCTCTGGAGCAC
GCCCTCTGGAGCACC
CCCTCTGGAGCACCT
CCTCTGGAGCACCTC
CTCTGGAGCACCTCT
TCTGGAGCACCTCTA
CTGGAGCACCTCTAC
TGGAGCACCTCTACT
GGAGCACCTCTACTC
GAGCACCTCTACTCC
AGCACCTCTACTCCC
GCACCTCTACTCCCT

	CACCTCTACTCCCTG	GTACAACCTCAAACA	GGGAGTGCTGGTGTG
	ACCTCTACTCCCTGC	TACAACCTCAAACAG	GGAGTGCTGGTGTGT
	CCTCTACTCCCTGCA	ACAACCTCAAACAGT	GAGTGCTGGTGTGTG
	CTCTACTCCCTGCAC	CAACCTCAAACAGTG	AGTGCTGGTGTGTGA
5	TCTACTCCCTGCACA	AACCTCAAACAGTGC	GTGCTGGTGTGTGAA
	CTACTCCCTGCACAT	ACCTCAAACAGTGCA	TGCTGGTGTGTGAAC
	TACTCCCTGCACATC	CCTCAAACAGTGCAA	GCTGGTGTGTGAACC
	ACTCCCTGCACATCC	CTCAAACAGTGCAAG	CTGGTGTGTGAACCC
	CTCCCTGCACATCCC	TCAAACAGTGCAAGA	TGGTGTGTGAACCCC
10	TCCCTGCACATCCCC	CAAACAGTGCAAGAT	GGTGTGTGAACCCCA
	CCCTGCACATCCCCA	AAACAGTGCAAGATG	GTGTGTGAACCCCAA
	CCTGCACATCCCCAA	AACAGTGCAAGATGT	TGTGTGAACCCCAAC
	CTGCACATCCCCAAC	ACAGTGCAAGATGTC	GTGTGAACCCCAACA
	TGCACATCCCCAACT	CAGTGCAAGATGTCT	TGTGAACCCCAACAC
15	GCACATCCCCAACTG	AGTGCAAGATGTCTC	GTGAACCCCAACACC
	CACATCCCCAACTGT	GTGCAAGATGTCTCT	TGAACCCCAACACCG
	ACATCCCCAACTGTG	TGCAAGATGTCTCTG	GAACCCCAACACCGG
	CATCCCCAACTGTGA	GCAAGATGTCTCTGA	AACCCCAACACCGGG
	ATCCCCAACTGTGAC	CAAGATGTCTCTGAA	ACCCCAACACCGGGA
20	TCCCCAACTGTGACA	AAGATGTCTCTGAAC	CCCCAACACCGGGAA
	CCCCAACTGTGACAA	AGATGTCTCTGAACG	CCCAACACCGGGAAG
	CCCAACTGTGACAAG	GATGTCTCTGAACGG	CCAACACCGGGAAGC
	CCAACTGTGACAAGC	ATGTCTCTGAACGGG	CAACACCGGGAAGCT
	CAACTGTGACAAGCA	TGTCTCTGAACGGGC	AACACCGGGAAGCTG
25	AACTGTGACAAGCAT	GTCTCTGAACGGGCA	ACACCGGGAAGCTGA
	ACTGTGACAAGCATG	TCTCTGAACGGGCAG	CACCGGGAAGCTGAT
	CTGTGACAAGCATGG	CTCTGAACGGGCAGC	ACCGGGAAGCTGATC
	TGTGACAAGCATGGC	TCTGAACGGGCAGCG	CCGGGAAGCTGATCC
	GTGACAAGCATGGCC	CTGAACGGGCAGCGT	CGGGAAGCTGATCCA
30	TGACAAGCATGGCCT	TGAACGGGCAGCGTG	GGGAAGCTGATCCAG
	GACAAGCATGGCCTG	GAACGGGCAGCGTGG	GGAAGCTGATCCAGG
	ACAAGCATGGCCTGT	AACGGGCAGCGTGGG	GAAGCTGATCCAGGG
	CAAGCATGGCCTGTA	ACGGGCAGCGTGGGG	AAGCTGATCCAGGGA
	AAGCATGGCCTGTAC	CGGGCAGCGTGGGGA	AGCTGATCCAGGGAG
35	AGCATGGCCTGTACA	GGGCAGCGTGGGGAG	GCTGATCCAGGGAGC
	GCATGGCCTGTACAA	GGCAGCGTGGGGAGT	CTGATCCAGGGAGCC
	CATGGCCTGTACAAC	GCAGCGTGGGGAGTG	TGATCCAGGGAGCCC
	ATGGCCTGTACAACC	CAGCGTGGGGAGTGC	GATCCAGGGAGCCCC
	TGGCCTGTACAACCT	AGCGTGGGGAGTGCT	ATCCAGGGAGCCCCC
40	GGCCTGTACAACCTC	GCGTGGGGAGTGCTG	TCCAGGGAGCCCCCA
	GCCTGTACAACCTCA	CGTGGGGAGTGCTGG	CCAGGGAGCCCCCAC
	CCTGTACAACCTCAA	GTGGGGAGTGCTGGT	CAGGGAGCCCCCACC
	CTGTACAACCTCAAA	TGGGGAGTGCTGGTG	AGGGAGCCCCCACCA
	TGTACAACCTCAAAC	GGGGAGTGCTGGTGT	GGGAGCCCCCACCAT

GGAGCCCCCACCATC
GAGCCCCCACCATCC
AGCCCCCACCATCCG
GCCCCCACCATCCGG
CCCCCACCATCCGGG
CCCCACCATCCGGGG
CCCACCATCCGGGGG
CCACCATCCGGGGGG
CACCATCCGGGGGGA
ACCATCCGGGGGGAC
CCATCCGGGGGGACC
CATCCGGGGGGACCC
ATCCGGGGGGACCCC
TCCGGGGGGACCCCG
CCGGGGGGACCCCGA
CGGGGGGACCCCGAG
GGGGGGACCCCGAGT
GGGGGACCCCGAGTG
GGGGACCCCGAGTGT
GGGACCCCGAGTGTC
GGACCCCGAGTGTCA
GACCCCGAGTGTCAT
ACCCCGAGTGTCATC
CCCCGAGTGTCATCT
CCCGAGTGTCATCTC
CCGAGTGTCATCTCT
CGAGTGTCATCTCTT
GAGTGTCATCTCTTC
AGTGTCATCTCTTCT
GTGTCATCTCTTCTA
TGTCATCTCTTCTAC
GTCATCTCTTCTACA
TCATCTCTTCTACAA
CATCTCTTCTACAAT
ATCTCTTCTACAATG
TCTCTTCTACAATGA
CTCTTCTACAATGAG
TCTTCTACAATGAGC
CTTCTACAATGAGCA
TTCTACAATGAGCAG
TCTACAATGAGCAGC
CTACAATGAGCAGCA
TACAATGAGCAGCAG
ACAATGAGCAGCAGG

CAATGAGCAGCAGGA
AATGAGCAGCAGGAG
ATGAGCAGCAGGAGG
TGAGCAGCAGGAGGC
GAGCAGCAGGAGGCT
AGCAGCAGGAGGCTT
GCAGCAGGAGGCTTG
CAGCAGGAGGCTTGC
AGCAGGAGGCTTGCG
GCAGGAGGCTTGCGG
CAGGAGGCTTGCGGG
AGGAGGCTTGCGGGG
GGAGGCTTGCGGGGT
GAGGCTTGCGGGGTG
AGGCTTGCGGGGTGC
GGCTTGCGGGGTGCA
GCTTGCGGGGTGCAC
CTTGCGGGGTGCACA
TTGCGGGGTGCACAC
TGCGGGGTGCACACC
GCGGGGTGCACACCC
CGGGGTGCACACCCA
GGGGTGCACACCCAG
GGGTGCACACCCAGC
GGTGCACACCCAGCG
GTGCACACCCAGCGG
TGCACACCCAGCGGA
GCACACCCAGCGGAT
CACACCCAGCGGATG
ACACCCAGCGGATGC
CACCCAGCGGATGCA
ACCCAGCGGATGCAG
CCCAGCGGATGCAGT
CCAGCGGATGCAGTA
CAGCGGATGCAGTAG
AGCGGATGCAGTAGA
GCGGATGCAGTAGAC
CGGATGCAGTAGACC
GGATGCAGTAGACCG
GATGCAGTAGACCGC
ATGCAGTAGACCGCA
TGCAGTAGACCGCAG
GCAGTAGACCGCAGC
CAGTAGACCGCAGCC

AGTAGACCGCAGCCA
GTAGACCGCAGCCAG
TAGACCGCAGCCAGC
AGACCGCAGCCAGCC
GACCGCAGCCAGCCG
ACCGCAGCCAGCCGG
CCGCAGCCAGCCGGT
CGCAGCCAGCCGGTG
GCAGCCAGCCGGTGC
CAGCCAGCCGGTGCC
AGCCAGCCGGTGCCT
GCCAGCCGGTGCCTG
CCAGCCGGTGCCTGG
CAGCCGGTGCCTGGC
AGCCGGTGCCTGGCG
GCCGGTGCCTGGCGC
CCGGTGCCTGGCGCC
CGGTGCCTGGCGCCC
GGTGCCTGGCGCCCC
GTGCCTGGCGCCCCT
TGCCTGGCGCCCCTG
GCCTGGCGCCCCTGC
CCTGGCGCCCCTGCC
CTGGCGCCCCTGCCC
TGGCGCCCCTGCCCC
GGCGCCCCTGCCCCC
GCGCCCCTGCCCCCC
CGCCCCTGCCCCCCG
GCCCCTGCCCCCCGC
CCCCTGCCCCCCGCC
CCCTGCCCCCCGCCC
CCTGCCCCCCGCCCC
CTGCCCCCCGCCCCT
TGCCCCCCGCCCCTC
GCCCCCCGCCCCTCT
CCCCCCGCCCCTCTC
CCCCCGCCCCTCTCC
CCCCGCCCCTCTCCA
CCCGCCCCTCTCCAA
CCGCCCCTCTCCAAA
CGCCCCTCTCCAAAC
GCCCCTCTCCAAACA
CCCCTCTCCAAACAC
CCCTCTCCAAACACC

	CCTCTCCAAACACCG	GTGCTGGAGGATTTT	AAAGAGACCAGCACC
	CTCTCCAAACACCGG	TGCTGGAGGATTTTC	AAGAGACCAGCACCG
	TCTCCAAACACCGGC	GCTGGAGGATTTTCC	AGAGACCAGCACCGA
	CTCCAAACACCGGCA	CTGGAGGATTTTCCA	GAGACCAGCACCGAG
5	TCCAAACACCGGCAG	TGGAGGATTTTCCAG	AGACCAGCACCGAGC
	CCAAACACCGGCAGA	GGAGGATTTTCCAGT	GACCAGCACCGAGCT
	CAAACACCGGCAGAA	GAGGATTTTCCAGTT	ACCAGCACCGAGCTC
	AAACACCGGCAGAAA	AGGATTTTCCAGTTC	CCAGCACCGAGCTCG
	AACACCGGCAGAAAA	GGATTTTCCAGTTCT	CAGCACCGAGCTCGG
10	ACACCGGCAGAAAAC	GATTTTCCAGTTCTG	AGCACCGAGCTCGGC
	CACCGGCAGAAAACG	ATTTTCCAGTTCTGA	GCACCGAGCTCGGCA
	ACCGGCAGAAAACGG	TTTTCCAGTTCTGAC	CACCGAGCTCGGCAC
	CCGGCAGAAAACGGA	TTTCCAGTTCTGACA	ACCGAGCTCGGCACC
	CGGCAGAAAACGGAG	TTCCAGTTCTGACAC	CCGAGCTCGGCACCT
15	GGCAGAAAACGGAGA	TCCAGTTCTGACACA	CGAGCTCGGCACCTC
	GCAGAAAACGGAGAG	CCAGTTCTGACACAC	GAGCTCGGCACCTCC
	CAGAAAACGGAGAGT	CAGTTCTGACACACG	AGCTCGGCACCTCCC
	AGAAAACGGAGAGTG	AGTTCTGACACACGT	GCTCGGCACCTCCCC
	GAAAACGGAGAGTGC	GTTCTGACACACGTA	CTCGGCACCTCCCCG
20	AAAACGGAGAGTGCT	TTCTGACACACGTAT	TCGGCACCTCCCCGG
	AAACGGAGAGTGCTT	TCTGACACACGTATT	CGGCACCTCCCCGGC
	AACGGAGAGTGCTTG	CTGACACACGTATTT	GGCACCTCCCCGGCC
	ACGGAGAGTGCTTGG	TGACACACGTATTTA	GCACCTCCCCGGCCT
	CGGAGAGTGCTTGGG	GACACACGTATTTAT	CACCTCCCCGGCCTC
25	GGAGAGTGCTTGGGT	ACACACGTATTTATA	ACCTCCCCGGCCTCT
	GAGAGTGCTTGGGTG	CACACGTATTTATAT	CCTCCCCGGCCTCTC
	AGAGTGCTTGGGTGG	ACACGTATTTATATT	CTCCCCGGCCTCTCT
	GAGTGCTTGGGTGGT	CACGTATTTATATTT	TCCCCGGCCTCTCTC
	AGTGCTTGGGTGGTG	ACGTATTTATATTTG	CCCCGGCCTCTCTCT
30	GTGCTTGGGTGGTGG	CGTATTTATATTTGG	CCCGGCCTCTCTCTT
	TGCTTGGGTGGTGGG	GTATTTATATTTGGA	CCGGCCTCTCTCTTC
	GCTTGGGTGGTGGGT	TATTTATATTTGGAA	CGGCCTCTCTCTTCC
	CTTGGGTGGTGGGTG	ATTTATATTTGGAAA	GGCCTCTCTCTTCCC
	TTGGGTGGTGGGTGC	TTTATATTTGGAAAG	GCCTCTCTCTTCCCA
35	TGGGTGGTGGGTGCT	TTATATTTGGAAAGA	CCTCTCTCTTCCCAG
	GGGTGGTGGGTGCTG	TATATTTGGAAAGAG	CTCTCTCTTCCCAGC
	GGTGGTGGGTGCTGG	ATATTTGGAAAGAGA	TCTCTCTTCCCAGCT
	GTGGTGGGTGCTGGA	TATTTGGAAAGAGAC	CTCTCTTCCCAGCTG
	TGGTGGGTGCTGGAG	ATTTGGAAAGAGACC	TCTCTTCCCAGCTGC
40	GGTGGGTGCTGGAGG	TTTGGAAAGAGACCA	CTCTTCCCAGCTGCA
	GTGGGTGCTGGAGGA	TTGGAAAGAGACCAG	TCTTCCCAGCTGCAG
	TGGGTGCTGGAGGAT	TGGAAAGAGACCAGC	CTTCCCAGCTGCAGA
	GGGTGCTGGAGGATT	GGAAAGAGACCAGCA	TTCCCAGCTGCAGAT
	GGTGCTGGAGGATTT	GAAAGAGACCAGCAC	TCCCAGCTGCAGATG

CCCAGCTGCAGATGC
CCAGCTGCAGATGCC
CAGCTGCAGATGCCA
AGCTGCAGATGCCAC
GCTGCAGATGCCACA
CTGCAGATGCCACAC
TGCAGATGCCACACC
GCAGATGCCACACCT
CAGATGCCACACCTG
AGATGCCACACCTGC
GATGCCACACCTGCT
ATGCCACACCTGCTC
TGCCACACCTGCTCC
GCCACACCTGCTCCT
CCACACCTGCTCCTT
CACACCTGCTCCTTC
ACACCTGCTCCTTCT
CACCTGCTCCTTCTT
ACCTGCTCCTTCTTG
CCTGCTCCTTCTTGC
CTGCTCCTTCTTGCT
TGCTCCTTCTTGCTT
GCTCCTTCTTGCTTT
CTCCTTCTTGCTTTC
TCCTTCTTGCTTTCC
CCTTCTTGCTTTCCC
CTTCTTGCTTTCCCC
TTCTTGCTTTCCCCG
TCTTGCTTTCCCCGG
CTTGCTTTCCCCGGG
TTGCTTTCCCCGGGG
TGCTTTCCCCGGGGG
GCTTTCCCCGGGGGA
CTTTCCCCGGGGGAG
TTTCCCCGGGGGAGG
TTCCCCGGGGGAGGA
TCCCCGGGGGAGGAA
CCCCGGGGGAGGAAG
CCCGGGGGAGGAAGG
CCGGGGGAGGAAGGG
CGGGGGAGGAAGGGG
GGGGGAGGAAGGGGG
GGGGAGGAAGGGGGT
GGGAGGAAGGGGGTT

GGAGGAAGGGGGTTG
GAGGAAGGGGGTTGT
AGGAAGGGGGTTGTG
GGAAGGGGGTTGTGG
GAAGGGGGTTGTGGT
AAGGGGGTTGTGGTC
AGGGGGTTGTGGTCG
GGGGGTTGTGGTCGG
GGGGTTGTGGTCGGG
GGGTTGTGGTCGGGG
GGTTGTGGTCGGGGA
GTTGTGGTCGGGGAG
TTGTGGTCGGGGAGC
TGTGGTCGGGGAGCT
GTGGTCGGGGAGCTG
TGGTCGGGGAGCTGG
GGTCGGGGAGCTGGG
GTCGGGGAGCTGGGG
TCGGGGAGCTGGGGT
CGGGGAGCTGGGGTA
GGGGAGCTGGGGTAC
GGGAGCTGGGGTACA
GGAGCTGGGGTACAG
GAGCTGGGGTACAGG
AGCTGGGGTACAGGT
GCTGGGGTACAGGTT
CTGGGGTACAGGTTT
TGGGGTACAGGTTTG
GGGGTACAGGTTTGG
GGGTACAGGTTTGGG
GGTACAGGTTTGGGG
GTACAGGTTTGGGGA
TACAGGTTTGGGGAG
ACAGGTTTGGGGAGG
CAGGTTTGGGGAGGG
AGGTTTGGGGAGGGG
GGTTTGGGGAGGGGG
GTTTGGGGAGGGGGA
TTTGGGGAGGGGGAA
TTGGGGAGGGGGAAG
TGGGGAGGGGGAAGA
GGGGAGGGGGAAGAG
GGGAGGGGGAAGAGA
GGAGGGGGAAGAGAA

GAGGGGGAAGAGAAA
AGGGGGAAGAGAAAT
GGGGGAAGAGAAATT
GGGGAAGAGAAATTT
GGGAAGAGAAATTTT
GGAAGAGAAATTTTT
GAAGAGAAATTTTTA
AAGAGAAATTTTTAT
AGAGAAATTTTTATT
GAGAAATTTTTATTT
AGAAATTTTTATTTT
GAAATTTTTATTTTT
AAATTTTTATTTTTG
AATTTTTATTTTTGA
ATTTTTATTTTTGAA
TTTTTATTTTTGAAC
TTTTATTTTTGAACC
TTTATTTTTGAACCC
TTATTTTTGAACCCC
TATTTTTGAACCCCT
ATTTTTGAACCCCTG
TTTTTGAACCCCTGT
TTTTGAACCCCTGTG
TTTGAACCCCTGTGT
TTGAACCCCTGTGTC
TGAACCCCTGTGTCC
GAACCCCTGTGTCCC
AACCCCTGTGTCCCT
ACCCCTGTGTCCCTT
CCCCTGTGTCCCTTT
CCCTGTGTCCCTTTT
CCTGTGTCCCTTTTG
CTGTGTCCCTTTTGC
TGTGTCCCTTTTGCA
GTGTCCCTTTTGCAT
TGTCCCTTTTGCATA
GTCCCTTTTGCATAA
TCCCTTTTGCATAAG
CCCTTTTGCATAAGA
CCTTTTGCATAAGAT
CTTTTGCATAAGATT
TTTTGCATAAGATTA
TTTGCATAAGATTAA
TTGCATAAGATTAAA

TGCATAAGATTAAAG
GCATAAGATTAAAGG
CATAAGATTAAAGGA
ATAAGATTAAAGGAA
TAAGATTAAAGGAAG
AAGATTAAAGGAAGG
AGATTAAAGGAAGGA
GATTAAAGGAAGGAA
ATTAAAGGAAGGAAA
TTAAAGGAAGGAAAA
TAAAGGAAGGAAAAG
AAAGGAAGGAAAAGT

EXAMPLE 7

Antisense oligonucleotides to IGFBP3 may be selected from molecules capable of interacting with one or more of the following sense oligonucleotides:

CTCAGCGCCCAGCCG	TGGATTCCACAGCTT	TACTGTCGCCCCATC
TCAGCGCCCAGCCGC	GGATTCCACAGCTTC	ACTGTCGCCCCATCC
CAGCGCCCAGCCGCT	GATTCCACAGCTTCG	CTGTCGCCCCATCCC
AGCGCCCAGCCGCTT	ATTCCACAGCTTCGC	TGTCGCCCCATCCCT
GCGCCCAGCCGCTTC	TTCCACAGCTTCGCG	GTCGCCCCATCCCTG
CGCCCAGCCGCTTCC	TCCACAGCTTCGCGC	TCGCCCCATCCCTGC
GCCCAGCCGCTTCCT	CCACAGCTTCGCGCC	CGCCCCATCCCTGCG
CCCAGCCGCTTCCTG	CACAGCTTCGCGCCG	GCCCCATCCCTGCGC
CCAGCCGCTTCCTGC	ACAGCTTCGCGCCGT	CCCCATCCCTGCGCG
CAGCCGCTTCCTGCC	CAGCTTCGCGCCGTG	CCCATCCCTGCGCGC
AGCCGCTTCCTGCCT	AGCTTCGCGCCGTGT	CCATCCCTGCGCGCC
GCCGCTTCCTGCCTG	GCTTCGCGCCGTGTA	CATCCCTGCGCGCCC
CCGCTTCCTGCCTGG	CTTCGCGCCGTGTAC	ATCCCTGCGCGCCCA
CGCTTCCTGCCTGGA	TTCGCGCCGTGTACT	TCCCTGCGCGCCCAG
GCTTCCTGCCTGGAT	TCGCGCCGTGTACTG	CCCTGCGCGCCCAGC
CTTCCTGCCTGGATT	CGCGCCGTGTACTGT	CCTGCGCGCCCAGCC
TTCCTGCCTGGATTC	GCGCCGTGTACTGTC	CTGCGCGCCCAGCCT
TCCTGCCTGGATTCC	CGCCGTGTACTGTCG	TGCGCGCCCAGCCTG
CCTGCCTGGATTCCA	GCCGTGTACTGTCGC	GCGCGCCCAGCCTGC
CTGCCTGGATTCCAC	CCGTGTACTGTCGCC	CGCGCCCAGCCTGCC
TGCCTGGATTCCACA	CGTGTACTGTCGCCC	GCGCCCAGCCTGCCA
GCCTGGATTCCACAG	GTGTACTGTCGCCCC	CGCCCAGCCTGCCAA
CCTGGATTCCACAGC	TGTACTGTCGCCCCA	GCCCAGCCTGCCAAG
CTGGATTCCACAGCT	GTACTGTCGCCCCAT	CCCAGCCTGCCAAGC

	CCAGCCTGCCAAGCA	GGGCGCGACCCACGC	CTGCTCCGCGGGCCG
	CAGCCTGCCAAGCAG	GGCGCGACCCACGCT	TGCTCCGCGGGCCGC
	AGCCTGCCAAGCAGC	GCGCGACCCACGCTC	GCTCCGCGGGCCGCC
	GCCTGCCAAGCAGCG	CGCGACCCACGCTCT	CTCCGCGGGCCGCCG
5	CCTGCCAAGCAGCGT	GCGACCCACGCTCTG	TCCGCGGGCCGCCGG
	CTGCCAAGCAGCGTG	CGACCCACGCTCTGG	CCGCGGGCCGCCGGT
	TGCCAAGCAGCGTGC	GACCCACGCTCTGGG	CGCGGGCCGCCGGTG
	GCCAAGCAGCGTGCC	ACCCACGCTCTGGGC	GCGGGCCGCCGGTGG
	CCAAGCAGCGTGCCC	CCCACGCTCTGGGCC	CGGGCCGCCGGTGGC
10	CAAGCAGCGTGCCCC	CCACGCTCTGGGCCG	GGGCCGCCGGTGGCG
	AAGCAGCGTGCCCCG	CACGCTCTGGGCCGC	GGCCGCCGGTGGCGC
	AGCAGCGTGCCCCGG	ACGCTCTGGGCCGCT	GCCGCCGGTGGCGCG
	GCAGCGTGCCCCGGT	CGCTCTGGGCCGCTG	CCGCCGGTGGCGCGG
	CAGCGTGCCCCGGTT	GCTCTGGGCCGCTGC	CGCCGGTGGCGCGGG
15	AGCGTGCCCCGGTTG	CTCTGGGCCGCTGCG	GCCGGTGGCGCGGGC
	GCGTGCCCCGGTTGC	TCTGGGCCGCTGCGC	CCGGTGGCGCGGGCT
	CGTGCCCCGGTTGCA	CTGGGCCGCTGCGCT	CGGTGGCGCGGGCTG
	GTGCCCCGGTTGCAG	TGGGCCGCTGCGCTG	GGTGGCGCGGGCTGG
	TGCCCCGGTTGCAGG	GGGCCGCTGCGCTGA	GTGGCGCGGGCTGGC
20	GCCCCGGTTGCAGGC	GGCCGCTGCGCTGAC	TGGCGCGGGCTGGCG
	CCCCGGTTGCAGGCG	GCCGCTGCGCTGACT	GGCGCGGGCTGGCGC
	CCCGGTTGCAGGCGT	CCGCTGCGCTGACTC	GCGCGGGCTGGCGCG
	CCGGTTGCAGGCGTC	CGCTGCGCTGACTCT	CGCGGGCTGGCGCGA
	CGGTTGCAGGCGTCA	GCTGCGCTGACTCTG	GCGGGCTGGCGCGAG
25	GGTTGCAGGCGTCAT	CTGCGCTGACTCTGC	CGGGCTGGCGCGAGC
	GTTGCAGGCGTCATG	TGCGCTGACTCTGCT	GGGCTGGCGCGAGCT
	TTGCAGGCGTCATGC	GCGCTGACTCTGCTG	GGCTGGCGCGAGCTC
	TGCAGGCGTCATGCA	CGCTGACTCTGCTGG	GCTGGCGCGAGCTCG
	GCAGGCGTCATGCAG	GCTGACTCTGCTGGT	CTGGCGCGAGCTCGG
30	CAGGCGTCATGCAGC	CTGACTCTGCTGGTG	TGGCGCGAGCTCGGG
	AGGCGTCATGCAGCG	TGACTCTGCTGGTGC	GGCGCGAGCTCGGGG
	GGCGTCATGCAGCGG	GACTCTGCTGGTGCT	GCGCGAGCTCGGGGG
	GCGTCATGCAGCGGG	ACTCTGCTGGTGCTG	CGCGAGCTCGGGGGG
	CGTCATGCAGCGGGC	CTCTGCTGGTGCTGC	GCGAGCTCGGGGGGC
35	GTCATGCAGCGGGCG	TCTGCTGGTGCTGCT	CGAGCTCGGGGGGCT
	TCATGCAGCGGGCGC	CTGCTGGTGCTGCTC	GAGCTCGGGGGGCTT
	CATGCAGCGGGCGCG	TGCTGGTGCTGCTCC	AGCTCGGGGGGCTTG
	ATGCAGCGGGCGCGA	GCTGGTGCTGCTCCG	GCTCGGGGGGCTTGG
	TGCAGCGGGCGCGAC	CTGGTGCTGCTCCGC	CTCGGGGGGCTTGGG
40	GCAGCGGGCGCGACC	TGGTGCTGCTCCGCG	TCGGGGGGCTTGGGT
	CAGCGGGCGCGACCC	GGTGCTGCTCCGCGG	CGGGGGGCTTGGGTC
	AGCGGGCGCGACCCA	GTGCTGCTCCGCGGG	GGGGGGCTTGGGTCC
	GCGGGCGCGACCCAC	TGCTGCTCCGCGGGC	GGGGGCTTGGGTCCC
	CGGGCGCGACCCACG	GCTGCTCCGCGGGCC	GGGGCTTGGGTCCCG

GGGCTTGGGTCCCGT
GGCTTGGGTCCCGTG
GCTTGGGTCCCGTGG
CTTGGGTCCCGTGGT
TTGGGTCCCGTGGTG
TGGGTCCCGTGGTGC
GGGTCCCGTGGTGCG
GGTCCCGTGGTGCGC
GTCCCGTGGTGCGCT
TCCCGTGGTGCGCTG
CCCGTGGTGCGCTGC
CCGTGGTGCGCTGCG
CGTGGTGCGCTGCGA
GTGGTGCGCTGCGAG
TGGTGCGCTGCGAGC
GGTGCGCTGCGAGCC
GTGCGCTGCGAGCCG
TGCGCTGCGAGCCGT
GCGCTGCGAGCCGTG
CGCTGCGAGCCGTGC
GCTGCGAGCCGTGCG
CTGCGAGCCGTGCGA
TGCGAGCCGTGCGAC
GCGAGCCGTGCGACG
CGAGCCGTGCGACGC
GAGCCGTGCGACGCG
AGCCGTGCGACGCGC
GCCGTGCGACGCGCG
CCGTGCGACGCGCGT
CGTGCGACGCGCGTG
GTGCGACGCGCGTGC
TGCGACGCGCGTGCA
GCGACGCGCGTGCAC
CGACGCGCGTGCACT
GACGCGCGTGCACTG
ACGCGCGTGCACTGG
CGCGCGTGCACTGGC
GCGCGTGCACTGGCC
CGCGTGCACTGGCCC
GCGTGCACTGGCCCA
CGTGCACTGGCCCAG
GTGCACTGGCCCAGT
TGCACTGGCCCAGTG
GCACTGGCCCAGTGC

CACTGGCCCAGTGCG
ACTGGCCCAGTGCGC
CTGGCCCAGTGCGCG
TGGCCCAGTGCGCGC
GGCCCAGTGCGCGCC
GCCCAGTGCGCGCCT
CCCAGTGCGCGCCTC
CCAGTGCGCGCCTCC
CAGTGCGCGCCTCCG
AGTGCGCGCCTCCGC
GTGCGCGCCTCCGCC
TGCGCGCCTCCGCCC
GCGCGCCTCCGCCCG
CGCGCCTCCGCCCGC
GCGCCTCCGCCCGCC
CGCCTCCGCCCGCCG
GCCTCCGCCCGCCGT
CCTCCGCCCGCCGTG
CTCCGCCCGCCGTGT
TCCGCCCGCCGTGTG
CCGCCCGCCGTGTGC
CGCCCGCCGTGTGCG
GCCCGCCGTGTGCGC
CCCGCCGTGTGCGCG
CCGCCGTGTGCGCGG
CGCCGTGTGCGCGGA
GCCGTGTGCGCGGAG
CCGTGTGCGCGGAGC
CGTGTGCGCGGAGCT
GTGTGCGCGGAGCTG
TGTGCGCGGAGCTGG
GTGCGCGGAGCTGGT
TGCGCGGAGCTGGTG
GCGCGGAGCTGGTGC
CGCGGAGCTGGTGCG
GCGGAGCTGGTGCGC
CGGAGCTGGTGCGCG
GGAGCTGGTGCGCGA
GAGCTGGTGCGCGAG
AGCTGGTGCGCGAGC
GCTGGTGCGCGAGCC
CTGGTGCGCGAGCCG
TGGTGCGCGAGCCGG
GGTGCGCGAGCCGGG

GTGCGCGAGCCGGGC
TGCGCGAGCCGGGCT
GCGCGAGCCGGGCTG
CGCGAGCCGGGCTGC
GCGAGCCGGGCTGCG
CGAGCCGGGCTGCGG
GAGCCGGGCTGCGGC
AGCCGGGCTGCGGCT
GCCGGGCTGCGGCTG
CCGGGCTGCGGCTGC
CGGGCTGCGGCTGCT
GGGCTGCGGCTGCTG
GGCTGCGGCTGCTGC
GCTGCGGCTGCTGCC
CTGCGGCTGCTGCCT
TGCGGCTGCTGCCTG
GCGGCTGCTGCCTGA
CGGCTGCTGCCTGAC
GGCTGCTGCCTGACG
GCTGCTGCCTGACGT
CTGCTGCCTGACGTG
TGCTGCCTGACGTGC
GCTGCCTGACGTGCG
CTGCCTGACGTGCGC
TGCCTGACGTGCGCA
GCCTGACGTGCGCAC
CCTGACGTGCGCACT
CTGACGTGCGCACTG
TGACGTGCGCACTGA
GACGTGCGCACTGAG
ACGTGCGCACTGAGC
CGTGCGCACTGAGCG
GTGCGCACTGAGCGA
TGCGCACTGAGCGAG
GCGCACTGAGCGAGG
CGCACTGAGCGAGGG
GCACTGAGCGAGGGC
CACTGAGCGAGGGCC
ACTGAGCGAGGGCCA
CTGAGCGAGGGCCAG
TGAGCGAGGGCCAGC
GAGCGAGGGCCAGCC
AGCGAGGGCCAGCCG
GCGAGGGCCAGCCGT

	CGAGGGCCAGCCGTG	GCCTTCGCTGCCAGC	GCGCTGCTGGACGGC
	GAGGGCCAGCCGTGC	CCTTCGCTGCCAGCC	CGCTGCTGGACGGCC
	AGGGCCAGCCGTGCG	CTTCGCTGCCAGCCG	GCTGCTGGACGGCCG
	GGGCCAGCCGTGCGG	TTCGCTGCCAGCCGT	CTGCTGGACGGCCGC
5	GGCCAGCCGTGCGGC	TCGCTGCCAGCCGTC	TGCTGGACGGCCGCG
	GCCAGCCGTGCGGCA	CGCTGCCAGCCGTCG	GCTGGACGGCCGCGG
	CCAGCCGTGCGGCAT	GCTGCCAGCCGTCGC	CTGGACGGCCGCGGG
	CAGCCGTGCGGCATC	CTGCCAGCCGTCGCC	TGGACGGCCGCGGGC
	AGCCGTGCGGCATCT	TGCCAGCCGTCGCCC	GGACGGCCGCGGGCT
10	GCCGTGCGGCATCTA	GCCAGCCGTCGCCCG	GACGGCCGCGGGCTC
	CCGTGCGGCATCTAC	CCAGCCGTCGCCCGA	ACGGCCGCGGGCTCT
	CGTGCGGCATCTACA	CAGCCGTCGCCCGAC	CGGCCGCGGGCTCTG
	GTGCGGCATCTACAC	AGCCGTCGCCCGACG	GGCCGCGGGCTCTGC
	TGCGGCATCTACACC	GCCGTCGCCCGACGA	GCCGCGGGCTCTGCG
15	GCGGCATCTACACCG	CCGTCGCCCGACGAG	CCGCGGGCTCTGCGT
	CGGCATCTACACCGA	CGTCGCCCGACGAGG	CGCGGGCTCTGCGTC
	GGCATCTACACCGAG	GTCGCCCGACGAGGC	GCGGGCTCTGCGTCA
	GCATCTACACCGAGC	TCGCCCGACGAGGCG	CGGGCTCTGCGTCAA
	CATCTACACCGAGCG	CGCCCGACGAGGCGC	GGGCTCTGCGTCAAC
20	ATCTACACCGAGCGC	GCCCGACGAGGCGCG	GGCTCTGCGTCAACG
	TCTACACCGAGCGCT	CCCGACGAGGCGCGA	GCTCTGCGTCAACGC
	CTACACCGAGCGCTG	CCGACGAGGCGCGAC	CTCTGCGTCAACGCT
	TACACCGAGCGCTGT	CGACGAGGCGCGACC	TCTGCGTCAACGCTA
	ACACCGAGCGCTGTG	GACGAGGCGCGACCG	CTGCGTCAACGCTAG
25	CACCGAGCGCTGTGG	ACGAGGCGCGACCGC	TGCGTCAACGCTAGT
	ACCGAGCGCTGTGGC	CGAGGCGCGACCGCT	GCGTCAACGCTAGTG
	CCGAGCGCTGTGGCT	GAGGCGCGACCGCTG	CGTCAACGCTAGTGC
	CGAGCGCTGTGGCTC	AGGCGCGACCGCTGC	GTCAACGCTAGTGCC
	GAGCGCTGTGGCTCC	GGCGCGACCGCTGCA	TCAACGCTAGTGCCG
30	AGCGCTGTGGCTCCG	GCGCGACCGCTGCAG	CAACGCTAGTGCCGT
	GCGCTGTGGCTCCGG	CGCGACCGCTGCAGG	AACGCTAGTGCCGTC
	CGCTGTGGCTCCGGC	GCGACCGCTGCAGGC	ACGCTAGTGCCGTCA
	GCTGTGGCTCCGGCC	CGACCGCTGCAGGCG	CGCTAGTGCCGTCAG
	CTGTGGCTCCGGCCT	GACCGCTGCAGGCGC	GCTAGTGCCGTCAGC
35	TGTGGCTCCGGCCTT	ACCGCTGCAGGCGCT	CTAGTGCCGTCAGCC
	GTGGCTCCGGCCTTC	CCGCTGCAGGCGCTG	TAGTGCCGTCAGCCG
	TGGCTCCGGCCTTCG	CGCTGCAGGCGCTGC	AGTGCCGTCAGCCGC
	GGCTCCGGCCTTCGC	GCTGCAGGCGCTGCT	GTGCCGTCAGCCGCC
	GCTCCGGCCTTCGCT	CTGCAGGCGCTGCTG	TGCCGTCAGCCGCCT
40	CTCCGGCCTTCGCTG	TGCAGGCGCTGCTGG	GCCGTCAGCCGCCTG
	TCCGGCCTTCGCTGC	GCAGGCGCTGCTGGA	CCGTCAGCCGCCTGC
	CCGGCCTTCGCTGCC	CAGGCGCTGCTGGAC	CGTCAGCCGCCTGCG
	CGGCCTTCGCTGCCA	AGGCGCTGCTGGACG	GTCAGCCGCCTGCGC
	GGCCTTCGCTGCCAG	GGCGCTGCTGGACGG	TCAGCCGCCTGCGCG

	CAGCCGCCTGCGCGC	GAAATGCTAGTGAGT	GAGAGCCCGTCCGTC
	AGCCGCCTGCGCGCC	AAATGCTAGTGAGTC	AGAGCCCGTCCGTCT
	GCCGCCTGCGCGCCT	AATGCTAGTGAGTCG	GAGCCCGTCCGTCTC
	CCGCCTGCGCGCCTA	ATGCTAGTGAGTCGG	AGCCCGTCCGTCTCC
5	CGCCTGCGCGCCTAC	TGCTAGTGAGTCGGA	GCCCGTCCGTCTCCA
	GCCTGCGCGCCTACC	GCTAGTGAGTCGGAG	CCCGTCCGTCTCCAG
	CCTGCGCGCCTACCT	CTAGTGAGTCGGAGG	CCGTCCGTCTCCAGC
	CTGCGCGCCTACCTG	TAGTGAGTCGGAGGA	CGTCCGTCTCCAGCA
	TGCGCGCCTACCTGC	AGTGAGTCGGAGGAA	GTCCGTCTCCAGCAC
10	GCGCGCCTACCTGCT	GTGAGTCGGAGGAAG	TCCGTCTCCAGCACG
	CGCGCCTACCTGCTG	TGAGTCGGAGGAAGA	CCGTCTCCAGCACGC
	GCGCCTACCTGCTGC	GAGTCGGAGGAAGAC	CGTCTCCAGCACGCA
	CGCCTACCTGCTGCC	AGTCGGAGGAAGACC	GTCTCCAGCACGCAC
	GCCTACCTGCTGCCA	GTCGGAGGAAGACCG	TCTCCAGCACGCACC
15	CCTACCTGCTGCCAG	TCGGAGGAAGACCGC	CTCCAGCACGCACCG
	CTACCTGCTGCCAGC	CGGAGGAAGACCGCA	TCCAGCACGCACCGG
	TACCTGCTGCCAGCG	GGAGGAAGACCGCAG	CCAGCACGCACCGGG
	ACCTGCTGCCAGCGC	GAGGAAGACCGCAGC	CAGCACGCACCGGGT
	CCTGCTGCCAGCGCC	AGGAAGACCGCAGCG	AGCACGCACCGGGTG
20	CTGCTGCCAGCGCCG	GGAAGACCGCAGCGC	GCACGCACCGGGTGT
	TGCTGCCAGCGCCGC	GAAGACCGCAGCGCC	CACGCACCGGGTGTC
	GCTGCCAGCGCCGCC	AAGACCGCAGCGCCG	ACGCACCGGGTGTCT
	CTGCCAGCGCCGCCA	AGACCGCAGCGCCGG	CGCACCGGGTGTCTG
	TGCCAGCGCCGCCAG	GACCGCAGCGCCGGC	GCACCGGGTGTCTGA
25	GCCAGCGCCGCCAGC	ACCGCAGCGCCGGCA	CACCGGGTGTCTGAT
	CCAGCGCCGCCAGCT	CCGCAGCGCCGGCAG	ACCGGGTGTCTGATC
	CAGCGCCGCCAGCTC	CGCAGCGCCGGCAGT	CCGGGTGTCTGATCC
	AGCGCCGCCAGCTCC	GCAGCGCCGGCAGTG	CGGGTGTCTGATCCC
	GCGCCGCCAGCTCCA	CAGCGCCGGCAGTGT	GGGTGTCTGATCCCA
30	CGCCGCCAGCTCCAG	AGCGCCGGCAGTGTG	GGTGTCTGATCCCAA
	GCCGCCAGCTCCAGG	GCGCCGGCAGTGTGG	GTGTCTGATCCCAAG
	CCGCCAGCTCCAGGA	CGCCGGCAGTGTGGA	TGTCTGATCCCAAGT
	CGCCAGCTCCAGGAA	GCCGGCAGTGTGGAG	GTCTGATCCCAAGTT
	GCCAGCTCCAGGAAA	CCGGCAGTGTGGAGA	TCTGATCCCAAGTTC
35	CCAGCTCCAGGAAAT	CGGCAGTGTGGAGAG	CTGATCCCAAGTTCC
	CAGCTCCAGGAAATG	GGCAGTGTGGAGAGC	TGATCCCAAGTTCCA
	AGCTCCAGGAAATGC	GCAGTGTGGAGAGCC	GATCCCAAGTTCCAC
	GCTCCAGGAAATGCT	CAGTGTGGAGAGCCC	ATCCCAAGTTCCACC
	CTCCAGGAAATGCTA	AGTGTGGAGAGCCCG	TCCCAAGTTCCACCC
40	TCCAGGAAATGCTAG	GTGTGGAGAGCCCGT	CCCAAGTTCCACCCC
	CCAGGAAATGCTAGT	TGTGGAGAGCCCGTC	CCAAGTTCCACCCCC
	CAGGAAATGCTAGTG	GTGGAGAGCCCGTCC	CAAGTTCCACCCCCT
	AGGAAATGCTAGTGA	TGGAGAGCCCGTCCG	AAGTTCCACCCCCTC
	GGAAATGCTAGTGAG	GGAGAGCCCGTCCGT	AGTTCCACCCCCTCC

GTTCCACCCCCTCCA
TTCCACCCCCTCCAT
TCCACCCCCTCCATT
CCACCCCCTCCATTC
CACCCCCTCCATTCA
ACCCCCTCCATTCAA
CCCCCTCCATTCAAA
CCCCTCCATTCAAAG
CCCTCCATTCAAAGA
CCTCCATTCAAAGAT
CTCCATTCAAAGATA
TCCATTCAAAGATAA
CCATTCAAAGATAAT
CATTCAAAGATAATC
ATTCAAAGATAATCA
TTCAAAGATAATCAT
TCAAAGATAATCATC
CAAAGATAATCATCA
AAAGATAATCATCAT
AAGATAATCATCATC
AGATAATCATCATCA
GATAATCATCATCAA
ATAATCATCATCAAG
TAATCATCATCAAGA
AATCATCATCAAGAA
ATCATCATCAAGAAA
TCATCATCAAGAAAG
CATCATCAAGAAAGG
ATCATCAAGAAAGGG
TCATCAAGAAAGGGC
CATCAAGAAAGGGCA
ATCAAGAAAGGGCAT
TCAAGAAAGGGCATG
CAAGAAAGGGCATGC
AAGAAAGGGCATGCT
AGAAAGGGCATGCTA
GAAAGGGCATGCTAA
AAAGGGCATGCTAAA
AAGGGCATGCTAAAG
AGGGCATGCTAAAGA
GGGCATGCTAAAGAC
GGCATGCTAAAGACA
GCATGCTAAAGACAG
CATGCTAAAGACAGC
ATGCTAAAGACAGCC
TGCTAAAGACAGCCA
GCTAAAGACAGCCAG
CTAAAGACAGCCAGC
TAAAGACAGCCAGCG
AAAGACAGCCAGCGC
AAGACAGCCAGCGCT
AGACAGCCAGCGCTA
GACAGCCAGCGCTAC
ACAGCCAGCGCTACA
CAGCCAGCGCTACAA
AGCCAGCGCTACAAA
GCCAGCGCTACAAAG
CCAGCGCTACAAAGT
CAGCGCTACAAAGTT
AGCGCTACAAAGTTG
GCGCTACAAAGTTGA
CGCTACAAAGTTGAC
GCTACAAAGTTGACT
CTACAAAGTTGACTA
TACAAAGTTGACTAC
ACAAAGTTGACTACG
CAAAGTTGACTACGA
AAAGTTGACTACGAG
AAGTTGACTACGAGT
AGTTGACTACGAGTC
GTTGACTACGAGTCT
TTGACTACGAGTCTC
TGACTACGAGTCTCA
GACTACGAGTCTCAG
ACTACGAGTCTCAGA
CTACGAGTCTCAGAG
TACGAGTCTCAGAGC
ACGAGTCTCAGAGCA
CGAGTCTCAGAGCAC
GAGTCTCAGAGCACA
AGTCTCAGAGCACAG
GTCTCAGAGCACAGA
TCTCAGAGCACAGAT
CTCAGAGCACAGATA
TCAGAGCACAGATAC
CAGAGCACAGATACC
AGAGCACAGATACCC
GAGCACAGATACCCA
AGCACAGATACCCAG
GCACAGATACCCAGA
CACAGATACCCAGAA
ACAGATACCCAGAAC
CAGATACCCAGAACT
AGATACCCAGAACTT
GATACCCAGAACTTC
ATACCCAGAACTTCT
TACCCAGAACTTCTC
ACCCAGAACTTCTCC
CCCAGAACTTCTCCT
CCAGAACTTCTCCTC
CAGAACTTCTCCTCC
AGAACTTCTCCTCCG
GAACTTCTCCTCCGA
AACTTCTCCTCCGAG
ACTTCTCCTCCGAGT
CTTCTCCTCCGAGTC
TTCTCCTCCGAGTCC
TCTCCTCCGAGTCCA
CTCCTCCGAGTCCAA
TCCTCCGAGTCCAAG
CCTCCGAGTCCAAGC
CTCCGAGTCCAAGCG
TCCGAGTCCAAGCGG
CCGAGTCCAAGCGGG
CGAGTCCAAGCGGGA
GAGTCCAAGCGGGAG
AGTCCAAGCGGGAGA
GTCCAAGCGGGAGAC
TCCAAGCGGGAGACA
CCAAGCGGGAGACAG
CAAGCGGGAGACAGA
AAGCGGGAGACAGAA
AGCGGGAGACAGAAT
GCGGGAGACAGAATA
CGGGAGACAGAATAT
GGGAGACAGAATATG
GGAGACAGAATATGG
GAGACAGAATATGGT
AGACAGAATATGGTC
GACAGAATATGGTCC
ACAGAATATGGTCCC
CAGAATATGGTCCCT

AGAATATGGTCCCTG
GAATATGGTCCCTGC
AATATGGTCCCTGCC
ATATGGTCCCTGCCG
TATGGTCCCTGCCGT
ATGGTCCCTGCCGTA
TGGTCCCTGCCGTAG
GGTCCCTGCCGTAGA
GTCCCTGCCGTAGAG
TCCCTGCCGTAGAGA
CCCTGCCGTAGAGAA
CCTGCCGTAGAGAAA
CTGCCGTAGAGAAAT
TGCCGTAGAGAAATG
GCCGTAGAGAAATGG
CCGTAGAGAAATGGA
CGTAGAGAAATGGAA
GTAGAGAAATGGAAG
TAGAGAAATGGAAGA
AGAGAAATGGAAGAC
GAGAAATGGAAGACA
AGAAATGGAAGACAC
GAAATGGAAGACACA
AAATGGAAGACACAC
AATGGAAGACACACT
ATGGAAGACACACTG
TGGAAGACACACTGA
GGAAGACACACTGAA
GAAGACACACTGAAT
AAGACACACTGAATC
AGACACACTGAATCA
GACACACTGAATCAC
ACACACTGAATCACC
CACACTGAATCACCT
ACACTGAATCACCTG
CACTGAATCACCTGA
ACTGAATCACCTGAA
CTGAATCACCTGAAG
TGAATCACCTGAAGT
GAATCACCTGAAGTT
AATCACCTGAAGTTC
ATCACCTGAAGTTCC
TCACCTGAAGTTCCT
CACCTGAAGTTCCTC

ACCTGAAGTTCCTCA
CCTGAAGTTCCTCAA
CTGAAGTTCCTCAAT
TGAAGTTCCTCAATG
GAAGTTCCTCAATGT
AAGTTCCTCAATGTG
AGTTCCTCAATGTGC
GTTCCTCAATGTGCT
TTCCTCAATGTGCTG
TCCTCAATGTGCTGA
CCTCAATGTGCTGAG
CTCAATGTGCTGAGT
TCAATGTGCTGAGTC
CAATGTGCTGAGTCC
AATGTGCTGAGTCCC
ATGTGCTGAGTCCCA
TGTGCTGAGTCCCAG
GTGCTGAGTCCCAGG
TGCTGAGTCCCAGGG
GCTGAGTCCCAGGGG
CTGAGTCCCAGGGGT
TGAGTCCCAGGGGTG
GAGTCCCAGGGGTGT
AGTCCCAGGGGTGTA
GTCCCAGGGGTGTAC
TCCCAGGGGTGTACA
CCCAGGGGTGTACAC
CCAGGGGTGTACACA
CAGGGGTGTACACAT
AGGGGTGTACACATT
GGGGTGTACACATTC
GGGTGTACACATTCC
GGTGTACACATTCCC
GTGTACACATTCCCA
TGTACACATTCCCAA
GTACACATTCCCAAC
TACACATTCCCAACT
ACACATTCCCAACTG
CACATTCCCAACTGT
ACATTCCCAACTGTG
CATTCCCAACTGTGA
ATTCCCAACTGTGAC
TTCCCAACTGTGACA
TCCCAACTGTGACAA

CCCAACTGTGACAAG
CCAACTGTGACAAGA
CAACTGTGACAAGAA
AACTGTGACAAGAAG
ACTGTGACAAGAAGG
CTGTGACAAGAAGGG
TGTGACAAGAAGGGA
GTGACAAGAAGGGAT
TGACAAGAAGGGATT
GACAAGAAGGGATTT
ACAAGAAGGGATTTT
CAAGAAGGGATTTTA
AAGAAGGGATTTTAT
AGAAGGGATTTTATA
GAAGGGATTTTATAA
AAGGGATTTTATAAG
AGGGATTTTATAAGA
GGGATTTTATAAGAA
GGATTTTATAAGAAA
GATTTTATAAGAAAA
ATTTTATAAGAAAAA
TTTTATAAGAAAAAG
TTTATAAGAAAAAGC
TTATAAGAAAAAGCA
TATAAGAAAAAGCAG
ATAAGAAAAAGCAGT
TAAGAAAAAGCAGTG
AAGAAAAAGCAGTGT
AGAAAAAGCAGTGTC
GAAAAAGCAGTGTCG
AAAAAGCAGTGTCGC
AAAAGCAGTGTCGCC
AAAGCAGTGTCGCCC
AAGCAGTGTCGCCCT
AGCAGTGTCGCCCTT
GCAGTGTCGCCCTTC
CAGTGTCGCCCTTCC
AGTGTCGCCCTTCCA
GTGTCGCCCTTCCAA
TGTCGCCCTTCCAAA
GTCGCCCTTCCAAAG
TCGCCCTTCCAAAGG
CGCCCTTCCAAAGGC
GCCCTTCCAAAGGCA

	CCCTTCCAAAGGCAG	AGTATGGGCAGCCTC	GACGTGCACTGCTAC
	CCTTCCAAAGGCAGG	GTATGGGCAGCCTCT	ACGTGCACTGCTACA
	CTTCCAAAGGCAGGA	TATGGGCAGCCTCTC	CGTGCACTGCTACAG
	TTCCAAAGGCAGGAA	ATGGGCAGCCTCTCC	GTGCACTGCTACAGC
5	TCCAAAGGCAGGAAG	TGGGCAGCCTCTCCC	TGCACTGCTACAGCA
	CCAAAGGCAGGAAGC	GGGCAGCCTCTCCCA	GCACTGCTACAGCAT
	CAAAGGCAGGAAGCG	GGCAGCCTCTCCCAG	CACTGCTACAGCATG
	AAAGGCAGGAAGCGG	GCAGCCTCTCCCAGG	ACTGCTACAGCATGC
	AAGGCAGGAAGCGGG	CAGCCTCTCCCAGGC	CTGCTACAGCATGCA
10	AGGCAGGAAGCGGGG	AGCCTCTCCCAGGCT	TGCTACAGCATGCAG
	GGCAGGAAGCGGGGC	GCCTCTCCCAGGCTA	GCTACAGCATGCAGA
	GCAGGAAGCGGGGCT	CCTCTCCCAGGCTAC	CTACAGCATGCAGAG
	CAGGAAGCGGGGCTT	CTCTCCCAGGCTACA	TACAGCATGCAGAGC
	AGGAAGCGGGGCTTC	TCTCCCAGGCTACAC	ACAGCATGCAGAGCA
15	GGAAGCGGGGCTTCT	CTCCCAGGCTACACC	CAGCATGCAGAGCAA
	GAAGCGGGGCTTCTG	TCCCAGGCTACACCA	AGCATGCAGAGCAAG
	AAGCGGGGCTTCTGC	CCCAGGCTACACCAC	GCATGCAGAGCAAGT
	AGCGGGGCTTCTGCT	CCAGGCTACACCACC	CATGCAGAGCAAGTA
	GCGGGGCTTCTGCTG	CAGGCTACACCACCA	ATGCAGAGCAAGTAG
20	CGGGGCTTCTGCTGG	AGGCTACACCACCAA	TGCAGAGCAAGTAGA
	GGGGCTTCTGCTGGT	GGCTACACCACCAAG	GCAGAGCAAGTAGAC
	GGGCTTCTGCTGGTG	GCTACACCACCAAGG	CAGAGCAAGTAGACG
	GGCTTCTGCTGGTGT	CTACACCACCAAGGG	AGAGCAAGTAGACGC
	GCTTCTGCTGGTGTG	TACACCACCAAGGGG	GAGCAAGTAGACGCC
25	CTTCTGCTGGTGTGT	ACACCACCAAGGGGA	AGCAAGTAGACGCCT
	TTCTGCTGGTGTGTG	CACCACCAAGGGGAA	GCAAGTAGACGCCTG
	TCTGCTGGTGTGTGG	ACCACCAAGGGGAAG	CAAGTAGACGCCTGC
	CTGCTGGTGTGTGGA	CCACCAAGGGGAAGG	AAGTAGACGCCTGCC
	TGCTGGTGTGTGGAT	CACCAAGGGGAAGGA	AGTAGACGCCTGCCG
30	GCTGGTGTGTGGATA	ACCAAGGGGAAGGAG	GTAGACGCCTGCCGC
	CTGGTGTGTGGATAA	CCAAGGGGAAGGAGG	TAGACGCCTGCCGCA
	TGGTGTGTGGATAAG	CAAGGGGAAGGAGGA	AGACGCCTGCCGCAA
	GGTGTGTGGATAAGT	AAGGGGAAGGAGGAC	GACGCCTGCCGCAAG
	GTGTGTGGATAAGTA	AGGGGAAGGAGGACG	ACGCCTGCCGCAAGT
35	TGTGTGGATAAGTAT	GGGGAAGGAGGACGT	CGCCTGCCGCAAGTT
	GTGTGGATAAGTATG	GGGAAGGAGGACGTG	GCCTGCCGCAAGTTA
	TGTGGATAAGTATGG	GGAAGGAGGACGTGC	CCTGCCGCAAGTTAA
	GTGGATAAGTATGGG	GAAGGAGGACGTGCA	CTGCCGCAAGTTAAT
	TGGATAAGTATGGGC	AAGGAGGACGTGCAC	TGCCGCAAGTTAATG
40	GGATAAGTATGGGCA	AGGAGGACGTGCACT	GCCGCAAGTTAATGT
	GATAAGTATGGGCAG	GGAGGACGTGCACTG	CCGCAAGTTAATGTG
	ATAAGTATGGGCAGC	GAGGACGTGCACTGC	CGCAAGTTAATGTGG
	TAAGTATGGGCAGCC	AGGACGTGCACTGCT	GCAAGTTAATGTGGA
	AAGTATGGGCAGCCT	GGACGTGCACTGCTA	CAAGTTAATGTGGAG

	AAGTTAATGTGGAGC	TGCCAAGGACATGAC	TTCTGTTTGTGGTGA
	AGTTAATGTGGAGCT	GCCAAGGACATGACC	TCTGTTTGTGGTGAA
	GTTAATGTGGAGCTC	CCAAGGACATGACCA	CTGTTTGTGGTGAAC
	TTAATGTGGAGCTCA	CAAGGACATGACCAG	TGTTTGTGGTGAACT
5	TAATGTGGAGCTCAA	AAGGACATGACCAGC	GTTTGTGGTGAACTG
	AATGTGGAGCTCAAA	AGGACATGACCAGCA	TTTGTGGTGAACTGA
	ATGTGGAGCTCAAAT	GGACATGACCAGCAG	TTGTGGTGAACTGAT
	TGTGGAGCTCAAATA	GACATGACCAGCAGC	TGTGGTGAACTGATT
	GTGGAGCTCAAATAT	ACATGACCAGCAGCT	GTGGTGAACTGATTT
10	TGGAGCTCAAATATG	CATGACCAGCAGCTG	TGGTGAACTGATTTT
	GGAGCTCAAATATGC	ATGACCAGCAGCTGG	GGTGAACTGATTTTT
	GAGCTCAAATATGCC	TGACCAGCAGCTGGC	GTGAACTGATTTTTT
	AGCTCAAATATGCCT	GACCAGCAGCTGGCT	TGAACTGATTTTTTT
	GCTCAAATATGCCTT	ACCAGCAGCTGGCTA	GAACTGATTTTTTTT
15	CTCAAATATGCCTTA	CCAGCAGCTGGCTAC	AACTGATTTTTTTTA
	TCAAATATGCCTTAT	CAGCAGCTGGCTACA	ACTGATTTTTTTTAA
	CAAATATGCCTTATT	AGCAGCTGGCTACAG	CTGATTTTTTTTAAA
	AAATATGCCTTATTT	GCAGCTGGCTACAGC	TGATTTTTTTTAAAC
	AATATGCCTTATTTT	CAGCTGGCTACAGCC	GATTTTTTTTAAACC
20	ATATGCCTTATTTTG	AGCTGGCTACAGCCT	ATTTTTTTTAAACCA
	TATGCCTTATTTTGC	GCTGGCTACAGCCTC	TTTTTTTTAAACCAA
	ATGCCTTATTTTGCA	CTGGCTACAGCCTCG	TTTTTTTAAACCAAA
	TGCCTTATTTTGCAC	TGGCTACAGCCTCGA	TTTTTTAAACCAAAG
	GCCTTATTTTGCACA	GGCTACAGCCTCGAT	TTTTTAAACCAAAGT
25	CCTTATTTTGCACAA	GCTACAGCCTCGATT	TTTTAAACCAAAGTT
	CTTATTTTGCACAAA	CTACAGCCTCGATTT	TTTAAACCAAAGTTT
	TTATTTTGCACAAAA	TACAGCCTCGATTTA	TTAAACCAAAGTTTA
	TATTTTGCACAAAAG	ACAGCCTCGATTTAT	TAAACCAAAGTTTAG
	ATTTTGCACAAAAGA	CAGCCTCGATTTATA	AAACCAAAGTTTAGA
30	TTTTGCACAAAAGAC	AGCCTCGATTTATAT	AACCAAAGTTTAGAA
	TTTGCACAAAAGACT	GCCTCGATTTATATT	ACCAAAGTTTAGAAA
	TTGCACAAAAGACTG	CCTCGATTTATATTT	CCAAAGTTTAGAAAG
	TGCACAAAAGACTGC	CTCGATTTATATTTC	CAAAGTTTAGAAAGA
	GCACAAAAGACTGCC	TCGATTTATATTTCT	AAAGTTTAGAAAGAG
35	CACAAAAGACTGCCA	CGATTTATATTTCTG	AAGTTTAGAAAGAGG
	ACAAAAGACTGCCAA	GATTTATATTTCTGT	AGTTTAGAAAGAGGT
	CAAAAGACTGCCAAG	ATTTATATTTCTGTT	GTTTAGAAAGAGGTT
	AAAAGACTGCCAAGG	TTTATATTTCTGTTT	TTTAGAAAGAGGTTT
	AAAGACTGCCAAGGA	TTATATTTCTGTTTG	TTAGAAAGAGGTTTT
40	AAGACTGCCAAGGAC	TATATTTCTGTTTGT	TAGAAAGAGGTTTTT
	AGACTGCCAAGGACA	ATATTTCTGTTTGTG	AGAAAGAGGTTTTTG
	GACTGCCAAGGACAT	TATTTCTGTTTGTGG	GAAAGAGGTTTTTGA
	ACTGCCAAGGACATG	ATTTCTGTTTGTGGT	AAAGAGGTTTTTGAA
	CTGCCAAGGACATGA	TTTCTGTTTGTGGTG	AAGAGGTTTTTGAAA

AGAGGTTTTTGAAAT
GAGGTTTTTGAAATG
AGGTTTTTGAAATGC
GGTTTTTGAAATGCC
GTTTTTGAAATGCCT
TTTTTGAAATGCCTA
TTTTGAAATGCCTAT
TTTGAAATGCCTATG
TTGAAATGCCTATGG
TGAAATGCCTATGGT
GAAATGCCTATGGTT
AAATGCCTATGGTTT
AATGCCTATGGTTTC
ATGCCTATGGTTTCT
TGCCTATGGTTTCTT
GCCTATGGTTTCTTT
CCTATGGTTTCTTTG
CTATGGTTTCTTTGA
TATGGTTTCTTTGAA
ATGGTTTCTTTGAAT
TGGTTTCTTTGAATG
GGTTTCTTTGAATGG
GTTTCTTTGAATGGT
TTTCTTTGAATGGTA
TTCTTTGAATGGTAA
TCTTTGAATGGTAAA
CTTTGAATGGTAAAC
TTTGAATGGTAAACT
TTGAATGGTAAACTT
TGAATGGTAAACTTG
GAATGGTAAACTTGA
AATGGTAAACTTGAG
ATGGTAAACTTGAGC
TGGTAAACTTGAGCA
GGTAAACTTGAGCAT
GTAAACTTGAGCATC
TAAACTTGAGCATCT
AAACTTGAGCATCTT
AACTTGAGCATCTTT
ACTTGAGCATCTTTT
CTTGAGCATCTTTTC
TTGAGCATCTTTTCA
TGAGCATCTTTTCAC
GAGCATCTTTTCACT

AGCATCTTTTCACTT
GCATCTTTTCACTTT
CATCTTTTCACTTTC
ATCTTTTCACTTTCC
TCTTTTCACTTTCCA
CTTTTCACTTTCCAG
TTTTCACTTTCCAGT
TTTCACTTTCCAGTA
TTCACTTTCCAGTAG
TCACTTTCCAGTAGT
CACTTTCCAGTAGTC
ACTTTCCAGTAGTCA
CTTTCCAGTAGTCAG
TTTCCAGTAGTCAGC
TTCCAGTAGTCAGCA
TCCAGTAGTCAGCAA
CCAGTAGTCAGCAAA
CAGTAGTCAGCAAAG
AGTAGTCAGCAAAGA
GTAGTCAGCAAAGAG
TAGTCAGCAAAGAGC
AGTCAGCAAAGAGCA
GTCAGCAAAGAGCAG
TCAGCAAAGAGCAGT
CAGCAAAGAGCAGTT
AGCAAAGAGCAGTTT
GCAAAGAGCAGTTTG
CAAAGAGCAGTTTGA
AAAGAGCAGTTTGAA
AAGAGCAGTTTGAAT
AGAGCAGTTTGAATT
GAGCAGTTTGAATTT
AGCAGTTTGAATTTT
GCAGTTTGAATTTTC
CAGTTTGAATTTTCT
AGTTTGAATTTTCTT
GTTTGAATTTTCTTG
TTTGAATTTTCTTGT
TTGAATTTTCTTGTC
TGAATTTTCTTGTCG
GAATTTTCTTGTCGC
AATTTTCTTGTCGCT
ATTTTCTTGTCGCTT
TTTTCTTGTCGCTTC

TTTCTTGTCGCTTCC
TTCTTGTCGCTTCCT
TCTTGTCGCTTCCTA
CTTGTCGCTTCCTAT
TTGTCGCTTCCTATC
TGTCGCTTCCTATCA
GTCGCTTCCTATCAA
TCGCTTCCTATCAAA
CGCTTCCTATCAAAA
GCTTCCTATCAAAAT
CTTCCTATCAAAATA
TTCCTATCAAAATAT
TCCTATCAAAATATT
CCTATCAAAATATTC
CTATCAAAATATTCA
TATCAAAATATTCAG
ATCAAAATATTCAGA
TCAAAATATTCAGAG
CAAAATATTCAGAGA
AAAATATTCAGAGAC
AAATATTCAGAGACT
AATATTCAGAGACTC
ATATTCAGAGACTCG
TATTCAGAGACTCGA
ATTCAGAGACTCGAG
TTCAGAGACTCGAGC
TCAGAGACTCGAGCA
CAGAGACTCGAGCAC
AGAGACTCGAGCACA
GAGACTCGAGCACAG
AGACTCGAGCACAGC
GACTCGAGCACAGCA
ACTCGAGCACAGCAC
CTCGAGCACAGCACC
TCGAGCACAGCACCC
CGAGCACAGCACCCA
GAGCACAGCACCCAG
AGCACAGCACCCAGA
GCACAGCACCCAGAC
CACAGCACCCAGACT
ACAGCACCCAGACTT
CAGCACCCAGACTTC
AGCACCCAGACTTCA
GCACCCAGACTTCAT

	CACCCAGACTTCATG	CGAAGCGGCCGACCA	CCTATGTAGAGAACA
	ACCCAGACTTCATGC	GAAGCGGCCGACCAC	CTATGTAGAGAACAC
	CCCAGACTTCATGCG	AAGCGGCCGACCACT	TATGTAGAGAACACG
	CCAGACTTCATGCGC	AGCGGCCGACCACTG	ATGTAGAGAACACGC
5	CAGACTTCATGCGCC	GCGGCCGACCACTGA	TGTAGAGAACACGCT
	AGACTTCATGCGCCC	CGGCCGACCACTGAC	GTAGAGAACACGCTT
	GACTTCATGCGCCCG	GGCCGACCACTGACT	TAGAGAACACGCTTC
	ACTTCATGCGCCCGT	GCCGACCACTGACTT	AGAGAACACGCTTCA
	CTTCATGCGCCCGTG	CCGACCACTGACTTT	GAGAACACGCTTCAC
10	TTCATGCGCCCGTGG	CGACCACTGACTTTG	AGAACACGCTTCACC
	TCATGCGCCCGTGGA	GACCACTGACTTTGT	GAACACGCTTCACCC
	CATGCGCCCGTGGAA	ACCACTGACTTTGTG	AACACGCTTCACCCC
	ATGCGCCCGTGGAAT	CCACTGACTTTGTGA	ACACGCTTCACCCCC
	TGCGCCCGTGGAATG	CACTGACTTTGTGAC	CACGCTTCACCCCCA
15	GCGCCCGTGGAATGC	ACTGACTTTGTGACT	ACGCTTCACCCCCAC
	CGCCCGTGGAATGCT	CTGACTTTGTGACTT	CGCTTCACCCCCACT
	GCCCGTGGAATGCTC	TGACTTTGTGACTTA	GCTTCACCCCCACTC
	CCCGTGGAATGCTCA	GACTTTGTGACTTAG	CTTCACCCCCACTCC
	CCGTGGAATGCTCAC	ACTTTGTGACTTAGG	TTCACCCCCACTCCC
20	CGTGGAATGCTCACC	CTTTGTGACTTAGGC	TCACCCCCACTCCCC
	GTGGAATGCTCACCA	TTTGTGACTTAGGCG	CACCCCCACTCCCCG
	TGGAATGCTCACCAC	TTGTGACTTAGGCGG	ACCCCCACTCCCCGT
	GGAATGCTCACCACA	TGTGACTTAGGCGGC	CCCCCACTCCCCGTA
	GAATGCTCACCACAT	GTGACTTAGGCGGCT	CCCCACTCCCCGTAC
25	AATGCTCACCACATG	TGACTTAGGCGGCTG	CCCCACTCCCCGTACA
	ATGCTCACCACATGT	GACTTAGGCGGCTGT	CCCACTCCCCGTACAG
	TGCTCACCACATGTT	ACTTAGGCGGCTGTG	CCACTCCCCGTACAGT
	GCTCACCACATGTTG	CTTAGGCGGCTGTGT	CACTCCCCGTACAGTG
	CTCACCACATGTTGG	TTAGGCGGCTGTGTT	ACTCCCCGTACAGTGC
30	TCACCACATGTTGGT	TAGGCGGCTGTGTTG	CTCCCCGTACAGTGCG
	CACCACATGTTGGTC	AGGCGGCTGTGTTGC	TCCCCGTACAGTGCGC
	ACCACATGTTGGTCG	GGCGGCTGTGTTGCC	CCCCGTACAGTGCGCA
	CCACATGTTGGTCGA	GCGGCTGTGTTGCCT	CCCGTACAGTGCGCAC
	CACATGTTGGTCGAA	CGGCTGTGTTGCCTA	CCGTACAGTGCGCACA
35	ACATGTTGGTCGAAG	GGCTGTGTTGCCTAT	CGTACAGTGCGCACAG
	CATGTTGGTCGAAGC	GCTGTGTTGCCTATG	GTACAGTGCGCACAGG
	ATGTTGGTCGAAGCG	CTGTGTTGCCTATGT	TACAGTGCGCACAGGC
	TGTTGGTCGAAGCGG	TGTGTTGCCTATGTA	ACAGTGCGCACAGGCT
	GTTGGTCGAAGCGGC	GTGTTGCCTATGTAG	CAGTGCGCACAGGCTT
40	TTGGTCGAAGCGGCC	TGTTGCCTATGTAGA	AGTGCGCACAGGCTTT
	TGGTCGAAGCGGCCG	GTTGCCTATGTAGAG	GTGCGCACAGGCTTTA
	GGTCGAAGCGGCCGA	TTGCCTATGTAGAGA	TGCGCACAGGCTTTAT
	GTCGAAGCGGCCGAC	TGCCTATGTAGAGAA	GCGCACAGGCTTTATC
	TCGAAGCGGCCGACC	GCCTATGTAGAGAAC	CGCACAGGCTTTATCG

CACAGGCTTTATCGA
ACAGGCTTTATCGAG
CAGGCTTTATCGAGA
AGGCTTTATCGAGAA
GGCTTTATCGAGAAT
GCTTTATCGAGAATA
CTTTATCGAGAATAG
TTTATCGAGAATAGG
TTATCGAGAATAGGA
TATCGAGAATAGGAA
ATCGAGAATAGGAAA
TCGAGAATAGGAAAA
CGAGAATAGGAAAAC
GAGAATAGGAAAACC
AGAATAGGAAAACCT
GAATAGGAAAACCTT
AATAGGAAAACCTTT
ATAGGAAAACCTTTA
TAGGAAAACCTTTAA
AGGAAAACCTTTAAA
GGAAAACCTTTAAAC
GAAAACCTTTAAACC
AAAACCTTTAAACCC
AAACCTTTAAACCCC
AACCTTTAAACCCCG
ACCTTTAAACCCCGG
CCTTTAAACCCCGGT
CTTTAAACCCCGGTC
TTTAAACCCCGGTCA
TTAAACCCCGGTCAT
TAAACCCCGGTCATC
AAACCCCGGTCATCC
AACCCCGGTCATCCG
ACCCCGGTCATCCGG
CCCCGGTCATCCGGA
CCCGGTCATCCGGAC
CCGGTCATCCGGACA
CGGTCATCCGGACAT
GGTCATCCGGACATC
GTCATCCGGACATCC
TCATCCGGACATCCC
CATCCGGACATCCCA
ATCCGGACATCCCAA
TCCGGACATCCCAAC

CCGGACATCCCAACG
CGGACATCCCAACGC
GGACATCCCAACGCA
GACATCCCAACGCAT
ACATCCCAACGCATG
CATCCCAACGCATGC
ATCCCAACGCATGCT
TCCCAACGCATGCTC
CCCAACGCATGCTCC
CCAACGCATGCTCCT
CAACGCATGCTCCTG
AACGCATGCTCCTGG
ACGCATGCTCCTGGA
CGCATGCTCCTGGAG
GCATGCTCCTGGAGC
CATGCTCCTGGAGCT
ATGCTCCTGGAGCTC
TGCTCCTGGAGCTCA
GCTCCTGGAGCTCAC
CTCCTGGAGCTCACA
TCCTGGAGCTCACAG
CCTGGAGCTCACAGC
CTGGAGCTCACAGCC
TGGAGCTCACAGCCT
GGAGCTCACAGCCTT
GAGCTCACAGCCTTC
AGCTCACAGCCTTCT
GCTCACAGCCTTCTG
CTCACAGCCTTCTGT
TCACAGCCTTCTGTG
CACAGCCTTCTGTGG
ACAGCCTTCTGTGGT
CAGCCTTCTGTGGTG
AGCCTTCTGTGGTGT
GCCTTCTGTGGTGTC
CCTTCTGTGGTGTCA
CTTCTGTGGTGTCAT
TTCTGTGGTGTCATT
TCTGTGGTGTCATTT
CTGTGGTGTCATTTC
TGTGGTGTCATTTCT
GTGGTGTCATTTCTG
TGGTGTCATTTCTGA
GGTGTCATTTCTGAA

GTGTCATTTCTGAAA
TGTCATTTCTGAAAC
GTCATTTCTGAAACA
TCATTTCTGAAACAA
CATTTCTGAAACAAG
ATTTCTGAAACAAGG
TTTCTGAAACAAGGG
TTCTGAAACAAGGGC
TCTGAAACAAGGGCG
CTGAAACAAGGGCGT
TGAAACAAGGGCGTG
GAAACAAGGGCGTGG
AAACAAGGGCGTGGA
AACAAGGGCGTGGAT
ACAAGGGCGTGGATC
CAAGGGCGTGGATCC
AAGGGCGTGGATCCC
AGGGCGTGGATCCCT
GGGCGTGGATCCCTC
GGCGTGGATCCCTCA
GCGTGGATCCCTCAA
CGTGGATCCCTCAAC
GTGGATCCCTCAACC
TGGATCCCTCAACCA
GGATCCCTCAACCAA
GATCCCTCAACCAAG
ATCCCTCAACCAAGA
TCCCTCAACCAAGAA
CCCTCAACCAAGAAG
CCTCAACCAAGAAGA
CTCAACCAAGAAGAA
TCAACCAAGAAGAAT
CAACCAAGAAGAATG
AACCAAGAAGAATGT
ACCAAGAAGAATGTT
CCAAGAAGAATGTTT
CAAGAAGAATGTTTA
AAGAAGAATGTTTAT
AGAAGAATGTTTATG
GAAGAATGTTTATGT
AAGAATGTTTATGTC
AGAATGTTTATGTCT
GAATGTTTATGTCTT
AATGTTTATGTCTTC

	ATGTTTATGTCTTCA	AGAAAATAAGGTGGA	AGAATGTTCTAGGGC
	TGTTTATGTCTTCAA	GAAAATAAGGTGGAG	GAATGTTCTAGGGCA
	GTTTATGTCTTCAAG	AAAATAAGGTGGAGT	AATGTTCTAGGGCAC
	TTTATGTCTTCAAGT	AAATAAGGTGGAGTC	ATGTTCTAGGGCACT
5	TTATGTCTTCAAGTG	AATAAGGTGGAGTCC	TGTTCTAGGGCACTC
	TATGTCTTCAAGTGA	ATAAGGTGGAGTCCT	GTTCTAGGGCACTCT
	ATGTCTTCAAGTGAC	TAAGGTGGAGTCCTA	TTCTAGGGCACTCTG
	TGTCTTCAAGTGACC	AAGGTGGAGTCCTAC	TCTAGGGCACTCTGG
	GTCTTCAAGTGACCT	AGGTGGAGTCCTACT	CTAGGGCACTCTGGG
10	TCTTCAAGTGACCTG	GGTGGAGTCCTACTT	TAGGGCACTCTGGGA
	CTTCAAGTGACCTGT	GTGGAGTCCTACTTG	AGGGCACTCTGGGAA
	TTCAAGTGACCTGTA	TGGAGTCCTACTTGT	GGGCACTCTGGGAAC
	TCAAGTGACCTGTAC	GGAGTCCTACTTGTT	GGCACTCTGGGAACC
	CAAGTGACCTGTACT	GAGTCCTACTTGTTT	GCACTCTGGGAACCT
15	AAGTGACCTGTACTG	AGTCCTACTTGTTTA	CACTCTGGGAACCTA
	AGTGACCTGTACTGC	GTCCTACTTGTTTAA	ACTCTGGGAACCTAT
	GTGACCTGTACTGCT	TCCTACTTGTTTAAA	CTCTGGGAACCTATA
	TGACCTGTACTGCTT	CCTACTTGTTTAAAA	TCTGGGAACCTATAA
	GACCTGTACTGCTTG	CTACTTGTTTAAAAA	CTGGGAACCTATAAA
20	ACCTGTACTGCTTGG	TACTTGTTTAAAAAA	TGGGAACCTATAAAG
	CCTGTACTGCTTGGG	ACTTGTTTAAAAAAT	GGGAACCTATAAAGG
	CTGTACTGCTTGGGG	CTTGTTTAAAAAATA	GGAACCTATAAAGGC
	TGTACTGCTTGGGGA	TTGTTTAAAAAATAT	GAACCTATAAAGGCA
	GTACTGCTTGGGGAC	TGTTTAAAAAATATG	AACCTATAAAGGCAG
25	TACTGCTTGGGGACT	GTTTAAAAAATATGT	ACCTATAAAGGCAGG
	ACTGCTTGGGGACTA	TTTAAAAAATATGTA	CCTATAAAGGCAGGT
	CTGCTTGGGGACTAT	TTAAAAAATATGTAT	CTATAAAGGCAGGTA
	TGCTTGGGGACTATT	TAAAAAATATGTATC	TATAAAGGCAGGTAT
	GCTTGGGGACTATTG	AAAAAATATGTATCT	ATAAAGGCAGGTATT
30	CTTGGGGACTATTGG	AAAAATATGTATCTA	TAAAGGCAGGTATTT
	TTGGGGACTATTGGA	AAAATATGTATCTAA	AAAGGCAGGTATTTC
	TGGGGACTATTGGAG	AAATATGTATCTAAG	AAGGCAGGTATTTCG
	GGGGACTATTGGAGA	AATATGTATCTAAGA	AGGCAGGTATTTCGG
	GGGACTATTGGAGAA	ATATGTATCTAAGAA	GGCAGGTATTTCGGG
35	GGACTATTGGAGAAA	TATGTATCTAAGAAT	GCAGGTATTTCGGGC
	GACTATTGGAGAAAA	ATGTATCTAAGAATG	CAGGTATTTCGGGCC
	ACTATTGGAGAAAAT	TGTATCTAAGAATGT	AGGTATTTCGGGCCC
	CTATTGGAGAAAATA	GTATCTAAGAATGTT	GGTATTTCGGGCCCT
	TATTGGAGAAAATAA	TATCTAAGAATGTTC	GTATTTCGGGCCCTC
40	ATTGGAGAAAATAAG	ATCTAAGAATGTTCT	TATTTCGGGCCCTCC
	TTGGAGAAAATAAGG	TCTAAGAATGTTCTA	ATTTCGGGCCCTCCT
	TGGAGAAAATAAGGT	CTAAGAATGTTCTAG	TTTCGGGCCCTCCTC
	GGAGAAAATAAGGTG	TAAGAATGTTCTAGG	TTCGGGCCCTCCTCT
	GAGAAAATAAGGTGG	AAGAATGTTCTAGGG	TCGGGCCCTCCTCTT

	CGGGCCCTCCTCTTC	GAAGGCCCAGGATGG	GACAGAGAGACGGGA
	GGGCCCTCCTCTTCA	AAGGCCCAGGATGGC	ACAGAGAGACGGGAG
	GGCCCTCCTCTTCAG	AGGCCCAGGATGGCT	CAGAGAGACGGGAGA
	GCCCTCCTCTTCAGG	GGCCCAGGATGGCTT	AGAGAGACGGGAGAG
5	CCCTCCTCTTCAGGA	GCCCAGGATGGCTTT	GAGAGACGGGAGAGT
	CCTCCTCTTCAGGAA	CCCAGGATGGCTTTT	AGAGACGGGAGAGTC
	CTCCTCTTCAGGAAT	CCAGGATGGCTTTTG	GAGACGGGAGAGTCA
	TCCTCTTCAGGAATC	CAGGATGGCTTTTGC	AGACGGGAGAGTCAG
	CCTCTTCAGGAATCT	AGGATGGCTTTTGCT	GACGGGAGAGTCAGC
10	CTCTTCAGGAATCTT	GGATGGCTTTTGCTG	ACGGGAGAGTCAGCC
	TCTTCAGGAATCTTC	GATGGCTTTTGCTGC	CGGGAGAGTCAGCCT
	CTTCAGGAATCTTCC	ATGGCTTTTGCTGCG	GGGAGAGTCAGCCTC
	TTCAGGAATCTTCCT	TGGCTTTTGCTGCGG	GGAGAGTCAGCCTCC
	TCAGGAATCTTCCTG	GGCTTTTGCTGCGGC	GAGAGTCAGCCTCCA
15	CAGGAATCTTCCTGA	GCTTTTGCTGCGGCC	AGAGTCAGCCTCCAC
	AGGAATCTTCCTGAA	CTTTTGCTGCGGCCC	GAGTCAGCCTCCACA
	GGAATCTTCCTGAAG	TTTTGCTGCGGCCCC	AGTCAGCCTCCACAT
	GAATCTTCCTGAAGA	TTTGCTGCGGCCCCG	GTCAGCCTCCACATT
	AATCTTCCTGAAGAC	TTGCTGCGGCCCCGT	TCAGCCTCCACATTC
20	ATCTTCCTGAAGACA	TGCTGCGGCCCCGTG	CAGCCTCCACATTCA
	TCTTCCTGAAGACAT	GCTGCGGCCCCGTGG	AGCCTCCACATTCAG
	CTTCCTGAAGACATG	CTGCGGCCCCGTGGG	GCCTCCACATTCAGA
	TTCCTGAAGACATGG	TGCGGCCCCGTGGGG	CCTCCACATTCAGAG
	TCCTGAAGACATGGC	GCGGCCCCGTGGGGT	CTCCACATTCAGAGG
25	CCTGAAGACATGGCC	CGGCCCCGTGGGGTA	TCCACATTCAGAGGC
	CTGAAGACATGGCCC	GGCCCCGTGGGGTAG	CCACATTCAGAGGCA
	TGAAGACATGGCCCA	GCCCCGTGGGGTAGG	CACATTCAGAGGCAT
	GAAGACATGGCCCAG	CCCCGTGGGGTAGGA	ACATTCAGAGGCATC
	AAGACATGGCCCAGT	CCCGTGGGGTAGGAG	CATTCAGAGGCATCA
30	AGACATGGCCCAGTC	CCGTGGGGTAGGAGG	ATTCAGAGGCATCAC
	GACATGGCCCAGTCG	CGTGGGGTAGGAGGG	TTCAGAGGCATCACA
	ACATGGCCCAGTCGA	GTGGGGTAGGAGGGA	TCAGAGGCATCACAA
	CATGGCCCAGTCGAA	TGGGGTAGGAGGGAC	CAGAGGCATCACAAG
	ATGGCCCAGTCGAAG	GGGGTAGGAGGGACA	AGAGGCATCACAAGT
35	TGGCCCAGTCGAAGG	GGGTAGGAGGGACAG	GAGGCATCACAAGTA
	GGCCCAGTCGAAGGC	GGTAGGAGGGACAGA	AGGCATCACAAGTAA
	GCCCAGTCGAAGGCC	GTAGGAGGGACAGAG	GGCATCACAAGTAAT
	CCCAGTCGAAGGCCC	TAGGAGGGACAGAGA	GCATCACAAGTAATG
	CCAGTCGAAGGCCCA	AGGAGGGACAGAGAG	CATCACAAGTAATGG
40	CAGTCGAAGGCCCAG	GGAGGGACAGAGAGA	ATCACAAGTAATGGC
	AGTCGAAGGCCCAGG	GAGGGACAGAGAGAC	TCACAAGTAATGGCA
	GTCGAAGGCCCAGGA	AGGGACAGAGAGACG	CACAAGTAATGGCAC
	TCGAAGGCCCAGGAT	GGGACAGAGAGACGG	ACAAGTAATGGCACA
	CGAAGGCCCAGGATG	GGACAGAGAGACGGG	CAAGTAATGGCACAA

AAGTAATGGCACAAT
AGTAATGGCACAATT
GTAATGGCACAATTC
TAATGGCACAATTCT
AATGGCACAATTCTT
ATGGCACAATTCTTC
TGGCACAATTCTTCG
GGCACAATTCTTCGG
GCACAATTCTTCGGA
CACAATTCTTCGGAT
ACAATTCTTCGGATG
CAATTCTTCGGATGA
AATTCTTCGGATGAC
ATTCTTCGGATGACT
TTCTTCGGATGACTG
TCTTCGGATGACTGC
CTTCGGATGACTGCA
TTCGGATGACTGCAG
TCGGATGACTGCAGA
CGGATGACTGCAGAA
GGATGACTGCAGAAA
GATGACTGCAGAAAA
ATGACTGCAGAAAAT
TGACTGCAGAAAATA
GACTGCAGAAAATAG
ACTGCAGAAAATAGT
CTGCAGAAAATAGTG
TGCAGAAAATAGTGT
GCAGAAAATAGTGTT
CAGAAAATAGTGTTT
AGAAAATAGTGTTTT
GAAAATAGTGTTTTG
AAAATAGTGTTTTGT
AAATAGTGTTTTGTA
AATAGTGTTTTGTAG
ATAGTGTTTTGTAGT
TAGTGTTTTGTAGTT
AGTGTTTTGTAGTTC
GTGTTTTGTAGTTCA
TGTTTTGTAGTTCAA
GTTTTGTAGTTCAAC
TTTTGTAGTTCAACA
TTTGTAGTTCAACAA
TTGTAGTTCAACAAC

TGTAGTTCAACAACT
GTAGTTCAACAACTC
TAGTTCAACAACTCA
AGTTCAACAACTCAA
GTTCAACAACTCAAG
TTCAACAACTCAAGA
TCAACAACTCAAGAC
CAACAACTCAAGACG
AACAACTCAAGACGA
ACAACTCAAGACGAA
CAACTCAAGACGAAG
AACTCAAGACGAAGC
ACTCAAGACGAAGCT
CTCAAGACGAAGCTT
TCAAGACGAAGCTTA
CAAGACGAAGCTTAT
AAGACGAAGCTTATT
AGACGAAGCTTATTT
GACGAAGCTTATTTC
ACGAAGCTTATTTCT
CGAAGCTTATTTCTG
GAAGCTTATTTCTGA
AAGCTTATTTCTGAG
AGCTTATTTCTGAGG
GCTTATTTCTGAGGA
CTTATTTCTGAGGAT
TTATTTCTGAGGATA
TATTTCTGAGGATAA
ATTTCTGAGGATAAG
TTTCTGAGGATAAGC
TTCTGAGGATAAGCT
TCTGAGGATAAGCTC
CTGAGGATAAGCTCT
TGAGGATAAGCTCTT
GAGGATAAGCTCTTT
AGGATAAGCTCTTTA
GGATAAGCTCTTTAA
GATAAGCTCTTTAAA
ATAAGCTCTTTAAAG
TAAGCTCTTTAAAGG
AAGCTCTTTAAAGGC
AGCTCTTTAAAGGCA
GCTCTTTAAAGGCAA
CTCTTTAAAGGCAAA

TCTTTAAAGGCAAAG
CTTTAAAGGCAAAGC
TTTAAAGGCAAAGCT
TTAAAGGCAAAGCTT
TAAAGGCAAAGCTTT
AAAGGCAAAGCTTTA
AAGGCAAAGCTTTAT
AGGCAAAGCTTTATT
GGCAAAGCTTTATTT
GCAAAGCTTTATTTT
CAAAGCTTTATTTTC
AAAGCTTTATTTTCA
AAGCTTTATTTTCAT
AGCTTTATTTTCATC
GCTTTATTTTCATCT
CTTTATTTTCATCTC
TTTATTTTCATCTCT
TTATTTTCATCTCTC
TATTTTCATCTCTCA
ATTTTCATCTCTCAT
TTTTCATCTCTCATC
TTTCATCTCTCATCT
TTCATCTCTCATCTT
TCATCTCTCATCTTT
CATCTCTCATCTTTT
ATCTCTCATCTTTTG
TCTCTCATCTTTTGT
CTCTCATCTTTTGTC
TCTCATCTTTTGTCC
CTCATCTTTTGTCCT
TCATCTTTTGTCCTC
CATCTTTTGTCCTCC
ATCTTTTGTCCTCCT
TCTTTTGTCCTCCTT
CTTTTGTCCTCCTTA
TTTTGTCCTCCTTAG
TTTGTCCTCCTTAGC
TTGTCCTCCTTAGCA
TGTCCTCCTTAGCAC
GTCCTCCTTAGCACA
TCCTCCTTAGCACAA
CCTCCTTAGCACAAT
CTCCTTAGCACAATG
TCCTTAGCACAATGT

	CCTTAGCACAATGTA	GAGGAATGGCTTGCT	ATAGAGATTCACCCA
	CTTAGCACAATGTAA	AGGAATGGCTTGCTG	TAGAGATTCACCCAT
	TTAGCACAATGTAAA	GGAATGGCTTGCTGG	AGAGATTCACCCATG
	TAGCACAATGTAAAA	GAATGGCTTGCTGGG	GAGATTCACCCATGT
5	AGCACAATGTAAAAA	AATGGCTTGCTGGGG	AGATTCACCCATGTT
	GCACAATGTAAAAAA	ATGGCTTGCTGGGGA	GATTCACCCATGTTT
	CACAATGTAAAAAAG	TGGCTTGCTGGGGAG	ATTCACCCATGTTTG
	ACAATGTAAAAAAGA	GGCTTGCTGGGGAGC	TTCACCCATGTTTGT
	CAATGTAAAAAAGAA	GCTTGCTGGGGAGCC	TCACCCATGTTTGTT
10	AATGTAAAAAAGAAT	CTTGCTGGGGAGCCC	CACCCATGTTTGTTG
	ATGTAAAAAAGAATA	TTGCTGGGGAGCCCA	ACCCATGTTTGTTGA
	TGTAAAAAAGAATAG	TGCTGGGGAGCCCAT	CCCATGTTTGTTGAA
	GTAAAAAAGAATAGT	GCTGGGGAGCCCATC	CCATGTTTGTTGAAC
	TAAAAAAGAATAGTA	CTGGGGAGCCCATCC	CATGTTTGTTGAACT
15	AAAAAAGAATAGTAA	TGGGGAGCCCATCCA	ATGTTTGTTGAACTT
	AAAAAGAATAGTAAT	GGGGAGCCCATCCAG	TGTTTGTTGAACTTA
	AAAAGAATAGTAATA	GGGAGCCCATCCAGG	GTTTGTTGAACTTAG
	AAAGAATAGTAATAT	GGAGCCCATCCAGGA	TTTGTTGAACTTAGA
	AAGAATAGTAATATC	GAGCCCATCCAGGAC	TTGTTGAACTTAGAG
20	AGAATAGTAATATCA	AGCCCATCCAGGACA	TGTTGAACTTAGAGT
	GAATAGTAATATCAG	GCCCATCCAGGACAC	GTTGAACTTAGAGTC
	AATAGTAATATCAGA	CCCATCCAGGACACT	TTGAACTTAGAGTCA
	ATAGTAATATCAGAA	CCATCCAGGACACTG	TGAACTTAGAGTCAT
	TAGTAATATCAGAAC	CATCCAGGACACTGG	GAACTTAGAGTCATT
25	AGTAATATCAGAACA	ATCCAGGACACTGGG	AACTTAGAGTCATTC
	GTAATATCAGAACAG	TCCAGGACACTGGGA	ACTTAGAGTCATTCT
	TAATATCAGAACAGG	CCAGGACACTGGGAG	CTTAGAGTCATTCTC
	AATATCAGAACAGGA	CAGGACACTGGGAGC	TTAGAGTCATTCTCA
	ATATCAGAACAGGAA	AGGACACTGGGAGCA	TAGAGTCATTCTCAT
30	TATCAGAACAGGAAG	GGACACTGGGAGCAC	AGAGTCATTCTCATG
	ATCAGAACAGGAAGG	GACACTGGGAGCACA	GAGTCATTCTCATGC
	TCAGAACAGGAAGGA	ACACTGGGAGCACAT	AGTCATTCTCATGCT
	CAGAACAGGAAGGAG	CACTGGGAGCACATA	GTCATTCTCATGCTT
	AGAACAGGAAGGAGG	ACTGGGAGCACATAG	TCATTCTCATGCTTT
35	GAACAGGAAGGAGGA	CTGGGAGCACATAGA	CATTCTCATGCTTTT
	AACAGGAAGGAGGAA	TGGGAGCACATAGAG	ATTCTCATGCTTTTC
	ACAGGAAGGAGGAAT	GGGAGCACATAGAGA	TTCTCATGCTTTTCT
	CAGGAAGGAGGAATG	GGAGCACATAGAGAT	TCTCATGCTTTTCTT
	AGGAAGGAGGAATGG	GAGCACATAGAGATT	CTCATGCTTTTCTTT
40	GGAAGGAGGAATGGC	AGCACATAGAGATTC	TCATGCTTTTCTTTA
	GAAGGAGGAATGGCT	GCACATAGAGATTCA	CATGCTTTTCTTTAT
	AAGGAGGAATGGCTT	CACATAGAGATTCAC	ATGCTTTTCTTTATA
	AGGAGGAATGGCTTG	ACATAGAGATTCACC	TGCTTTTCTTTATAA
	GGAGGAATGGCTTGC	CATAGAGATTCACCC	GCTTTTCTTTATAAT

	CTTTTCTTTATAATT	TGTTAACATTGTATA	TACTAGATAATCCTA
	TTTTCTTTATAATTC	GTTAACATTGTATAC	ACTAGATAATCCTAG
	TTTCTTTATAATTCA	TTAACATTGTATACA	CTAGATAATCCTAGA
	TTCTTTATAATTCAC	TAACATTGTATACAA	TAGATAATCCTAGAT
5	TCTTTATAATTCACA	AACATTGTATACAAC	AGATAATCCTAGATG
	CTTTATAATTCACAC	ACATTGTATACAACA	GATAATCCTAGATGA
	TTTATAATTCACACA	CATTGTATACAACAT	ATAATCCTAGATGAA
	TTATAATTCACACAT	ATTGTATACAACATA	TAATCCTAGATGAAA
	TATAATTCACACATA	TTGTATACAACATAG	AATCCTAGATGAAAT
10	ATAATTCACACATAT	TGTATACAACATAGC	ATCCTAGATGAAATG
	TAATTCACACATATA	GTATACAACATAGCC	TCCTAGATGAAATGT
	AATTCACACATATAT	TATACAACATAGCCC	CCTAGATGAAATGTT
	ATTCACACATATATG	ATACAACATAGCCCC	CTAGATGAAATGTTA
	TTCACACATATATGC	TACAACATAGCCCCA	TAGATGAAATGTTAG
15	TCACACATATATGCA	ACAACATAGCCCCAA	AGATGAAATGTTAGA
	CACACATATATGCAG	CAACATAGCCCCAAA	GATGAAATGTTAGAG
	ACACATATATGCAGA	AACATAGCCCCAAAT	ATGAAATGTTAGAGA
	CACATATATGCAGAG	ACATAGCCCCAAATA	TGAAATGTTAGAGAT
	ACATATATGCAGAGA	CATAGCCCCAAATAT	GAAATGTTAGAGATG
20	CATATATGCAGAGAA	ATAGCCCCAAATATA	AAATGTTAGAGATGC
	ATATATGCAGAGAAG	TAGCCCCAAATATAG	AATGTTAGAGATGCT
	TATATGCAGAGAAGA	AGCCCCAAATATAGT	ATGTTAGAGATGCTA
	ATATGCAGAGAAGAT	GCCCCAAATATAGTA	TGTTAGAGATGCTAT
	TATGCAGAGAAGATA	CCCCAAATATAGTAA	GTTAGAGATGCTATA
25	ATGCAGAGAAGATAT	CCCAAATATAGTAAG	TTAGAGATGCTATAT
	TGCAGAGAAGATATG	CCAAATATAGTAAGA	TAGAGATGCTATATG
	GCAGAGAAGATATGT	CAAATATAGTAAGAT	AGAGATGCTATATGA
	CAGAGAAGATATGTT	AAATATAGTAAGATC	GAGATGCTATATGAT
	AGAGAAGATATGTTC	AATATAGTAAGATCT	AGATGCTATATGATA
30	GAGAAGATATGTTCT	ATATAGTAAGATCTA	GATGCTATATGATAC
	AGAAGATATGTTCTT	TATAGTAAGATCTAT	ATGCTATATGATACA
	GAAGATATGTTCTTG	ATAGTAAGATCTATA	TGCTATATGATACAA
	AAGATATGTTCTTGT	TAGTAAGATCTATAC	GCTATATGATACAAC
	AGATATGTTCTTGTT	AGTAAGATCTATACT	CTATATGATACAACT
35	GATATGTTCTTGTTA	GTAAGATCTATACTA	TATATGATACAACTG
	ATATGTTCTTGTTAA	TAAGATCTATACTAG	ATATGATACAACTGT
	TATGTTCTTGTTAAC	AAGATCTATACTAGA	TATGATACAACTGTG
	ATGTTCTTGTTAACA	AGATCTATACTAGAT	ATGATACAACTGTGG
	TGTTCTTGTTAACAT	GATCTATACTAGATA	TGATACAACTGTGGC
40	GTTCTTGTTAACATT	ATCTATACTAGATAA	GATACAACTGTGGCC
	TTCTTGTTAACATTG	TCTATACTAGATAAT	ATACAACTGTGGCCA
	TCTTGTTAACATTGT	CTATACTAGATAATC	TACAACTGTGGCCAT
	CTTGTTAACATTGTA	TATACTAGATAATCC	ACAACTGTGGCCATG
	TTGTTAACATTGTAT	ATACTAGATAATCCT	CAACTGTGGCCATGA

AACTGTGGCCATGAC	GGCTGCTCTCCCGGA	AGGCTCAGGGAGACT
ACTGTGGCCATGACT	GCTGCTCTCCCGGAG	GGCTCAGGGAGACTC
CTGTGGCCATGACTG	CTGCTCTCCCGGAGG	GCTCAGGGAGACTCT
TGTGGCCATGACTGA	TGCTCTCCCGGAGGC	CTCAGGGAGACTCTG
GTGGCCATGACTGAG	GCTCTCCCGGAGGCC	TCAGGGAGACTCTGC
TGGCCATGACTGAGG	CTCTCCCGGAGGCCA	CAGGGAGACTCTGCC
GGCCATGACTGAGGA	TCTCCCGGAGGCCAA	AGGGAGACTCTGCCC
GCCATGACTGAGGAA	CTCCCGGAGGCCAAA	GGGAGACTCTGCCCT
CCATGACTGAGGAAA	TCCCGGAGGCCAAAC	GGAGACTCTGCCCTG
CATGACTGAGGAAAG	CCCGGAGGCCAAACC	GAGACTCTGCCCTGC
ATGACTGAGGAAAGG	CCGGAGGCCAAACCC	AGACTCTGCCCTGCT
TGACTGAGGAAAGGA	CGGAGGCCAAACCCA	GACTCTGCCCTGCTG
GACTGAGGAAAGGAG	GGAGGCCAAACCCAA	ACTCTGCCCTGCTGC
ACTGAGGAAAGGAGC	GAGGCCAAACCCAAG	CTCTGCCCTGCTGCA
CTGAGGAAAGGAGCT	AGGCCAAACCCAAGA	TCTGCCCTGCTGCAG
TGAGGAAAGGAGCTC	GGCCAAACCCAAGAA	CTGCCCTGCTGCAGA
GAGGAAAGGAGCTCA	GCCAAACCCAAGAAG	TGCCCTGCTGCAGAC
AGGAAAGGAGCTCAC	CCAAACCCAAGAAGG	GCCCTGCTGCAGACC
GGAAAGGAGCTCACG	CAAACCCAAGAAGGT	CCCTGCTGCAGACCT
GAAAGGAGCTCACGC	AAACCCAAGAAGGTC	CCTGCTGCAGACCTC
AAAGGAGCTCACGCC	AACCCAAGAAGGTCT	CTGCTGCAGACCTCG
AAGGAGCTCACGCCC	ACCCAAGAAGGTCTG	TGCTGCAGACCTCGG
AGGAGCTCACGCCCA	CCCAAGAAGGTCTGG	GCTGCAGACCTCGGT
GGAGCTCACGCCCAG	CCAAGAAGGTCTGGC	CTGCAGACCTCGGTG
GAGCTCACGCCCAGA	CAAGAAGGTCTGGCA	TGCAGACCTCGGTGT
AGCTCACGCCCAGAG	AAGAAGGTCTGGCAA	GCAGACCTCGGTGTG
GCTCACGCCCAGAGA	AGAAGGTCTGGCAAA	CAGACCTCGGTGTGG
CTCACGCCCAGAGAC	GAAGGTCTGGCAAAG	AGACCTCGGTGTGGA
TCACGCCCAGAGACT	AAGGTCTGGCAAAGT	GACCTCGGTGTGGAC
CACGCCCAGAGACTG	AGGTCTGGCAAAGTC	ACCTCGGTGTGGACA
ACGCCCAGAGACTGG	GGTCTGGCAAAGTCA	CCTCGGTGTGGACAC
CGCCCAGAGACTGGG	GTCTGGCAAAGTCAG	CTCGGTGTGGACACA
GCCCAGAGACTGGGC	TCTGGCAAAGTCAGG	TCGGTGTGGACACAC
CCCAGAGACTGGGCT	CTGGCAAAGTCAGGC	CGGTGTGGACACACG
CCAGAGACTGGGCTG	TGGCAAAGTCAGGCT	GGTGTGGACACACGC
CAGAGACTGGGCTGC	GGCAAAGTCAGGCTC	GTGTGGACACACGCT
AGAGACTGGGCTGCT	GCAAAGTCAGGCTCA	TGTGGACACACGCTG
GAGACTGGGCTGCTC	CAAAGTCAGGCTCAG	GTGGACACACGCTGC
AGACTGGGCTGCTCT	AAAGTCAGGCTCAGG	TGGACACACGCTGCA
GACTGGGCTGCTCTC	AAGTCAGGCTCAGGG	GGACACACGCTGCAT
ACTGGGCTGCTCTCC	AGTCAGGCTCAGGGA	GACACACGCTGCATA
CTGGGCTGCTCTCCC	GTCAGGCTCAGGGAG	ACACACGCTGCATAG
TGGGCTGCTCTCCCG	TCAGGCTCAGGGAGA	CACACGCTGCATAGA
GGGCTGCTCTCCCGG	CAGGCTCAGGGAGAC	ACACGCTGCATAGAG

CACGCTGCATAGAGC
ACGCTGCATAGAGCT
CGCTGCATAGAGCTC
GCTGCATAGAGCTCT
CTGCATAGAGCTCTC
TGCATAGAGCTCTCC
GCATAGAGCTCTCCT
CATAGAGCTCTCCTT
ATAGAGCTCTCCTTG
TAGAGCTCTCCTTGA
AGAGCTCTCCTTGAA
GAGCTCTCCTTGAAA
AGCTCTCCTTGAAAA
GCTCTCCTTGAAAAC
CTCTCCTTGAAAACA
TCTCCTTGAAAACAG
CTCCTTGAAAACAGA
TCCTTGAAAACAGAG
CCTTGAAAACAGAGG
CTTGAAAACAGAGGG
TTGAAAACAGAGGGG
TGAAAACAGAGGGGT
GAAAACAGAGGGGTC
AAAACAGAGGGGTCT
AAACAGAGGGGTCTC
AACAGAGGGGTCTCA
ACAGAGGGGTCTCAA
CAGAGGGGTCTCAAG
AGAGGGGTCTCAAGA
GAGGGGTCTCAAGAC
AGGGGTCTCAAGACA
GGGGTCTCAAGACAT
GGGTCTCAAGACATT
GGTCTCAAGACATTC
GTCTCAAGACATTCT
TCTCAAGACATTCTG
CTCAAGACATTCTGC
TCAAGACATTCTGCC
CAAGACATTCTGCCT
AAGACATTCTGCCTA
AGACATTCTGCCTAC
GACATTCTGCCTACC
ACATTCTGCCTACCT
CATTCTGCCTACCTA

ATTCTGCCTACCTAT
TTCTGCCTACCTATT
TCTGCCTACCTATTA
CTGCCTACCTATTAG
TGCCTACCTATTAGC
GCCTACCTATTAGCT
CCTACCTATTAGCTT
CTACCTATTAGCTTT
TACCTATTAGCTTTT
ACCTATTAGCTTTTC
CCTATTAGCTTTTCT
CTATTAGCTTTTCTT
TATTAGCTTTTCTTT
ATTAGCTTTTCTTTA
TTAGCTTTTCTTTAT
TAGCTTTTCTTTATT
AGCTTTTCTTTATTT
GCTTTTCTTTATTTT
CTTTTCTTTATTTTT
TTTTCTTTATTTTTT
TTTCTTTATTTTTTT
TTCTTTATTTTTTTA
TCTTTATTTTTTTAA
CTTTATTTTTTTAAC
TTTATTTTTTTAACT
TTATTTTTTTAACTT
TATTTTTTTAACTTT
ATTTTTTTAACTTTT
TTTTTTTAACTTTTT
TTTTTTAACTTTTTG
TTTTTAACTTTTTGG
TTTTAACTTTTTGGG
TTTAACTTTTTGGGG
TTAACTTTTTGGGGG
TAACTTTTTGGGGGG
AACTTTTTGGGGGGA
ACTTTTTGGGGGGAA
CTTTTTGGGGGGAAA
TTTTTGGGGGGAAAA
TTTTGGGGGGAAAAG
TTTGGGGGGAAAAGT
TTGGGGGGAAAAGTA
TGGGGGGAAAAGTAT
GGGGGGAAAAGTATT

GGGGGAAAAGTATTT
GGGGAAAAGTATTTT
GGGAAAAGTATTTTT
GGAAAAGTATTTTTG
GAAAAGTATTTTTGA
AAAAGTATTTTTGAG
AAAGTATTTTTGAGA
AAGTATTTTTGAGAA
AGTATTTTTGAGAAG
GTATTTTTGAGAAGT
TATTTTTGAGAAGTT
ATTTTTGAGAAGTTT
TTTTTGAGAAGTTTG
TTTTGAGAAGTTTGT
TTTGAGAAGTTTGTC
TTGAGAAGTTTGTCT
TGAGAAGTTTGTCTT
GAGAAGTTTGTCTTG
AGAAGTTTGTCTTGC
GAAGTTTGTCTTGCA
AAGTTTGTCTTGCAA
AGTTTGTCTTGCAAT
GTTTGTCTTGCAATG
TTTGTCTTGCAATGT
TTGTCTTGCAATGTA
TGTCTTGCAATGTAT
GTCTTGCAATGTATT
TCTTGCAATGTATTT
CTTGCAATGTATTTA
TTGCAATGTATTTAT
TGCAATGTATTTATA
GCAATGTATTTATAA
CAATGTATTTATAAA
AATGTATTTATAAAT
ATGTATTTATAAATA
TGTATTTATAAATAG
GTATTTATAAATAGT
TATTTATAAATAGTA
ATTTATAAATAGTAA
TTTATAAATAGTAAA
TTATAAATAGTAAAT
TATAAATAGTAAATA
ATAAATAGTAAATAA
TAAATAGTAAATAAA

AAATAGTAAATAAAG
AATAGTAAATAAAGT
ATAGTAAATAAAGTT
TAGTAAATAAAGTTT
AGTAAATAAAGTTTT
GTAAATAAAGTTTTT
TAAATAAAGTTTTTA
AAATAAAGTTTTTAC
AATAAAGTTTTTACC
ATAAAGTTTTTACCA
TAAAGTTTTTACCAT
AAAGTTTTTACCATT

EXAMPLE 8

Antisense oligonucleotides to IGF-I may be selected from molecules capable of interacting with one or more of the following sense oligonucleotides:

TTTTTTTTTTTTTTG	ATTTCATCCCAAATA	AAGTCTGGCTCCGGA
TTTTTTTTTTTTTGA	TTTCATCCCAAATAA	AGTCTGGCTCCGGAG
TTTTTTTTTTTTGAG	TTCATCCCAAATAAA	GTCTGGCTCCGGAGG
TTTTTTTTTTTGAGA	TCATCCCAAATAAAA	TCTGGCTCCGGAGGA
TTTTTTTTTTGAGAA	CATCCCAAATAAAAG	CTGGCTCCGGAGGAG
TTTTTTTTTGAGAAA	ATCCCAAATAAAAGG	TGGCTCCGGAGGAGG
TTTTTTTTGAGAAAG	TCCCAAATAAAAGGA	GGCTCCGGAGGAGGG
TTTTTTTGAGAAAGG	CCCAAATAAAAGGAA	GCTCCGGAGGAGGGT
TTTTTTGAGAAAGGG	CCAAATAAAAGGAAT	CTCCGGAGGAGGGTC
TTTTTGAGAAAGGGA	CAAATAAAAGGAATG	TCCGGAGGAGGGTCC
TTTTGAGAAAGGGAA	AAATAAAAGGAATGA	CCGGAGGAGGGTCCC
TTTGAGAAAGGGAAT	AATAAAAGGAATGAA	CGGAGGAGGGTCCCC
TTGAGAAAGGGAATT	ATAAAAGGAATGAAG	GGAGGAGGGTCCCCG
TGAGAAAGGGAATTT	TAAAAGGAATGAAGT	GAGGAGGGTCCCCGA
GAGAAAGGGAATTTC	AAAAGGAATGAAGTC	AGGAGGGTCCCCGAC
AGAAAGGGAATTTCA	AAAGGAATGAAGTCT	GGAGGGTCCCCGACC
GAAAGGGAATTTCAT	AAGGAATGAAGTCTG	GAGGGTCCCCGACCT
AAAGGGAATTTCATC	AGGAATGAAGTCTGG	AGGGTCCCCGACCTC
AAGGGAATTTCATCC	GGAATGAAGTCTGGC	GGGTCCCCGACCTCG
AGGGAATTTCATCCC	GAATGAAGTCTGGCT	GGTCCCCGACCTCGC
GGGAATTTCATCCCA	AATGAAGTCTGGCTC	GTCCCCGACCTCGCT
GGAATTTCATCCCAA	ATGAAGTCTGGCTCC	TCCCCGACCTCGCTG
GAATTTCATCCCAAA	TGAAGTCTGGCTCCG	CCCCGACCTCGCTGT
AATTTCATCCCAAAT	GAAGTCTGGCTCCGG	CCCGACCTCGCTGTG

	CCGACCTCGCTGTGG	GCTCTGGCCGACGAG	TCCGCAACGACTATC
	CGACCTCGCTGTGGG	CTCTGGCCGACGAGT	CCGCAACGACTATCA
	GACCTCGCTGTGGGG	TCTGGCCGACGAGTG	CGCAACGACTATCAG
	ACCTCGCTGTGGGGG	CTGGCCGACGAGTGG	GCAACGACTATCAGC
5	CCTCGCTGTGGGGGC	TGGCCGACGAGTGGA	CAACGACTATCAGCA
	CTCGCTGTGGGGGCT	GGCCGACGAGTGGAG	AACGACTATCAGCAG
	TCGCTGTGGGGGCTC	GCCGACGAGTGGAGA	ACGACTATCAGCAGC
	CGCTGTGGGGGCTCC	CCGACGAGTGGAGAA	CGACTATCAGCAGCT
	GCTGTGGGGGCTCCT	CGACGAGTGGAGAAA	GACTATCAGCAGCTG
10	CTGTGGGGGCTCCTG	GACGAGTGGAGAAAT	ACTATCAGCAGCTGA
	TGTGGGGGCTCCTGT	ACGAGTGGAGAAATC	CTATCAGCAGCTGAA
	GTGGGGGCTCCTGTT	CGAGTGGAGAAATCT	TATCAGCAGCTGAAG
	TGGGGGCTCCTGTTT	GAGTGGAGAAATCTG	ATCAGCAGCTGAAGC
	GGGGGCTCCTGTTTC	AGTGGAGAAATCTGC	TCAGCAGCTGAAGCG
15	GGGGCTCCTGTTTCT	GTGGAGAAATCTGCG	CAGCAGCTGAAGCGC
	GGGCTCCTGTTTCTC	TGGAGAAATCTGCGG	AGCAGCTGAAGCGCC
	GGCTCCTGTTTCTCT	GGAGAAATCTGCGGG	GCAGCTGAAGCGCCT
	GCTCCTGTTTCTCTC	GAGAAATCTGCGGGC	CAGCTGAAGCGCCTG
	CTCCTGTTTCTCTCC	AGAAATCTGCGGGCC	AGCTGAAGCGCCTGG
20	TCCTGTTTCTCTCCG	GAAATCTGCGGGCCA	GCTGAAGCGCCTGGA
	CCTGTTTCTCTCCGC	AAATCTGCGGGCCAG	CTGAAGCGCCTGGAG
	CTGTTTCTCTCCGCC	AATCTGCGGGCCAGG	TGAAGCGCCTGGAGA
	TGTTTCTCTCCGCCG	ATCTGCGGGCCAGGC	GAAGCGCCTGGAGAA
	GTTTCTCTCCGCCGC	TCTGCGGGCCAGGCA	AAGCGCCTGGAGAAC
25	TTTCTCTCCGCCGCG	CTGCGGGCCAGGCAT	AGCGCCTGGAGAACT
	TTCTCTCCGCCGCGC	TGCGGGCCAGGCATC	GCGCCTGGAGAACTG
	TCTCTCCGCCGCGCT	GCGGGCCAGGCATCG	CGCCTGGAGAACTGC
	CTCTCCGCCGCGCTC	CGGGCCAGGCATCGA	GCCTGGAGAACTGCA
	TCTCCGCCGCGCTCT	GGGCCAGGCATCGAC	CCTGGAGAACTGCAC
30	CTCCGCCGCGCTCTC	GGCCAGGCATCGACA	CTGGAGAACTGCACG
	TCCGCCGCGCTCTCG	GCCAGGCATCGACAT	TGGAGAACTGCACGG
	CCGCCGCGCTCTCGC	CCAGGCATCGACATC	GGAGAACTGCACGGT
	CGCCGCGCTCTCGCT	CAGGCATCGACATCC	GAGAACTGCACGGTG
	GCCGCGCTCTCGCTC	AGGCATCGACATCCG	AGAACTGCACGGTGA
35	CCGCGCTCTCGCTCT	GGCATCGACATCCGC	GAACTGCACGGTGAT
	CGCGCTCTCGCTCTG	GCATCGACATCCGCA	AACTGCACGGTGATC
	GCGCTCTCGCTCTGG	CATCGACATCCGCAA	ACTGCACGGTGATCG
	CGCTCTCGCTCTGGC	ATCGACATCCGCAAC	CTGCACGGTGATCGA
	GCTCTCGCTCTGGCC	TCGACATCCGCAACG	TGCACGGTGATCGAG
40	CTCTCGCTCTGGCCG	CGACATCCGCAACGA	GCACGGTGATCGAGG
	TCTCGCTCTGGCCGA	GACATCCGCAACGAC	CACGGTGATCGAGGG
	CTCGCTCTGGCCGAC	ACATCCGCAACGACT	ACGGTGATCGAGGGC
	TCGCTCTGGCCGACG	CATCCGCAACGACTA	CGGTGATCGAGGGCT
	CGCTCTGGCCGACGA	ATCCGCAACGACTAT	GGTGATCGAGGGCTA

GTGATCGAGGGCTAC
TGATCGAGGGCTACC
GATCGAGGGCTACCT
ATCGAGGGCTACCTC
TCGAGGGCTACCTCC
CGAGGGCTACCTCCA
GAGGGCTACCTCCAC
AGGGCTACCTCCACA
GGGCTACCTCCACAT
GGCTACCTCCACATC
GCTACCTCCACATCC
CTACCTCCACATCCT
TACCTCCACATCCTG
ACCTCCACATCCTGC
CCTCCACATCCTGCT
CTCCACATCCTGCTC
TCCACATCCTGCTCA
CCACATCCTGCTCAT
CACATCCTGCTCATC
ACATCCTGCTCATCT
CATCCTGCTCATCTC
ATCCTGCTCATCTCC
TCCTGCTCATCTCCA
CCTGCTCATCTCCAA
CTGCTCATCTCCAAG
TGCTCATCTCCAAGG
GCTCATCTCCAAGGC
CTCATCTCCAAGGCC
TCATCTCCAAGGCCG
CATCTCCAAGGCCGA
ATCTCCAAGGCCGAG
TCTCCAAGGCCGAGG
CTCCAAGGCCGAGGA
TCCAAGGCCGAGGAC
CCAAGGCCGAGGACT
CAAGGCCGAGGACTA
AAGGCCGAGGACTAC
AGGCCGAGGACTACC
GGCCGAGGACTACCG
GCCGAGGACTACCGC
CCGAGGACTACCGCA
CGAGGACTACCGCAG
GAGGACTACCGCAGC
AGGACTACCGCAGCT

GGACTACCGCAGCTA
GACTACCGCAGCTAC
ACTACCGCAGCTACC
CTACCGCAGCTACCG
TACCGCAGCTACCGC
ACCGCAGCTACCGCT
CCGCAGCTACCGCTT
CGCAGCTACCGCTTC
GCAGCTACCGCTTCC
CAGCTACCGCTTCCC
AGCTACCGCTTCCCC
GCTACCGCTTCCCCA
CTACCGCTTCCCCAA
TACCGCTTCCCCAAG
ACCGCTTCCCCAAGC
CCGCTTCCCCAAGCT
CGCTTCCCCAAGCTC
GCTTCCCCAAGCTCA
CTTCCCCAAGCTCAC
TTCCCCAAGCTCACG
TCCCCAAGCTCACGG
CCCCAAGCTCACGGT
CCCCAAGCTCACGGTC
CCCAAGCTCACGGTCA
CCAAGCTCACGGTCAT
CAAGCTCACGGTCATT
AAGCTCACGGTCATTA
AGCTCACGGTCATTAC
GCTCACGGTCATTACC
CTCACGGTCATTACCG
TCACGGTCATTACCGA
CACGGTCATTACCGAG
ACGGTCATTACCGAGT
CGGTCATTACCGAGTA
GGTCATTACCGAGTAC
GTCATTACCGAGTACT
TCATTACCGAGTACTT
CATTACCGAGTACTTG
ATTACCGAGTACTTGC
TTACCGAGTACTTGCT
TACCGAGTACTTGCTG
ACCGAGTACTTGCTGC
CCGAGTACTTGCTGCT
CGAGTACTTGCTGCTG
GAGTACTTGCTGCTGT
AGTACTTGCTGCTGTT
GTACTTGCTGCTGTTC
TACTTGCTGCTGTTCC
ACTTGCTGCTGTTCCG
CTTGCTGCTGTTCCGA
TTGCTGCTGTTCCGAG
TGCTGCTGTTCCGAGT
GCTGCTGTTCCGAGTG
CTGCTGTTCCGAGTGG
TGCTGTTCCGAGTGGC
GCTGTTCCGAGTGGCT
CTGTTCCGAGTGGCTG
TGTTCCGAGTGGCTGG
GTTCCGAGTGGCTGGC
TTCCGAGTGGCTGGCC
TCCGAGTGGCTGGCCT
CCGAGTGGCTGGCCTC
CGAGTGGCTGGCCTCG
GAGTGGCTGGCCTCGA
AGTGGCTGGCCTCGAG
GTGGCTGGCCTCGAGA
TGGCTGGCCTCGAGAG
GGCTGGCCTCGAGAGC
GCTGGCCTCGAGAGCC
CTGGCCTCGAGAGCCT
TGGCCTCGAGAGCCTC
GGCCTCGAGAGCCTCG
GCCTCGAGAGCCTCGG
CCTCGAGAGCCTCGGA
CTCGAGAGCCTCGGAG
TCGAGAGCCTCGGAGA
CGAGAGCCTCGGAGAC
GAGAGCCTCGGAGACC
AGAGCCTCGGAGACCT
GAGCCTCGGAGACCTC
AGCCTCGGAGACCTCT
GCCTCGGAGACCTCTT
CCTCGGAGACCTCTTC
CTCGGAGACCTCTTCC
TCGGAGACCTCTTCCC
CGGAGACCTCTTCCCC
GGAGACCTCTTCCCCA
GAGACCTCTTCCCCAA

	GACCTCTTCCCCAAC	CTACAACTACGCCCT	ATATTGGGCTTTACA
	ACCTCTTCCCCAACC	TACAACTACGCCCTG	TATTGGGCTTTACAA
	CCTCTTCCCCAACCT	ACAACTACGCCCTGG	ATTGGGCTTTACAAC
	CTCTTCCCCAACCTC	CAACTACGCCCTGGT	TTGGGCTTTACAACC
5	TCTTCCCCAACCTCA	AACTACGCCCTGGTC	TGGGCTTTACAACCT
	CTTCCCCAACCTCAC	ACTACGCCCTGGTCA	GGGCTTTACAACCTG
	TTCCCCAACCTCACG	CTACGCCCTGGTCAT	GGCTTTACAACCTGA
	TCCCCAACCTCACGG	TACGCCCTGGTCATC	GCTTTACAACCTGAG
	CCCCAACCTCACGGT	ACGCCCTGGTCATCT	CTTTACAACCTGAGG
10	CCCAACCTCACGGTC	CGCCCTGGTCATCTT	TTTACAACCTGAGGA
	CCAACCTCACGGTCA	GCCCTGGTCATCTTC	TTACAACCTGAGGAA
	CAACCTCACGGTCAT	CCCTGGTCATCTTCG	TACAACCTGAGGAAC
	AACCTCACGGTCATC	CCTGGTCATCTTCGA	ACAACCTGAGGAACA
	ACCTCACGGTCATCC	CTGGTCATCTTCGAG	CAACCTGAGGAACAT
15	CCTCACGGTCATCCG	TGGTCATCTTCGAGA	AACCTGAGGAACATT
	CTCACGGTCATCCGC	GGTCATCTTCGAGAT	ACCTGAGGAACATTA
	TCACGGTCATCCGCG	GTCATCTTCGAGATG	CCTGAGGAACATTAC
	CACGGTCATCCGCGG	TCATCTTCGAGATGA	CTGAGGAACATTACT
	ACGGTCATCCGCGGC	CATCTTCGAGATGAC	TGAGGAACATTACTC
20	CGGTCATCCGCGGCT	ATCTTCGAGATGACC	GAGGAACATTACTCG
	GGTCATCCGCGGCTG	TCTTCGAGATGACCA	AGGAACATTACTCGG
	GTCATCCGCGGCTGG	CTTCGAGATGACCAA	GGAACATTACTCGGG
	TCATCCGCGGCTGGA	TTCGAGATGACCAAT	GAACATTACTCGGGG
	CATCCGCGGCTGGAA	TCGAGATGACCAATC	AACATTACTCGGGGG
25	ATCCGCGGCTGGAAA	CGAGATGACCAATCT	ACATTACTCGGGGGG
	TCCGCGGCTGGAAAC	GAGATGACCAATCTC	CATTACTCGGGGGGC
	CCGCGGCTGGAAACT	AGATGACCAATCTCA	ATTACTCGGGGGGCC
	CGCGGCTGGAAACTC	GATGACCAATCTCAA	TTACTCGGGGGGCCA
	GCGGCTGGAAACTCT	ATGACCAATCTCAAG	TACTCGGGGGGCCAT
30	CGGCTGGAAACTCTT	TGACCAATCTCAAGG	ACTCGGGGGGCCATC
	GGCTGGAAACTCTTC	GACCAATCTCAAGGA	CTCGGGGGGCCATCA
	GCTGGAAACTCTTCT	ACCAATCTCAAGGAT	TCGGGGGGCCATCAG
	CTGGAAACTCTTCTA	CCAATCTCAAGGATA	CGGGGGGCCATCAGG
	TGGAAACTCTTCTAC	CAATCTCAAGGATAT	GGGGGGCCATCAGGA
35	GGAAACTCTTCTACA	AATCTCAAGGATATT	GGGGGCCATCAGGAT
	GAAACTCTTCTACAA	ATCTCAAGGATATTG	GGGGCCATCAGGATT
	AAACTCTTCTACAAC	TCTCAAGGATATTGG	GGGCCATCAGGATTG
	AACTCTTCTACAACT	CTCAAGGATATTGGG	GGCCATCAGGATTGA
	ACTCTTCTACAACTA	TCAAGGATATTGGGC	GCCATCAGGATTGAG
40	CTCTTCTACAACTAC	CAAGGATATTGGGCT	CCATCAGGATTGAGA
	TCTTCTACAACTACG	AAGGATATTGGGCTT	CATCAGGATTGAGAA
	CTTCTACAACTACGC	AGGATATTGGGCTTT	ATCAGGATTGAGAAA
	TTCTACAACTACGCC	GGATATTGGGCTTTA	TCAGGATTGAGAAAA
	TCTACAACTACGCCC	GATATTGGGCTTTAC	CAGGATTGAGAAAAA

	AGGATTGAGAAAAAT	CTGGTCCCTGATCCT	GGAATAAGCCCCCAA
	GGATTGAGAAAAATG	TGGTCCCTGATCCTG	GAATAAGCCCCCAAA
	GATTGAGAAAAATGC	GGTCCCTGATCCTGG	AATAAGCCCCCAAAG
	ATTGAGAAAAATGCT	GTCCCTGATCCTGGA	ATAAGCCCCCAAAGG
5	TTGAGAAAAATGCTG	TCCCTGATCCTGGAT	TAAGCCCCCAAAGGA
	TGAGAAAAATGCTGA	CCCTGATCCTGGATG	AAGCCCCCAAAGGAA
	GAGAAAAATGCTGAC	CCTGATCCTGGATGC	AGCCCCCAAAGGAAT
	AGAAAAATGCTGACC	CTGATCCTGGATGCG	GCCCCCAAAGGAATG
	GAAAAATGCTGACCT	TGATCCTGGATGCGG	CCCCCAAAGGAATGT
10	AAAAATGCTGACCTC	GATCCTGGATGCGGT	CCCCAAAGGAATGTG
	AAAATGCTGACCTCT	ATCCTGGATGCGGTG	CCCAAAGGAATGTGG
	AAATGCTGACCTCTG	TCCTGGATGCGGTGT	CCAAAGGAATGTGGG
	AATGCTGACCTCTGT	CCTGGATGCGGTGTC	CAAAGGAATGTGGGG
	ATGCTGACCTCTGTT	CTGGATGCGGTGTCC	AAAGGAATGTGGGGA
15	TGCTGACCTCTGTTA	TGGATGCGGTGTCCA	AAGGAATGTGGGGAC
	GCTGACCTCTGTTAC	GGATGCGGTGTCCAA	AGGAATGTGGGGACC
	CTGACCTCTGTTACC	GATGCGGTGTCCAAT	GGAATGTGGGGACCT
	TGACCTCTGTTACCT	ATGCGGTGTCCAATA	GAATGTGGGGACCTG
	GACCTCTGTTACCTC	TGCGGTGTCCAATAA	AATGTGGGGACCTGT
20	ACCTCTGTTACCTCT	GCGGTGTCCAATAAC	ATGTGGGGACCTGTG
	CCTCTGTTACCTCTC	CGGTGTCCAATAACT	TGTGGGGACCTGTGT
	CTCTGTTACCTCTCC	GGTGTCCAATAACTA	GTGGGGACCTGTGTC
	TCTGTTACCTCTCCA	GTGTCCAATAACTAC	TGGGGACCTGTGTCC
	CTGTTACCTCTCCAC	TGTCCAATAACTACA	GGGGACCTGTGTCCA
25	TGTTACCTCTCCACT	GTCCAATAACTACAT	GGGACCTGTGTCCAG
	GTTACCTCTCCACTG	TCCAATAACTACATT	GGACCTGTGTCCAGG
	TTACCTCTCCACTGT	CCAATAACTACATTG	GACCTGTGTCCAGGG
	TACCTCTCCACTGTG	CAATAACTACATTGT	ACCTGTGTCCAGGGA
	ACCTCTCCACTGTGG	AATAACTACATTGTG	CCTGTGTCCAGGGAC
30	CCTCTCCACTGTGGA	ATAACTACATTGTGG	CTGTGTCCAGGGACC
	CTCTCCACTGTGGAC	TAACTACATTGTGGG	TGTGTCCAGGGACCA
	TCTCCACTGTGGACT	AACTACATTGTGGGG	GTGTCCAGGGACCAT
	CTCCACTGTGGACTG	ACTACATTGTGGGGA	TGTCCAGGGACCATG
	TCCACTGTGGACTGG	CTACATTGTGGGGAA	GTCCAGGGACCATGG
35	CCACTGTGGACTGGT	TACATTGTGGGGAAT	TCCAGGGACCATGGA
	CACTGTGGACTGGTC	ACATTGTGGGGAATA	CCAGGGACCATGGAG
	ACTGTGGACTGGTCC	CATTGTGGGGAATAA	CAGGGACCATGGAGG
	CTGTGGACTGGTCCC	ATTGTGGGGAATAAG	AGGGACCATGGAGGA
	TGTGGACTGGTCCCT	TTGTGGGGAATAAGC	GGGACCATGGAGGAG
40	GTGGACTGGTCCCTG	TGTGGGGAATAAGCC	GGACCATGGAGGAGA
	TGGACTGGTCCCTGA	GTGGGGAATAAGCCC	GACCATGGAGGAGAA
	GGACTGGTCCCTGAT	TGGGGAATAAGCCCC	ACCATGGAGGAGAAG
	GACTGGTCCCTGATC	GGGGAATAAGCCCCC	CCATGGAGGAGAAGC
	ACTGGTCCCTGATCC	GGGAATAAGCCCCCA	CATGGAGGAGAAGCC

	ATGGAGGAGAAGCCG	GTACAACTACCGCTG	GCCCAAGCACGTGTG
	TGGAGGAGAAGCCGA	TACAACTACCGCTGC	CCCAAGCACGTGTGG
	GGAGGAGAAGCCGAT	ACAACTACCGCTGCT	CCAAGCACGTGTGGG
	GAGGAGAAGCCGATG	CAACTACCGCTGCTG	CAAGCACGTGTGGGA
5	AGGAGAAGCCGATGT	AACTACCGCTGCTGG	AAGCACGTGTGGGAA
	GGAGAAGCCGATGTG	ACTACCGCTGCTGGA	AGCACGTGTGGGAAG
	GAGAAGCCGATGTGT	CTACCGCTGCTGGAC	GCACGTGTGGGAAGC
	AGAAGCCGATGTGTG	TACCGCTGCTGGACC	CACGTGTGGGAAGCG
	GAAGCCGATGTGTGA	ACCGCTGCTGGACCA	ACGTGTGGGAAGCGG
10	AAGCCGATGTGTGAG	CCGCTGCTGGACCAC	CGTGTGGGAAGCGGG
	AGCCGATGTGTGAGA	CGCTGCTGGACCACA	GTGTGGGAAGCGGGC
	GCCGATGTGTGAGAA	GCTGCTGGACCACAA	TGTGGGAAGCGGGCG
	CCGATGTGTGAGAAG	CTGCTGGACCACAAA	GTGGGAAGCGGGCGT
	CGATGTGTGAGAAGA	TGCTGGACCACAAAC	TGGGAAGCGGGCGTG
15	GATGTGTGAGAAGAC	GCTGGACCACAAACC	GGGAAGCGGGCGTGC
	ATGTGTGAGAAGACC	CTGGACCACAAACCG	GGAAGCGGGCGTGCA
	TGTGTGAGAAGACCA	TGGACCACAAACCGC	GAAGCGGGCGTGCAC
	GTGTGAGAAGACCAC	GGACCACAAACCGCT	AAGCGGGCGTGCACC
	TGTGAGAAGACCACC	GACCACAAACCGCTG	AGCGGGCGTGCACCG
20	GTGAGAAGACCACCA	ACCACAAACCGCTGC	GCGGGCGTGCACCGA
	TGAGAAGACCACCAT	CCACAAACCGCTGCC	CGGGCGTGCACCGAG
	GAGAAGACCACCATC	CACAAACCGCTGCCA	GGGCGTGCACCGAGA
	AGAAGACCACCATCA	ACAAACCGCTGCCAG	GGCGTGCACCGAGAA
	GAAGACCACCATCAA	CAAACCGCTGCCAGA	GCGTGCACCGAGAAC
25	AAGACCACCATCAAC	AAACCGCTGCCAGAA	CGTGCACCGAGAACA
	AGACCACCATCAACA	AACCGCTGCCAGAAA	GTGCACCGAGAACAA
	GACCACCATCAACAA	ACCGCTGCCAGAAAA	TGCACCGAGAACAAT
	ACCACCATCAACAAT	CCGCTGCCAGAAAAT	GCACCGAGAACAATG
	CCACCATCAACAATG	CGCTGCCAGAAAATG	CACCGAGAACAATGA
30	CACCATCAACAATGA	GCTGCCAGAAAATGT	ACCGAGAACAATGAG
	ACCATCAACAATGAG	CTGCCAGAAAATGTG	CCGAGAACAATGAGT
	CCATCAACAATGAGT	TGCCAGAAAATGTGC	CGAGAACAATGAGTG
	CATCAACAATGAGTA	GCCAGAAAATGTGCC	GAGAACAATGAGTGC
	ATCAACAATGAGTAC	CCAGAAAATGTGCCC	AGAACAATGAGTGCT
35	TCAACAATGAGTACA	CAGAAAATGTGCCCA	GAACAATGAGTGCTG
	CAACAATGAGTACAA	AGAAAATGTGCCCAA	AACAATGAGTGCTGC
	AACAATGAGTACAAC	GAAAATGTGCCCAAG	ACAATGAGTGCTGCC
	ACAATGAGTACAACT	AAAATGTGCCCAAGC	CAATGAGTGCTGCCA
	CAATGAGTACAACTA	AAATGTGCCCAAGCA	AATGAGTGCTGCCAC
40	AATGAGTACAACTAC	AATGTGCCCAAGCAC	ATGAGTGCTGCCACC
	ATGAGTACAACTACC	ATGTGCCCAAGCACG	TGAGTGCTGCCACCC
	TGAGTACAACTACCG	TGTGCCCAAGCACGT	GAGTGCTGCCACCCC
	GAGTACAACTACCGC	GTGCCCAAGCACGTG	AGTGCTGCCACCCCG
	AGTACAACTACCGCT	TGCCCAAGCACGTGT	GTGCTGCCACCCCGA

	TGCTGCCACCCCGAG	CGACACGGCCTGTGT	TCTGTGTGCCTGCCT
	GCTGCCACCCCGAGT	GACACGGCCTGTGTA	CTGTGTGCCTGCCTG
	CTGCCACCCCGAGTG	ACACGGCCTGTGTAG	TGTGTGCCTGCCTGC
	TGCCACCCCGAGTGC	CACGGCCTGTGTAGC	GTGTGCCTGCCTGCC
5	GCCACCCCGAGTGCC	ACGGCCTGTGTAGCT	TGTGCCTGCCTGCCC
	CCACCCCGAGTGCCT	CGGCCTGTGTAGCTT	GTGCCTGCCTGCCCG
	CACCCCGAGTGCCTG	GGCCTGTGTAGCTTG	TGCCTGCCTGCCCGC
	ACCCCGAGTGCCTGG	GCCTGTGTAGCTTGC	GCCTGCCTGCCCGCC
	CCCCGAGTGCCTGGG	CCTGTGTAGCTTGCC	CCTGCCTGCCCGCCC
10	CCCGAGTGCCTGGGC	CTGTGTAGCTTGCCG	CTGCCTGCCCGCCCA
	CCGAGTGCCTGGGCA	TGTGTAGCTTGCCGC	TGCCTGCCCGCCCAA
	CGAGTGCCTGGGCAG	GTGTAGCTTGCCGCC	GCCTGCCCGCCCAAC
	GAGTGCCTGGGCAGC	TGTAGCTTGCCGCCA	CCTGCCCGCCCAACA
	AGTGCCTGGGCAGCT	GTAGCTTGCCGCCAC	CTGCCCGCCCAACAC
15	GTGCCTGGGCAGCTG	TAGCTTGCCGCCACT	TGCCCGCCCAACACC
	TGCCTGGGCAGCTGC	AGCTTGCCGCCACTA	GCCCGCCCAACACCT
	GCCTGGGCAGCTGCA	GCTTGCCGCCACTAC	CCCGCCCAACACCTA
	CCTGGGCAGCTGCAG	CTTGCCGCCACTACT	CCGCCCAACACCTAC
	CTGGGCAGCTGCAGC	TTGCCGCCACTACTA	CGCCCAACACCTACA
20	TGGGCAGCTGCAGCG	TGCCGCCACTACTAC	GCCCAACACCTACAG
	GGGCAGCTGCAGCGC	GCCGCCACTACTACT	CCCAACACCTACAGG
	GGCAGCTGCAGCGCG	CCGCCACTACTACTA	CCAACACCTACAGGT
	GCAGCTGCAGCGCGC	CGCCACTACTACTAT	CAACACCTACAGGTT
	CAGCTGCAGCGCGCC	GCCACTACTACTATG	AACACCTACAGGTTT
25	AGCTGCAGCGCGCCT	CCACTACTACTATGC	ACACCTACAGGTTTG
	GCTGCAGCGCGCCTG	CACTACTACTATGCC	CACCTACAGGTTTGA
	CTGCAGCGCGCCTGA	ACTACTACTATGCCG	ACCTACAGGTTTGAG
	TGCAGCGCGCCTGAC	CTACTACTATGCCGG	CCTACAGGTTTGAGG
	GCAGCGCGCCTGACA	TACTACTATGCCGGT	CTACAGGTTTGAGGG
30	CAGCGCGCCTGACAA	ACTACTATGCCGGTG	TACAGGTTTGAGGGC
	AGCGCGCCTGACAAC	CTACTATGCCGGTGT	ACAGGTTTGAGGGCT
	GCGCGCCTGACAACG	TACTATGCCGGTGTC	CAGGTTTGAGGGCTG
	CGCGCCTGACAACGA	ACTATGCCGGTGTCT	AGGTTTGAGGGCTGG
	GCGCCTGACAACGAC	CTATGCCGGTGTCTG	GGTTTGAGGGCTGGC
35	CGCCTGACAACGACA	TATGCCGGTGTCTGT	GTTTGAGGGCTGGCG
	GCCTGACAACGACAC	ATGCCGGTGTCTGTG	TTTGAGGGCTGGCGC
	CCTGACAACGACACG	TGCCGGTGTCTGTGT	TTGAGGGCTGGCGCT
	CTGACAACGACACGG	GCCGGTGTCTGTGTG	TGAGGGCTGGCGCTG
	TGACAACGACACGGC	CCGGTGTCTGTGTGC	GAGGGCTGGCGCTGT
40	GACAACGACACGGCC	CGGTGTCTGTGTGCC	AGGGCTGGCGCTGTG
	ACAACGACACGGCCT	GGTGTCTGTGTGCCT	GGGCTGGCGCTGTGT
	CAACGACACGGCCTG	GTGTCTGTGTGCCTG	GGCTGGCGCTGTGTG
	AACGACACGGCCTGT	TGTCTGTGTGCCTGC	GCTGGCGCTGTGTGG
	ACGACACGGCCTGTG	GTCTGTGTGCCTGCC	CTGGCGCTGTGTGGA

	TGGCGCTGTGTGGAC	CGAGAGCAGCGACTC	GCATGCAGGAGTGCC
	GGCGCTGTGTGGACC	GAGAGCAGCGACTCC	CATGCAGGAGTGCCC
	GCGCTGTGTGGACCG	AGAGCAGCGACTCCG	ATGCAGGAGTGCCCC
	CGCTGTGTGGACCGT	GAGCAGCGACTCCGA	TGCAGGAGTGCCCCT
5	GCTGTGTGGACCGTG	AGCAGCGACTCCGAG	GCAGGAGTGCCCCTC
	CTGTGTGGACCGTGA	GCAGCGACTCCGAGG	CAGGAGTGCCCCTCG
	TGTGTGGACCGTGAC	CAGCGACTCCGAGGG	AGGAGTGCCCCTCGG
	GTGTGGACCGTGACT	AGCGACTCCGAGGGG	GGAGTGCCCCTCGGG
	TGTGGACCGTGACTT	GCGACTCCGAGGGGT	GAGTGCCCCTCGGGC
10	GTGGACCGTGACTTC	CGACTCCGAGGGGTT	AGTGCCCCTCGGGCT
	TGGACCGTGACTTCT	GACTCCGAGGGGTTT	GTGCCCCTCGGGCTT
	GGACCGTGACTTCTG	ACTCCGAGGGGTTTG	TGCCCCTCGGGCTTC
	GACCGTGACTTCTGC	CTCCGAGGGGTTTGT	GCCCCTCGGGCTTCA
	ACCGTGACTTCTGCG	TCCGAGGGGTTTGTG	CCCCTCGGGCTTCAT
15	CCGTGACTTCTGCGC	CCGAGGGGTTTGTGA	CCCTCGGGCTTCATC
	CGTGACTTCTGCGCC	CGAGGGGTTTGTGAT	CCTCGGGCTTCATCC
	GTGACTTCTGCGCCA	GAGGGGTTTGTGATC	CTCGGGCTTCATCCG
	TGACTTCTGCGCCAA	AGGGGTTTGTGATCC	TCGGGCTTCATCCGC
	GACTTCTGCGCCAAC	GGGGTTTGTGATCCA	CGGGCTTCATCCGCA
20	ACTTCTGCGCCAACA	GGGTTTGTGATCCAC	GGGCTTCATCCGCAA
	CTTCTGCGCCAACAT	GGTTTGTGATCCACG	GGCTTCATCCGCAAC
	TTCTGCGCCAACATC	GTTTGTGATCCACGA	GCTTCATCCGCAACG
	TCTGCGCCAACATCC	TTTGTGATCCACGAC	CTTCATCCGCAACGG
	CTGCGCCAACATCCT	TTGTGATCCACGACG	TTCATCCGCAACGGC
25	TGCGCCAACATCCTC	TGTGATCCACGACGG	TCATCCGCAACGGCA
	GCGCCAACATCCTCA	GTGATCCACGACGGC	CATCCGCAACGGCAG
	CGCCAACATCCTCAG	TGATCCACGACGGCG	ATCCGCAACGGCAGC
	GCCAACATCCTCAGC	GATCCACGACGGCGA	TCCGCAACGGCAGCC
	CCAACATCCTCAGCG	ATCCACGACGGCGAG	CCGCAACGGCAGCCA
30	CAACATCCTCAGCGC	TCCACGACGGCGAGT	CGCAACGGCAGCCAG
	AACATCCTCAGCGCC	CCACGACGGCGAGTG	GCAACGGCAGCCAGA
	ACATCCTCAGCGCCG	CACGACGGCGAGTGC	CAACGGCAGCCAGAG
	CATCCTCAGCGCCGA	ACGACGGCGAGTGCA	AACGGCAGCCAGAGC
	ATCCTCAGCGCCGAG	CGACGGCGAGTGCAT	ACGGCAGCCAGAGCA
35	TCCTCAGCGCCGAGA	GACGGCGAGTGCATG	CGGCAGCCAGAGCAT
	CCTCAGCGCCGAGAG	ACGGCGAGTGCATGC	GGCAGCCAGAGCATG
	CTCAGCGCCGAGAGC	CGGCGAGTGCATGCA	GCAGCCAGAGCATGT
	TCAGCGCCGAGAGCA	GGCGAGTGCATGCAG	CAGCCAGAGCATGTA
	CAGCGCCGAGAGCAG	GCGAGTGCATGCAGG	AGCCAGAGCATGTAC
40	AGCGCCGAGAGCAGC	CGAGTGCATGCAGGA	GCCAGAGCATGTACT
	GCGCCGAGAGCAGCG	GAGTGCATGCAGGAG	CCAGAGCATGTACTG
	CGCCGAGAGCAGCGA	AGTGCATGCAGGAGT	CAGAGCATGTACTGC
	GCCGAGAGCAGCGAC	GTGCATGCAGGAGTG	AGAGCATGTACTGCA
	CCGAGAGCAGCGACT	TGCATGCAGGAGTGC	GAGCATGTACTGCAT

	AGCATGTACTGCATC	TGAGGAAGAAAAGAA	CTCAGATGCTCCAAG
	GCATGTACTGCATCC	GAGGAAGAAAAGAAA	TCAGATGCTCCAAGG
	CATGTACTGCATCCC	AGGAAGAAAAGAAAA	CAGATGCTCCAAGGA
	ATGTACTGCATCCCT	GGAAGAAAAGAAAAC	AGATGCTCCAAGGAT
5	TGTACTGCATCCCTT	GAAGAAAAGAAAACA	GATGCTCCAAGGATG
	GTACTGCATCCCTTG	AAGAAAAGAAAACAA	ATGCTCCAAGGATGC
	TACTGCATCCCTTGT	AGAAAAGAAAACAAA	TGCTCCAAGGATGCA
	ACTGCATCCCTTGTG	GAAAAGAAAACAAAG	GCTCCAAGGATGCAC
	CTGCATCCCTTGTGA	AAAAGAAAACAAAGA	CTCCAAGGATGCACC
10	TGCATCCCTTGTGAA	AAAGAAAACAAAGAC	TCCAAGGATGCACCA
	GCATCCCTTGTGAAG	AAGAAAACAAAGACC	CCAAGGATGCACCAT
	CATCCCTTGTGAAGG	AGAAAACAAAGACCA	CAAGGATGCACCATC
	ATCCCTTGTGAAGGT	GAAAACAAAGACCAT	AAGGATGCACCATCT
	TCCCTTGTGAAGGTC	AAAACAAAGACCATT	AGGATGCACCATCTT
15	CCCTTGTGAAGGTCC	AAACAAAGACCATTG	GGATGCACCATCTTC
	CCTTGTGAAGGTCCT	AACAAAGACCATTGA	GATGCACCATCTTCA
	CTTGTGAAGGTCCTT	ACAAAGACCATTGAT	ATGCACCATCTTCAA
	TTGTGAAGGTCCTTG	CAAAGACCATTGATT	TGCACCATCTTCAAG
	TGTGAAGGTCCTTGC	AAAGACCATTGATTC	GCACCATCTTCAAGG
20	GTGAAGGTCCTTGCC	AAGACCATTGATTCT	CACCATCTTCAAGGG
	TGAAGGTCCTTGCCC	AGACCATTGATTCTG	ACCATCTTCAAGGGC
	GAAGGTCCTTGCCCG	GACCATTGATTCTGT	CCATCTTCAAGGGCA
	AAGGTCCTTGCCCGA	ACCATTGATTCTGTT	CATCTTCAAGGGCAA
	AGGTCCTTGCCCGAA	CCATTGATTCTGTTA	ATCTTCAAGGGCAAT
25	GGTCCTTGCCCGAAG	CATTGATTCTGTTAC	TCTTCAAGGGCAATT
	GTCCTTGCCCGAAGG	ATTGATTCTGTTACT	CTTCAAGGGCAATTT
	TCCTTGCCCGAAGGT	TTGATTCTGTTACTT	TTCAAGGGCAATTTG
	CCTTGCCCGAAGGTC	TGATTCTGTTACTTC	TCAAGGGCAATTTGC
	CTTGCCCGAAGGTCT	GATTCTGTTACTTCT	CAAGGGCAATTTGCT
30	TTGCCCGAAGGTCTG	ATTCTGTTACTTCTG	AAGGGCAATTTGCTC
	TGCCCGAAGGTCTGT	TTCTGTTACTTCTGC	AGGGCAATTTGCTCA
	GCCCGAAGGTCTGTG	TCTGTTACTTCTGCT	GGGCAATTTGCTCAT
	CCCGAAGGTCTGTGA	CTGTTACTTCTGCTC	GGCAATTTGCTCATT
	CCGAAGGTCTGTGAG	TGTTACTTCTGCTCA	GCAATTTGCTCATTA
35	CGAAGGTCTGTGAGG	GTTACTTCTGCTCAG	CAATTTGCTCATTAA
	GAAGGTCTGTGAGGA	TTACTTCTGCTCAGA	AATTTGCTCATTAAC
	AAGGTCTGTGAGGAA	TACTTCTGCTCAGAT	ATTTGCTCATTAACA
	AGGTCTGTGAGGAAG	ACTTCTGCTCAGATG	TTTGCTCATTAACAT
	GGTCTGTGAGGAAGA	CTTCTGCTCAGATGC	TTGCTCATTAACATC
40	GTCTGTGAGGAAGAA	TTCTGCTCAGATGCT	TGCTCATTAACATCC
	TCTGTGAGGAAGAAA	TCTGCTCAGATGCTC	GCTCATTAACATCCG
	CTGTGAGGAAGAAAA	CTGCTCAGATGCTCC	CTCATTAACATCCGA
	TGTGAGGAAGAAAAG	TGCTCAGATGCTCCA	TCATTAACATCCGAC
	GTGAGGAAGAAAAGA	GCTCAGATGCTCCAA	CATTAACATCCGACG

	ATTAACATCCGACGG	CTTCATGGGGCTCAT	GCCATTCTCATGCCT
	TTAACATCCGACGGG	TTCATGGGGCTCATC	CCATTCTCATGCCTT
	TAACATCCGACGGGG	TCATGGGGCTCATCG	CATTCTCATGCCTTG
	AACATCCGACGGGGG	CATGGGGCTCATCGA	ATTCTCATGCCTTGG
5	ACATCCGACGGGGGA	ATGGGGCTCATCGAG	TTCTCATGCCTTGGT
	CATCCGACGGGGGAA	TGGGGCTCATCGAGG	TCTCATGCCTTGGTC
	ATCCGACGGGGGAAT	GGGGCTCATCGAGGT	CTCATGCCTTGGTCT
	TCCGACGGGGGAATA	GGGCTCATCGAGGTG	TCATGCCTTGGTCTC
	CCGACGGGGGAATAA	GGCTCATCGAGGTGG	CATGCCTTGGTCTCC
10	CGACGGGGGAATAAC	GCTCATCGAGGTGGT	ATGCCTTGGTCTCCT
	GACGGGGGAATAACA	CTCATCGAGGTGGTG	TGCCTTGGTCTCCTT
	ACGGGGGAATAACAT	TCATCGAGGTGGTGA	GCCTTGGTCTCCTTG
	CGGGGGAATAACATT	CATCGAGGTGGTGAC	CCTTGGTCTCCTTGT
	GGGGGAATAACATTG	ATCGAGGTGGTGACG	CTTGGTCTCCTTGTC
15	GGGGAATAACATTGC	TCGAGGTGGTGACGG	TTGGTCTCCTTGTCC
	GGGAATAACATTGCT	CGAGGTGGTGACGGG	TGGTCTCCTTGTCCT
	GGAATAACATTGCTT	GAGGTGGTGACGGGC	GGTCTCCTTGTCCTT
	GAATAACATTGCTTC	AGGTGGTGACGGGCT	GTCTCCTTGTCCTTC
	AATAACATTGCTTCA	GGTGGTGACGGGCTA	TCTCCTTGTCCTTCC
20	ATAACATTGCTTCAG	GTGGTGACGGGCTAC	CTCCTTGTCCTTCCT
	TAACATTGCTTCAGA	TGGTGACGGGCTACG	TCCTTGTCCTTCCTA
	AACATTGCTTCAGAG	GGTGACGGGCTACGT	CCTTGTCCTTCCTAA
	ACATTGCTTCAGAGC	GTGACGGGCTACGTG	CTTGTCCTTCCTAAA
	CATTGCTTCAGAGCT	TGACGGGCTACGTGA	TTGTCCTTCCTAAAA
25	ATTGCTTCAGAGCTG	GACGGGCTACGTGAA	TGTCCTTCCTAAAAA
	TTGCTTCAGAGCTGG	ACGGGCTACGTGAAG	GTCCTTCCTAAAAAA
	TGCTTCAGAGCTGGA	CGGGCTACGTGAAGA	TCCTTCCTAAAAAAC
	GCTTCAGAGCTGGAG	GGGCTACGTGAAGAT	CCTTCCTAAAAAACC
	CTTCAGAGCTGGAGA	GGCTACGTGAAGATC	CTTCCTAAAAAACCT
30	TTCAGAGCTGGAGAA	GCTACGTGAAGATCC	TTCCTAAAAAACCTT
	TCAGAGCTGGAGAAC	CTACGTGAAGATCCG	TCCTAAAAAACCTTC
	CAGAGCTGGAGAACT	TACGTGAAGATCCGC	CCTAAAAAACCTTCG
	AGAGCTGGAGAACTT	ACGTGAAGATCCGCC	CTAAAAAACCTTCGC
	GAGCTGGAGAACTTC	CGTGAAGATCCGCCA	TAAAAAACCTTCGCC
35	AGCTGGAGAACTTCA	GTGAAGATCCGCCAT	AAAAAACCTTCGCCT
	GCTGGAGAACTTCAT	TGAAGATCCGCCATT	AAAAACCTTCGCCTC
	CTGGAGAACTTCATG	GAAGATCCGCCATTC	AAAACCTTCGCCTCA
	TGGAGAACTTCATGG	AAGATCCGCCATTCT	AAACCTTCGCCTCAT
	GGAGAACTTCATGGG	AGATCCGCCATTCTC	AACCTTCGCCTCATC
40	GAGAACTTCATGGGG	GATCCGCCATTCTCA	ACCTTCGCCTCATCC
	AGAACTTCATGGGGC	ATCCGCCATTCTCAT	CCTTCGCCTCATCCT
	GAACTTCATGGGGCT	TCCGCCATTCTCATG	CTTCGCCTCATCCTA
	AACTTCATGGGGCTC	CCGCCATTCTCATGC	TTCGCCTCATCCTAG
	ACTTCATGGGGCTCA	CGCCATTCTCATGCC	TCGCCTCATCCTAGG

	CGCCTCATCCTAGGA	CTACGTCCTCGACAA	ACCACCGCAACCTGA
	GCCTCATCCTAGGAG	TACGTCCTCGACAAC	CCACCGCAACCTGAC
	CCTCATCCTAGGAGA	ACGTCCTCGACAACC	CACCGCAACCTGACC
	CTCATCCTAGGAGAG	CGTCCTCGACAACCA	ACCGCAACCTGACCA
5	TCATCCTAGGAGAGG	GTCCTCGACAACCAG	CCGCAACCTGACCAT
	CATCCTAGGAGAGGA	TCCTCGACAACCAGA	CGCAACCTGACCATC
	ATCCTAGGAGAGGAG	CCTCGACAACCAGAA	GCAACCTGACCATCA
	TCCTAGGAGAGGAGC	CTCGACAACCAGAAC	CAACCTGACCATCAA
	CCTAGGAGAGGAGCA	TCGACAACCAGAACT	AACCTGACCATCAAA
10	CTAGGAGAGGAGCAG	CGACAACCAGAACTT	ACCTGACCATCAAAG
	TAGGAGAGGAGCAGC	GACAACCAGAACTTG	CCTGACCATCAAAGC
	AGGAGAGGAGCAGCT	ACAACCAGAACTTGC	CTGACCATCAAAGCA
	GGAGAGGAGCAGCTA	CAACCAGAACTTGCA	TGACCATCAAAGCAG
	GAGAGGAGCAGCTAG	AACCAGAACTTGCAG	GACCATCAAAGCAGG
15	AGAGGAGCAGCTAGA	ACCAGAACTTGCAGC	ACCATCAAAGCAGGG
	GAGGAGCAGCTAGAA	CCAGAACTTGCAGCA	CCATCAAAGCAGGGA
	AGGAGCAGCTAGAAG	CAGAACTTGCAGCAA	CATCAAAGCAGGGAA
	GGAGCAGCTAGAAGG	AGAACTTGCAGCAAC	ATCAAAGCAGGGAAA
	GAGCAGCTAGAAGGG	GAACTTGCAGCAACT	TCAAAGCAGGGAAAA
20	AGCAGCTAGAAGGGA	AACTTGCAGCAACTG	CAAAGCAGGGAAAAT
	GCAGCTAGAAGGGAA	ACTTGCAGCAACTGT	AAAGCAGGGAAAATG
	CAGCTAGAAGGGAAT	CTTGCAGCAACTGTG	AAGCAGGGAAAATGT
	AGCTAGAAGGGAATT	TTGCAGCAACTGTGG	AGCAGGGAAAATGTA
	GCTAGAAGGGAATTA	TGCAGCAACTGTGGG	GCAGGGAAAATGTAC
25	CTAGAAGGGAATTAC	GCAGCAACTGTGGGA	CAGGGAAAATGTACT
	TAGAAGGGAATTACT	CAGCAACTGTGGGAC	AGGGAAAATGTACTT
	AGAAGGGAATTACTC	AGCAACTGTGGGACT	GGGAAAATGTACTTT
	GAAGGGAATTACTCC	GCAACTGTGGGACTG	GGAAAATGTACTTTG
	AAGGGAATTACTCCT	CAACTGTGGGACTGG	GAAAATGTACTTTGC
30	AGGGAATTACTCCTT	AACTGTGGGACTGGG	AAAATGTACTTTGCT
	GGGAATTACTCCTTC	ACTGTGGGACTGGGA	AAATGTACTTTGCTT
	GGAATTACTCCTTCT	CTGTGGGACTGGGAC	AATGTACTTTGCTTT
	GAATTACTCCTTCTA	TGTGGGACTGGGACC	ATGTACTTTGCTTTC
	AATTACTCCTTCTAC	GTGGGACTGGGACCA	TGTACTTTGCTTTCA
35	ATTACTCCTTCTACG	TGGGACTGGGACCAC	GTACTTTGCTTTCAA
	TTACTCCTTCTACGT	GGGACTGGGACCACC	TACTTTGCTTTCAAT
	TACTCCTTCTACGTC	GGACTGGGACCACCG	ACTTTGCTTTCAATC
	ACTCCTTCTACGTCC	GACTGGGACCACCGC	CTTTGCTTTCAATCC
	CTCCTTCTACGTCCT	ACTGGGACCACCGCA	TTTGCTTTCAATCCC
40	TCCTTCTACGTCCTC	CTGGGACCACCGCAA	TTGCTTTCAATCCCA
	CCTTCTACGTCCTCG	TGGGACCACCGCAAC	TGCTTTCAATCCCAA
	CTTCTACGTCCTCGA	GGGACCACCGCAACC	GCTTTCAATCCCAAA
	TTCTACGTCCTCGAC	GGACCACCGCAACCT	CTTTCAATCCCAAAT
	TCTACGTCCTCGACA	GACCACCGCAACCTG	TTTCAATCCCAAATT

	TTCAATCCCAAATTA	AGTGACGGGGACTAA	CCAGGAACAACGGGG
	TCAATCCCAAATTAT	GTGACGGGGACTAAA	CAGGAACAACGGGGA
	CAATCCCAAATTATG	TGACGGGGACTAAAG	AGGAACAACGGGGAG
	AATCCCAAATTATGT	GACGGGGACTAAAGG	GGAACAACGGGGAGA
5	ATCCCAAATTATGTG	ACGGGGACTAAAGGG	GAACAACGGGGAGAG
	TCCCAAATTATGTGT	CGGGGACTAAAGGGC	AACAACGGGGAGAGA
	CCCAAATTATGTGTT	GGGGACTAAAGGGCG	ACAACGGGGAGAGAG
	CCAAATTATGTGTTT	GGGACTAAAGGGCGC	CAACGGGGAGAGAGC
	CAAATTATGTGTTTC	GGACTAAAGGGCGCC	AACGGGGAGAGAGCC
10	AAATTATGTGTTTCC	GACTAAAGGGCGCCA	ACGGGGAGAGAGCCT
	AATTATGTGTTTCCG	ACTAAAGGGCGCCAA	CGGGGAGAGAGCCTC
	ATTATGTGTTTCCGA	CTAAAGGGCGCCAAA	GGGGAGAGAGCCTCC
	TTATGTGTTTCCGAA	TAAAGGGCGCCAAAG	GGGAGAGAGCCTCCT
	TATGTGTTTCCGAAA	AAAGGGCGCCAAAGC	GGAGAGAGCCTCCTG
15	ATGTGTTTCCGAAAT	AAGGGCGCCAAAGCA	GAGAGAGCCTCCTGT
	TGTGTTTCCGAAATT	AGGGCGCCAAAGCAA	AGAGAGCCTCCTGTG
	GTGTTTCCGAAATTT	GGGCGCCAAAGCAAA	GAGAGCCTCCTGTGA
	TGTTTCCGAAATTTA	GGCGCCAAAGCAAAG	AGAGCCTCCTGTGAA
	GTTTCCGAAATTTAC	GCGCCAAAGCAAAGG	GAGCCTCCTGTGAAA
20	TTTCCGAAATTTACC	CGCCAAAGCAAAGGG	AGCCTCCTGTGAAAG
	TTCCGAAATTTACCG	GCCAAAGCAAAGGGG	GCCTCCTGTGAAAGT
	TCCGAAATTTACCGC	CCAAAGCAAAGGGGA	CCTCCTGTGAAAGTG
	CCGAAATTTACCGCA	CAAAGCAAAGGGGAC	CTCCTGTGAAAGTGA
	CGAAATTTACCGCAT	AAAGCAAAGGGGACA	TCCTGTGAAAGTGAC
25	GAAATTTACCGCATG	AAGCAAAGGGGACAT	CCTGTGAAAGTGACG
	AAATTTACCGCATGG	AGCAAAGGGGACATA	CTGTGAAAGTGACGT
	AATTTACCGCATGGA	GCAAAGGGGACATAA	TGTGAAAGTGACGTC
	ATTTACCGCATGGAG	CAAAGGGGACATAAA	GTGAAAGTGACGTCC
	TTTACCGCATGGAGG	AAAGGGGACATAAAC	TGAAAGTGACGTCCT
30	TTACCGCATGGAGGA	AAGGGGACATAAACA	GAAAGTGACGTCCTG
	TACCGCATGGAGGAA	AGGGGACATAAACAC	AAAGTGACGTCCTGC
	ACCGCATGGAGGAAG	GGGGACATAAACACC	AAGTGACGTCCTGCA
	CCGCATGGAGGAAGT	GGGACATAAACACCA	AGTGACGTCCTGCAT
	CGCATGGAGGAAGTG	GGACATAAACACCAG	GTGACGTCCTGCATT
35	GCATGGAGGAAGTGA	GACATAAACACCAGG	TGACGTCCTGCATTT
	CATGGAGGAAGTGAC	ACATAAACACCAGGA	GACGTCCTGCATTTC
	ATGGAGGAAGTGACG	CATAAACACCAGGAA	ACGTCCTGCATTTCA
	TGGAGGAAGTGACGG	ATAAACACCAGGAAC	CGTCCTGCATTTCAC
	GGAGGAAGTGACGGG	TAAACACCAGGAACA	GTCCTGCATTTCACC
40	GAGGAAGTGACGGGG	AAACACCAGGAACAA	TCCTGCATTTCACCT
	AGGAAGTGACGGGGA	AACACCAGGAACAAC	CCTGCATTTCACCTC
	GGAAGTGACGGGGAC	ACACCAGGAACAACG	CTGCATTTCACCTCC
	GAAGTGACGGGGACT	CACCAGGAACAACGG	TGCATTTCACCTCCA
	AAGTGACGGGGACTA	ACCAGGAACAACGGG	GCATTTCACCTCCAC

	CATTTCACCTCCACC	CTGGCACCGGTACCG	TCACCGTTTACTACA
	ATTTCACCTCCACCA	TGGCACCGGTACCGG	CACCGTTTACTACAA
	TTTCACCTCCACCAC	GGCACCGGTACCGGC	ACCGTTTACTACAAG
	TTCACCTCCACCACC	GCACCGGTACCGGCC	CCGTTTACTACAAGG
5	TCACCTCCACCACCA	CACCGGTACCGGCCC	CGTTTACTACAAGGA
	CACCTCCACCACCAC	ACCGGTACCGGCCCC	GTTTACTACAAGGAA
	ACCTCCACCACCACG	CCGGTACCGGCCCCC	TTTACTACAAGGAAG
	CCTCCACCACCACGT	CGGTACCGGCCCCCT	TTACTACAAGGAAGC
	CTCCACCACCACGTC	GGTACCGGCCCCCTG	TACTACAAGGAAGCA
10	TCCACCACCACGTCG	GTACCGGCCCCCTGA	ACTACAAGGAAGCAC
	CCACCACCACGTCGA	TACCGGCCCCCTGAC	CTACAAGGAAGCACC
	CACCACCACGTCGAA	ACCGGCCCCCTGACT	TACAAGGAAGCACCC
	ACCACCACGTCGAAG	CCGGCCCCCTGACTA	ACAAGGAAGCACCCT
	CCACCACGTCGAAGA	CGGCCCCCTGACTAC	CAAGGAAGCACCCTT
15	CACCACGTCGAAGAA	GGCCCCCTGACTACA	AAGGAAGCACCCTTT
	ACCACGTCGAAGAAT	GCCCCCTGACTACAG	AGGAAGCACCCTTTA
	CCACGTCGAAGAATC	CCCCCTGACTACAGG	GGAAGCACCCTTTAA
	CACGTCGAAGAATCG	CCCCTGACTACAGGG	GAAGCACCCTTTAAG
	ACGTCGAAGAATCGC	CCCTGACTACAGGGA	AAGCACCCTTTAAGA
20	CGTCGAAGAATCGCA	CCTGACTACAGGGAT	AGCACCCTTTAAGAA
	GTCGAAGAATCGCAT	CTGACTACAGGGATC	GCACCCTTTAAGAAT
	TCGAAGAATCGCATC	TGACTACAGGGATCT	CACCCTTTAAGAATG
	CGAAGAATCGCATCA	GACTACAGGGATCTC	ACCCTTTAAGAATGT
	GAAGAATCGCATCAT	ACTACAGGGATCTCA	CCCTTTAAGAATGTC
25	AAGAATCGCATCATC	CTACAGGGATCTCAT	CCTTTAAGAATGTCA
	AGAATCGCATCATCA	TACAGGGATCTCATC	CTTTAAGAATGTCAC
	GAATCGCATCATCAT	ACAGGGATCTCATCA	TTTAAGAATGTCACA
	AATCGCATCATCATA	CAGGGATCTCATCAG	TTAAGAATGTCACAG
	ATCGCATCATCATAA	AGGGATCTCATCAGC	TAAGAATGTCACAGA
30	TCGCATCATCATAAC	GGGATCTCATCAGCT	AAGAATGTCACAGAG
	CGCATCATCATAACC	GGATCTCATCAGCTT	AGAATGTCACAGAGT
	GCATCATCATAACCT	GATCTCATCAGCTTC	GAATGTCACAGAGTA
	CATCATCATAACCTG	ATCTCATCAGCTTCA	AATGTCACAGAGTAT
	ATCATCATAACCTGG	TCTCATCAGCTTCAC	ATGTCACAGAGTATG
35	TCATCATAACCTGGC	CTCATCAGCTTCACC	TGTCACAGAGTATGA
	CATCATAACCTGGCA	TCATCAGCTTCACCG	GTCACAGAGTATGAT
	ATCATAACCTGGCAC	CATCAGCTTCACCGT	TCACAGAGTATGATG
	TCATAACCTGGCACC	ATCAGCTTCACCGTT	CACAGAGTATGATGG
	CATAACCTGGCACCG	TCAGCTTCACCGTTT	ACAGAGTATGATGGG
40	ATAACCTGGCACCGG	CAGCTTCACCGTTTA	CAGAGTATGATGGGC
	TAACCTGGCACCGGT	AGCTTCACCGTTTAC	AGAGTATGATGGGCA
	AACCTGGCACCGGTA	GCTTCACCGTTTACT	GAGTATGATGGGCAG
	ACCTGGCACCGGTAC	CTTCACCGTTTACTA	AGTATGATGGGCAGG
	CCTGGCACCGGTACC	TTCACCGTTTACTAC	GTATGATGGGCAGGA

	TATGATGGGCAGGAT	GGACGTGGACCTCCC	TACTACATGGGCTGA
	ATGATGGGCAGGATG	GACGTGGACCTCCCG	ACTACATGGGCTGAA
	TGATGGGCAGGATGC	ACGTGGACCTCCCGC	CTACATGGGCTGAAG
	GATGGGCAGGATGCC	CGTGGACCTCCCGCC	TACATGGGCTGAAGC
5	ATGGGCAGGATGCCT	GTGGACCTCCCGCCC	ACATGGGCTGAAGCC
	TGGGCAGGATGCCTG	TGGACCTCCCGCCCA	CATGGGCTGAAGCCC
	GGGCAGGATGCCTGC	GGACCTCCCGCCCAA	ATGGGCTGAAGCCCT
	GGCAGGATGCCTGCG	GACCTCCCGCCCAAC	TGGGCTGAAGCCCTG
	GCAGGATGCCTGCGG	ACCTCCCGCCCAACA	GGGCTGAAGCCCTGG
10	CAGGATGCCTGCGGC	CCTCCCGCCCAACAA	GGCTGAAGCCCTGGA
	AGGATGCCTGCGGCT	CTCCCGCCCAACAAG	GCTGAAGCCCTGGAC
	GGATGCCTGCGGCTC	TCCCGCCCAACAAGG	CTGAAGCCCTGGACT
	GATGCCTGCGGCTCC	CCCGCCCAACAAGGA	TGAAGCCCTGGACTC
	ATGCCTGCGGCTCCA	CCGCCCAACAAGGAC	GAAGCCCTGGACTCA
15	TGCCTGCGGCTCCAA	CGCCCAACAAGGACG	AAGCCCTGGACTCAG
	GCCTGCGGCTCCAAC	GCCCAACAAGGACGT	AGCCCTGGACTCAGT
	CCTGCGGCTCCAACA	CCCAACAAGGACGTG	GCCCTGGACTCAGTA
	CTGCGGCTCCAACAG	CCAACAAGGACGTGG	CCCTGGACTCAGTAC
	TGCGGCTCCAACAGC	CAACAAGGACGTGGA	CCTGGACTCAGTACG
20	GCGGCTCCAACAGCT	AACAAGGACGTGGAG	CTGGACTCAGTACGC
	CGGCTCCAACAGCTG	ACAAGGACGTGGAGC	TGGACTCAGTACGCC
	GGCTCCAACAGCTGG	CAAGGACGTGGAGCC	GGACTCAGTACGCCG
	GCTCCAACAGCTGGA	AAGGACGTGGAGCCC	GACTCAGTACGCCGT
	CTCCAACAGCTGGAA	AGGACGTGGAGCCCG	ACTCAGTACGCCGTT
25	TCCAACAGCTGGAAC	GGACGTGGAGCCCGG	CTCAGTACGCCGTTT
	CCAACAGCTGGAACA	GACGTGGAGCCCGGC	TCAGTACGCCGTTTA
	CAACAGCTGGAACAT	ACGTGGAGCCCGGCA	CAGTACGCCGTTTAC
	AACAGCTGGAACATG	CGTGGAGCCCGGCAT	AGTACGCCGTTTACG
	ACAGCTGGAACATGG	GTGGAGCCCGGCATC	GTACGCCGTTTACGT
30	CAGCTGGAACATGGT	TGGAGCCCGGCATCT	TACGCCGTTTACGTC
	AGCTGGAACATGGTG	GGAGCCCGGCATCTT	ACGCCGTTTACGTCA
	GCTGGAACATGGTGG	GAGCCCGGCATCTTA	CGCCGTTTACGTCAA
	CTGGAACATGGTGGA	AGCCCGGCATCTTAC	GCCGTTTACGTCAAG
	TGGAACATGGTGGAC	GCCCGGCATCTTACT	CCGTTTACGTCAAGG
35	GGAACATGGTGGACG	CCCGGCATCTTACTA	CGTTTACGTCAAGGC
	GAACATGGTGGACGT	CCGGCATCTTACTAC	GTTTACGTCAAGGCT
	AACATGGTGGACGTG	CGGCATCTTACTACA	TTTACGTCAAGGCTG
	ACATGGTGGACGTGG	GGCATCTTACTACAT	TTACGTCAAGGCTGT
	CATGGTGGACGTGGA	GCATCTTACTACATG	TACGTCAAGGCTGTG
40	ATGGTGGACGTGGAC	CATCTTACTACATGG	ACGTCAAGGCTGTGA
	TGGTGGACGTGGACC	ATCTTACTACATGGG	CGTCAAGGCTGTGAC
	GGTGGACGTGGACCT	TCTTACTACATGGGC	GTCAAGGCTGTGACC
	GTGGACGTGGACCTC	CTTACTACATGGGCT	TCAAGGCTGTGACCC
	TGGACGTGGACCTCC	TTACTACATGGGCTG	CAAGGCTGTGACCCT

	AAGGCTGTGACCCTC	GGCCAAGAGTGAGAT	CTTCCATTCCCTTGG
	AGGCTGTGACCCTCA	GCCAAGAGTGAGATC	TTCCATTCCCTTGGA
	GGCTGTGACCCTCAC	CCAAGAGTGAGATCT	TCCATTCCCTTGGAC
	GCTGTGACCCTCACC	CAAGAGTGAGATCTT	CCATTCCCTTGGACG
5	CTGTGACCCTCACCA	AAGAGTGAGATCTTG	CATTCCCTTGGACGT
	TGTGACCCTCACCAT	AGAGTGAGATCTTGT	ATTCCCTTGGACGTT
	GTGACCCTCACCATG	GAGTGAGATCTTGTA	TTCCCTTGGACGTTC
	TGACCCTCACCATGG	AGTGAGATCTTGTAC	TCCCTTGGACGTTCT
	GACCCTCACCATGGT	GTGAGATCTTGTACA	CCCTTGGACGTTCTT
10	ACCCTCACCATGGTG	TGAGATCTTGTACAT	CCTTGGACGTTCTTT
	CCCTCACCATGGTGG	GAGATCTTGTACATT	CTTGGACGTTCTTTC
	CCTCACCATGGTGGA	AGATCTTGTACATTC	TTGGACGTTCTTTCA
	CTCACCATGGTGGAG	GATCTTGTACATTCG	TGGACGTTCTTTCAG
	TCACCATGGTGGAGA	ATCTTGTACATTCGC	GGACGTTCTTTCAGC
15	CACCATGGTGGAGAA	TCTTGTACATTCGCA	GACGTTCTTTCAGCA
	ACCATGGTGGAGAAC	CTTGTACATTCGCAC	ACGTTCTTTCAGCAT
	CCATGGTGGAGAACG	TTGTACATTCGCACC	CGTTCTTTCAGCATC
	CATGGTGGAGAACGA	TGTACATTCGCACCA	GTTCTTTCAGCATCG
	ATGGTGGAGAACGAC	GTACATTCGCACCAA	TTCTTTCAGCATCGA
20	TGGTGGAGAACGACC	TACATTCGCACCAAT	TCTTTCAGCATCGAA
	GGTGGAGAACGACCA	ACATTCGCACCAATG	CTTTCAGCATCGAAC
	GTGGAGAACGACCAT	CATTCGCACCAATGC	TTTCAGCATCGAACT
	TGGAGAACGACCATA	ATTCGCACCAATGCT	TTCAGCATCGAACTC
	GGAGAACGACCATAT	TTCGCACCAATGCTT	TCAGCATCGAACTCC
25	GAGAACGACCATATC	TCGCACCAATGCTTC	CAGCATCGAACTCCT
	AGAACGACCATATCC	CGCACCAATGCTTCA	AGCATCGAACTCCTC
	GAACGACCATATCCG	GCACCAATGCTTCAG	GCATCGAACTCCTCT
	AACGACCATATCCGT	CACCAATGCTTCAGT	CATCGAACTCCTCTT
	ACGACCATATCCGTG	ACCAATGCTTCAGTT	ATCGAACTCCTCTTC
30	CGACCATATCCGTGG	CCAATGCTTCAGTTC	TCGAACTCCTCTTCT
	GACCATATCCGTGGG	CAATGCTTCAGTTCC	CGAACTCCTCTTCTC
	ACCATATCCGTGGGG	AATGCTTCAGTTCCT	GAACTCCTCTTCTCA
	CCATATCCGTGGGGC	ATGCTTCAGTTCCTT	AACTCCTCTTCTCAG
	CATATCCGTGGGGCC	TGCTTCAGTTCCTTC	ACTCCTCTTCTCAGT
35	ATATCCGTGGGGCCA	GCTTCAGTTCCTTCC	CTCCTCTTCTCAGTT
	TATCCGTGGGGCCAA	CTTCAGTTCCTTCCA	TCCTCTTCTCAGTTA
	ATCCGTGGGGCCAAG	TTCAGTTCCTTCCAT	CCTCTTCTCAGTTAA
	TCCGTGGGGCCAAGA	TCAGTTCCTTCCATT	CTCTTCTCAGTTAAT
	CCGTGGGGCCAAGAG	CAGTTCCTTCCATTC	TCTTCTCAGTTAATC
40	CGTGGGGCCAAGAGT	AGTTCCTTCCATTCC	CTTCTCAGTTAATCG
	GTGGGGCCAAGAGTG	GTTCCTTCCATTCCC	TTCTCAGTTAATCGT
	TGGGGCCAAGAGTGA	TTCCTTCCATTCCCT	TCTCAGTTAATCGTG
	GGGGCCAAGAGTGAG	TCCTTCCATTCCCTT	CTCAGTTAATCGTGA
	GGGCCAAGAGTGAGA	CCTTCCATTCCCTTG	TCAGTTAATCGTGAA

	CAGTTAATCGTGAAG	CCTGAGTTACTACAT	GCTACCTTTACCGGC
	AGTTAATCGTGAAGT	CTGAGTTACTACATT	CTACCTTTACCGGCA
	GTTAATCGTGAAGTG	TGAGTTACTACATTG	TACCTTTACCGGCAC
	TTAATCGTGAAGTGG	GAGTTACTACATTGT	ACCTTTACCGGCACA
5	TAATCGTGAAGTGGA	AGTTACTACATTGTG	CCTTTACCGGCACAA
	AATCGTGAAGTGGAA	GTTACTACATTGTGC	CTTTACCGGCACAAT
	ATCGTGAAGTGGAAC	TTACTACATTGTGCG	TTTACCGGCACAATT
	TCGTGAAGTGGAACC	TACTACATTGTGCGC	TTACCGGCACAATTA
	CGTGAAGTGGAACCC	ACTACATTGTGCGCT	TACCGGCACAATTAC
10	GTGAAGTGGAACCCT	CTACATTGTGCGCTG	ACCGGCACAATTACT
	TGAAGTGGAACCCTC	TACATTGTGCGCTGG	CCGGCACAATTACTG
	GAAGTGGAACCCTCC	ACATTGTGCGCTGGC	CGGCACAATTACTGC
	AAGTGGAACCCTCCC	CATTGTGCGCTGGCA	GGCACAATTACTGCT
	AGTGGAACCCTCCCT	ATTGTGCGCTGGCAG	GCACAATTACTGCTC
15	GTGGAACCCTCCCTC	TTGTGCGCTGGCAGC	CACAATTACTGCTCC
	TGGAACCCTCCCTCT	TGTGCGCTGGCAGCG	ACAATTACTGCTCCA
	GGAACCCTCCCTCTC	GTGCGCTGGCAGCGG	CAATTACTGCTCCAA
	GAACCCTCCCTCTCT	TGCGCTGGCAGCGGC	AATTACTGCTCCAAA
	AACCCTCCCTCTCTG	GCGCTGGCAGCGGCA	ATTACTGCTCCAAAG
20	ACCCTCCCTCTCTGC	CGCTGGCAGCGGCAG	TTACTGCTCCAAAGA
	CCCTCCCTCTCTGCC	GCTGGCAGCGGCAGC	TACTGCTCCAAAGAC
	CCTCCCTCTCTGCCC	CTGGCAGCGGCAGCC	ACTGCTCCAAAGACA
	CTCCCTCTCTGCCCA	TGGCAGCGGCAGCCT	CTGCTCCAAAGACAA
	TCCCTCTCTGCCCAA	GGCAGCGGCAGCCTC	TGCTCCAAAGACAAA
25	CCCTCTCTGCCCAAC	GCAGCGGCAGCCTCA	GCTCCAAAGACAAAA
	CCTCTCTGCCCAACG	CAGCGGCAGCCTCAG	CTCCAAAGACAAAAT
	CTCTCTGCCCAACGG	AGCGGCAGCCTCAGG	TCCAAAGACAAAATC
	TCTCTGCCCAACGGC	GCGGCAGCCTCAGGA	CCAAAGACAAAATCC
	CTCTGCCCAACGGCA	CGGCAGCCTCAGGAC	CAAAGACAAAATCCC
30	TCTGCCCAACGGCAA	GGCAGCCTCAGGACG	AAAGACAAAATCCCC
	CTGCCCAACGGCAAC	GCAGCCTCAGGACGG	AAGACAAAATCCCCA
	TGCCCAACGGCAACC	CAGCCTCAGGACGGC	AGACAAAATCCCCAT
	GCCCAACGGCAACCT	AGCCTCAGGACGGCT	GACAAAATCCCCATC
	CCCAACGGCAACCTG	GCCTCAGGACGGCTA	ACAAAATCCCCATCA
35	CCAACGGCAACCTGA	CCTCAGGACGGCTAC	CAAAATCCCCATCAG
	CAACGGCAACCTGAG	CTCAGGACGGCTACC	AAAATCCCCATCAGG
	AACGGCAACCTGAGT	TCAGGACGGCTACCT	AAATCCCCATCAGGA
	ACGGCAACCTGAGTT	CAGGACGGCTACCTT	AATCCCCATCAGGAA
	CGGCAACCTGAGTTA	AGGACGGCTACCTTT	ATCCCCATCAGGAAG
40	GGCAACCTGAGTTAC	GGACGGCTACCTTTA	TCCCCATCAGGAAGT
	GCAACCTGAGTTACT	GACGGCTACCTTTAC	CCCCATCAGGAAGTA
	CAACCTGAGTTACTA	ACGGCTACCTTTACC	CCCATCAGGAAGTAT
	AACCTGAGTTACTAC	CGGCTACCTTTACCG	CCATCAGGAAGTATG
	ACCTGAGTTACTACA	GGCTACCTTTACCGG	CATCAGGAAGTATGC

	ATCAGGAAGTATGCC	AGAGAACCCCAAGAC	GCTGCGCCTGCCCCA
	TCAGGAAGTATGCCG	GAGAACCCCAAGACT	CTGCGCCTGCCCCAA
	CAGGAAGTATGCCGA	AGAACCCCAAGACTG	TGCGCCTGCCCCAAA
	AGGAAGTATGCCGAC	GAACCCCAAGACTGA	GCGCCTGCCCCAAAA
5	GGAAGTATGCCGACG	AACCCCAAGACTGAG	CGCCTGCCCCAAAAC
	GAAGTATGCCGACGG	ACCCCAAGACTGAGG	GCCTGCCCCAAAACT
	AAGTATGCCGACGGC	CCCCAAGACTGAGGT	CCTGCCCCAAAACTG
	AGTATGCCGACGGCA	CCCAAGACTGAGGTG	CTGCCCCAAAACTGA
	GTATGCCGACGGCAC	CCAAGACTGAGGTGT	TGCCCCAAAACTGAA
10	TATGCCGACGGCACC	CAAGACTGAGGTGTG	GCCCCAAAACTGAAG
	ATGCCGACGGCACCA	AAGACTGAGGTGTGT	CCCCAAAACTGAAGC
	TGCCGACGGCACCAT	AGACTGAGGTGTGTG	CCCAAAACTGAAGCC
	GCCGACGGCACCATC	GACTGAGGTGTGTGG	CCAAAACTGAAGCCG
	CCGACGGCACCATCG	ACTGAGGTGTGTGGT	CAAAACTGAAGCCGA
15	CGACGGCACCATCGA	CTGAGGTGTGTGGTG	AAAACTGAAGCCGAG
	GACGGCACCATCGAC	TGAGGTGTGTGGTGG	AAACTGAAGCCGAGA
	ACGGCACCATCGACA	GAGGTGTGTGGTGGG	AACTGAAGCCGAGAA
	CGGCACCATCGACAT	AGGTGTGTGGTGGGG	ACTGAAGCCGAGAAG
	GGCACCATCGACATT	GGTGTGTGGTGGGGA	CTGAAGCCGAGAAGC
20	GCACCATCGACATTG	GTGTGTGGTGGGGAG	TGAAGCCGAGAAGCA
	CACCATCGACATTGA	TGTGTGGTGGGGAGA	GAAGCCGAGAAGCAG
	ACCATCGACATTGAG	GTGTGGTGGGGAGAA	AAGCCGAGAAGCAGG
	CCATCGACATTGAGG	TGTGGTGGGGAGAAA	AGCCGAGAAGCAGGC
	CATCGACATTGAGGA	GTGGTGGGGAGAAAG	GCCGAGAAGCAGGCC
25	ATCGACATTGAGGAG	TGGTGGGGAGAAAGG	CCGAGAAGCAGGCCG
	TCGACATTGAGGAGG	GGTGGGGAGAAAGGG	CGAGAAGCAGGCCGA
	CGACATTGAGGAGGT	GTGGGGAGAAAGGGC	GAGAAGCAGGCCGAG
	GACATTGAGGAGGTC	TGGGGAGAAAGGGCC	AGAAGCAGGCCGAGA
	ACATTGAGGAGGTCA	GGGGAGAAAGGGCCT	GAAGCAGGCCGAGAA
30	CATTGAGGAGGTCAC	GGGAGAAAGGGCCTT	AAGCAGGCCGAGAAG
	ATTGAGGAGGTCACA	GGAGAAAGGGCCTTG	AGCAGGCCGAGAAGG
	TTGAGGAGGTCACAG	GAGAAAGGGCCTTGC	GCAGGCCGAGAAGGA
	TGAGGAGGTCACAGA	AGAAAGGGCCTTGCT	CAGGCCGAGAAGGAG
	GAGGAGGTCACAGAG	GAAAGGGCCTTGCTG	AGGCCGAGAAGGAGG
35	AGGAGGTCACAGAGA	AAAGGGCCTTGCTGC	GGCCGAGAAGGAGGA
	GGAGGTCACAGAGAA	AAGGGCCTTGCTGCG	GCCGAGAAGGAGGAG
	GAGGTCACAGAGAAC	AGGGCCTTGCTGCGC	CCGAGAAGGAGGAGG
	AGGTCACAGAGAACC	GGGCCTTGCTGCGCC	CGAGAAGGAGGAGGC
	GGTCACAGAGAACCC	GGCCTTGCTGCGCCT	GAGAAGGAGGAGGCT
40	GTCACAGAGAACCCC	GCCTTGCTGCGCCTG	AGAAGGAGGAGGCTG
	TCACAGAGAACCCCA	CCTTGCTGCGCCTGC	GAAGGAGGAGGCTGA
	CACAGAGAACCCCAA	CTTGCTGCGCCTGCC	AAGGAGGAGGCTGAA
	ACAGAGAACCCCAAG	TTGCTGCGCCTGCCC	AGGAGGAGGCTGAAT
	CAGAGAACCCCAAGA	TGCTGCGCCTGCCCC	GGAGGAGGCTGAATA

GAGGAGGCTGAATAC
AGGAGGCTGAATACC
GGAGGCTGAATACCG
GAGGCTGAATACCGC
AGGCTGAATACCGCA
GGCTGAATACCGCAA
GCTGAATACCGCAAA
CTGAATACCGCAAAG
TGAATACCGCAAAGT
GAATACCGCAAAGTC
AATACCGCAAAGTCT
ATACCGCAAAGTCTT
TACCGCAAAGTCTTT
ACCGCAAAGTCTTTG
CCGCAAAGTCTTTGA
CGCAAAGTCTTTGAG
GCAAAGTCTTTGAGA
CAAAGTCTTTGAGAA
AAAGTCTTTGAGAAT
AAGTCTTTGAGAATT
AGTCTTTGAGAATTT
GTCTTTGAGAATTTC
TCTTTGAGAATTTCC
CTTTGAGAATTTCCT
TTTGAGAATTTCCTG
TTGAGAATTTCCTGC
TGAGAATTTCCTGCA
GAGAATTTCCTGCAC
AGAATTTCCTGCACA
GAATTTCCTGCACAA
AATTTCCTGCACAAC
ATTTCCTGCACAACT
TTTCCTGCACAACTC
TTCCTGCACAACTCC
TCCTGCACAACTCCA
CCTGCACAACTCCAT
CTGCACAACTCCATC
TGCACAACTCCATCT
GCACAACTCCATCTT
CACAACTCCATCTTC
ACAACTCCATCTTCG
CAACTCCATCTTCGT
AACTCCATCTTCGTG
ACTCCATCTTCGTGC

CTCCATCTTCGTGCC
TCCATCTTCGTGCCC
CCATCTTCGTGCCCA
CATCTTCGTGCCCAG
ATCTTCGTGCCCAGA
TCTTCGTGCCCAGAC
CTTCGTGCCCAGACC
TTCGTGCCCAGACCT
TCGTGCCCAGACCTG
CGTGCCCAGACCTGA
GTGCCCAGACCTGAA
TGCCCAGACCTGAAA
GCCCAGACCTGAAAG
CCCAGACCTGAAAGG
CCAGACCTGAAAGGA
CAGACCTGAAAGGAA
AGACCTGAAAGGAAG
GACCTGAAAGGAAGC
ACCTGAAAGGAAGCG
CCTGAAAGGAAGCGG
CTGAAAGGAAGCGGA
TGAAAGGAAGCGGAG
GAAAGGAAGCGGAGA
AAAGGAAGCGGAGAG
AAGGAAGCGGAGAGA
AGGAAGCGGAGAGAT
GGAAGCGGAGAGATG
GAAGCGGAGAGATGT
AAGCGGAGAGATGTC
AGCGGAGAGATGTCA
GCGGAGAGATGTCAT
CGGAGAGATGTCATG
GGAGAGATGTCATGC
GAGAGATGTCATGCA
AGAGATGTCATGCAA
GAGATGTCATGCAAG
AGATGTCATGCAAGT
GATGTCATGCAAGTG
ATGTCATGCAAGTGG
TGTCATGCAAGTGGC
GTCATGCAAGTGGCC
TCATGCAAGTGGCCA
CATGCAAGTGGCCAA
ATGCAAGTGGCCAAC

TGCAAGTGGCCAACA
GCAAGTGGCCAACAC
CAAGTGGCCAACACC
AAGTGGCCAACACCA
AGTGGCCAACACCAC
GTGGCCAACACCACC
TGGCCAACACCACCA
GGCCAACACCACCAT
GCCAACACCACCATG
CCAACACCACCATGT
CAACACCACCATGTC
AACACCACCATGTCC
ACACCACCATGTCCA
CACCACCATGTCCAG
ACCACCATGTCCAGC
CCACCATGTCCAGCC
CACCATGTCCAGCCG
ACCATGTCCAGCCGA
CCATGTCCAGCCGAA
CATGTCCAGCCGAAG
ATGTCCAGCCGAAGC
TGTCCAGCCGAAGCA
GTCCAGCCGAAGCAG
TCCAGCCGAAGCAGG
CCAGCCGAAGCAGGA
CAGCCGAAGCAGGAA
AGCCGAAGCAGGAAC
GCCGAAGCAGGAACA
CCGAAGCAGGAACAC
CGAAGCAGGAACACC
GAAGCAGGAACACCA
AAGCAGGAACACCAC
AGCAGGAACACCACG
GCAGGAACACCACGG
CAGGAACACCACGGC
AGGAACACCACGGCC
GGAACACCACGGCCG
GAACACCACGGCCGC
AACACCACGGCCGCA
ACACCACGGCCGCAG
CACCACGGCCGCAGA
ACCACGGCCGCAGAC
CCACGGCCGCAGACA
CACGGCCGCAGACAC

	ACGGCCGCAGACACC	GACAGAGTACCCTTT	GAACTGTCATTTCTA
	CGGCCGCAGACACCT	ACAGAGTACCCTTTC	AACTGTCATTTCTAA
	GGCCGCAGACACCTA	CAGAGTACCCTTTCT	ACTGTCATTTCTAAC
	GCCGCAGACACCTAC	AGAGTACCCTTTCTT	CTGTCATTTCTAACC
5	CCGCAGACACCTACA	GAGTACCCTTTCTTT	TGTCATTTCTAACCT
	CGCAGACACCTACAA	AGTACCCTTTCTTTG	GTCATTTCTAACCTT
	GCAGACACCTACAAC	GTACCCTTTCTTTGA	TCATTTCTAACCTTC
	CAGACACCTACAACA	TACCCTTTCTTTGAG	CATTTCTAACCTTCG
	AGACACCTACAACAT	ACCCTTTCTTTGAGA	ATTTCTAACCTTCGG
10	GACACCTACAACATC	CCCTTTCTTTGAGAG	TTTCTAACCTTCGGC
	ACACCTACAACATCA	CCTTTCTTTGAGAGC	TTCTAACCTTCGGCC
	CACCTACAACATCAC	CTTTCTTTGAGAGCA	TCTAACCTTCGGCCT
	ACCTACAACATCACC	TTTCTTTGAGAGCAG	CTAACCTTCGGCCTT
	CCTACAACATCACCG	TTCTTTGAGAGCAGA	TAACCTTCGGCCTTT
15	CTACAACATCACCGA	TCTTTGAGAGCAGAG	AACCTTCGGCCTTTC
	TACAACATCACCGAC	CTTTGAGAGCAGAGT	ACCTTCGGCCTTTCA
	ACAACATCACCGACC	TTTGAGAGCAGAGTG	CCTTCGGCCTTTCAC
	CAACATCACCGACCC	TTGAGAGCAGAGTGG	CTTCGGCCTTTCACA
	AACATCACCGACCCG	TGAGAGCAGAGTGGA	TTCGGCCTTTCACAT
20	ACATCACCGACCCGG	GAGAGCAGAGTGGAT	TCGGCCTTTCACATT
	CATCACCGACCCGGA	AGAGCAGAGTGGATA	CGGCCTTTCACATTG
	ATCACCGACCCGGAA	GAGCAGAGTGGATAA	GGCCTTTCACATTGT
	TCACCGACCCGGAAG	AGCAGAGTGGATAAC	GCCTTTCACATTGTA
	CACCGACCCGGAAGA	GCAGAGTGGATAACA	CCTTTCACATTGTAC
25	ACCGACCCGGAAGAG	CAGAGTGGATAACAA	CTTTCACATTGTACC
	CCGACCCGGAAGAGC	AGAGTGGATAACAAG	TTTCACATTGTACCG
	CGACCCGGAAGAGCT	GAGTGGATAACAAGG	TTCACATTGTACCGC
	GACCCGGAAGAGCTG	AGTGGATAACAAGGA	TCACATTGTACCGCA
	ACCCGGAAGAGCTGG	GTGGATAACAAGGAG	CACATTGTACCGCAT
30	CCCGGAAGAGCTGGA	TGGATAACAAGGAGA	ACATTGTACCGCATC
	CCGGAAGAGCTGGAG	GGATAACAAGGAGAG	CATTGTACCGCATCG
	CGGAAGAGCTGGAGA	GATAACAAGGAGAGA	ATTGTACCGCATCGA
	GGAAGAGCTGGAGAC	ATAACAAGGAGAGAA	TTGTACCGCATCGAT
	GAAGAGCTGGAGACA	TAACAAGGAGAGAAC	TGTACCGCATCGATA
35	AAGAGCTGGAGACAG	AACAAGGAGAGAACT	GTACCGCATCGATAT
	AGAGCTGGAGACAGA	ACAAGGAGAGAACTG	TACCGCATCGATATC
	GAGCTGGAGACAGAG	CAAGGAGAGAACTGT	ACCGCATCGATATCC
	AGCTGGAGACAGAGT	AAGGAGAGAACTGTC	CCGCATCGATATCCA
	GCTGGAGACAGAGTA	AGGAGAGAACTGTCA	CGCATCGATATCCAC
40	CTGGAGACAGAGTAC	GGAGAGAACTGTCAT	GCATCGATATCCACA
	TGGAGACAGAGTACC	GAGAGAACTGTCATT	CATCGATATCCACAG
	GGAGACAGAGTACCC	AGAGAACTGTCATTT	ATCGATATCCACAGC
	GAGACAGAGTACCCT	GAGAACTGTCATTTC	TCGATATCCACAGCT
	AGACAGAGTACCCTT	AGAACTGTCATTTCT	CGATATCCACAGCTG

	GATATCCACAGCTGC	CGCCTCCAACTTCGT	CAGATGACATTCCTG
	ATATCCACAGCTGCA	GCCTCCAACTTCGTC	AGATGACATTCCTGG
	TATCCACAGCTGCAA	CCTCCAACTTCGTCT	GATGACATTCCTGGG
	ATCCACAGCTGCAAC	CTCCAACTTCGTCTT	ATGACATTCCTGGGC
5	TCCACAGCTGCAACC	TCCAACTTCGTCTTT	TGACATTCCTGGGCC
	CCACAGCTGCAACCA	CCAACTTCGTCTTTG	GACATTCCTGGGCCA
	CACAGCTGCAACCAC	CAACTTCGTCTTTGC	ACATTCCTGGGCCAG
	ACAGCTGCAACCACG	AACTTCGTCTTTGCA	CATTCCTGGGCCAGT
	CAGCTGCAACCACGA	ACTTCGTCTTTGCAA	ATTCCTGGGCCAGTG
10	AGCTGCAACCACGAG	CTTCGTCTTTGCAAG	TTCCTGGGCCAGTGA
	GCTGCAACCACGAGG	TTCGTCTTTGCAAGG	TCCTGGGCCAGTGAC
	CTGCAACCACGAGGC	TCGTCTTTGCAAGGA	CCTGGGCCAGTGACC
	TGCAACCACGAGGCT	CGTCTTTGCAAGGAC	CTGGGCCAGTGACCT
	GCAACCACGAGGCTG	GTCTTTGCAAGGACT	TGGGCCAGTGACCTG
15	CAACCACGAGGCTGA	TCTTTGCAAGGACTA	GGGCCAGTGACCTGG
	AACCACGAGGCTGAG	CTTTGCAAGGACTAT	GGCCAGTGACCTGGG
	ACCACGAGGCTGAGA	TTTGCAAGGACTATG	GCCAGTGACCTGGGA
	CCACGAGGCTGAGAA	TTGCAAGGACTATGC	CCAGTGACCTGGGAG
	CACGAGGCTGAGAAG	TGCAAGGACTATGCC	CAGTGACCTGGGAGC
20	ACGAGGCTGAGAAGC	GCAAGGACTATGCCC	AGTGACCTGGGAGCC
	CGAGGCTGAGAAGCT	CAAGGACTATGCCCG	GTGACCTGGGAGCCA
	GAGGCTGAGAAGCTG	AAGGACTATGCCCGC	TGACCTGGGAGCCAA
	AGGCTGAGAAGCTGG	AGGACTATGCCCGCA	GACCTGGGAGCCAAG
	GGCTGAGAAGCTGGG	GGACTATGCCCGCAG	ACCTGGGAGCCAAGG
25	GCTGAGAAGCTGGGC	GACTATGCCCGCAGA	CCTGGGAGCCAAGGC
	CTGAGAAGCTGGGCT	ACTATGCCCGCAGAA	CTGGGAGCCAAGGCC
	TGAGAAGCTGGGCTG	CTATGCCCGCAGAAG	TGGGAGCCAAGGCCT
	GAGAAGCTGGGCTGC	TATGCCCGCAGAAGG	GGGAGCCAAGGCCTG
	AGAAGCTGGGCTGCA	ATGCCCGCAGAAGGA	GGAGCCAAGGCCTGA
30	GAAGCTGGGCTGCAG	TGCCCGCAGAAGGAG	GAGCCAAGGCCTGAA
	AAGCTGGGCTGCAGC	GCCCGCAGAAGGAGC	AGCCAAGGCCTGAAA
	AGCTGGGCTGCAGCG	CCCGCAGAAGGAGCA	GCCAAGGCCTGAAAA
	GCTGGGCTGCAGCGC	CCGCAGAAGGAGCAG	CCAAGGCCTGAAAAC
	CTGGGCTGCAGCGCC	CGCAGAAGGAGCAGA	CAAGGCCTGAAAACT
35	TGGGCTGCAGCGCCT	GCAGAAGGAGCAGAT	AAGGCCTGAAAACTC
	GGGCTGCAGCGCCTC	CAGAAGGAGCAGATG	AGGCCTGAAAACTCC
	GGCTGCAGCGCCTCC	AGAAGGAGCAGATGA	GGCCTGAAAACTCCA
	GCTGCAGCGCCTCCA	GAAGGAGCAGATGAC	GCCTGAAAACTCCAT
	CTGCAGCGCCTCCAA	AAGGAGCAGATGACA	CCTGAAAACTCCATC
40	TGCAGCGCCTCCAAC	AGGAGCAGATGACAT	CTGAAAACTCCATCT
	GCAGCGCCTCCAACT	GGAGCAGATGACATT	TGAAAACTCCATCTT
	CAGCGCCTCCAACTT	GAGCAGATGACATTC	GAAAACTCCATCTTT
	AGCGCCTCCAACTTC	AGCAGATGACATTCC	AAAACTCCATCTTTT
	GCGCCTCCAACTTCG	GCAGATGACATTCCT	AAACTCCATCTTTTT

	AACTCCATCTTTTTA	ATTGATTCTAATGTA	ATCAGCGAGAATGTG
	ACTCCATCTTTTTAA	TTGATTCTAATGTAT	TCAGCGAGAATGTGT
	CTCCATCTTTTTAAA	TGATTCTAATGTATG	CAGCGAGAATGTGTG
	TCCATCTTTTTAAAG	GATTCTAATGTATGA	AGCGAGAATGTGTGT
5	CCATCTTTTTAAAGT	ATTCTAATGTATGAA	GCGAGAATGTGTGTC
	CATCTTTTTAAAGTG	TTCTAATGTATGAAA	CGAGAATGTGTGTCC
	ATCTTTTTAAAGTGG	TCTAATGTATGAAAT	GAGAATGTGTGTCCA
	TCTTTTTAAAGTGGC	CTAATGTATGAAATA	AGAATGTGTGTCCAG
	CTTTTTAAAGTGGCC	TAATGTATGAAATAA	GAATGTGTGTCCAGA
10	TTTTTAAAGTGGCCG	AATGTATGAAATAAA	AATGTGTGTCCAGAC
	TTTTAAAGTGGCCGG	ATGTATGAAATAAAA	ATGTGTGTCCAGACA
	TTTAAAGTGGCCGGA	TGTATGAAATAAAAT	TGTGTGTCCAGACAG
	TTAAAGTGGCCGGAA	GTATGAAATAAAATA	GTGTGTCCAGACAGG
	TAAAGTGGCCGGAAC	TATGAAATAAAATAC	TGTGTCCAGACAGGA
15	AAAGTGGCCGGAACC	ATGAAATAAAATACG	GTGTCCAGACAGGAA
	AAGTGGCCGGAACCT	TGAAATAAAATACGG	TGTCCAGACAGGAAT
	AGTGGCCGGAACCTG	GAAATAAAATACGGA	GTCCAGACAGGAATA
	GTGGCCGGAACCTGA	AAATAAAATACGGAT	TCCAGACAGGAATAC
	TGGCCGGAACCTGAG	AATAAAATACGGATC	CCAGACAGGAATACA
20	GGCCGGAACCTGAGA	ATAAAATACGGATCA	CAGACAGGAATACAG
	GCCGGAACCTGAGAA	TAAAATACGGATCAC	AGACAGGAATACAGG
	CCGGAACCTGAGAAT	AAAATACGGATCACA	GACAGGAATACAGGA
	CGGAACCTGAGAATC	AAATACGGATCACAA	ACAGGAATACAGGAA
	GGAACCTGAGAATCC	AATACGGATCACAAG	CAGGAATACAGGAAG
25	GAACCTGAGAATCCC	ATACGGATCACAAGT	AGGAATACAGGAAGT
	AACCTGAGAATCCCA	TACGGATCACAAGTT	GGAATACAGGAAGTA
	ACCTGAGAATCCCAA	ACGGATCACAAGTTG	GAATACAGGAAGTAT
	CCTGAGAATCCCAAT	CGGATCACAAGTTGA	AATACAGGAAGTATG
	CTGAGAATCCCAATG	GGATCACAAGTTGAG	ATACAGGAAGTATGG
30	TGAGAATCCCAATGG	GATCACAAGTTGAGG	TACAGGAAGTATGGA
	GAGAATCCCAATGGA	ATCACAAGTTGAGGA	ACAGGAAGTATGGAG
	AGAATCCCAATGGAT	TCACAAGTTGAGGAT	CAGGAAGTATGGAGG
	GAATCCCAATGGATT	CACAAGTTGAGGATC	AGGAAGTATGGAGGG
	AATCCCAATGGATTG	ACAAGTTGAGGATCA	GGAAGTATGGAGGGG
35	ATCCCAATGGATTGA	CAAGTTGAGGATCAG	GAAGTATGGAGGGGC
	TCCCAATGGATTGAT	AAGTTGAGGATCAGC	AAGTATGGAGGGGCC
	CCCAATGGATTGATT	AGTTGAGGATCAGCG	AGTATGGAGGGGCCA
	CCAATGGATTGATTC	GTTGAGGATCAGCGA	GTATGGAGGGGCCAA
	CAATGGATTGATTCT	TTGAGGATCAGCGAG	TATGGAGGGGCCAAG
40	AATGGATTGATTCTA	TGAGGATCAGCGAGA	ATGGAGGGGCCAAGC
	ATGGATTGATTCTAA	GAGGATCAGCGAGAA	TGGAGGGGCCAAGCT
	TGGATTGATTCTAAT	AGGATCAGCGAGAAT	GGAGGGGCCAAGCTA
	GGATTGATTCTAATG	GGATCAGCGAGAATG	GAGGGGCCAAGCTAA
	GATTGATTCTAATGT	GATCAGCGAGAATGT	AGGGGCCAAGCTAAA

	GGGGCCAAGCTAAAC	GATTCAGGCCACATC	CTGTGTTCTTCTATG
	GGGCCAAGCTAAACC	ATTCAGGCCACATCT	TGTGTTCTTCTATGT
	GGCCAAGCTAAACCG	TTCAGGCCACATCTC	GTGTTCTTCTATGTC
	GCCAAGCTAAACCGG	TCAGGCCACATCTCT	TGTTCTTCTATGTCC
5	CCAAGCTAAACCGGC	CAGGCCACATCTCTC	GTTCTTCTATGTCCA
	CAAGCTAAACCGGCT	AGGCCACATCTCTCT	TTCTTCTATGTCCAG
	AAGCTAAACCGGCTA	GGCCACATCTCTCTC	TCTTCTATGTCCAGG
	AGCTAAACCGGCTAA	GCCACATCTCTCTCT	CTTCTATGTCCAGGC
	GCTAAACCGGCTAAA	CCACATCTCTCTCTG	TTCTATGTCCAGGCC
10	CTAAACCGGCTAAAC	CACATCTCTCTCTGG	TCTATGTCCAGGCCA
	TAAACCGGCTAAACC	ACATCTCTCTCTGGG	CTATGTCCAGGCCAA
	AAACCGGCTAAACCC	CATCTCTCTCTGGGA	TATGTCCAGGCCAAA
	AACCGGCTAAACCCG	ATCTCTCTCTGGGAA	ATGTCCAGGCCAAAA
	ACCGGCTAAACCCGG	TCTCTCTCTGGGAAT	TGTCCAGGCCAAAAC
15	CCGGCTAAACCCGGG	CTCTCTCTGGGAATG	GTCCAGGCCAAAACA
	CGGCTAAACCCGGGG	TCTCTCTGGGAATGG	TCCAGGCCAAAACAG
	GGCTAAACCCGGGGA	CTCTCTGGGAATGGG	CCAGGCCAAAACAGG
	GCTAAACCCGGGGAA	TCTCTGGGAATGGGT	CAGGCCAAAACAGGA
	CTAAACCCGGGGAAC	CTCTGGGAATGGGTC	AGGCCAAAACAGGAT
20	TAAACCCGGGGAACT	TCTGGGAATGGGTCG	GGCCAAAACAGGATA
	AAACCCGGGGAACTA	CTGGGAATGGGTCGT	GCCAAAACAGGATAT
	AACCCGGGGAACTAC	TGGGAATGGGTCGTG	CCAAAACAGGATATG
	ACCCGGGGAACTACA	GGGAATGGGTCGTGG	CAAAACAGGATATGA
	CCCGGGGAACTACAC	GGAATGGGTCGTGGA	AAAACAGGATATGAA
25	CCGGGGAACTACACA	GAATGGGTCGTGGAC	AAACAGGATATGAAA
	CGGGGAACTACACAG	AATGGGTCGTGGACA	AACAGGATATGAAAA
	GGGGAACTACACAGC	ATGGGTCGTGGACAG	ACAGGATATGAAAAC
	GGGAACTACACAGCC	TGGGTCGTGGACAGA	CAGGATATGAAAACT
	GGAACTACACAGCCC	GGGTCGTGGACAGAT	AGGATATGAAAACTT
30	GAACTACACAGCCCG	GGTCGTGGACAGATC	GGATATGAAAACTTC
	AACTACACAGCCCGG	GTCGTGGACAGATCC	GATATGAAAACTTCA
	ACTACACAGCCCGGA	TCGTGGACAGATCCT	ATATGAAAACTTCAT
	CTACACAGCCCGGAT	CGTGGACAGATCCTG	TATGAAAACTTCATC
	TACACAGCCCGGATT	GTGGACAGATCCTGT	ATGAAAACTTCATCC
35	ACACAGCCCGGATTC	TGGACAGATCCTGTG	TGAAAACTTCATCCA
	CACAGCCCGGATTCA	GGACAGATCCTGTGT	GAAAACTTCATCCAT
	ACAGCCCGGATTCAG	GACAGATCCTGTGTT	AAAACTTCATCCATC
	CAGCCCGGATTCAGG	ACAGATCCTGTGTTC	AAACTTCATCCATCT
	AGCCCGGATTCAGGC	CAGATCCTGTGTTCT	AACTTCATCCATCTG
40	GCCCGGATTCAGGCC	AGATCCTGTGTTCTT	ACTTCATCCATCTGA
	CCCGGATTCAGGCCA	GATCCTGTGTTCTTC	CTTCATCCATCTGAT
	CCGGATTCAGGCCAC	ATCCTGTGTTCTTCT	TTCATCCATCTGATC
	CGGATTCAGGCCACA	TCCTGTGTTCTTCTA	TCATCCATCTGATCA
	GGATTCAGGCCACAT	CCTGTGTTCTTCTAT	CATCCATCTGATCAT

	ATCCATCTGATCATC	GGGAGGGTTGGTGAT	ATAACAGCAGGCTGG
	TCCATCTGATCATCG	GGAGGGTTGGTGATT	TAACAGCAGGCTGGG
	CCATCTGATCATCGC	GAGGGTTGGTGATTA	AACAGCAGGCTGGGG
	CATCTGATCATCGCT	AGGGTTGGTGATTAT	ACAGCAGGCTGGGGA
5	ATCTGATCATCGCTC	GGGTTGGTGATTATG	CAGCAGGCTGGGGAA
	TCTGATCATCGCTCT	GGTTGGTGATTATGC	AGCAGGCTGGGGAAT
	CTGATCATCGCTCTG	GTTGGTGATTATGCT	GCAGGCTGGGGAATG
	TGATCATCGCTCTGC	TTGGTGATTATGCTG	CAGGCTGGGGAATGG
	GATCATCGCTCTGCC	TGGTGATTATGCTGT	AGGCTGGGGAATGGA
10	ATCATCGCTCTGCCC	GGTGATTATGCTGTA	GGCTGGGGAATGGAG
	TCATCGCTCTGCCCG	GTGATTATGCTGTAC	GCTGGGGAATGGAGT
	CATCGCTCTGCCCGT	TGATTATGCTGTACG	CTGGGGAATGGAGTG
	ATCGCTCTGCCCGTC	GATTATGCTGTACGT	TGGGGAATGGAGTGC
	TCGCTCTGCCCGTCG	ATTATGCTGTACGTC	GGGGAATGGAGTGCT
15	CGCTCTGCCCGTCGC	TTATGCTGTACGTCT	GGGAATGGAGTGCTG
	GCTCTGCCCGTCGCT	TATGCTGTACGTCTT	GGAATGGAGTGCTGT
	CTCTGCCCGTCGCTG	ATGCTGTACGTCTTC	GAATGGAGTGCTGTA
	TCTGCCCGTCGCTGT	TGCTGTACGTCTTCC	AATGGAGTGCTGTAT
	CTGCCCGTCGCTGTC	GCTGTACGTCTTCCA	ATGGAGTGCTGTATG
20	TGCCCGTCGCTGTCC	CTGTACGTCTTCCAT	TGGAGTGCTGTATGC
	GCCCGTCGCTGTCCT	TGTACGTCTTCCATA	GGAGTGCTGTATGCC
	CCCGTCGCTGTCCTG	GTACGTCTTCCATAG	GAGTGCTGTATGCCT
	CCGTCGCTGTCCTGT	TACGTCTTCCATAGA	AGTGCTGTATGCCTC
	CGTCGCTGTCCTGTT	ACGTCTTCCATAGAA	GTGCTGTATGCCTCT
25	GTCGCTGTCCTGTTG	CGTCTTCCATAGAAA	TGCTGTATGCCTCTG
	TCGCTGTCCTGTTGA	GTCTTCCATAGAAAG	GCTGTATGCCTCTGT
	CGCTGTCCTGTTGAT	TCTTCCATAGAAAGA	CTGTATGCCTCTGTG
	GCTGTCCTGTTGATC	CTTCCATAGAAAGAG	TGTATGCCTCTGTGA
	CTGTCCTGTTGATCG	TTCCATAGAAAGAGA	GTATGCCTCTGTGAA
30	TGTCCTGTTGATCGT	TCCATAGAAAGAGAA	TATGCCTCTGTGAAC
	GTCCTGTTGATCGTG	CCATAGAAAGAGAAA	ATGCCTCTGTGAACC
	TCCTGTTGATCGTGG	CATAGAAAGAGAAAT	TGCCTCTGTGAACCC
	CCTGTTGATCGTGGG	ATAGAAAGAGAAATA	GCCTCTGTGAACCCG
	CTGTTGATCGTGGGA	TAGAAAGAGAAATAA	CCTCTGTGAACCCGG
35	TGTTGATCGTGGGAG	AGAAAGAGAAATAAC	CTCTGTGAACCCGGA
	GTTGATCGTGGGAGG	GAAAGAGAAATAACA	TCTGTGAACCCGGAG
	TTGATCGTGGGAGGG	AAAGAGAAATAACAG	CTGTGAACCCGGAGT
	TGATCGTGGGAGGGT	AAGAGAAATAACAGC	TGTGAACCCGGAGTA
	GATCGTGGGAGGGTT	AGAGAAATAACAGCA	GTGAACCCGGAGTAC
40	ATCGTGGGAGGGTTG	GAGAAATAACAGCAG	TGAACCCGGAGTACT
	TCGTGGGAGGGTTGG	AGAAATAACAGCAGG	GAACCCGGAGTACTT
	CGTGGGAGGGTTGGT	GAAATAACAGCAGGC	AACCCGGAGTACTTC
	GTGGGAGGGTTGGTG	AAATAACAGCAGGCT	ACCCGGAGTACTTCA
	TGGGAGGGTTGGTGA	AATAACAGCAGGCTG	CCCGGAGTACTTCAG

	CCGGAGTACTTCAGC	GGAGGTGGCTCGGGA	AGGGGTCGTTTGGGA
	CGGAGTACTTCAGCG	GAGGTGGCTCGGGAG	GGGGTCGTTTGGGAT
	GGAGTACTTCAGCGC	AGGTGGCTCGGGAGA	GGGTCGTTTGGGATG
	GAGTACTTCAGCGCT	GGTGGCTCGGGAGAA	GGTCGTTTGGGATGG
5	AGTACTTCAGCGCTG	GTGGCTCGGGAGAAG	GTCGTTTGGGATGGT
	GTACTTCAGCGCTGC	TGGCTCGGGAGAAGA	TCGTTTGGGATGGTC
	TACTTCAGCGCTGCT	GGCTCGGGAGAAGAT	CGTTTGGGATGGTCT
	ACTTCAGCGCTGCTG	GCTCGGGAGAAGATC	GTTTGGGATGGTCTA
	CTTCAGCGCTGCTGA	CTCGGGAGAAGATCA	TTTGGGATGGTCTAT
10	TTCAGCGCTGCTGAT	TCGGGAGAAGATCAC	TTGGGATGGTCTATG
	TCAGCGCTGCTGATG	CGGGAGAAGATCACC	TGGGATGGTCTATGA
	CAGCGCTGCTGATGT	GGGAGAAGATCACCA	GGGATGGTCTATGAA
	AGCGCTGCTGATGTG	GGAGAAGATCACCAT	GGATGGTCTATGAAG
	GCGCTGCTGATGTGT	GAGAAGATCACCATG	GATGGTCTATGAAGG
15	CGCTGCTGATGTGTA	AGAAGATCACCATGA	ATGGTCTATGAAGGA
	GCTGCTGATGTGTAC	GAAGATCACCATGAG	TGGTCTATGAAGGAG
	CTGCTGATGTGTACG	AAGATCACCATGAGC	GGTCTATGAAGGAGT
	TGCTGATGTGTACGT	AGATCACCATGAGCC	GTCTATGAAGGAGTT
	GCTGATGTGTACGTT	GATCACCATGAGCCG	TCTATGAAGGAGTTG
20	CTGATGTGTACGTTC	ATCACCATGAGCCGG	CTATGAAGGAGTTGC
	TGATGTGTACGTTCC	TCACCATGAGCCGGG	TATGAAGGAGTTGCC
	GATGTGTACGTTCCT	CACCATGAGCCGGGA	ATGAAGGAGTTGCCA
	ATGTGTACGTTCCTG	ACCATGAGCCGGGAA	TGAAGGAGTTGCCAA
	TGTGTACGTTCCTGA	CCATGAGCCGGGAAC	GAAGGAGTTGCCAAG
25	GTGTACGTTCCTGAT	CATGAGCCGGGAACT	AAGGAGTTGCCAAGG
	TGTACGTTCCTGATG	ATGAGCCGGGAACTT	AGGAGTTGCCAAGGG
	GTACGTTCCTGATGA	TGAGCCGGGAACTTG	GGAGTTGCCAAGGGT
	TACGTTCCTGATGAG	GAGCCGGGAACTTGG	GAGTTGCCAAGGGTG
	ACGTTCCTGATGAGT	AGCCGGGAACTTGGG	AGTTGCCAAGGGTGT
30	CGTTCCTGATGAGTG	GCCGGGAACTTGGGC	GTTGCCAAGGGTGTG
	GTTCCTGATGAGTGG	CCGGGAACTTGGGCA	TTGCCAAGGGTGTGG
	TTCCTGATGAGTGGG	CGGGAACTTGGGCAG	TGCCAAGGGTGTGGT
	TCCTGATGAGTGGGA	GGGAACTTGGGCAGG	GCCAAGGGTGTGGTG
	CCTGATGAGTGGGAG	GGAACTTGGGCAGGG	CCAAGGGTGTGGTGA
35	CTGATGAGTGGGAGG	GAACTTGGGCAGGGG	CAAGGGTGTGGTGAA
	TGATGAGTGGGAGGT	AACTTGGGCAGGGGT	AAGGGTGTGGTGAAA
	GATGAGTGGGAGGTG	ACTTGGGCAGGGGTC	AGGGTGTGGTGAAAG
	ATGAGTGGGAGGTGG	CTTGGGCAGGGGTCG	GGGTGTGGTGAAAGA
	TGAGTGGGAGGTGGC	TTGGGCAGGGGTCGT	GGTGTGGTGAAAGAT
40	GAGTGGGAGGTGGCT	TGGGCAGGGGTCGTT	GTGTGGTGAAAGATG
	AGTGGGAGGTGGCTC	GGGCAGGGGTCGTTT	TGTGGTGAAAGATGA
	GTGGGAGGTGGCTCG	GGCAGGGGTCGTTTG	GTGGTGAAAGATGAA
	TGGGAGGTGGCTCGG	GCAGGGGTCGTTTGG	TGGTGAAAGATGAAC
	GGGAGGTGGCTCGGG	CAGGGGTCGTTTGGG	GGTGAAAGATGAACC

	GTGAAAGATGAACCT	CGAGGCCGCAAGCAT	CTTCTGTGATGAAGG
	TGAAAGATGAACCTG	GAGGCCGCAAGCATG	TTCTGTGATGAAGGA
	GAAAGATGAACCTGA	AGGCCGCAAGCATGC	TCTGTGATGAAGGAG
	AAAGATGAACCTGAA	GGCCGCAAGCATGCG	CTGTGATGAAGGAGT
5	AAGATGAACCTGAAA	GCCGCAAGCATGCGT	TGTGATGAAGGAGTT
	AGATGAACCTGAAAC	CCGCAAGCATGCGTG	GTGATGAAGGAGTTC
	GATGAACCTGAAACC	CGCAAGCATGCGTGA	TGATGAAGGAGTTCA
	ATGAACCTGAAACCA	GCAAGCATGCGTGAG	GATGAAGGAGTTCAA
	TGAACCTGAAACCAG	CAAGCATGCGTGAGA	ATGAAGGAGTTCAAT
10	GAACCTGAAACCAGA	AAGCATGCGTGAGAG	TGAAGGAGTTCAATT
	AACCTGAAACCAGAG	AGCATGCGTGAGAGG	GAAGGAGTTCAATTG
	ACCTGAAACCAGAGT	GCATGCGTGAGAGGA	AAGGAGTTCAATTGT
	CCTGAAACCAGAGTG	CATGCGTGAGAGGAT	AGGAGTTCAATTGTC
	CTGAAACCAGAGTGG	ATGCGTGAGAGGATT	GGAGTTCAATTGTCA
15	TGAAACCAGAGTGGC	TGCGTGAGAGGATTG	GAGTTCAATTGTCAC
	GAAACCAGAGTGGCC	GCGTGAGAGGATTGA	AGTTCAATTGTCACC
	AAACCAGAGTGGCCA	CGTGAGAGGATTGAG	GTTCAATTGTCACCA
	AACCAGAGTGGCCAT	GTGAGAGGATTGAGT	TTCAATTGTCACCAT
	ACCAGAGTGGCCATT	TGAGAGGATTGAGTT	TCAATTGTCACCATG
20	CCAGAGTGGCCATTA	GAGAGGATTGAGTTT	CAATTGTCACCATGT
	CAGAGTGGCCATTAA	AGAGGATTGAGTTTC	AATTGTCACCATGTG
	AGAGTGGCCATTAAA	GAGGATTGAGTTTCT	ATTGTCACCATGTGG
	GAGTGGCCATTAAAA	AGGATTGAGTTTCTC	TTGTCACCATGTGGT
	AGTGGCCATTAAAAC	GGATTGAGTTTCTCA	TGTCACCATGTGGTG
25	GTGGCCATTAAAACA	GATTGAGTTTCTCAA	GTCACCATGTGGTGC
	TGGCCATTAAAACAG	ATTGAGTTTCTCAAC	TCACCATGTGGTGCG
	GGCCATTAAAACAGT	TTGAGTTTCTCAACG	CACCATGTGGTGCGA
	GCCATTAAAACAGTG	TGAGTTTCTCAACGA	ACCATGTGGTGCGAT
	CCATTAAAACAGTGA	GAGTTTCTCAACGAA	CCATGTGGTGCGATT
30	CATTAAAACAGTGAA	AGTTTCTCAACGAAG	CATGTGGTGCGATTG
	ATTAAAACAGTGAAC	GTTTCTCAACGAAGC	ATGTGGTGCGATTGC
	TTAAAACAGTGAACG	TTTCTCAACGAAGCT	TGTGGTGCGATTGCT
	TAAAACAGTGAACGA	TTCTCAACGAAGCTT	GTGGTGCGATTGCTG
	AAAACAGTGAACGAG	TCTCAACGAAGCTTC	TGGTGCGATTGCTGG
35	AAACAGTGAACGAGG	CTCAACGAAGCTTCT	GGTGCGATTGCTGGG
	AACAGTGAACGAGGC	TCAACGAAGCTTCTG	GTGCGATTGCTGGGT
	ACAGTGAACGAGGCC	CAACGAAGCTTCTGT	TGCGATTGCTGGGTG
	CAGTGAACGAGGCCG	AACGAAGCTTCTGTG	GCGATTGCTGGGTGT
	AGTGAACGAGGCCGC	ACGAAGCTTCTGTGA	CGATTGCTGGGTGTG
40	GTGAACGAGGCCGCA	CGAAGCTTCTGTGAT	GATTGCTGGGTGTGG
	TGAACGAGGCCGCAA	GAAGCTTCTGTGATG	ATTGCTGGGTGTGGT
	GAACGAGGCCGCAAG	AAGCTTCTGTGATGA	TTGCTGGGTGTGGTG
	AACGAGGCCGCAAGC	AGCTTCTGTGATGAA	TGCTGGGTGTGGTGT
	ACGAGGCCGCAAGCA	GCTTCTGTGATGAAG	GCTGGGTGTGGTGTC

	CTGGGTGTGGTGTCC	ACTGATGACACGGGG	GGCCAGAAATGGAGA
	TGGGTGTGGTGTCCC	CTGATGACACGGGGC	GCCAGAAATGGAGAA
	GGGTGTGGTGTCCCA	TGATGACACGGGGCG	CCAGAAATGGAGAAT
	GGTGTGGTGTCCCAA	GATGACACGGGGCGA	CAGAAATGGAGAATA
5	GTGTGGTGTCCCAAG	ATGACACGGGGCGAT	AGAAATGGAGAATAA
	TGTGGTGTCCCAAGG	TGACACGGGGCGATC	GAAATGGAGAATAAT
	GTGGTGTCCCAAGGC	GACACGGGGCGATCT	AAATGGAGAATAATC
	TGGTGTCCCAAGGCC	ACACGGGGCGATCTC	AATGGAGAATAATCC
	GGTGTCCCAAGGCCA	CACGGGGCGATCTCA	ATGGAGAATAATCCA
10	GTGTCCCAAGGCCAG	ACGGGGCGATCTCAA	TGGAGAATAATCCAG
	TGTCCCAAGGCCAGC	CGGGGCGATCTCAAA	GGAGAATAATCCAGT
	GTCCCAAGGCCAGCC	GGGGCGATCTCAAAA	GAGAATAATCCAGTC
	TCCCAAGGCCAGCCA	GGGCGATCTCAAAAG	AGAATAATCCAGTCC
	CCCAAGGCCAGCCAA	GGCGATCTCAAAAGT	GAATAATCCAGTCCT
15	CCAAGGCCAGCCAAC	GCGATCTCAAAAGTT	AATAATCCAGTCCTA
	CAAGGCCAGCCAACA	CGATCTCAAAAGTTA	ATAATCCAGTCCTAG
	AAGGCCAGCCAACAC	GATCTCAAAAGTTAT	TAATCCAGTCCTAGC
	AGGCCAGCCAACACT	ATCTCAAAAGTTATC	AATCCAGTCCTAGCA
	GGCCAGCCAACACTG	TCTCAAAAGTTATCT	ATCCAGTCCTAGCAC
20	GCCAGCCAACACTGG	CTCAAAAGTTATCTC	TCCAGTCCTAGCACC
	CCAGCCAACACTGGT	TCAAAAGTTATCTCC	CCAGTCCTAGCACCT
	CAGCCAACACTGGTC	CAAAAGTTATCTCCG	CAGTCCTAGCACCTC
	AGCCAACACTGGTCA	AAAAGTTATCTCCGG	AGTCCTAGCACCTCC
	GCCAACACTGGTCAT	AAAGTTATCTCCGGT	GTCCTAGCACCTCCA
25	CCAACACTGGTCATC	AAGTTATCTCCGGTC	TCCTAGCACCTCCAA
	CAACACTGGTCATCA	AGTTATCTCCGGTCT	CCTAGCACCTCCAAG
	AACACTGGTCATCAT	GTTATCTCCGGTCTC	CTAGCACCTCCAAGC
	ACACTGGTCATCATG	TTATCTCCGGTCTCT	TAGCACCTCCAAGCC
	CACTGGTCATCATGG	TATCTCCGGTCTCTG	AGCACCTCCAAGCCT
30	ACTGGTCATCATGGA	ATCTCCGGTCTCTGA	GCACCTCCAAGCCTG
	CTGGTCATCATGGAA	TCTCCGGTCTCTGAG	CACCTCCAAGCCTGA
	TGGTCATCATGGAAC	CTCCGGTCTCTGAGG	ACCTCCAAGCCTGAG
	GGTCATCATGGAACT	TCCGGTCTCTGAGGC	CCTCCAAGCCTGAGC
	GTCATCATGGAACTG	CCGGTCTCTGAGGCC	CTCCAAGCCTGAGCA
35	TCATCATGGAACTGA	CGGTCTCTGAGGCCA	TCCAAGCCTGAGCAA
	CATCATGGAACTGAT	GGTCTCTGAGGCCAG	CCAAGCCTGAGCAAG
	ATCATGGAACTGATG	GTCTCTGAGGCCAGA	CAAGCCTGAGCAAGA
	TCATGGAACTGATGA	TCTCTGAGGCCAGAA	AAGCCTGAGCAAGAT
	CATGGAACTGATGAC	CTCTGAGGCCAGAAA	AGCCTGAGCAAGATG
40	ATGGAACTGATGACA	TCTGAGGCCAGAAAT	GCCTGAGCAAGATGA
	TGGAACTGATGACAC	CTGAGGCCAGAAATG	CCTGAGCAAGATGAT
	GGAACTGATGACACG	TGAGGCCAGAAATGG	CTGAGCAAGATGATT
	GAACTGATGACACGG	GAGGCCAGAAATGGA	TGAGCAAGATGATTC
	AACTGATGACACGGG	AGGCCAGAAATGGAG	GAGCAAGATGATTCA

	AGCAAGATGATTCAG	ATACCTCAACGCCAA	GGAATTGCATGGTAG
	GCAAGATGATTCAGA	TACCTCAACGCCAAT	GAATTGCATGGTAGC
	CAAGATGATTCAGAT	ACCTCAACGCCAATA	AATTGCATGGTAGCC
	AAGATGATTCAGATG	CCTCAACGCCAATAA	ATTGCATGGTAGCCG
5	AGATGATTCAGATGG	CTCAACGCCAATAAG	TTGCATGGTAGCCGA
	GATGATTCAGATGGC	TCAACGCCAATAAGT	TGCATGGTAGCCGAA
	ATGATTCAGATGGCC	CAACGCCAATAAGTT	GCATGGTAGCCGAAG
	TGATTCAGATGGCCG	AACGCCAATAAGTTC	CATGGTAGCCGAAGA
	GATTCAGATGGCCGG	ACGCCAATAAGTTCG	ATGGTAGCCGAAGAT
10	ATTCAGATGGCCGGA	CGCCAATAAGTTCGT	TGGTAGCCGAAGATT
	TTCAGATGGCCGGAG	GCCAATAAGTTCGTC	GGTAGCCGAAGATTT
	TCAGATGGCCGGAGA	CCAATAAGTTCGTCC	GTAGCCGAAGATTTC
	CAGATGGCCGGAGAG	CAATAAGTTCGTCCA	TAGCCGAAGATTTCA
	AGATGGCCGGAGAGA	AATAAGTTCGTCCAC	AGCCGAAGATTTCAC
15	GATGGCCGGAGAGAT	ATAAGTTCGTCCACA	GCCGAAGATTTCACA
	ATGGCCGGAGAGATT	TAAGTTCGTCCACAG	CCGAAGATTTCACAG
	TGGCCGGAGAGATTG	AAGTTCGTCCACAGA	CGAAGATTTCACAGT
	GGCCGGAGAGATTGC	AGTTCGTCCACAGAG	GAAGATTTCACAGTC
	GCCGGAGAGATTGCA	GTTCGTCCACAGAGA	AAGATTTCACAGTCA
20	CCGGAGAGATTGCAG	TTCGTCCACAGAGAC	AGATTTCACAGTCAA
	CGGAGAGATTGCAGA	TCGTCCACAGAGACC	GATTTCACAGTCAAA
	GGAGAGATTGCAGAC	CGTCCACAGAGACCT	ATTTCACAGTCAAAA
	GAGAGATTGCAGACG	GTCCACAGAGACCTT	TTTCACAGTCAAAAT
	AGAGATTGCAGACGG	TCCACAGAGACCTTG	TTCACAGTCAAAATC
25	GAGATTGCAGACGGC	CCACAGAGACCTTGC	TCACAGTCAAAATCG
	AGATTGCAGACGGCA	CACAGAGACCTTGCT	CACAGTCAAAATCGG
	GATTGCAGACGGCAT	ACAGAGACCTTGCTG	ACAGTCAAAATCGGA
	ATTGCAGACGGCATG	CAGAGACCTTGCTGC	CAGTCAAAATCGGAG
	TTGCAGACGGCATGG	AGAGACCTTGCTGCC	AGTCAAAATCGGAGA
30	TGCAGACGGCATGGC	GAGACCTTGCTGCCC	GTCAAAATCGGAGAT
	GCAGACGGCATGGCA	AGACCTTGCTGCCCG	TCAAAATCGGAGATT
	CAGACGGCATGGCAT	GACCTTGCTGCCCGG	CAAAATCGGAGATTT
	AGACGGCATGGCATA	ACCTTGCTGCCCGGA	AAAATCGGAGATTTT
	GACGGCATGGCATAC	CCTTGCTGCCCGGAA	AAATCGGAGATTTTG
35	ACGGCATGGCATACC	CTTGCTGCCCGGAAT	AATCGGAGATTTTGG
	CGGCATGGCATACCT	TTGCTGCCCGGAATT	ATCGGAGATTTTGGT
	GGCATGGCATACCTC	TGCTGCCCGGAATTG	TCGGAGATTTTGGTA
	GCATGGCATACCTCA	GCTGCCCGGAATTGC	CGGAGATTTTGGTAT
	CATGGCATACCTCAA	CTGCCCGGAATTGCA	GGAGATTTTGGTATG
40	ATGGCATACCTCAAC	TGCCCGGAATTGCAT	GAGATTTTGGTATGA
	TGGCATACCTCAACG	GCCCGGAATTGCATG	AGATTTTGGTATGAC
	GGCATACCTCAACGC	CCCGGAATTGCATGG	GATTTTGGTATGACG
	GCATACCTCAACGCC	CCGGAATTGCATGGT	ATTTTGGTATGACGC
	CATACCTCAACGCCA	CGGAATTGCATGGTA	TTTTGGTATGACGCG

	TTTGGTATGACGCGA	AGGAGGCAAAGGGCT	CCCTCAAGGATGGAG
	TTGGTATGACGCGAG	GGAGGCAAAGGGCTG	CCTCAAGGATGGAGT
	TGGTATGACGCGAGA	GAGGCAAAGGGCTGC	CTCAAGGATGGAGTC
	GGTATGACGCGAGAT	AGGCAAAGGGCTGCT	TCAAGGATGGAGTCT
5	GTATGACGCGAGATA	GGCAAAGGGCTGCTG	CAAGGATGGAGTCTT
	TATGACGCGAGATAT	GCAAAGGGCTGCTGC	AAGGATGGAGTCTTC
	ATGACGCGAGATATC	CAAAGGGCTGCTGCC	AGGATGGAGTCTTCA
	TGACGCGAGATATCT	AAAGGGCTGCTGCCC	GGATGGAGTCTTCAC
	GACGCGAGATATCTA	AAGGGCTGCTGCCCG	GATGGAGTCTTCACC
10	ACGCGAGATATCTAT	AGGGCTGCTGCCCGT	ATGGAGTCTTCACCA
	CGCGAGATATCTATG	GGGCTGCTGCCCGTG	TGGAGTCTTCACCAC
	GCGAGATATCTATGA	GGCTGCTGCCCGTGC	GGAGTCTTCACCACT
	CGAGATATCTATGAG	GCTGCTGCCCGTGCG	GAGTCTTCACCACTT
	GAGATATCTATGAGA	CTGCTGCCCGTGCGC	AGTCTTCACCACTTA
15	AGATATCTATGAGAC	TGCTGCCCGTGCGCT	GTCTTCACCACTTAC
	GATATCTATGAGACA	GCTGCCCGTGCGCTG	TCTTCACCACTTACT
	ATATCTATGAGACAG	CTGCCCGTGCGCTGG	CTTCACCACTTACTC
	TATCTATGAGACAGA	TGCCCGTGCGCTGGA	TTCACCACTTACTCG
	ATCTATGAGACAGAC	GCCCGTGCGCTGGAT	TCACCACTTACTCGG
20	TCTATGAGACAGACT	CCCGTGCGCTGGATG	CACCACTTACTCGGA
	CTATGAGACAGACTA	CCGTGCGCTGGATGT	ACCACTTACTCGGAC
	TATGAGACAGACTAT	CGTGCGCTGGATGTC	CCACTTACTCGGACG
	ATGAGACAGACTATT	GTGCGCTGGATGTCT	CACTTACTCGGACGT
	TGAGACAGACTATTA	TGCGCTGGATGTCTC	ACTTACTCGGACGTC
25	GAGACAGACTATTAC	GCGCTGGATGTCTCC	CTTACTCGGACGTCT
	AGACAGACTATTACC	CGCTGGATGTCTCCT	TTACTCGGACGTCTG
	GACAGACTATTACCG	GCTGGATGTCTCCTG	TACTCGGACGTCTGG
	ACAGACTATTACCGG	CTGGATGTCTCCTGA	ACTCGGACGTCTGGT
	CAGACTATTACCGGA	TGGATGTCTCCTGAG	CTCGGACGTCTGGTC
30	AGACTATTACCGGAA	GGATGTCTCCTGAGT	TCGGACGTCTGGTCC
	GACTATTACCGGAAA	GATGTCTCCTGAGTC	CGGACGTCTGGTCCT
	ACTATTACCGGAAAG	ATGTCTCCTGAGTCC	GGACGTCTGGTCCTT
	CTATTACCGGAAAGG	TGTCTCCTGAGTCCC	GACGTCTGGTCCTTC
	TATTACCGGAAAGGA	GTCTCCTGAGTCCCT	ACGTCTGGTCCTTCG
35	ATTACCGGAAAGGAG	TCTCCTGAGTCCCTC	CGTCTGGTCCTTCGG
	TTACCGGAAAGGAGG	CTCCTGAGTCCCTCA	GTCTGGTCCTTCGGG
	TACCGGAAAGGAGGC	TCCTGAGTCCCTCAA	TCTGGTCCTTCGGGG
	ACCGGAAAGGAGGCA	CCTGAGTCCCTCAAG	CTGGTCCTTCGGGGT
	CCGGAAAGGAGGCAA	CTGAGTCCCTCAAGG	TGGTCCTTCGGGGTC
40	CGGAAAGGAGGCAAA	TGAGTCCCTCAAGGA	GGTCCTTCGGGGTCG
	GGAAAGGAGGCAAAG	GAGTCCCTCAAGGAT	GTCCTTCGGGGTCGT
	GAAAGGAGGCAAAGG	AGTCCCTCAAGGATG	TCCTTCGGGGTCGTC
	AAAGGAGGCAAAGGG	GTCCCTCAAGGATGG	CCTTCGGGGTCGTCC
	AAGGAGGCAAAGGGC	TCCCTCAAGGATGGA	CTTCGGGGTCGTCCT

	TTCGGGGTCGTCCTC	CTACCAGGGCTTGTC	AGGGCGGCCTTCTGG
	TCGGGGTCGTCCTCT	TACCAGGGCTTGTCC	GGGCGGCCTTCTGGA
	CGGGGTCGTCCTCTG	ACCAGGGCTTGTCCA	GGCGGCCTTCTGGAC
	GGGGTCGTCCTCTGG	CCAGGGCTTGTCCAA	GCGGCCTTCTGGACA
5	GGGTCGTCCTCTGGG	CAGGGCTTGTCCAAC	CGGCCTTCTGGACAA
	GGTCGTCCTCTGGGA	AGGGCTTGTCCAACG	GGCCTTCTGGACAAG
	GTCGTCCTCTGGGAG	GGGCTTGTCCAACGA	GCCTTCTGGACAAGC
	TCGTCCTCTGGGAGA	GGCTTGTCCAACGAG	CCTTCTGGACAAGCC
	CGTCCTCTGGGAGAT	GCTTGTCCAACGAGC	CTTCTGGACAAGCCA
10	GTCCTCTGGGAGATC	CTTGTCCAACGAGCA	TTCTGGACAAGCCAG
	TCCTCTGGGAGATCG	TTGTCCAACGAGCAA	TCTGGACAAGCCAGA
	CCTCTGGGAGATCGC	TGTCCAACGAGCAAG	CTGGACAAGCCAGAC
	CTCTGGGAGATCGCC	GTCCAACGAGCAAGT	TGGACAAGCCAGACA
	TCTGGGAGATCGCCA	TCCAACGAGCAAGTC	GGACAAGCCAGACAA
15	CTGGGAGATCGCCAC	CCAACGAGCAAGTCC	GACAAGCCAGACAAC
	TGGGAGATCGCCACA	CAACGAGCAAGTCCT	ACAAGCCAGACAACT
	GGGAGATCGCCACAC	AACGAGCAAGTCCTT	CAAGCCAGACAACTG
	GGAGATCGCCACACT	ACGAGCAAGTCCTTC	AAGCCAGACAACTGT
	GAGATCGCCACACTG	CGAGCAAGTCCTTCG	AGCCAGACAACTGTC
20	AGATCGCCACACTGG	GAGCAAGTCCTTCGC	GCCAGACAACTGTCC
	GATCGCCACACTGGC	AGCAAGTCCTTCGCT	CCAGACAACTGTCCT
	ATCGCCACACTGGCC	GCAAGTCCTTCGCTT	CAGACAACTGTCCTG
	TCGCCACACTGGCCG	CAAGTCCTTCGCTTC	AGACAACTGTCCTGA
	CGCCACACTGGCCGA	AAGTCCTTCGCTTCG	GACAACTGTCCTGAC
25	GCCACACTGGCCGAG	AGTCCTTCGCTTCGT	ACAACTGTCCTGACA
	CCACACTGGCCGAGC	GTCCTTCGCTTCGTC	CAACTGTCCTGACAT
	CACACTGGCCGAGCA	TCCTTCGCTTCGTCA	AACTGTCCTGACATG
	ACACTGGCCGAGCAG	CCTTCGCTTCGTCAT	ACTGTCCTGACATGC
	CACTGGCCGAGCAGC	CTTCGCTTCGTCATG	CTGTCCTGACATGCT
30	ACTGGCCGAGCAGCC	TTCGCTTCGTCATGG	TGTCCTGACATGCTG
	CTGGCCGAGCAGCCC	TCGCTTCGTCATGGA	GTCCTGACATGCTGT
	TGGCCGAGCAGCCCT	CGCTTCGTCATGGAG	TCCTGACATGCTGTT
	GGCCGAGCAGCCCTA	GCTTCGTCATGGAGG	CCTGACATGCTGTTT
	GCCGAGCAGCCCTAC	CTTCGTCATGGAGGG	CTGACATGCTGTTTG
35	CCGAGCAGCCCTACC	TTCGTCATGGAGGGC	TGACATGCTGTTTGA
	CGAGCAGCCCTACCA	TCGTCATGGAGGGCG	GACATGCTGTTTGAA
	GAGCAGCCCTACCAG	CGTCATGGAGGGCGG	ACATGCTGTTTGAAC
	AGCAGCCCTACCAGG	GTCATGGAGGGCGGC	CATGCTGTTTGAACT
	GCAGCCCTACCAGGG	TCATGGAGGGCGGCC	ATGCTGTTTGAACTG
40	CAGCCCTACCAGGGC	CATGGAGGGCGGCCT	TGCTGTTTGAACTGA
	AGCCCTACCAGGGCT	ATGGAGGGCGGCCTT	GCTGTTTGAACTGAT
	GCCCTACCAGGGCTT	TGGAGGGCGGCCTTC	CTGTTTGAACTGATG
	CCCTACCAGGGCTTG	GGAGGGCGGCCTTCT	TGTTTGAACTGATGC
	CCTACCAGGGCTTGT	GAGGGCGGCCTTCTG	GTTTGAACTGATGCG

	TTTGAACTGATGCGC	GCCTTCCTTCCTGGA	AGCCTGGCTTCCGGG
	TTGAACTGATGCGCA	CCTTCCTTCCTGGAG	GCCTGGCTTCCGGGA
	TGAACTGATGCGCAT	CTTCCTTCCTGGAGA	CCTGGCTTCCGGGAG
	GAACTGATGCGCATG	TTCCTTCCTGGAGAT	CTGGCTTCCGGGAGG
5	AACTGATGCGCATGT	TCCTTCCTGGAGATC	TGGCTTCCGGGAGGT
	ACTGATGCGCATGTG	CCTTCCTGGAGATCA	GGCTTCCGGGAGGTC
	CTGATGCGCATGTGC	CTTCCTGGAGATCAT	GCTTCCGGGAGGTCT
	TGATGCGCATGTGCT	TTCCTGGAGATCATC	CTTCCGGGAGGTCTC
	GATGCGCATGTGCTG	TCCTGGAGATCATCA	TTCCGGGAGGTCTCC
10	ATGCGCATGTGCTGG	CCTGGAGATCATCAG	TCCGGGAGGTCTCCT
	TGCGCATGTGCTGGC	CTGGAGATCATCAGC	CCGGGAGGTCTCCTT
	GCGCATGTGCTGGCA	TGGAGATCATCAGCA	CGGGAGGTCTCCTTC
	CGCATGTGCTGGCAG	GGAGATCATCAGCAG	GGGAGGTCTCCTTCT
	GCATGTGCTGGCAGT	GAGATCATCAGCAGC	GGAGGTCTCCTTCTA
15	CATGTGCTGGCAGTA	AGATCATCAGCAGCA	GAGGTCTCCTTCTAC
	ATGTGCTGGCAGTAT	GATCATCAGCAGCAT	AGGTCTCCTTCTACT
	TGTGCTGGCAGTATA	ATCATCAGCAGCATC	GGTCTCCTTCTACTA
	GTGCTGGCAGTATAA	TCATCAGCAGCATCA	GTCTCCTTCTACTAC
	TGCTGGCAGTATAAC	CATCAGCAGCATCAA	TCTCCTTCTACTACA
20	GCTGGCAGTATAACC	ATCAGCAGCATCAAA	CTCCTTCTACTACAG
	CTGGCAGTATAACCC	TCAGCAGCATCAAAG	TCCTTCTACTACAGC
	TGGCAGTATAACCCC	CAGCAGCATCAAAGA	CCTTCTACTACAGCG
	GGCAGTATAACCCCA	AGCAGCATCAAAGAG	CTTCTACTACAGCGA
	GCAGTATAACCCCAA	GCAGCATCAAAGAGG	TTCTACTACAGCGAG
25	CAGTATAACCCCAAG	CAGCATCAAAGAGGA	TCTACTACAGCGAGG
	AGTATAACCCCAAGA	AGCATCAAAGAGGAG	CTACTACAGCGAGGA
	GTATAACCCCAAGAT	GCATCAAAGAGGAGA	TACTACAGCGAGGAG
	TATAACCCCAAGATG	CATCAAAGAGGAGAT	ACTACAGCGAGGAGA
	ATAACCCCAAGATGA	ATCAAAGAGGAGATG	CTACAGCGAGGAGAA
30	TAACCCCAAGATGAG	TCAAAGAGGAGATGG	TACAGCGAGGAGAAC
	AACCCCAAGATGAGG	CAAAGAGGAGATGGA	ACAGCGAGGAGAACA
	ACCCCAAGATGAGGC	AAAGAGGAGATGGAG	CAGCGAGGAGAACAA
	CCCCAAGATGAGGCC	AAGAGGAGATGGAGC	AGCGAGGAGAACAAG
	CCCAAGATGAGGCCT	AGAGGAGATGGAGCC	GCGAGGAGAACAAGC
35	CCAAGATGAGGCCTT	GAGGAGATGGAGCCT	CGAGGAGAACAAGCT
	CAAGATGAGGCCTTC	AGGAGATGGAGCCTG	GAGGAGAACAAGCTG
	AAGATGAGGCCTTCC	GGAGATGGAGCCTGG	AGGAGAACAAGCTGC
	AGATGAGGCCTTCCT	GAGATGGAGCCTGGC	GGAGAACAAGCTGCC
	GATGAGGCCTTCCTT	AGATGGAGCCTGGCT	GAGAACAAGCTGCCC
40	ATGAGGCCTTCCTTC	GATGGAGCCTGGCTT	AGAACAAGCTGCCCG
	TGAGGCCTTCCTTCC	ATGGAGCCTGGCTTC	GAACAAGCTGCCCGA
	GAGGCCTTCCTTCCT	TGGAGCCTGGCTTCC	AACAAGCTGCCCGAG
	AGGCCTTCCTTCCTG	GGAGCCTGGCTTCCG	ACAAGCTGCCCGAGC
	GGCCTTCCTTCCTGG	GAGCCTGGCTTCCGG	CAAGCTGCCCGAGCC

	AAGCTGCCCGAGCCG	GGAGAGCGTCCCCCT	CACTGCCCGACAGAC
	AGCTGCCCGAGCCGG	GAGAGCGTCCCCCTG	ACTGCCCGACAGACA
	GCTGCCCGAGCCGGA	AGAGCGTCCCCCTGG	CTGCCCGACAGACAC
	CTGCCCGAGCCGGAG	GAGCGTCCCCCTGGA	TGCCCGACAGACACT
5	TGCCCGAGCCGGAGG	AGCGTCCCCCTGGAC	GCCCGACAGACACTC
	GCCCGAGCCGGAGGA	GCGTCCCCCTGGACC	CCCGACAGACACTCA
	CCCGAGCCGGAGGAG	CGTCCCCCTGGACCC	CCGACAGACACTCAG
	CCGAGCCGGAGGAGC	GTCCCCCTGGACCCC	CGACAGACACTCAGG
	CGAGCCGGAGGAGCT	TCCCCCTGGACCCCT	GACAGACACTCAGGA
10	GAGCCGGAGGAGCTG	CCCCCTGGACCCCTC	ACAGACACTCAGGAC
	AGCCGGAGGAGCTGG	CCCCTGGACCCCTCG	CAGACACTCAGGACA
	GCCGGAGGAGCTGGA	CCCTGGACCCCTCGG	AGACACTCAGGACAC
	CCGGAGGAGCTGGAC	CCTGGACCCCTCGGC	GACACTCAGGACACA
	CGGAGGAGCTGGACC	CTGGACCCCTCGGCC	ACACTCAGGACACAA
15	GGAGGAGCTGGACCT	TGGACCCCTCGGCCT	CACTCAGGACACAAG
	GAGGAGCTGGACCTG	GGACCCCTCGGCCTC	ACTCAGGACACAAGG
	AGGAGCTGGACCTGG	GACCCCTCGGCCTCC	CTCAGGACACAAGGC
	GGAGCTGGACCTGGA	ACCCCTCGGCCTCCT	TCAGGACACAAGGCC
	GAGCTGGACCTGGAG	CCCCTCGGCCTCCTC	CAGGACACAAGGCCG
20	AGCTGGACCTGGAGC	CCCTCGGCCTCCTCG	AGGACACAAGGCCGA
	GCTGGACCTGGAGCC	CCTCGGCCTCCTCGT	GGACACAAGGCCGAG
	CTGGACCTGGAGCCA	CTCGGCCTCCTCGTC	GACACAAGGCCGAGA
	TGGACCTGGAGCCAG	TCGGCCTCCTCGTCC	ACACAAGGCCGAGAA
	GGACCTGGAGCCAGA	CGGCCTCCTCGTCCT	CACAAGGCCGAGAAC
25	GACCTGGAGCCAGAG	GGCCTCCTCGTCCTC	ACAAGGCCGAGAACG
	ACCTGGAGCCAGAGA	GCCTCCTCGTCCTCC	CAAGGCCGAGAACGG
	CCTGGAGCCAGAGAA	CCTCCTCGTCCTCCC	AAGGCCGAGAACGGC
	CTGGAGCCAGAGAAC	CTCCTCGTCCTCCCT	AGGCCGAGAACGGCC
	TGGAGCCAGAGAACA	TCCTCGTCCTCCCTG	GGCCGAGAACGGCCC
30	GGAGCCAGAGAACAT	CCTCGTCCTCCCTGC	GCCGAGAACGGCCCC
	GAGCCAGAGAACATG	CTCGTCCTCCCTGCC	CCGAGAACGGCCCCG
	AGCCAGAGAACATGG	TCGTCCTCCCTGCCA	CGAGAACGGCCCCGG
	GCCAGAGAACATGGA	CGTCCTCCCTGCCAC	GAGAACGGCCCCGGC
	CCAGAGAACATGGAG	GTCCTCCCTGCCACT	AGAACGGCCCCGGCC
35	CAGAGAACATGGAGA	TCCTCCCTGCCACTG	GAACGGCCCCGGCCC
	AGAGAACATGGAGAG	CCTCCCTGCCACTGC	AACGGCCCCGGCCCT
	GAGAACATGGAGAGC	CTCCCTGCCACTGCC	ACGGCCCCGGCCCTG
	AGAACATGGAGAGCG	TCCCTGCCACTGCCC	CGGCCCCGGCCCTGG
	GAACATGGAGAGCGT	CCCTGCCACTGCCCG	GGCCCCGGCCCTGGG
40	AACATGGAGAGCGTC	CCTGCCACTGCCCGA	GCCCCGGCCCTGGGG
	ACATGGAGAGCGTCC	CTGCCACTGCCCGAC	CCCCGGCCCTGGGGT
	CATGGAGAGCGTCCC	TGCCACTGCCCGACA	CCCGGCCCTGGGGTG
	ATGGAGAGCGTCCCC	GCCACTGCCCGACAG	CCGGCCCTGGGGTGC
	TGGAGAGCGTCCCCC	CCACTGCCCGACAGA	CGGCCCTGGGGTGCT

	GGCCCTGGGGTGCTG	GCCTTACGCCCACAT	TGCCGCTGCCCCAGT
	GCCCTGGGGTGCTGG	CCTTACGCCCACATG	GCCGCTGCCCCAGTC
	CCCTGGGGTGCTGGT	CTTACGCCCACATGA	CCGCTGCCCCAGTCT
	CCTGGGGTGCTGGTC	TTACGCCCACATGAA	CGCTGCCCCAGTCTT
5	CTGGGGTGCTGGTCC	TACGCCCACATGAAC	GCTGCCCCAGTCTTC
	TGGGGTGCTGGTCCT	ACGCCCACATGAACG	CTGCCCCAGTCTTCG
	GGGGTGCTGGTCCTC	CGCCCACATGAACGG	TGCCCCAGTCTTCGA
	GGGTGCTGGTCCTCC	GCCCACATGAACGGG	GCCCCAGTCTTCGAC
	GGTGCTGGTCCTCCG	CCCACATGAACGGGG	CCCCAGTCTTCGACC
10	GTGCTGGTCCTCCGC	CCACATGAACGGGGG	CCCAGTCTTCGACCT
	TGCTGGTCCTCCGCG	CACATGAACGGGGGC	CCAGTCTTCGACCTG
	GCTGGTCCTCCGCGC	ACATGAACGGGGGCC	CAGTCTTCGACCTGC
	CTGGTCCTCCGCGCC	CATGAACGGGGGCCG	AGTCTTCGACCTGCT
	TGGTCCTCCGCGCCA	ATGAACGGGGGCCGC	GTCTTCGACCTGCTG
15	GGTCCTCCGCGCCAG	TGAACGGGGGCCGCA	TCTTCGACCTGCTGA
	GTCCTCCGCGCCAGC	GAACGGGGGCCGCAA	CTTCGACCTGCTGAT
	TCCTCCGCGCCAGCT	AACGGGGGCCGCAAG	TTCGACCTGCTGATC
	CCTCCGCGCCAGCTT	ACGGGGGCCGCAAGA	TCGACCTGCTGATCC
	CTCCGCGCCAGCTTC	CGGGGGCCGCAAGAA	CGACCTGCTGATCCT
20	TCCGCGCCAGCTTCG	GGGGGCCGCAAGAAC	GACCTGCTGATCCTT
	CCGCGCCAGCTTCGA	GGGGCCGCAAGAACG	ACCTGCTGATCCTTG
	CGCGCCAGCTTCGAC	GGGCCGCAAGAACGA	CCTGCTGATCCTTGG
	GCGCCAGCTTCGACG	GGCCGCAAGAACGAG	CTGCTGATCCTTGGA
	CGCCAGCTTCGACGA	GCCGCAAGAACGAGC	TGCTGATCCTTGGAT
25	GCCAGCTTCGACGAG	CCGCAAGAACGAGCG	GCTGATCCTTGGATC
	CCAGCTTCGACGAGA	CGCAAGAACGAGCGG	CTGATCCTTGGATCC
	CAGCTTCGACGAGAG	GCAAGAACGAGCGGG	TGATCCTTGGATCCT
	AGCTTCGACGAGAGA	CAAGAACGAGCGGGC	GATCCTTGGATCCTG
	GCTTCGACGAGAGAC	AAGAACGAGCGGGCC	ATCCTTGGATCCTGA
30	CTTCGACGAGAGACA	AGAACGAGCGGGCCT	TCCTTGGATCCTGAA
	TTCGACGAGAGACAG	GAACGAGCGGGCCTT	CCTTGGATCCTGAAT
	TCGACGAGAGACAGC	AACGAGCGGGCCTTG	CTTGGATCCTGAATC
	CGACGAGAGACAGCC	ACGAGCGGGCCTTGC	TTGGATCCTGAATCT
	GACGAGAGACAGCCT	CGAGCGGGCCTTGCC	TGGATCCTGAATCTG
35	ACGAGAGACAGCCTT	GAGCGGGCCTTGCCG	GGATCCTGAATCTGT
	CGAGAGACAGCCTTA	AGCGGGCCTTGCCGC	GATCCTGAATCTGTG
	GAGAGACAGCCTTAC	GCGGGCCTTGCCGCT	ATCCTGAATCTGTGC
	AGAGACAGCCTTACG	CGGGCCTTGCCGCTG	TCCTGAATCTGTGCA
	GAGACAGCCTTACGC	GGGCCTTGCCGCTGC	CCTGAATCTGTGCAA
40	AGACAGCCTTACGCC	GGCCTTGCCGCTGCC	CTGAATCTGTGCAAA
	GACAGCCTTACGCCC	GCCTTGCCGCTGCCC	TGAATCTGTGCAAAC
	ACAGCCTTACGCCCA	CCTTGCCGCTGCCCC	GAATCTGTGCAAACA
	CAGCCTTACGCCCAC	CTTGCCGCTGCCCCA	AATCTGTGCAAACAG
	AGCCTTACGCCCACA	TTGCCGCTGCCCCAG	ATCTGTGCAAACAGT

	TCTGTGCAAACAGTA	GGGAGAGAGAGTTTT	CAGTGGATCTTCAGT
	CTGTGCAAACAGTAA	GGAGAGAGAGTTTTA	AGTGGATCTTCAGTT
	TGTGCAAACAGTAAC	GAGAGAGAGTTTTAA	GTGGATCTTCAGTTC
	GTGCAAACAGTAACG	AGAGAGAGTTTTAAC	TGGATCTTCAGTTCT
5	TGCAAACAGTAACGT	GAGAGAGTTTTAACA	GGATCTTCAGTTCTG
	GCAAACAGTAACGTG	AGAGAGTTTTAACAA	GATCTTCAGTTCTGC
	CAAACAGTAACGTGT	GAGAGTTTTAACAAT	ATCTTCAGTTCTGCC
	AAACAGTAACGTGTG	AGAGTTTTAACAATC	TCTTCAGTTCTGCCC
	AACAGTAACGTGTGC	GAGTTTTAACAATCC	CTTCAGTTCTGCCCT
10	ACAGTAACGTGTGCG	AGTTTTAACAATCCA	TTCAGTTCTGCCCTT
	CAGTAACGTGTGCGC	GTTTTAACAATCCAT	TCAGTTCTGCCCTTG
	AGTAACGTGTGCGCA	TTTTAACAATCCATT	CAGTTCTGCCCTTGC
	GTAACGTGTGCGCAC	TTTAACAATCCATTC	AGTTCTGCCCTTGCT
	TAACGTGTGCGCACG	TTAACAATCCATTCA	GTTCTGCCCTTGCTG
15	AACGTGTGCGCACGC	TAACAATCCATTCAC	TTCTGCCCTTGCTGC
	ACGTGTGCGCACGCG	AACAATCCATTCACA	TCTGCCCTTGCTGCC
	CGTGTGCGCACGCGC	ACAATCCATTCACAA	CTGCCCTTGCTGCCC
	GTGTGCGCACGCGCA	CAATCCATTCACAAG	TGCCCTTGCTGCCCG
	TGTGCGCACGCGCAG	AATCCATTCACAAGC	GCCCTTGCTGCCCGC
20	GTGCGCACGCGCAGC	ATCCATTCACAAGCC	CCCTTGCTGCCCGCG
	TGCGCACGCGCAGCG	TCCATTCACAAGCCT	CCTTGCTGCCCGCGG
	GCGCACGCGCAGCGG	CCATTCACAAGCCTC	CTTGCTGCCCGCGGG
	CGCACGCGCAGCGGG	CATTCACAAGCCTCC	TTGCTGCCCGCGGGA
	GCACGCGCAGCGGGG	ATTCACAAGCCTCCT	TGCTGCCCGCGGGAG
25	CACGCGCAGCGGGGT	TTCACAAGCCTCCTG	GCTGCCCGCGGGAGA
	ACGCGCAGCGGGGTG	TCACAAGCCTCCTGT	CTGCCCGCGGGAGAC
	CGCGCAGCGGGGTGG	CACAAGCCTCCTGTA	TGCCCGCGGGAGACA
	GCGCAGCGGGGTGGG	ACAAGCCTCCTGTAC	GCCCGCGGGAGACAG
	CGCAGCGGGGTGGGG	CAAGCCTCCTGTACC	CCCGCGGGAGACAGC
30	GCAGCGGGGTGGGGG	AAGCCTCCTGTACCT	CCGCGGGAGACAGCT
	CAGCGGGGTGGGGGG	AGCCTCCTGTACCTC	CGCGGGAGACAGCTT
	AGCGGGGTGGGGGGG	GCCTCCTGTACCTCA	GCGGGAGACAGCTTC
	GCGGGGTGGGGGGGG	CCTCCTGTACCTCAG	CGGGAGACAGCTTCT
	CGGGGTGGGGGGGGA	CTCCTGTACCTCAGT	GGGAGACAGCTTCTC
35	GGGGTGGGGGGGGAG	TCCTGTACCTCAGTG	GGAGACAGCTTCTCT
	GGGTGGGGGGGGAGA	CCTGTACCTCAGTGG	GAGACAGCTTCTCTG
	GGTGGGGGGGGAGAG	CTGTACCTCAGTGGA	AGACAGCTTCTCTGC
	GTGGGGGGGGAGAGA	TGTACCTCAGTGGAT	GACAGCTTCTCTGCA
	TGGGGGGGGAGAGAG	GTACCTCAGTGGATC	ACAGCTTCTCTGCAG
40	GGGGGGGGAGAGAGA	TACCTCAGTGGATCT	CAGCTTCTCTGCAGT
	GGGGGGGAGAGAGAG	ACCTCAGTGGATCTT	AGCTTCTCTGCAGTA
	GGGGGGAGAGAGAGT	CCTCAGTGGATCTTC	GCTTCTCTGCAGTAA
	GGGGGAGAGAGAGTT	CTCAGTGGATCTTCA	CTTCTCTGCAGTAAA
	GGGGAGAGAGAGTTT	TCAGTGGATCTTCAG	TTCTCTGCAGTAAAA

	TCTCTGCAGTAAAAC	CAAGCAGCTTTTTAT	CCTTTAAGAACCTTA
	CTCTGCAGTAAAACA	AAGCAGCTTTTTATT	CTTTAAGAACCTTAA
	TCTGCAGTAAAACAC	AGCAGCTTTTTATTC	TTTAAGAACCTTAAT
	CTGCAGTAAAACACA	GCAGCTTTTTATTCC	TTAAGAACCTTAATG
5	TGCAGTAAAACACAT	CAGCTTTTTATTCCC	TAAGAACCTTAATGA
	GCAGTAAAACACATT	AGCTTTTTATTCCCT	AAGAACCTTAATGAC
	CAGTAAAACACATTT	GCTTTTTATTCCCTG	AGAACCTTAATGACA
	AGTAAAACACATTTG	CTTTTTATTCCCTGC	GAACCTTAATGACAA
	GTAAAACACATTTGG	TTTTTATTCCCTGCC	AACCTTAATGACAAC
10	TAAAACACATTTGGG	TTTTATTCCCTGCCC	ACCTTAATGACAACA
	AAAACACATTTGGGA	TTTATTCCCTGCCCA	CCTTAATGACAACAC
	AAACACATTTGGGAT	TTATTCCCTGCCCAA	CTTAATGACAACACT
	AACACATTTGGGATG	TATTCCCTGCCCAAA	TTAATGACAACACTT
	ACACATTTGGGATGT	ATTCCCTGCCCAAAC	TAATGACAACACTTA
15	CACATTTGGGATGTT	TTCCCTGCCCAAACC	AATGACAACACTTAA
	ACATTTGGGATGTTC	TCCCTGCCCAAACCC	ATGACAACACTTAAT
	CATTTGGGATGTTCC	CCCTGCCCAAACCCT	TGACAACACTTAATA
	ATTTGGGATGTTCCT	CCTGCCCAAACCCTT	GACAACACTTAATAG
	TTTGGGATGTTCCTT	CTGCCCAAACCCTTA	ACAACACTTAATAGC
20	TTGGGATGTTCCTTT	TGCCCAAACCCTTAA	CAACACTTAATAGCA
	TGGGATGTTCCTTTT	GCCCAAACCCTTAAC	AACACTTAATAGCAA
	GGGATGTTCCTTTTT	CCCAAACCCTTAACT	ACACTTAATAGCAAC
	GGATGTTCCTTTTTT	CCAAACCCTTAACTG	CACTTAATAGCAACA
	GATGTTCCTTTTTTC	CAAACCCTTAACTGA	ACTTAATAGCAACAG
25	ATGTTCCTTTTTTCA	AAACCCTTAACTGAC	CTTAATAGCAACAGA
	TGTTCCTTTTTTCAA	AACCCTTAACTGACA	TTAATAGCAACAGAG
	GTTCCTTTTTTCAAT	ACCCTTAACTGACAT	TAATAGCAACAGAGC
	TTCCTTTTTTCAATA	CCCTTAACTGACATG	AATAGCAACAGAGCA
	TCCTTTTTTCAATAT	CCTTAACTGACATGG	ATAGCAACAGAGCAC
30	CCTTTTTTCAATATG	CTTAACTGACATGGG	TAGCAACAGAGCACT
	CTTTTTTCAATATGC	TTAACTGACATGGGC	AGCAACAGAGCACTT
	TTTTTTCAATATGCA	TAACTGACATGGGCC	GCAACAGAGCACTTG
	TTTTTCAATATGCAA	AACTGACATGGGCCT	CAACAGAGCACTTGA
	TTTTCAATATGCAAG	ACTGACATGGGCCTT	AACAGAGCACTTGAG
35	TTTCAATATGCAAGC	CTGACATGGGCCTTT	ACAGAGCACTTGAGA
	TTCAATATGCAAGCA	TGACATGGGCCTTTA	CAGAGCACTTGAGAA
	TCAATATGCAAGCAG	GACATGGGCCTTTAA	AGAGCACTTGAGAAC
	CAATATGCAAGCAGC	ACATGGGCCTTTAAG	GAGCACTTGAGAACC
	AATATGCAAGCAGCT	CATGGGCCTTTAAGA	AGCACTTGAGAACCA
40	ATATGCAAGCAGCTT	ATGGGCCTTTAAGAA	GCACTTGAGAACCAG
	TATGCAAGCAGCTTT	TGGGCCTTTAAGAAC	CACTTGAGAACCAGT
	ATGCAAGCAGCTTTT	GGGCCTTTAAGAACC	ACTTGAGAACCAGTC
	TGCAAGCAGCTTTTT	GGCCTTTAAGAACCT	CTTGAGAACCAGTCT
	GCAAGCAGCTTTTTA	GCCTTTAAGAACCTT	TTGAGAACCAGTCTC

	TGAGAACCAGTCTCC	CCTTTCTCTCTCCTC	CAAGTCCAGCTGGGA
	GAGAACCAGTCTCCT	CTTTCTCTCTCCTCT	AAGTCCAGCTGGGAA
	AGAACCAGTCTCCTC	TTTCTCTCTCCTCTC	AGTCCAGCTGGGAAG
	GAACCAGTCTCCTCA	TTCTCTCTCCTCTCT	GTCCAGCTGGGAAGC
5	AACCAGTCTCCTCAC	TCTCTCTCCTCTCTG	TCCAGCTGGGAAGCC
	ACCAGTCTCCTCACT	CTCTCTCCTCTCTGC	CCAGCTGGGAAGCCC
	CCAGTCTCCTCACTC	TCTCTCCTCTCTGCT	CAGCTGGGAAGCCCT
	CAGTCTCCTCACTCT	CTCTCCTCTCTGCTT	AGCTGGGAAGCCCTT
	AGTCTCCTCACTCTG	TCTCCTCTCTGCTTC	GCTGGGAAGCCCTTT
10	GTCTCCTCACTCTGT	CTCCTCTCTGCTTCA	CTGGGAAGCCCTTTT
	TCTCCTCACTCTGTC	TCCTCTCTGCTTCAT	TGGGAAGCCCTTTTT
	CTCCTCACTCTGTCC	CCTCTCTGCTTCATA	GGGAAGCCCTTTTTA
	TCCTCACTCTGTCCC	CTCTCTGCTTCATAA	GGAAGCCCTTTTTAT
	CCTCACTCTGTCCCT	TCTCTGCTTCATAAC	GAAGCCCTTTTTATC
15	CTCACTCTGTCCCTG	CTCTGCTTCATAACG	AAGCCCTTTTTATCA
	TCACTCTGTCCCTGT	TCTGCTTCATAACGG	AGCCCTTTTTATCAG
	CACTCTGTCCCTGTC	CTGCTTCATAACGGA	GCCCTTTTTATCAGT
	ACTCTGTCCCTGTCC	TGCTTCATAACGGAA	CCCTTTTTATCAGTT
	CTCTGTCCCTGTCCT	GCTTCATAACGGAAA	CCTTTTTATCAGTTT
20	TCTGTCCCTGTCCTT	CTTCATAACGGAAAA	CTTTTTATCAGTTTG
	CTGTCCCTGTCCTTC	TTCATAACGGAAAAA	TTTTTATCAGTTTGA
	TGTCCCTGTCCTTCC	TCATAACGGAAAAAT	TTTTATCAGTTTGAG
	GTCCCTGTCCTTCCC	CATAACGGAAAAATA	TTTATCAGTTTGAGG
	TCCCTGTCCTTCCCT	ATAACGGAAAAATAA	TTATCAGTTTGAGGA
25	CCCTGTCCTTCCCTG	TAACGGAAAAATAAT	TATCAGTTTGAGGAA
	CCTGTCCTTCCCTGT	AACGGAAAAATAATT	ATCAGTTTGAGGAAG
	CTGTCCTTCCCTGTT	ACGGAAAAATAATTG	TCAGTTTGAGGAAGT
	TGTCCTTCCCTGTTC	CGGAAAAATAATTGC	CAGTTTGAGGAAGTG
	GTCCTTCCCTGTTCT	GGAAAAATAATTGCC	AGTTTGAGGAAGTGG
30	TCCTTCCCTGTTCTC	GAAAAATAATTGCCA	GTTTGAGGAAGTGGC
	CCTTCCCTGTTCTCC	AAAAATAATTGCCAC	TTTGAGGAAGTGGCT
	CTTCCCTGTTCTCCC	AAAATAATTGCCACA	TTGAGGAAGTGGCTG
	TTCCCTGTTCTCCCT	AAATAATTGCCACAA	TGAGGAAGTGGCTGT
	TCCCTGTTCTCCCTT	AATAATTGCCACAAG	GAGGAAGTGGCTGTC
35	CCCTGTTCTCCCTTT	ATAATTGCCACAAGT	AGGAAGTGGCTGTCC
	CCTGTTCTCCCTTTC	TAATTGCCACAAGTC	GGAAGTGGCTGTCCC
	CTGTTCTCCCTTTCT	AATTGCCACAAGTCC	GAAGTGGCTGTCCCT
	TGTTCTCCCTTTCTC	ATTGCCACAAGTCCA	AAGTGGCTGTCCCTG
	GTTCTCCCTTTCTCT	TTGCCACAAGTCCAG	AGTGGCTGTCCCTGT
40	TTCTCCCTTTCTCTC	TGCCACAAGTCCAGC	GTGGCTGTCCCTGTG
	TCTCCCTTTCTCTCT	GCCACAAGTCCAGCT	TGGCTGTCCCTGTGG
	CTCCCTTTCTCTCTC	CCACAAGTCCAGCTG	GGCTGTCCCTGTGGC
	TCCCTTTCTCTCTCC	CACAAGTCCAGCTGG	GCTGTCCCTGTGGCC
	CCCTTTCTCTCTCCT	ACAAGTCCAGCTGGG	CTGTCCCTGTGGCCC

	TGTCCCTGTGGCCCC	CCGTGGGTCATTACA	CTTTATCTTTCACCT
	GTCCCTGTGGCCCCA	CGTGGGTCATTACAA	TTTATCTTTCACCTT
	TCCCTGTGGCCCCAT	GTGGGTCATTACAAA	TTATCTTTCACCTTT
	CCCTGTGGCCCCATC	TGGGTCATTACAAAA	TATCTTTCACCTTTC
5	CCTGTGGCCCCATCC	GGGTCATTACAAAAA	ATCTTTCACCTTTCT
	CTGTGGCCCCATCCA	GGTCATTACAAAAAA	TCTTTCACCTTTCTA
	TGTGGCCCCATCCAA	GTCATTACAAAAAAA	CTTTCACCTTTCTAG
	GTGGCCCCATCCAAC	TCATTACAAAAAAAC	TTTCACCTTTCTAGG
	TGGCCCCATCCAACC	CATTACAAAAAAACA	TTCACCTTTCTAGGG
10	GGCCCCATCCAACCA	ATTACAAAAAAACAC	TCACCTTTCTAGGGA
	GCCCCATCCAACCAC	TTACAAAAAAACACG	CACCTTTCTAGGGAC
	CCCCATCCAACCACT	TACAAAAAAACACGT	ACCTTTCTAGGGACA
	CCCATCCAACCACTG	ACAAAAAAACACGTG	CCTTTCTAGGGACAT
	CCATCCAACCACTGT	CAAAAAAACACGTGG	CTTTCTAGGGACATG
15	CATCCAACCACTGTA	AAAAAAACACGTGGA	TTTCTAGGGACATGA
	ATCCAACCACTGTAC	AAAAAACACGTGGAG	TTCTAGGGACATGAA
	TCCAACCACTGTACA	AAAAACACGTGGAGA	TCTAGGGACATGAAA
	CCAACCACTGTACAC	AAAACACGTGGAGAT	CTAGGGACATGAAAT
	CAACCACTGTACACA	AAACACGTGGAGATG	TAGGGACATGAAATT
20	AACCACTGTACACAC	AACACGTGGAGATGG	AGGGACATGAAATTT
	ACCACTGTACACACC	ACACGTGGAGATGGA	GGGACATGAAATTTA
	CCACTGTACACACCC	CACGTGGAGATGGAA	GGACATGAAATTTAC
	CACTGTACACACCCG	ACGTGGAGATGGAAA	GACATGAAATTTACA
	ACTGTACACACCCGC	CGTGGAGATGGAAAT	ACATGAAATTTACAA
25	CTGTACACACCCGCC	GTGGAGATGGAAATT	CATGAAATTTACAAA
	TGTACACACCCGCCT	TGGAGATGGAAATTT	ATGAAATTTACAAAG
	GTACACACCCGCCTG	GGAGATGGAAATTTT	TGAAATTTACAAAGG
	TACACACCCGCCTGA	GAGATGGAAATTTTT	GAAATTTACAAAGGG
	ACACACCCGCCTGAC	AGATGGAAATTTTTA	AAATTTACAAAGGGC
30	CACACCCGCCTGACA	GATGGAAATTTTTAC	AATTTACAAAGGGCC
	ACACCCGCCTGACAC	ATGGAAATTTTTACC	ATTTACAAAGGGCCA
	CACCCGCCTGACACC	TGGAAATTTTTACCT	TTTACAAAGGGCCAT
	ACCCGCCTGACACCG	GGAAATTTTTACCTT	TTACAAAGGGCCATC
	CCCGCCTGACACCGT	GAAATTTTTACCTTT	TACAAAGGGCCATCG
35	CCGCCTGACACCGTG	AAATTTTTACCTTTA	ACAAAGGGCCATCGT
	CGCCTGACACCGTGG	AATTTTTACCTTTAT	CAAAGGGCCATCGTT
	GCCTGACACCGTGGG	ATTTTTACCTTTATC	AAAGGGCCATCGTTC
	CCTGACACCGTGGGT	TTTTTACCTTTATCT	AAGGGCCATCGTTCA
	CTGACACCGTGGGTC	TTTTACCTTTATCTT	AGGGCCATCGTTCAT
40	TGACACCGTGGGTCA	TTTACCTTTATCTTT	GGGCCATCGTTCATC
	GACACCGTGGGTCAT	TTACCTTTATCTTTC	GGCCATCGTTCATCC
	ACACCGTGGGTCATT	TACCTTTATCTTTCA	GCCATCGTTCATCCA
	CACCGTGGGTCATTA	ACCTTTATCTTTCAC	CCATCGTTCATCCAA
	ACCGTGGGTCATTAC	CCTTTATCTTTCACC	CATCGTTCATCCAAG

	ATCGTTCATCCAAGG	GCCAAAATCCTGAAC	CTCGTGTCCGGAGGC
	TCGTTCATCCAAGGC	CCAAAATCCTGAACT	TCGTGTCCGGAGGCA
	CGTTCATCCAAGGCT	CAAAATCCTGAACTT	CGTGTCCGGAGGCAT
	GTTCATCCAAGGCTG	AAAATCCTGAACTTT	GTGTCCGGAGGCATG
5	TTCATCCAAGGCTGT	AAATCCTGAACTTTC	TGTCCGGAGGCATGG
	TCATCCAAGGCTGTT	AATCCTGAACTTTCT	GTCCGGAGGCATGGG
	CATCCAAGGCTGTTA	ATCCTGAACTTTCTC	TCCGGAGGCATGGGT
	ATCCAAGGCTGTTAC	TCCTGAACTTTCTCC	CCGGAGGCATGGGTG
	TCCAAGGCTGTTACC	CCTGAACTTTCTCCC	CGGAGGCATGGGTGA
10	CCAAGGCTGTTACCA	CTGAACTTTCTCCCT	GGAGGCATGGGTGAG
	CAAGGCTGTTACCAT	TGAACTTTCTCCCTC	GAGGCATGGGTGAGC
	AAGGCTGTTACCATT	GAACTTTCTCCCTCA	AGGCATGGGTGAGCA
	AGGCTGTTACCATTT	AACTTTCTCCCTCAT	GGCATGGGTGAGCAT
	GGCTGTTACCATTTT	ACTTTCTCCCTCATC	GCATGGGTGAGCATG
15	GCTGTTACCATTTTA	CTTTCTCCCTCATCG	CATGGGTGAGCATGG
	CTGTTACCATTTTAA	TTTCTCCCTCATCGG	ATGGGTGAGCATGGC
	TGTTACCATTTTAAC	TTCTCCCTCATCGGC	TGGGTGAGCATGGCA
	GTTACCATTTTAACG	TCTCCCTCATCGGCC	GGGTGAGCATGGCAG
	TTACCATTTTAACGC	CTCCCTCATCGGCCC	GGTGAGCATGGCAGC
20	TACCATTTTAACGCT	TCCCTCATCGGCCCG	GTGAGCATGGCAGCT
	ACCATTTTAACGCTG	CCCTCATCGGCCCGG	TGAGCATGGCAGCTG
	CCATTTTAACGCTGC	CCTCATCGGCCCGGC	GAGCATGGCAGCTGG
	CATTTTAACGCTGCC	CTCATCGGCCCGGCG	AGCATGGCAGCTGGT
	ATTTTAACGCTGCCT	TCATCGGCCCGGCGC	GCATGGCAGCTGGTT
25	TTTTAACGCTGCCTA	CATCGGCCCGGCGCT	CATGGCAGCTGGTTG
	TTTAACGCTGCCTAA	ATCGGCCCGGCGCTG	ATGGCAGCTGGTTGC
	TTAACGCTGCCTAAT	TCGGCCCGGCGCTGA	TGGCAGCTGGTTGCT
	TAACGCTGCCTAATT	CGGCCCGGCGCTGAT	GGCAGCTGGTTGCTC
	AACGCTGCCTAATTT	GGCCCGGCGCTGATT	GCAGCTGGTTGCTCC
30	ACGCTGCCTAATTTT	GCCCGGCGCTGATTC	CAGCTGGTTGCTCCA
	CGCTGCCTAATTTTG	CCCGGCGCTGATTCC	AGCTGGTTGCTCCAT
	GCTGCCTAATTTTGC	CCGGCGCTGATTCCT	GCTGGTTGCTCCATT
	CTGCCTAATTTTGCC	CGGCGCTGATTCCTC	CTGGTTGCTCCATTT
	TGCCTAATTTTGCCA	GGCGCTGATTCCTCG	TGGTTGCTCCATTTG
35	GCCTAATTTTGCCAA	GCGCTGATTCCTCGT	GGTTGCTCCATTTGA
	CCTAATTTTGCCAAA	CGCTGATTCCTCGTG	GTTGCTCCATTTGAG
	CTAATTTTGCCAAAA	GCTGATTCCTCGTGT	TTGCTCCATTTGAGA
	TAATTTTGCCAAAAT	CTGATTCCTCGTGTC	TGCTCCATTTGAGAG
	AATTTTGCCAAAATC	TGATTCCTCGTGTCC	GCTCCATTTGAGAGA
40	ATTTTGCCAAAATCC	GATTCCTCGTGTCCG	CTCCATTTGAGAGAC
	TTTTGCCAAAATCCT	ATTCCTCGTGTCCGG	TCCATTTGAGAGACA
	TTTGCCAAAATCCTG	TTCCTCGTGTCCGGA	CCATTTGAGAGACAC
	TTGCCAAAATCCTGA	TCCTCGTGTCCGGAG	CATTTGAGAGACACG
	TGCCAAAATCCTGAA	CCTCGTGTCCGGAGG	ATTTGAGAGACACGC

	TTTGAGAGACACGCT	CTGCTGTGCTGCTCA	CTGACTAGATTATTA
	TTGAGAGACACGCTG	TGCTGTGCTGCTCAA	TGACTAGATTATTAT
	TGAGAGACACGCTGG	GCTGTGCTGCTCAAG	GACTAGATTATTATT
	GAGAGACACGCTGGC	CTGTGCTGCTCAAGG	ACTAGATTATTATTT
5	AGAGACACGCTGGCG	TGTGCTGCTCAAGGC	CTAGATTATTATTTG
	GAGACACGCTGGCGA	GTGCTGCTCAAGGCC	TAGATTATTATTTGG
	AGACACGCTGGCGAC	TGCTGCTCAAGGCCA	AGATTATTATTTGGG
	GACACGCTGGCGACA	GCTGCTCAAGGCCAC	GATTATTATTTGGGG
	ACACGCTGGCGACAC	CTGCTCAAGGCCACA	ATTATTATTTGGGGG
10	CACGCTGGCGACACA	TGCTCAAGGCCACAG	TTATTATTTGGGGGA
	ACGCTGGCGACACAC	GCTCAAGGCCACAGG	TATTATTTGGGGGAA
	CGCTGGCGACACACT	CTCAAGGCCACAGGC	ATTATTTGGGGGAAC
	GCTGGCGACACACTC	TCAAGGCCACAGGCA	TTATTTGGGGGAACT
	CTGGCGACACACTCC	CAAGGCCACAGGCAC	TATTTGGGGGAACTG
15	TGGCGACACACTCCG	AAGGCCACAGGCACA	ATTTGGGGGAACTGG
	GGCGACACACTCCGT	AGGCCACAGGCACAC	TTTGGGGGAACTGGA
	GCGACACACTCCGTC	GGCCACAGGCACACA	TTGGGGGAACTGGAC
	CGACACACTCCGTCC	GCCACAGGCACACAG	TGGGGGAACTGGACA
	GACACACTCCGTCCA	CCACAGGCACACAGG	GGGGGAACTGGACAC
20	ACACACTCCGTCCAT	CACAGGCACACAGGT	GGGGAACTGGACACA
	CACACTCCGTCCATC	ACAGGCACACAGGTC	GGGAACTGGACACAA
	ACACTCCGTCCATCC	CAGGCACACAGGTCT	GGAACTGGACACAAT
	CACTCCGTCCATCCG	AGGCACACAGGTCTC	GAACTGGACACAATA
	ACTCCGTCCATCCGA	GGCACACAGGTCTCA	AACTGGACACAATAG
25	CTCCGTCCATCCGAC	GCACACAGGTCTCAT	ACTGGACACAATAGG
	TCCGTCCATCCGACT	CACACAGGTCTCATT	CTGGACACAATAGGT
	CCGTCCATCCGACTG	ACACAGGTCTCATTG	TGGACACAATAGGTC
	CGTCCATCCGACTGC	CACAGGTCTCATTGC	GGACACAATAGGTCT
	GTCCATCCGACTGCC	ACAGGTCTCATTGCT	GACACAATAGGTCTT
30	TCCATCCGACTGCCC	CAGGTCTCATTGCTT	ACACAATAGGTCTTT
	CCATCCGACTGCCCC	AGGTCTCATTGCTTC	CACAATAGGTCTTTC
	CATCCGACTGCCCCT	GGTCTCATTGCTTCT	ACAATAGGTCTTTCT
	ATCCGACTGCCCCTG	GTCTCATTGCTTCTG	CAATAGGTCTTTCTC
	TCCGACTGCCCCTGC	TCTCATTGCTTCTGA	AATAGGTCTTTCTCT
35	CCGACTGCCCCTGCT	CTCATTGCTTCTGAC	ATAGGTCTTTCTCTC
	CGACTGCCCCTGCTG	TCATTGCTTCTGACT	TAGGTCTTTCTCTCA
	GACTGCCCCTGCTGT	CATTGCTTCTGACTA	AGGTCTTTCTCTCAG
	ACTGCCCCTGCTGTG	ATTGCTTCTGACTAG	GGTCTTTCTCTCAGT
	CTGCCCCTGCTGTGC	TTGCTTCTGACTAGA	GTCTTTCTCTCAGTG
40	TGCCCCTGCTGTGCT	TGCTTCTGACTAGAT	TCTTTCTCTCAGTGA
	GCCCCTGCTGTGCTG	GCTTCTGACTAGATT	CTTTCTCTCAGTGAA
	CCCCTGCTGTGCTGC	CTTCTGACTAGATTA	TTTCTCTCAGTGAAG
	CCCTGCTGTGCTGCT	TTCTGACTAGATTAT	TTCTCTCAGTGAAGG
	CCTGCTGTGCTGCTC	TCTGACTAGATTATT	TCTCTCAGTGAAGGT

CTCTCAGTGAAGGTG
TCTCAGTGAAGGTGG
CTCAGTGAAGGTGGG
TCAGTGAAGGTGGGG
CAGTGAAGGTGGGGA
AGTGAAGGTGGGGAG
GTGAAGGTGGGGAGA
TGAAGGTGGGGAGAA
GAAGGTGGGGAGAAG
AAGGTGGGGAGAAGC
AGGTGGGGAGAAGCT
GGTGGGGAGAAGCTG
GTGGGGAGAAGCTGA
TGGGGAGAAGCTGAA
GGGGAGAAGCTGAAC
GGGAGAAGCTGAACC
GGAGAAGCTGAACCG
GAGAAGCTGAACCGG
AGAAGCTGAACCGGC

EXAMPLE 9

Sub-confluent HaCaT cells were treated as described above with phosphorothioate oligonucleotides IGFR.AS (antisense: 5′-ATCTCTCCGCTTCCTTTC-3′; (<400>10); ref 13) and IGFR.S (sense control: 5′-GAAAGGAAGCGGAGAGAT-3′; (<400>11); ref 13) IGF-I binding to the cell monolayers was then measured as ^{125}I-IGF-I.

EXAMPLE 10

The results of this experiment are shown in Figures 7 and 8.

HaCaT cells were initially plated in DMEM with 10% v/v serum, then AS oligo experiments were performed in complete "Keratinocyte-SFM" (Gibco) to exclude the influence of exogenous IGFBPs. Oligos were synthesised as phosphorothioate (nuclease-resistant) derivatives (Bresatec, South Australia) and were as follows: antisense: AS2, 5′-GCGCCCGCTGCATGACGCCTGCAAC-3′ (IGFBP-3 start codon); controls: AS2NS, 5′-CGGAGATGCCGCATGCCAGCGCAGG-3′; AS4,

5′-AGGCGGCTGACGGCACTA-3′; AS4NS, 5′-GACAGCGTCGGAGCGATC-3′; IGFRAS, 5′-ATCTCTCCGCTTCCTTTC-3′;

IGFRS, 5′-GAAAGGAAGCGGAGAGAT-3′. Oligos to IGFBP-3 were based on the published sequence of Spratt *et al* [12]. AS oligos were added to HaCaT monolayers in 0.5ml medium in 24-well plates at the concentrations and addition frequencies indicated. IGFBP-3 measured in cell-conditioned medium using a dot-blot assay, adapted from the Western ligand blot method of Hossenlopp *et al* [11], in which 100μl of conditioned medium was applied to nitrocellulose filters with a vacuum dot-blot apparatus. After drying the membranes at 37°C, relative amounts of IGFBP are determined by ^{125}I-IGF-I-binding, autoradiography and computerised imaging densitometry. Triplicate wells (except in Figure 7, where duplicate wells were measured as shown) were analysed and corrected for changes in cell number per well. Relative cell number per well was determined using an amido black dye method, developed specifically for cultured monolayers of HaCaT cells [14]. Cell numbers differed by less than 10% after treatment. For oligos to the IGF receptor, receptor quantitation in intact HaCaT monolayers was by overnight incubation with ^{125}I-IGF-I (30,000cpm/well) at 4°C.

EXAMPLE 11

Experiments involving ribozymes are generally conducted as described in Internaitonal Patent Application No. WO 89/05852 and in Haselhoff and Gerlach [8]. Ribozymes are constructed with a hybridising region which is complementary in nucleotide sequence to at least part of a target RNA which, in this case, encodes IGFBP-2. Activity of ribozymes is measurable on, for example, Northern blots or using animal models such as in the nude mouse model (15; 16) or the "flaky skin" mouse model (17; 18).

EXAMPLE 12

The methods described in Example 11 are used for the screening of ribozymes which inhibit IGFBP-3 production. The activity of the ribozymes is determined as in Example 11.

EXAMPLE 13

The methods described in Example 11 are used for the screening of ribozymes which inhibit IGF-1 production. The activity of the ribozymes is determined as in Example 11.

EXAMPLE 14

The methods described in Example 11 are used for the screening of ribozymes which inhibit IGF-1 production. The activity of the ribozymes is determined as in Example 11.

EXAMPLE 15

Twenty-one antisense oligonucleotides targeted to mRNA sequences enducing the IGF-1 receptor, and four random oligonucleotides were synthesized. The antisense oligonucleotides are C5-propynyl-dU, dC 15mer phosphorothioate oligodeoxyribonucleotides. In these oligonucleotides, a phosphorothioate backbone replaces the phosphodiester backbone of naturally occurring DNA. The positions of the 21 sequence specific antisense oligonucleotides relative to the IGF-1 receptor mRNA structure are shown in Figure 9.

EXAMPLE 16

Experiments were performed to determine the uptake of the antisense oligonucleotides of Example 15 into keratinocytes. Cells of the differentiated human keratinocyte cell line, HaCaT, were incubated for 24 hours in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (w/v) fetal calf serum (FCS) containing fluorescently labelled oligonucleotide (R451, a randomized sequence oligonucleotide, 30nM) and cytofectin GSV (2μg/ml, Glen Research, 44901 Falcon Place, Sterling, VA 20166, Cat. No. 70-3815-78). Cells were then transferred to oligonucleotide-free medium and fluorescence microcopy and phase contrast images of the cells were obtained. Figure 10 shows fluorescence microscopy (Panel A) and phase contrast (Panel B) images of uptake of fluorescently labelled oligonucleotide in the majority of cells in a HaCaT monolayer. The degree of uptake obtained with the cationic lipid cytofectin was far greater than the uptake obtained with the next best lipid tried, Tfx-50.

A further experiment was performed to assess the uptake and toxicity associated with the use of cytofectin GSV over five days. Confluent HaCaT keratinocytes were incubated in DMEM containing fluorescently labelled oligonucleotide R451 (30nM or 100 nM) plus cytofectin GSV (2μg/ml or 5μg/ml) over 120 hours, viewed by fluorescence microscopy, tryptan blue stained, and counted. The graphs in Figure 11 depict uptake (Panel A) and toxicity (Panel B). The proportion of cells containing oligonucleotide remained high over the 120 hour period. The combination of 30 nM oligonucleotide and 2μg/ml GSV provided optimal uptake and minimal toxicity.

EXAMPLE 17

The twenty-one oligonucleotides of Example 15 were then screened for their ability to inhibit IGF-I receptor mRNA levels in HaCaT cells, in accordance with the teachings herein. HaCaT cells were grown to 90% confluence in DMEM supplemented with 10% (v/v) FCS. Antisense oligonucleotides (30nM) were completed with cytofectin GSV (2μg/ml) and added tot he cells in the presence of serum. HaCaT keratinocytes were treated with the oligonucleotide/GSV complexes or randomized sequence oligonucleotides (R451, R766), liposome alone (GSV), or were left untreated (UT). Duplicate treatments were performed. Repeat additions of the oligonucleotides/GSV complex were performed at 24, 48 and 76 hours following the first addition. Total RNA was isolated as per the RNAzolB protocol (Biotecx Laboratories, Inc. 6023 South Loop East, Houston, TX 77033) 96 hours following the first addition.

IGF-I receptor mRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels were simultaneously determined by a ribonuclease (RNase) protection assay. The RNase Protection Assay kit, *in vitro* transcription kit, and IGF-I receptor and GAPDH DNA templates were obtained from Ambion, Inc. (2130 Woodward St., Houston, TX 78744). The amount of IGF-I receptor mRNA in any given sample was expressed as the amount of IGF-I receptor mRNA relative to the amount of GAPDH mRNA. Each oligonucleotide was tested in at least two separate experiments.

Figure 12 depicts representative results of the screening process. Panel A shows an electrophoretic analysis of IGF-I receptor and GAPDH mRNA fragments after RNase protection. Molecular weight markers are shown on the right hand side. The full-length probe is shown on the left hand side; G-probe indicates the IGF-I receptor probe. GAPDH protected fragments (G) are seen at 316 bases and IGF-I protected fragments (I) are seen at 276 bases. Exhibit E, Panel B provides a graph indicating the relative level of IGF-I receptor mRNA following each treatment.

The results obtaining from the above screening assays are summarized in Figure 13. The graph depicts the relative level of IGF-I receptor mRNA after treatment with oligonucleotides complementary to the human IGF-I receptor mRNA (26-86), four randomized sequence oligonucleotides (R1, R4, R7, R9), liposome alone (GSV), or no treatment (UT). Asterisks indicate a significant different in relative IGF-I receptor mRNA as compared to GSV treated cells ($n=4\text{-}10$, $p<0.05$).

As demonstrated in Figure 13, treatment with eighteen of the twenty-one oligonucleotides resulted in a significant different in levels of IGF-I receptor mRNA relative to GSV treated cells. Three of the antisense oligonucleotides tested in the screening assay reduce IGF-I receptor mRNA to less than 35% of GSV-treated cells. These antisense oligonucleotides have the following sequences, presented in the 5′ to 3′ direction:

#27 UCCGGAGCCAGACUU

#64 CACAGUUGCUGCAAG

#78 UCUCCGCUUCCUUUC

As further demonstrated in Figure 13, six of the antisense oligonucleotides tested in the screening assay reduce IGF-I receptor mRNA to between 35 and 50% of GSV-treated cells. These antisense oligonucleotides have the following sequences, presented in the 5′ to 3′ direction:

#28 AGCCCCCACAGCGAG

#32 GCCUUGGAGAUGAGC

#40 UAACAGAGGUCAGCA

#42 GGAUCAGGGACCAGU

#46 CGGCAAGCUACACAG

#50 GGCAGGCAGGCACAC

EXAMPLE 19

Another experiment was performed demonstrating that antisense oligonucleotides targeted to genetic sequences encoding the IGF0I receptor and that reduce IGF-I receptor mRNA levels also inhibit the IGF-I receptor level on the surface of the treated cultured keratinocytes. HaCaT cells were grown to confluence in 24-well plates in DMEM containing 10% (v/v) FCS. Oligodeoxynucleotide and cytofectin GSV were mixed together in serum-free DMEM, and incubated at room temperature for 10 minutes before being diluted ten-fold in medium and placed on the cells. Cells were incubated for 72 hours with 30nM random sequence or antisense oligonucleotide and 2μm/ml GSV, or with GSV alone in DMEM containing 10% (v/v) FCS with solutions replaced every 24 hours. This was followed by incubation with oligonucleotide/GSV in serum-free DMEM for 48 hours. All incubations were performed at 37°C. Cells were washed twice with 1ml cold PBS. Serum-free DMEM containing 10^{-10}M ^{125}I-IGF-I was added with or without the IGF-I analogue, des (1-3) IGF-I, at 10^{-11}M to 10^{-7}M. Cells were incubated at 4°C for 17 hours with gentle shaking, then washed three times with 1ml cold PBS and lysed in 250μl 0.5M NaOH/0.1% (v/v) Triton X-100 at room temperature for 4 hours. Specific binding of the solubilised cell extract was measured using a gamma counter. As shown in Figure 14, treatment of HaCaT keratinocytes with oligonucleotide reduced cell surface IGF-I receptor levels to 30% of levels in untreated keratinocytes or in keratinocytes treated with liposome alone or a random oligonucleotide, R766. As shown in Figure 15, treatment with oligonucleotide #27 also significantly reduced cell surface IGF-I receptor levels relative to untreated keratinocytes or treatment with liposome alone or random nucleotide R451. As demonstrated in Example 17,

oligonucleotides #64 and #27 reduce IGF-I receptor mRNA levels in cultured keratinocytes to less than 35% of GSV-treated cells. Accordingly, the ability of an oligonucleotide to reduce IGF-I receptor mRNA levels in correlated with its ability to reduce cell surface IGF-I receptor levels.

The forgoing Examples demonstrate that antisense oligonucleotides targeted to the IGF-I receptor can be delivered to human keratinocytes *in vitro*, can inhibit IGF-I receptor mRNA levels in human keratinocytes *in vitro*, and that inhibition of mRNA levels is correlated with reduction of cell surface IGF-I receptor levels.

EXAMPLE 19

Further experiments demonstrated the efficacy of antisense oligonucleotides targeted tot he IGF-I receptor in an *in vivo* model of psoriasis. An animal model of psoriasis is the human psoriatic skin xenograft model. The skin used in this model contains the true disease state. In this model, reduction in epidermal thickness of psoriatic grafts in response to treatment is positively correlated with efficacy of treatment. Both normal and psoriatic human skin were grated into a thymic (nude) mice in accordance with a thymic (nude) mice in accordance with the methods of Baker *et al* (1992) *Brit. J. Dermatol.* 126:105 and Nanney *et al* (1992) *J. Invest. Dermatol,* 92:296. Successful grafting was achieved, as demonstrated in Figure 16, which shows hemotoxylin and eosin (H&E) stained sections of a 49-day old psoriatic human skin graft (Panel B) compared to the histology of the skin graft prior to grafting (Panel A). The histological features of psoriasis present in the pregraft section (e.g., parakeratosis, acanthosis and pronounced rete ridges) are present in the grafts more than seven weeks post grafting.

Using the model, oligonucleotide uptake was measured in epidermal keratinocytes *in vivo* after intradermal injection. Fluorescently labelled oligonucleotide (R451, 50μl, 10μM injection) was intradermally injected into psoriatic and normal skin grafts on a thymic mice. Live confocal microscopy and fluorescence microscopy of fixed sections was then employed.

Using both techniques, oligonucleotide was found to localize in the nucleus of over 90% of basal keratinocytes. Figure 17 shows the nuclear localization of oligonucleotide in psoriatic skin cells using conventional fluorescence microscopy of a graft that was removed and sectioned after 24 hours.

After establishing oligonucleotide uptake in the *in vivo* model, a small number of pilots experiments were performed to determine a schedule for treatment of grated mice with antisense oligonucleotides targeted to genetic sequences encoding the IGF-I receptor. The treatment schedule was finalized as follows:

Graft Number	Treatment	Volume of Injection	ODN Concentration	Duration of Treatment
1-3	Vehicle (PBS)	50μl	-	20 days
4-6	RandomODN#R451	50μl	10μM	20 days
7-9	ODN#27	50μl	10μM	20 days
10-12	ODN#74	50μl	10μM	20 days
13-15	ODN#50	50μl	10μM	20 days

As determined above, oligonucleotide #27 (ODN #27) reduced IGF-I receptor mRNA *in vitro* to less than 35% of GSV-treated cells. Oligonucleotide #50 (ODN#50) reduced IGF-I receptor mRNA *in vitro* to between 35 and 50% of GSV-treated cells. Oligonucleotide #74 (ODN #74) was not inhibitory to IGF-I receptor mRNA *in vitro*. In the *in vivo* model, each mouse received two grafts. Random oligonucleotide or vehicle was injected intradermally in one graft and acted as a control. The second graft was injected with the targeted oligonucleotide. Each graft received an injection every second day for the duration of the treatment.

Histology of representative grafts from each treatment type are shown in Figures 18(a)-(d) and 19(a) - (d). Each sheet shows three images of H&E stained sections: the pregraft histology, the control treated graft, and the targeted oligonucleotide treated graft. Figures 18(a)-(d) are shown at 100x magnification; figures 19(a)-(d) are shown at 400x magnification. The total cross sectional area of epidermis of each graft was assessed using MCID analysis software. The pooled results from all of the treated grafts are shown in Figure 20.

As shown in Figures 18(a)-(d) and 19(a)-(d), the vehicle-treated (control) grafts were marginally thinner than thepregraft sections. The degree of regression in these

experiments (ie., less than 10%) is not significant. A similar amount of marginal thinning of epidermis compared to pregraft also occurred in pilot experiments in which psoriatic grafts were not injected, and thsu it is unlikely that the vehicle itself has any effect. Histological features of psoriasis present in skin samples prior to grafting (clubbing of rete ridges, parakeratosis, acanthosis) were present in these grafts.

The random oliognucleotide treated grafts varied in epidermal thickness after 20 days of treatment. Grafts were either a similar thickness to the pregraft histology, or marginally thinner. Random oligonucleotide treated grafts were in each case significantly thicker than their targeted oligonucleotide treated pairs.

As shown in Figure 20, the targeted oligonucleotide treated grafts were significantly thinner than the pregraft sections and showed less parakeratosis and clubbing of rete ridges. Antisense oligonucleotides which were effective at reducing IGF-I receptor mRNA levels *in vitro* (#27 and #50) produced greatere epidermal thinning than an oligonucleotide which was not inhibitory to IGF-I receptor mRNA *in vitro* (#74). Accordingly, there is a direct correlation between the ability of an oligonucleotide targeted to the IGF-I receptor to inhibit IGF-I receptor mRNA levels *in vitro* and the efficacy of the oligonucleotide as an anti-psoriasis agent in an *in vivo* model.

EXAMPLE 20

Another experiment demonstrated that treatment of psoriatic grafts with an oligonucleotide targeted to a genetic sequence encoding the IGF-I receptor results in inhibition of proliferation. Pregrafts from psoriatic patients, control grafts treated with R4541, and grafts treated with oligonucleotide #27 were obtained as described in Example 19. An antibody to the cell cycle-specific nuclear antigen Ki67 was used to immunohistochemically detect actively dividing cells and tereby assess proliferation. The αKi67 antibody (DAKO, Glostrup, Denmark) recognizes the Ki67 antigen transiently expressed in nuclei of proliferating cells during late G_1, S, M and G_2 phases of the cycle

and thsu provides a marker for proliferation. Pregraft and graft sections were immunohistochemically processed by standard methods using αKi67 (according to the manufacturer's instructions), peroxidase-conjugated anti-rabbit second stage antibody, and a chromogenic peroxidase substrate.

The results of this experiment are presented in Figure 21 as immunohistochemical sections at 100x magnification. The top panel of Figure 21 depicts a pregraft section obtained from a psoriatic patient. The epidermis is thicker than normal and nucleic are evident in the stratum corneum. Ki67 positive cells, appearing as brown dots, are evidence in the basal and suprabasal layers, and indicate actively proliferating cells. The control (R450-treated) graft in the bottom panel of Figure 21 also exhibits evidence of proliferation, including parakeratosis and Ki67-positive cells appearing as brown-staining nuclei. The center panel of Figure 21 exhibits the oligonucleotide #27-treated graft. This graft exhibits significantly reduced proliferation as evidenced by normal (thin) epidermis, lack of invaginations, and substantial loss of Ki67-positive cells.

These results indicate that treatment of human psoriatic grafts with an oligonucleotide targeted to mRNA encoding the IGF-I receptor results in inhibition of epidermal proliferation.

EXAMPLE 21

Topical formulations of complexes of oligonucleotides with cytofectin GSV in aqueous or methylcellulose gel formulations were prepared and assessed foruptake of the oligonucleotide by keratinocytes *in vivo*. The topical formulations contained oligonucleotides complexed with cytofectin GSV in an aqueous solution or methylcellulose carrier, as taught herein. With both aqueous and methylcellulose gel formulations, locatlization of oligonucleotide R451 to nuclei and cytoplasm of keratinocytes in normal human skin grafts on nuce mice was observed. Figure 22 shows an image from confocal microscopy demonstrating oligonucleotide locatlization in the nuclei and cytoplasm of

keratinocytes in normal human skin grafts after topical application of fluroescently labeled oligonucleotide (10μM R451) complexed with cytofectin GSV (10μg/ml). Figure 23 shows an image from confocal microscopy demonstrating that topical application of the same oligonucleotide/GSV concentrations in a 3% (w/v) methylcellulose gel produced similar uptake in the target keratinocyte population. Using an aqueous formulation of oligonucleotide/GSV complexes, penetration of oligonucleotide into the viable epidermis was observed, whereas application of formulations of oliognucleotide complexed with other cationic lipids resulted in localization of oligonucleotide in the stratum corneum.

EXAMPLE 22

Thirteen antisense oligonucleotides targeted to IGFBP-3 were synthesized. The antisense oligonucleotides are C5-propynyl-dU, Dc15 mer phosphorothioate oligodeoxyribonucleotides. Figure 24 attached hereto is a schematic diagram indicating the position of the thirteen oligonucleotides relative to the IGFBP-3 mRNA structure.

These oligonucleotides were screened for their ability to inhibit IGFBP-3 mRNA levels of HaCaT cells in accordance with the teachings herein. HaCaT cells were grown to 90% confluence in DMEM supplemented with 10% (v/v) FCS, then placed in complete keratinocyte serum free medium (KSFM, Gibco), which has a defined amount of EGF, for 24 hours. Oligonucleotides (30nM or 100nM) were complexed with GSV cytofectin (2μg/ml) and added to cells in complete KSFM to allow oligonucleotides to enter the nucleus before removal of EGF. Repeat additions were performed at three hours (in serum free DMEM, which releases the EGF inhibition of IGFBP-3 mRNA) and again after another 24 hours. HaCaT cells were also treated with randomized sequence oligonucleotides (R121, R451, R766 and R961), liposome alone (GSV) or were left untreated (UT). Total RNA was isolated as described in Example 17, 24 hours after the last treatment. Total RNA (15μg) was analyzed by Northern analysis and phosphoroimager quantitation for IGFBP-3 and GADPH mRNA. IGFBP-3 mRNA is expressed as the amount of IGFBP-3 mRNA relative to the amount of GAPDH mRNA.

Figures 25(a)-(d) provide graphs which depict results in this screening process. In these graphs, R1 and R12 refer to R121; R4, R4(0) and R45 rfer to R451; R7, R7(0) and R76 refer to R766; and R9 and R96 refer to R961. The values were standardized to GSV-treated cells, and data was pooled and statistically analyzed by ANOVA followed by Domet's test to compare each treatment to GSV-treated cells. The pooled data are presented as a bar graph in Figure 26. As demonstrated, at a concentration of 30nM, treatment of HaCaT cells with 8 of the 12 targeted oligonucleotides tested resulted in a statistically significant reduction in levels of IGFBP-3 mRNA relative to GSV-treated cells. At a concentration of 100nM, treatment with 9 fo the 13 targeted oligonucleotides tested resulted in a statistically significant reduction in levels of IGFBP-3 mRNA relative to GSV-treated cells.

These experiments demonstrate that antisense oligonucleotides targeted to genetic sequences encoding IGFBP-3 can inhibit IGFBP-3 mRNA levels in human keratinocytes *in vitro*.

EXAMPLE 23

IGF-I receptor is a potent mitotic signalling molecule for keratinocytes and the human receptor elicits separate intracellular signals that prevent apoptosis (19). It is proposed in accordance with the present invention that inactivation of IGF-I receptors in epidermal keratinocytes will achieve three important outcomes in subsequent UV treatment of lesions:

(i) Acute epidermal hyperplasia following UV has been suggested to increase the risk of keratinocyte carcinogenic transformation (22). By reducing IGF-I receptor expression in the epidermis, the incidence of epidermal hyperplasia following UV exposure is likely to be reduced leading to an overall acceleration in normalization of the lesion and reduced carcinogenic risk.

(ii) Inhibition of anti-apoptotic action of IGF-I receptor will enhance the reversal of epidermal thickening and accelerate normalization of differentiation. Topical or injected IGF-I receptor antisense as adjunctive treatment will increase apoptosis in the epidermal layer thereby enhancing the reduction in acanthosis observed in UV treatments.

(iii) Survival of keratinocytes, ie. those which evade apoptosis is likely to occur when cells have damaged DNA. Such mutations may be in the tumor suppressor region. Consequently, the use of antisense therapy will result in less frequent selection of mutated keratinocytes and therefore reduced incidence of basal cell carcinomas and squamous.

Accordingly, antisense therapy, especially against IGF-I-receptor is useful in combination with UV therapy in the treatment of epidermal hyperplasia.

EXAMPLE 24

HaCaT cells were treated with antisense oligonucleotides directed to IGF-I receptor mRNA. Levels of IGF-I receptor mRNA were then monitored. In essence, confluent HaCaT cells were treated every 24 hours for four days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific oligonucleotides (#26 to #86) or random sequence oligonucleotides (*R121, R451 and R766*). Figure 27(a) is a photographic representation showing representative RNase protection assay gel showing IGF-I receptor (IGFR) and GAPDH mRNA in untreated or treated HaCaT cells. Figure 27(b) is a densitometric quantification of IGF-I receptor mRNA in a HaCaT cells following treatment with IGF-I receptor specific oligonucleotides (solid black) random sequence oligonucleotides (horizontal striped bar) or GSV alone (shaded bar) compared to untreated cells (UT, vertical striped bar).

EXAMPLE 25

In this example, reduction in total cellular IGF-I receptor protein was monitored following antisense oligonucleotide treatment. Confluence HaCaT cells were treated with 24 hours for 4 days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM IGF-I receptor specific AONS (#27, #50 and #64) or the random sequence oligonucleotide, R451. Total cellular protein was isolated and analysed for IGF-I receptor by SDS PAGE followed by western blotting with antibody specific for the human IGF-I receptor. Figure 28(a) shows duplicate treated cellular extracts following the IGF-I receptor at the predicted size of 110 kD. Figure 28(b) is a densitometric quantification of IGF-I receptor protein.

EXAMPLE 26

The reduction in IGF-I receptor numbers was determined on the keratinocyte cell surface after antisense oligonucleotide treatment. HaCaT cells were tranfected with IGF-I receptor specific AONs #27, #50, #64, a random sequence oligonucleotides (R451) or following treatment with GSV a lipid alone every 24 hours for 4 days. Competition binding assays using ^{125}I-IGF-I and the receptor-specific analogue, des(1-3)IGF-I were performed. Results are shown in Figure 29.

EXAMPLE 27

In this example, the apoptotic protecting effects of IGF-I receptor on keratinocyte cells was tested by following the reduction in keratino cell numbers following antisense oligonucleotide treatment. HaCaT cells, initially at 40% confluence, were transfected with the IGF-I receptor specific AON #64, control sequences R451 and 6414 or treated with GSV a lipid alone every 24 hours for 2 days. The cell number was measured in culture wells using a dye binding assay. The results are presented in Figure 30. The results clearly confirm that the IGF-I receptor exhibits an anti-apoptotic effect. By reducing IGF-I receptor levels using antisense oligonucleotide treatment, the anti-apoptotic effect is interrupted and apoptosis results in the reduction in keratinocyte cell number. Results are shown in Figure 30.

EXAMPLE 28

This example shows a reversal of epidermal hyperplasia in psoriatic human skin grafts on nude mice following intradermal injection with antisense oligonucleotides. Grafted psoriasis lesions were injected with IGF-I receptor specific AONs, a random sequence oligonucleotide in PBS, or with PBS alone, every 2 days for 20 days, then analysed histologically. The results are shown in Figure 31. In Figure 31(a), donor A graft treated with AON #50 showing epidermal thinning compared with the pregraft and control (PBS) treated graft and donor graft treated with AON #27 showing epidermal thinning compared with pregraft and control (R451) treated graft. In Figure 31(b), the mean epidermal cross-sectional area over the full width of grafts is shown as determined by digital image analysis. The results show that epidermal hyperplasia is reversed following the intradermal injection of antisense oligonucleotides.

EXAMPLE 29

Figure 32 shows the reversal of epidermal hyperplasia correlating with reduced IGF-I receptor mRNA in grafted psoriasis lesions treated with antisense oligonucleotides. Figure 32(a) shows a psoriasis lesion prior to grafting and after grafting and treatment with IGF-I receptor specific oligonucleotide #27 (AON #27) or random sequence (R451) immunostained with antibodies to Ki67 to identify proliferating cells. Proliferating cells are indicated by a dark brown nucleus (arrows). Figure 32(b) shows the same lesion prior to grafting and after oligonucleotide treatment as in Figure 32(a) but subjected to *in situ* hybridisation with ^{35}S-labelled cRNA probe complementary to the human IGF-I receptor mRNA. The presence of IGF-I receptor mRNA is indicated by silver grains which are almost eliminated in the epidermis of the lesion treated with IGF-I receptor specific oligonucleotide # 27 (AON #27). This experiment shows that reversal of epidermal hyperplasia correlates with reduced IGF-I receptor mRNA in grafted psoriasis lesions treated with antisense oligonucleotides.

EXAMPLE 30

Figure 33 treatment with oligonucleotides. HaCaT cell monolayers were grown to 90% confluence in DMEM containing 10% fetal calf serum treated every 24 hours for two days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Total RNA was isolated and analysed for IGF-I receptor and GAPDH mRNA using a commercially available ribonuclease protection assay kit. The results show a reduction in IGF-I receptor mRNA in the HaCaT keratinocyte cells.

EXAMPLE 31

Figure 34 treatment with oligonucleotides. HaCaT cell monolayers were grown to 90% confluence in DMEM containing 10% fetal calf serum treated every 24 hours for 4 days with 2 μg/ml GSV lipid alone (GSV) or complexed with 30 nM oligonucleotide. Cells were lysed in a buffer containing 50 mM HEPES, 150 mM NaCl, 10% v/v glycerol, 1 v/v Trison X-100 and 100 μg/ml aprotinin on ice for 30 minutes, then 30 μg of lysate was loaded onto a denaturing 7% w/v polyacrylamide gel followed by transfer onto an Immobilon-P membrane. Membranes were then incubated with anti-IGF-I receptor antibodies C20 (available from Santa Cruz Biotechnology Inc., Santa Cruz, California) for 1 hour at room temperature and developed using the Vistra ECF western blotting kit (Amersham). The results shown in Figure 34 confirm that IGF-I receptor protein is reduced in HaCaT keratinocytes following treatment with oligonucleotides.

EXAMPLE 32

This example shows a reduction in HaCaT keratinocyte cell number following treatment with oligonucleotides. The results are shown in Figure 35. HaCaT cell monolayers were grown at 40% confluence in DMEM containing 10% fetal calf serum treated every 24 hours for 3 days with 2 μg/ml GSV lipid alone (GSV) or complexed with 15 nM oligonucleotide. Cell numbers were then measured every 24 hours using the amido black dye binding assay [32]. Results show that HaCaT keratino cells decrease in number following treatment with oligonucleotides due to a reduction in the anti-apoptotic effect of the IGF-I receptor.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

REFERENCES:

1. Sara V *Physiological Reviews* ***70:***591-614, 1990.

2. Rechler MM and Brown AL *Growth Regulation* ***2:***55-68, 1992.

3. Clemmons DR *Growth Regn* ***2:***80, 1992.

4. Oakes SR, KM Haynes, MJ Waters, AC Herington and GA Werther *J. Clin Endocrinol Metab* ***73:***1368-1373, 1992.

5. Camacho-Hubner C *et al. J Biol Chem* ***267:***11949-11956, 1992.

6. Neely KE *et al. J Inv Derm* ***96:***104, 1991.

7. Ts'O POP, Aurelian L, Chang E and Miller PS. Nonionic oligonucleotide analogs (Matagen TM) as anticodic agents in duplex and triplex formation. in "Antisense Strategies", Annals of the New York Academy of Sciences ***660:***159-177 (Baserga R and Denhardt DT, eds.), 1993.

8. Haseloff J and Gerlach L *Nature* ***334:***586-591, 1988.

9. Boukamp P, Petrussevska RT, Breitkreuz D, Hornung J, Markham A, Fusenig NE. *J Cell Biol* ***106:***761-771, 1988.

10. Rheinwald and Green *Cell* ***6:***331-344, 1975.

11. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. *Anal Biochem* ***154:***138-143, 1986.

12. Spratt SK, Tatsuno GP, Yamanaka MK, Ark BC, Detmer J, Mascarenhas D, Flynn J, Talkington-Verser C, Spencer EM. *Growth Factors* ***3:***63-72, 1990.

13. Pietrzkowski, Z, Sell C, Lammers R, Ullrich A and Baserga R. *Mol. Cell. Biol.* ***12:*** 3883-3889, 1992.

14. Schulz J, Dettlaff S, Fritzsche U, Harms U, Schiebel H, Derer W, Fusenig NE, Hulsen A and Bohm M. *J. Immunol. Meth.* ***167:***1-13, 1994.

15. Baker BS, Brent L, Valdimarsson H, Powles AV, Al-Imara L, Walker M and Fry L. *Brit. J. Bermatol* ***126:***105-110, 1992.

16. Nanney LB *et al J. Invest. Bermatol* ***98:***296-301, 1992.

17. Sundberg JP *et al Immunol. Investigations* ***22:***389-401, 1993.

18. Sundberg JP *et al J. Invest. Dermatol* ***102:***781-788, 1994.

19. O'Connor *et al Mol Cell Biol* ***17:***427-435, 1997.

20. Kuhn *et al Int J Cancer* ***80:***431-438, 1999.

21. Resnicoff *et al Cancer Res* ***55:***3739-3741, 1995.

22. Ouhtit *et al Am J Pathol* ***156:***201-207, 2000.

23. Froehler *et al Tetrahedrin Lett* ***34:***1003-1006, 1992.

24. Gennaro (Ed) *Remington's Pharmaceutical Sciences* 18th Edition Mack Publishing Co., Easton PA USA, 1990.

25. Flanagan *et al Nat Biotechnol* ***14:***1139-1145, 1996.

26. Flanagan *et al Nucleic Acids Res* ***24:***2936-2941, 1996.

27. Flanagan *et al Mol Cell Biochem* ***172:***213-225, 1997.

28. Gutierrez *et al Biochemistry* ***36:***743-748, 1997.

29. Moulds *et al Biochemistry* ***34:***5044-5053, 1995.

30. Wagner *et al Science* ***260:***1510-1513, 1993.

31. Wagner *et al Nature* ***372:***333-335, 1994.

32. Schultz *et al J Immunol Meth* ***167:***1-13, 1994.

CLAIMS:

1. A method for ameliorating the effects of a medical disorder such as a proliferative and/or inflammatory skin disorder in a mammal, said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation or a cell otherwise involved with said medical disorder with an effective amount of a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing growth factor mediated cell proliferation and/or inflammation and/or other medical disorders.

2. A method according to claim 1 wherein cell proliferation and/or inflammation or other medical disorder is mediated by at least one of insulin-like growth factor I (IGF-I), keratinocyte growth factor (KGF), transforming growth factor-α (TGFα), tumour necrosis factor-α (TNFα), interleukin (IL) -1 (IL-1), IL-4, IL-6, IL-8 and/or basic fibroblast growth factor (bFGF).

3. A method according to claim 2 wherein cell proliferation and/or inflammation or other medical disorder is mediated by IGF-I.

4. A method according to claim 1 wherein the nucleic acid molecule inhibits or otherwise reduces IGF-I mediated cell proliferation and/or inflammation or other medical disorder.

5. A method according to claim 1 wherein the proliferative or inflammatory skin disorder is psoriasis, ichthyosis, pityriasis, rubra, pilaris, serborrhoea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.

6. A method according to claim 5 wherein the skin condition is psoriasis.

7. A method according to claim 1 wherein the other medical disorder is a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease or hyperproliferation of the inside of blood vessels or any other hyperplasia.

8. A method according to claim 1 wherein the mammal is a human.

9. A method according to claim 1 wherein the nucleic acid molecule is capable of inhibiting, reducing or otherwise interfering with IGF-I-interaction with its receptor.

10. A method according to claim 9 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGF-I, IGF-I-receptor or an IGF binding protein (IGFBP).

11. A method according to claim 10 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2, -3, -4, -5 or -6.

12. A method according to claim 11 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2 or IGFBP-3.

13. A method according to claim 10 wherein the antisense molecule is at least about 15 nucleotides in length and is capable of interacting with at least one sequence selected from the list set forth in Example 6 or Example 7 or Example 8.

14. A method according to claim 12 wherein the antisense molecule comprises the nucleotide sequence:

5′-ATCTCTCCGCTTCCTTTC-3′ (<400>10)

15. A method according to claim 12 wherein the antisense molecule is selected from the following:

UCCGGAGCCAGACUU (<400>12)
CACAGUUGCUGCAAG (<400>13)
UCUCCGCUUCCUUUC (<400>14)
AGCCCCCACAGCGAG (<400>15)
GCCUUGGAGAUGAGC (<400>16)
UAACAGAGGUCAGCA (<400>17)
GGAUCAGGGACCAGU (<400>18)
CGGCAAGCUACACAG (<400>19)
GGCAGGCAGGCACAC (<400>20)

16. A method according to claim 15 wherein the antisense molecule is <400>12, <400>13 or <400>14.

17. A method according to claim 15 wherein the antisense molecule is <400>12.

18. A nucleic acid molecule comprising at least about 10 nucleotides capable of hybridising to or forming a heteroduplex or otherwise interacting with a complementary form of <400>12 to <400>20 inclusive.

19. A nucleic acid molecule comprising at least about 15 nucleotides capable of hybridising to or form a heteroduplex or otherwise interacting with a complementary form of <400>12 to <400>14 inclusive.

20. A method of ameliorating the effects of psoriasis or other medical disorder, said method comprising contacting proliferating skin or skin capable of proliferation or cell otherwise associated with said medical disorder with an effective amount of one

or more nucleic acid molecules or chemical analogues thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation other medical disorder wherein said one or more molecules comprises a polynucleotide capable of interacting with mRNA directed from an IGF-I gene, an IGF-I receptor gene or a gene encoding an IGFBP.

21. A method according to claim 20 wherein the IGFBP is IGFBP-2 or IGFBP-3.

22. A method according to claim 20 wherein the mammal is a human.

23. A method according to claim 22 wherein the nucleic acid molecule is capable of interacting with a nucleotide sequence selected from the list set forth in <400>12 to <400>14 inclusive.

24. A method according to claim 23 wherein the nucleic acid molecule comprises the nucleotide sequence selected from <400>12 to <400>14.

25. A composition comprising a nucleic acid molecule capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation or other medical disorder said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents.

26. A composition according to claim 25 wherein the nucleic acid molecule is antisense molecule to a gene encoding IGF-I, IGF-I-receptor or an IGFBP.

27. A composition according to claim 26 wherein the nucleic acid molecule is selected from <400>12 to <400>20 inclusive.

28. A composition according to claim 26 selected from <400>12 to <400>14 inclusive.

29. A method for ameliorating the effects of a proliferative and/or inflammatory skin disorder such as psoriasis said method comprising contacting the proliferating and/or inflamed skin or skin capable of proliferation and/or inflammation with effective amounts of UV treatment and a nucleic acid molecule or chemical analogue thereof capable of inhibiting or otherwise reducing IGF-I mediated cell proliferation and/or inflammation.

30. A method according to claim 29 wherein the proliferative or inflammatory skin disorder is psoriasis, ichthyosis, pityriasis, rubra, pilaris, serborrhoea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths or cancers of the skin.

31. A method according to claim 30 wherein the proliferative or inflammatory skin disorder is psoriasis.

32. A method according to claim 29 wherein the nucleic acid molecule is capable of inhibiting, reducing or otherwise interfering with IGF-I-interaction with its receptor.

33. A method according to claim 32 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGF-I, IGF-I-receptor or an IGF binding protein (IGFBP).

34. A method according to claim 33 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2, -3, -4, -5 or -6.

35. A method according to claim 34 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGFBP-2 or IGFBP-3.

36. A method according to claim 33 wherein the nucleic acid molecule is an antisense molecule capable of reducing expression of a gene encoding IGF-I receptor.

37. A method according to claim 29 wherein the antisense molecule is at least about 15 nucleotides in length and is capable of interacting with at least one sequence selected from the list set forth in Example 6 or Example 7 or Example 8.

38. A method according to claim 37 wherein the antisense molecule comprises the nucleotide sequence:

5′-ATCTCTCCGCTTCCTTTC-3′ (<400>10)

39. A method according to claim 37 wherein the antisense molecule is selected from the following:

UCCGGAGCCAGACUU (<400>12)

CACAGUUGCUGCAAG (<400>13)

UCUCCGCUUCCUUUC (<400>14)

AGCCCCCACAGCGAG (<400>15)

GCCUUGGAGAUGAGC (<400>16)

UAACAGAGGUCAGCA (<400>17)

GGAUCAGGGACCAGU (<400>18)

CGGCAAGCUACACAG (<400>19)

GGCAGGCAGGCACAC (<400>20)

40. A method according to claim 39 wherein the antisense molecule in <400>12, <400>13 or <400>14.

41. A method according to claim 40 wherein the antisense molecule in <400>12.

42. A method according to claim 39 wherein the UV treatment occurs simultaneously with or following contact with the nucleic acid molecule or its chemical analogue.

43. Use of an antisense molecule directed to the gene encoding IGF-I receptor or its mRNA as adjunct therapy in combination with UV treatment to reduce proliferation and/or inflammation of keratinocyte cells.

44. Use according to claim 43 in the treatment of psoriasis.

ABSTRACT

The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes to inhibit, reduce or otherwise decrease stimulation of this layer of cells. The present invention contemplates, in a most preferred embodiment, a method for the prophylaxis and/or treatment of psoriasis.

1/65



Figure 1

FIGURE 1

1	ATTCGGGGCG	AGGGAGGAGG	AAGAAGCGGA	GGAGGCGGCT	CCCGCTCGCA
51	GGGCCGTGCA	CCTGCCCGCC	CGCCCGCTCG	CTCGCTCGCC	CGCCGCGCCG
101	CGCTGCCGAC	CGCCAGCATG	CTGCCGAGAG	TGGGCTGCCC	CGCGCTGCCG
151	CTGCCGCCGC	CGCCGCTGCT	GCCGCTGCTG	CCGCTGCTGC	TGCTGCTACT
201	GGGCGCGAGT	GGCGGCGGCG	GCGGGGCGCG	CGCGGAGGTG	CTGTTCCGCT
251	GCCCGCCCTG	CACACCCGAG	CGCCTGGCCG	CCTGCGGGCC	CCCGCCGGTT
301	GCGCCGCCCG	CCGCGGTGGC	CGCAGTGGCC	GGAGGCGCCC	GCATGCCATG
351	CGCGGAGCTC	GTCCGGGAGC	CGGGCTGCGG	CTGCTGCTCG	GTGTGCGCCC
401	GGCTGGAGGG	CGAGGCGTGC	GGCGTCTACA	CCCCGCGCTG	CGGCCAGGGG
451	CTGCGCTGCT	ATCCCCACCC	GGGCTCCGAG	CTGCCCCTGC	AGGCGCTGGT
501	CATGGGCGAG	GGCACTTGTG	AGAAGCGCCG	GGACGCCGAG	TATGGCGCCA
551	GCCCGGAGCA	GGTTGCAGAC	AATGGCGATG	ACCACTCAGA	AGGAGGCCTG
601	GTGGAGAACC	ACGTGGACAG	CACCATGAAC	ATGTTGGGCG	GGGGAGGCAG
651	TGCTGGCCGG	AAGCCCCTCA	AGTCGGGTAT	GAAGGAGCTG	GCCGTGTTCC
701	GGGAGAAGGT	CACTGAGCAG	CACCGGCAGA	TGGGCAAGGG	TGGCAAGCAT

FIGURE 1 (continued...)

```
751    CACCTTGGCC TGGAGGAGCC CAAGAAGCTG CGACCACCCC CTGCCAGGAC
801    TCCCTGCCAA CAGGAACTGG ACCAGGTCCT GGAGCGGATC TCCACCATGC
851    GCCTTCCGGA TGAGCGGGGC CCTCTGGAGC ACCTCTACTC CCTGCACATC
901    CCCAACTGTG ACAAGCATGG CCTGTACAAC CTCAAACAGT GCAAGATGTC
951    TCTGAACGGG CAGCGTGGGG AGTGCTGGTG TGTGAACCCC AACACCGGGA
1001   AGCTGATCCA GGGAGCCCCC ACCATCCGGG GGGACCCCGA GTGTCATCTC
1051   TTCTACAATG AGCAGCAGGA GGCTTGCGGG GTGCACACCC AGCGGATGCA
1101   GTAGACCGCA GCCAGCCGGT GCCTGGCGCC CCTGCCCCCC GCCCCTCTCC
1151   AAACACCGGC AGAAAACGGA GAGTGCTTGG GTGGTGGGTG CTGGAGGATT
1201   TTCCAGTTCT GACACACGTA TTTATATTTG GAAAGAGACC AGCACCGAGC
1251   TCGGCACCTC CCCGGCCTCT CTCTTCCCAG CTGCAGATGC CACACCTGCT
1301   CCTTCTTGCT TTCCCCGGGG GAGGAAGGGG GTTGTGGTCG GGGAGCTGGG
1351   GTACAGGTTT GGGGAGGGGG AAGAGAAATT TTTATTTTTG AACCCCTGTG
1401   TCCCTTTTGC ATAAGATTAA AGGAAGGAAA AGT
```



Figure 2

FIGURE 2

1	CTCAGCGCCC	AGCCGCTTCC	TGCCTGGATT	CCACAGCTTC	GCGCCGTGTA
51	CTGTCGCCCC	ATCCCTGCGC	GCCCAGCCTG	CCAAGCAGCG	TGCCCCGGTT
101	GCAGGCGTCA	TGCAGCGGGC	GCGACCCACG	CTCTGGGCCG	CTGCGCTGAC
151	TCTGCTGGTG	CTGCTCCGCG	GGCCGCCGGT	GGCGCGGGCT	GGCGCGAGCT
201	CGGGGGGCTT	GGGTCCCGTG	GTGCGCTGCG	AGCCGTGCGA	CGCGCGTGCA
251	CTGGCCCAGT	GCGCGCCTCC	GCCCGCCGTG	TGCGCGGAGC	TGGTGCGCGA
301	GCCGGGCTGC	GGCTGCTGCC	TGACGTGCGC	ACTGAGCGAG	GGCCAGCCGT
351	GCGGCATCTA	CACCGAGCGC	TGTGGCTCCG	GCCTTCGCTG	CCAGCCGTCG
401	CCCGACGAGG	CGCGACCGCT	GCAGGCGCTG	CTGGACGGCC	GCGGGCTCTG
451	CGTCAACGCT	AGTGCCGTCA	GCCGCCTGCG	CGCCTACCTG	CTGCCAGCGC
501	CGCCAGCTCC	AGGAAATGCT	AGTGAGTCGG	AGGAAGACCG	CAGCGCCGGC
551	AGTGTGGAGA	GCCCGTCCGT	CTCCAGCACG	CACCGGGTGT	CTGATCCCAA
601	GTTCCACCCC	CTCCATTCAA	AGATAATCAT	CATCAAGAAA	GGGCATGCTA
651	AAGACAGCCA	GCGCTACAAA	GTTGACTACG	AGTCTCAGAG	CACAGATACC
701	CAGAACTTCT	CCTCCGAGTC	CAAGCGGGAG	ACAGAATATG	GTCCCTGCCG

FIGURE 2 (Continued...)

751	TAGAGAAATG	GAAGACACAC	TGAATCACCT	GAAGTTCCTC	AATGTGCTGA
801	GTCCCAGGGG	TGTACACATT	CCCAACTGTG	ACAAGAAGGG	ATTTTATAAG
851	AAAAAGCAGT	GTCGCCCTTC	CAAAGGCAGG	AAGCGGGGCT	TCTGCTGGTG
901	TGTGGATAAG	TATGGGCAGC	CTCTCCCAGG	CTACACCACC	AAGGGGAAGG
951	AGGACGTGCA	CTGCTACAGC	ATGCAGAGCA	AGTAGACGCC	TGCCGCAAGT
1001	TAATGTGGAG	CTCAAATATG	CCTTATTTTG	CACAAAAGAC	TGCCAAGGAC
1051	ATGACCAGCA	GCTGGCTACA	GCCTCGATTT	ATATTTCTGT	TTGTGGTGAA
1101	CTGATTTTTT	TTAAACCAAA	GTTTAGAAAG	AGGTTTTTGA	AATGCCTATG
1151	GTTTCTTTGA	ATGGTAAACT	TGAGCATCTT	TTCACTTTCC	AGTAGTCAGC
1201	AAAGAGCAGT	TTGAATTTTC	TTGTCGCTTC	CTATCAAAAT	ATTCAGAGAC
1251	TCGAGCACAG	CACCCAGACT	TCATGCGCCC	GTGGAATGCT	CACCACATGT
1301	TGGTCGAAGC	GGCCGACCAC	TGACTTTGTG	ACTTAGGCGG	CTGTGTTGCC
1351	TATGTAGAGA	ACACGCTTCA	CCCCCACTCC	CCGTACAGTG	CGCACAGGCT
1401	TTATCGAGAA	TAGGAAAACC	TTTAAACCCC	GGTCATCCGG	ACATCCCAAC
1451	GCATGCTCCT	GGAGCTCACA	GCCTTCTGTG	GTGTCATTTC	TGAAACAAGG

FIGURE 2 (Continued...)

```
1501   GCGTGGATCC CTCAACCAAG AAGAATGTTT ATGTCTTCAA GTGACCTGTA
1551   CTGCTTGGGG ACTATTGGAG AAAATAAGGT GGAGTCCTAC TTGTTTAAAA
1601   AATATGTATC TAAGAATGTT CTAGGGCACT CTGGGAACCT ATAAAGGCAG
1651   GTATTTCGGG CCCTCCTCTT CAGGAATCTT CCTGAAGACA TGGCCCAGTC
1701   GAAGGCCCAG GATGGCTTTT GCTGCGGCCC CGTGGGGTAG GAGGGACAGA
1751   GAGACGGGAG AGTCAGCCTC CACATTCAGA GGCATCACAA GTAATGGCAC
1801   AATTCTTCGG ATGACTGCAG AAAATAGTGT TTTGTAGTTC AACAACTCAA
1851   GACGAAGCTT ATTTCTGAGG ATAAGCTCTT TAAAGGCAAA GCTTTATTTT
1901   CATCTCTCAT CTTTTGTCCT CCTTAGCACA ATGTAAAAAA GAATAGTAAT
1951   ATCAGAACAG GAAGGAGGAA TGGCTTGCTG GGGAGCCCAT CCAGGACACT
2001   GGGAGCACAT AGAGATTCAC CCATGTTTGT TGAACTTAGA GTCATTCTCA
2051   TGCTTTTCTT TATAATTCAC ACATATATGC AGAGAAGATA TGTTCTTGTT
2101   AACATTGTAT ACAACATAGC CCCAAATATA GTAAGATCTA TACTAGATAA
2151   TCCTAGATGA AATGTTAGAG ATGCTATATG ATACAACTGT GGCCATGACT
2201   GAGGAAAGGA GCTCACGCCC AGAGACTGGG CTGCTCTCCC GGAGGCCAAA
```

FIGURE 2 (Continued...)

```
2251   CCCAAGAAGG TCTGGCAAAG TCAGGCTCAG GGAGACTCTG CCCTGCTGCA
2301   GACCTCGGTG TGGACACACG CTGCATAGAG CTCTCCTTGA AAACAGAGGG
2351   GTCTCAAGAC ATTCTGCCTA CCTATTAGCT TTTCTTTATT TTTTTAACTT
2401   TTTGGGGGGA AAAGTATTTT TGAGAAGTTT GTCTTGCAAT GTATTTATAA
2451   ATAGTAAATA AGTTTTTTAC CATT
```



Figure 3

FIGURE 3

```
1      TTTTTTTTTT TTTTGAGAAA GGGAATTTCA TCCCAAATAA AAGGAATGAA
51     GTCTGGCTCC GGAGGAGGGT CCCCGACCTC GCTGTGGGGG CTCCTGTTTC
101    TCTCCGCCGC GCTCTCGCTC TGGCCGACGA GTGGAGAAAT CTGCGGGCCA
151    GGCATCGACA TCCGCAACGA CTATCAGCAG CTGAAGCGCC TGGAGAACTG
201    CACGGTGATC GAGGGCTACC TCCACATCCT GCTCATCTCC AAGGCCGAGG
251    ACTACCGCAG CTACCGCTTC CCCAAGCTCA CGGTCATTAC CGAGTACTTG
301    CTGCTGTTCC GAGTGGCTGG CCTCGAGAGC CTCGGAGACC TCTTCCCCAA
351    CCTCACGGTC ATCCGCGGCT GGAAACTCTT CTACAACTAC GCCCTGGTCA
401    TCTTCGAGAT GACCAATCTC AAGGATATTG GGCTTTACAA CCTGAGGAAC
451    ATTACTCGGG GGGCCATCAG GATTGAGAAA AATGCTGACC TCTGTTACCT
501    CTCCACTGTG GACTGGTCCC TGATCCTGGA TGCGGTGTCC AATAACTACA
551    TTGTGGGGAA TAAGCCCCCA AAGGAATGTG GGGACCTGTG TCCAGGGACC
601    ATGGAGGAGA AGCCGATGTG TGAGAAGACC ACCATCAACA ATGAGTACAA
651    CTACCGCTGC TGGACCACAA ACCGCTGCCA GAAAATGTGC CCAAGCACGT
701    GTGGGAAGCG GGCGTGCACC GAGAACAATG AGTGCTGCCA CCCCGAGTGC
```

FIGURE 3 (Continued...)

751	CTGGGCAGCT	GCAGCGCGCC	TGACAACGAC	ACGGCCTGTG	TAGCTTGCCG
801	CCACTACTAC	TATGCCGGTG	TCTGTGTGCC	TGCCTGCCCG	CCCAACACCT
851	ACAGGTTTGA	GGGCTGGCGC	TGTGTGGACC	GTGACTTCTG	CGCCAACATC
901	CTCAGCGCCG	AGAGCAGCGA	CTCCGAGGGG	TTTGTGATCC	ACGACGGCGA
951	GTGCATGCAG	GAGTGCCCCT	CGGGCTTCAT	CCGCAACGGC	AGCCAGAGCA
1001	TGTACTGCAT	CCCTTGTGAA	GGTCCTTGCC	CGAAGGTCTG	TGAGGAAGAA
1051	AAGAAAACAA	AGACCATTGA	TTCTGTTACT	TCTGCTCAGA	TGCTCCAAGG
1101	ATGCACCATC	TTCAAGGGCA	ATTTGCTCAT	TAACATCCGA	CGGGGGAATA
1151	ACATTGCTTC	AGAGCTGGAG	AACTTCATGG	GGCTCATCGA	GGTGGTGACG
1201	GGCTACGTGA	AGATCCGCCA	TTCTCATGCC	TTGGTCTCCT	TGTCCTTCCT
1251	AAAAAACCTT	CGCCTCATCC	TAGGAGAGGA	GCAGCTAGAA	GGGAATTACT
1301	CCTTCTACGT	CCTCGACAAC	CAGAACTTGC	AGCAACTGTG	GGACTGGGAC
1351	CACCGCAACC	TGACCATCAA	AGCAGGGAAA	ATGTACTTTG	CTTTCAATCC
1401	CAAATTATGT	GTTTCCGAAA	TTTACCGCAT	GGAGGAAGTG	ACGGGGACTA
1451	AAGGGCGCCA	AAGCAAAGGG	GACATAAACA	CCAGGAACAA	CGGGGAGAGA

FIGURE 3 (Continued...)

```
1501   GCCTCCTGTG AAAGTGACGT CCTGCATTTC ACCTCCACCA CCACGTCGAA
1551   GAATCGCATC ATCATAACCT GGCACCGGTA CCGGCCCCCT GACTACAGGG
1601   ATCTCATCAG CTTCACCGTT TACTACAAGG AAGCACCCTT TAAGAATGTC
1651   ACAGAGTATG ATGGGCAGGA TGCCTGCGGC TCCAACAGCT GGAACATGGT
1701   GGACGTGGAC CTCCCGCCCA ACAAGGACGT GGAGCCCGGC ATCTTACTAC
1751   ATGGGCTGAA GCCCTGGACT CAGTACGCCG TTTACGTCAA GGCTGTGACC
1801   CTCACCATGG TGGAGAACGA CCATATCCGT GGGGCCAAGA GTGAGATCTT
1851   GTACATTCGC ACCAATGCTT CAGTTCCTTC CATTCCCTTG GACGTTCTTT
1901   CAGCATCGAA CTCCTCTTCT CAGTTAATCG TGAAGTGGAA CCCTCCCTCT
1951   CTGCCCAACG GCAACCTGAG TTACTACATT GTGCGCTGGC AGCGGCAGCC
2001   TCAGGACGGC TACCTTTACC GGCACAATTA CTGCTCCAAA GACAAAATCC
2051   CCATCAGGAA GTATGCCGAC GGCACCATCG ACATTGAGGA GGTCACAGAG
2101   AACCCCAAGA CTGAGGTGTG TGGTGGGGAG AAAGGGCCTT GCTGCGCCTG
2151   CCCCAAAACT GAAGCCGAGA AGCAGGCCGA GAAGGAGGAG GCTGAATACC
2201   GCAAAGTCTT TGAGAATTTC CTGCACAACT CCATCTTCGT GCCCAGACCT
```

FIGURE 3 (Continued...)

2251	GAAAGGAAGC	GGAGAGATGT	CATGCAAGTG	GCCAACACCA	CCATGTCCAG
2301	CCGAAGCAGG	AACACCACGG	CCGCAGACAC	CTACAACATC	ACCGACCCGG
2351	AAGAGCTGGA	GACAGAGTAC	CCTTTCTTTG	AGAGCAGAGT	GGATAACAAG
2401	GAGAGAACTG	TCATTTCTAA	CCTTCGGCCT	TTCACATTGT	ACCGCATCGA
2451	TATCCACAGC	TGCAACCACG	AGGCTGAGAA	GCTGGGCTGC	AGCGCCTCCA
2501	ACTTCGTCTT	TGCAAGGACT	ATGCCCGCAG	AAGGAGCAGA	TGACATTCCT
2551	GGGCCAGTGA	CCTGGGAGCC	AAGGCCTGAA	AACTCCATCT	TTTTAAAGTG
2601	GCCGGAACCT	GAGAATCCCA	ATGGATTGAT	TCTAATGTAT	GAAATAAAAT
2651	ACGGATCACA	AGTTGAGGAT	CAGCGAGAAT	GTGTGTCCAG	ACAGGAATAC
2701	AGGAAGTATG	GAGGGGCCAA	GCTAAACCGG	CTAAACCCGG	GGAACTACAC
2751	AGCCCGGATT	CAGGCCACAT	CTCTCTCTGG	GAATGGGTCG	TGGACAGATC
2801	CTGTGTTCTT	CTATGTCCAG	GCCAAAACAG	GATATGAAAA	CTTCATCCAT
2851	CTGATCATCG	CTCTGCCCGT	CGCTGTCCTG	TTGATCGTGG	GAGGGTTGGT
2901	GATTATGCTG	TACGTCTTCC	ATAGAAAGAG	AAATAACAGC	AGGCTGGGGA
2951	ATGGAGTGCT	GTATGCCTCT	GTGAACCCGG	AGTACTTCAG	CGCTGCTGAT

FIGURE 3 (Continued...)

```
3001   GTGTACGTTC CTGATGAGTG GGAGGTGGCT CGGGAGAAGA TCACCATGAG
3051   CCGGGAACTT GGGCAGGGGT CGTTTGGGAT GGTCTATGAA GGAGTTGCCA
3101   AGGGTGTGGT GAAAGATGAA CCTGAAACCA GAGTGGCCAT TAAAACAGTG
3151   AACGAGGCCG CAAGCATGCG TGAGAGGATT GAGTTTCTCA ACGAAGCTTC
3201   TGTGATGAAG GAGTTCAATT GTCACCATGT GGTGCGATTG CTGGGTGTGG
3251   TGTCCCAAGG CCAGCCAACA CTGGTCATCA TGGAACTGAT GACACGGGGC
3301   GATCTCAAAA GTTATCTCCG GTCTCTGAGG CCAGAAATGG AGAATAATCC
3351   AGTCCTAGCA CCTCCAAGCC TGAGCAAGAT GATTCAGATG GCCGGAGAGA
3401   TTGCAGACGG CATGGCATAC CTCAACGCCA ATAAGTTCGT CCACAGAGAC
3451   CTTGCTGCCC GGAATTGCAT GGTAGCCGAA GATTTCACAG TCAAAATCGG
3501   AGATTTTGGT ATGACGCGAG ATATCTATGA GACAGACTAT TACCGGAAAG
3551   GAGGCAAAGG GCTGCTGCCC GTGCGCTGGA TGTCTCCTGA GTCCCTCAAG
3601   GATGGAGTCT TCACCACTTA CTCGGACGTC TGGTCCTTCG GGGTCGTCCT
3651   CTGGGAGATC GCCACACTGG CCGAGCAGCC CTACCAGGGC TTGTCCAACG
3701   AGCAAGTCCT TCGCTTCGTC ATGGAGGGCG GCCTTCTGGA CAAGCCAGAC
```

FIGURE 3 (Continued...)

```
3751  AACTGTCCTG ACATGCTGTT TGAACTGATG CGCATGTGCT GGCAGTATAA
3801  CCCCAAGATG AGGCCTTCCT TCCTGGAGAT CATCAGCAGC ATCAAAGAGG
3851  AGATGGAGCC TGGCTTCCGG GAGGTCTCCT TCTACTACAG CGAGGAGAAC
3901  AAGCTGCCCG AGCCGGAGGA GCTGGACCTG GAGCCAGAGA ACATGGAGAG
3951  CGTCCCCCTG GACCCCTCGG CCTCCTCGTC CTCCCTGCCA CTGCCCGACA
4001  GACACTCAGG ACACAAGGCC GAGAACGGCC CCGGCCCTGG GGTGCTGGTC
4051  CTCCGCGCCA GCTTCGACGA GAGACAGCCT TACGCCCACA TGAACGGGGG
4101  CCGCAAGAAC GAGCGGGCCT TGCCGCTGCC CCAGTCTTCG ACCTGCTGAT
4151  CCTTGGATCC TGAATCTGTG CAAACAGTAA CGTGTGCGCA CGCGCAGCGG
4201  GGTGGGGGGG GAGAGAGAGT TTTAACAATC CATTCACAAG CCTCCTGTAC
4251  CTCAGTGGAT CTTCAGTTCT GCCCTTGCTG CCCGCGGGAG ACAGCTTCTC
4301  TGCAGTAAAA CACATTTGGG ATGTTCCTTT TTTCAATATG CAAGCAGCTT
4351  TTTATTCCCT GCCCAAACCC TTAACTGACA TGGGCCTTTA AGAACCTTAA
4401  TGACAACACT TAATAGCAAC AGAGCACTTG AGAACCAGTC TCCTCACTCT
4451  GTCCCTGTCC TTCCCTGTTC TCCCTTTCTC TCTCCTCTCT GCTTCATAAC
```

FIGURE 3 (Continued...)

```
4501   GGAAAAATAA TTGCCACAAG TCCAGCTGGG AAGCCCTTTT TATCAGTTTG
4551   AGGAAGTGGC TGTCCCTGTG GCCCCATCCA ACCACTGTAC ACACCCGCCT
4601   GACACCGTGG GTCATTACAA AAAAACACGT GGAGATGGAA ATTTTTACCT
4651   TTATCTTTCA CCTTTCTAGG GACATGAAAT TTACAAAGGG CCATCGTTCA
4701   TCCAAGGCTG TTACCATTTT AACGCTGCCT AATTTTGCCA AAATCCTGAA
4751   CTTTCTCCCT CATCGGCCCG GCGCTGATTC CTCGTGTCCG GAGGCATGGG
4801   TGAGCATGGC AGCTGGTTGC TCCATTTGAG AGACACGCTG GCGACACACT
4851   CCGTCCATCC GACTGCCCCT GCTGTGCTGC TCAAGGCCAC AGGCACACAG
4901   GTCTCATTGC TTCTGACTAG ATTATTATTT GGGGGAACTG GACACAATAG
4951   GTCTTTCTCT CAGTGAAGGT GGGGAGAAGC TGAACCGGC
```



Figure 4a

Figure 4b



Figure 5a


% untreated control (*)
160
140
120
100
80
60
40
20
0
BP3A52
control oligos
a
b
c
untreated(*)

FIG 5B

FIGURE 6 Inhibition of IGF-I binding by antisense oligonucleotides to IGF-I receptor



Figure 7


Initial treatment with AS oligos (once daily over 2 days)
RELATIVE IGFBP-3 IN MEDIUM (scanned OD)
4
3·5
3
2·5
2
1·5
1
0·5
0
untreated
BP3AS2
0·5μM 5μM
BP3AS2NS
BP3AS4
BP3AS4NS
0·5μM
BP3AS2NS
BP3AS4
BP3AS4NS
5μM

Optimization of IGFBP-3 AS oligo concentration



Figure 8

Figure 9 Map of IGF-I Receptor mRNA and position of target ODNs



- Position of the 21 tested ODNs (|)
- mRNA transcript lengths = 7Kb and 11Kb
- coding sequence 46-4149

Figure 10 Lipid-mediated uptake of oligonucleotide in keratinocytes

A



B

Figure 11 Uptake (A) and toxicity (B) of ODN/ lipid complexes in keratinocytes





Figure 12 IGF-I Receptor mRNA in ODN treated (30nM) HaCaT cells (2μg/ml GSV)

A



B



Figure 13 IGF-I receptor mRNA in ODN treated (30nM) HaCaT cells (2μg/ml GSV)



Figure 14

Effect of antisense oligonucleotides on IGF-1 receptor levels on the surface of keratinocytes:
Competition Assay - ^{125}I IGF-1 vs Des 1-3 IGF-1



Figure 15

Effect of antisense oligonucleotides on IGF-1 receptor levels on the surface of keratinocytes:

Competition Assay - ^{125}I IGF-I vs Des 1-3 IGF-I



Figure 16 — **H&E stained sections of (A) psoriatic skin biopsy prior to grafting and (B) 49 day old psoriatic skin graft using skin from the same donor**

A)

B)

Figure 17 Uptake of oligonucleotide after intradermal injection into psoriatic skin graft on a nude mouse



Figure 18a

Pregraft, Donor JH

Donor JH, PBS treated, 50 µl

Donor JH, #50 treated, 50 µl, 10 µM



Figure 18b

Donor LB, pregraft

Donor LB, PBS treated (50 µl)

Donor LB, #74 treated (50 µl, 10 µM)

Figure 18c

Donor PW, pregraft

Donor PW, R451 treated (50 µl, 10 µM)

Donor LB, #74 treated (50 µl, 10 µM)



Figure 18d

Donor GM, pregraft

Donor GM, R451treated (50 µl, 10 µM)

Donor GM, #27 treated (50 µl, 10 µM)

Figure 19a

Donor JH
Pregraft

Donor JH
PBS treated
50 ul

Donor JH
50 treated
50 ul, 10 uM

Figure 19b

Donor LB
Pregraft

Donor LB
PBS treated
50 ul



Donor LB
74 treated
50 ul, 10 uM

Figure 19c

Donor PW
Pregraft



Donor PW
R451 treated
50 ul, 10 uM

Donor PW
#74 treated
50 ul, 10 uM

Figure 19d

Donor GM
Pregraft

Donor GM
R451 treated
50 ul, 10 uM

Donor GM
27 treated
50 ul, 10 uM



Figure 20 Suppression of psoriasis after treatment with oligonucleotide (quantification)



Figure 21

αhKi-67

Figure 22 Penetration of oligonucleotide into human skin after topical treatment



Figure 23 Penetration of oligonucleotide into human skin after application of topical gel formulation

Figure 24

IGFBP-3 mRNA



- Position of the 13 tested ODNs (I)
- mRNA transcript length = 2.5Kb
- coding sequence 133-1009


IGFBP-3 mRNA in AON treated (100nM) HaCaT cells (2ug/ml GSV)
relative IGFBP-3 mRNA
2.0
1.5
1.0
0.5
0.0
1
2
3
4
5
6
13
14
15
22
23
24
R1
R4
R4(O
R7
R7(O
R9
GSV
UT
Treatment

Figure 25a

Figure 25b


IGFBP-3 mRNA levels in AON treated (100nM) HaCaT cells
(2ug/ml GSV)
relative IGFBP-3 mRNA
1.00
0.75
0.50
0.25
0.00
1
2
3
4
5
6
13
14
15
22
23
24
25
R1
R4
R7
R9
GS
UT
Treatment


IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2ug/ml GSV)
relative IGFBP-3 mRNA
0.0
0.5
1.0
1.5
2.0
1
2
3
4
5
6
13
14
15
22
23
24
R121
R451
R766
R961
GSV
UT
Treatment

Figure 25c

Figure 25d


IGFBP-3 mRNA in AON treated (30nM) HaCaT cells (2µg/ml GSV)
relative IGFBP-3 mRNA
0
1
2
3
4
5
6
7
1
2
3
4
5
6
13
14
15
22
23
24
R12
R45
R76
R96
GS
UT
Treatment


IGFBP-3 mRNA in ODN treated (30nM) HaCaT cells (2µg/ml)
Relative IGFBP-3 mRNA
1.25
1.00
0.75
0.50
0.25
0.00
1 2 3 4 5 6 13 14 15 22 23 24 R1 R4 R7 R9 GS UT
Treatment

Figure 26a

Figure 26b


IGFBP-3 mRNA in ODN treated (100nM) HaCaT cells (2µg/ml GSV)
Relative IGFBP-3 mRNA
2.0
1.5
1.0
0.5
0.0
1 2 3 4 5 6 13 14 15 22 23 24 R1 R4 R7 R9 GS UT
Treatment

Figure 27a


27 32 74 78 R4 R7 G UT
IGFR probe
GAPDH probe
bases
500
400
300
200
GAPDH
IGFR

Figure 27b


Relative IGF-I receptor mRNA
1.25
1.00
0.75
0.50
0.25
0.00
26 27 28 32 40 42 44 46 48 50 51 54 56 62 64 66 68 74 78 85 86
R121
R451
R766
GSV
UT
Oligonucleotide treatment

Figure 28a



Figure 28b


Relative IGF-I receptor protein (% of GSV-treated)
125
100
75
50
25
0
*
*
*
GSV
UT
R451
64
50
27
Treatment

Figure 29


0.4
0.3
0.2
0.1
0.0
bound / free
0
0.05
0.10
0.15
0.20
0.25
bound IGF-I (nM)
specific 125I-IGF-I bound (cpm X10-4)
2
1
0
10-11
10-10
10-9
10-8
des (1-3) IGF-I conc (M)

Figure 30


Cell number
(% of untreated cells)
125
100
75
50
25
0
UT
GSV
R451
6416
64
Treatment

Figure 31a




Epidermal thickness (pixels)
125000
100000
75000
50000
25000
0
pregraft
vehicle
R451
#64
#50
#27
Treatment

Figure 31b

60/65



Figure 31c



Figure 32a



Figure 32b


Effect of sequential base changes on
in vitro efficacy of AON #64
IGF receptor mRNA
(% of GSV-treated)
125
100
75
50
25
0
0
30
60
90
Oligonucleotide concentration (nM)
#64
#64-1 (1 mismatch)
#64-2 (2 mismatches)
#64-4 (4 mismatches)
#64-8 (8 mismatches)
#64-15 (15 mismatches)

Figure 33

Figure 34


IGF-I receptor immunoblots
30nM ODN, 4 x 24h treatments
2 exps in duplicate
IGF-I receptor protein
(% GSV)
150
125
100
75
50
25
0
UT
GSV
64
64-1
64-2
64-4
64-8
64-15
Treament

Figure 35


Amido black assay - 3 x 24h treatments (15nM ODN, 2ug/ml GSV)
Absorbance (620nm-405nm)
2.5
2.0
1.5
1.0
0.5
0.0
0
20
40
60
80
Time (hours)
GSV
64
6412
6413
6414
6415
6416
UT

SEQUENCE LISTING

<110> MURDOCH CHILDREN'S RESEARCH INSTITUTE

<120> A METHOD FOR THE PROPHYLAXIS AND/OR TREATMENT OF MEDICAL DISORDERS

<130> 2288267/EJH

<140> INTERNATIONAL
<141> 2000-06-21

<150> 60/140345
<151> 1999-06-21

<160> 24

<170> PatentIn Ver. 2.1

<210> 1
<211> 1433
<212> DNA
<213> synthetic construct

<400> 1
attcggggcg agggaggagg aagaagcgga ggaggcggct cccgctcgca gggccgtgca 60
cctgcccgcc cgcccgctcg ctcgctcgcc cgccgcgccg cgctgccgac cgccagcatg 120
ctgccgagag tgggctgccc cgcgctgccg ctgccgccgc cgccgctgct gccgctgctg 180
ccgctgctgc tgctgctact gggcgcgagt ggcggcggcg gcggggcgcg cgcggaggtg 240
ctgttccgct gcccgccctg cacacccgag cgcctggccg cctgcgggcc cccgccggtt 300
gcgccgcccg ccgcggtggc cgcagtggcc ggaggcgccc gcatgccatg cgcggagctc 360
gtccgggagc cgggctgcgg ctgctgctcg gtgtgcgccc ggctggaggg cgaggcgtgc 420
ggcgtctaca ccccgcgctg cggccagggg ctgcgctgct atccccaccc gggctccgag 480
ctgcccctgc aggcgctggt catgggcgag ggcacttgtg agaagcgccg ggacgccgag 540

tatggcgcca gcccggagca ggttgcagac aatggcgatg accactcaga aggaggcctg 600
gtggagaacc acgtggacag caccatgaac atgttgggcg ggggaggcag tgctggccgg 660
aagcccctca agtcgggtat gaaggagctg gccgtgttcc gggagaaggt cactgagcag 720
caccggcaga tgggcaaggg tggcaagcat caccttggcc tggaggagcc caagaagctg 780
cgaccacccc ctgccaggac tccctgccaa caggaactgg accaggtcct ggagcggatc 840
tccaccatgc gccttccgga tgagcggggc cctctggagc acctctactc cctgcacatc 900
cccaactgtg acaagcatgg cctgtacaac ctcaaacagt gcaagatgtc tctgaacggg 960
cagcgtgggg agtgctggtg tgtgaacccc aacaccggga agctgatcca gggagccccc 1020
accatccggg gggaccccga gtgtcatctc ttctacaatg agcagcagga ggcttgcggg 1080
gtgcacaccc agcggatgca gtagaccgca gccagccggt gcctggcgcc cctgcccccc 1140
gcccctctcc aaacaccggc agaaaacgga gagtgcttgg gtggtgggtg ctggaggatt 1200
ttccagttct gacacacgta tttatatttg gaaagagacc agcaccgagc tcggcacctc 1260
cccggcctct ctcttcccag ctgcagatgc cacacctgct ccttcttgct ttccccgggg 1320
gaggaagggg gttgtggtcg gggagctggg gtacaggttt ggggaggggg aagagaaatt 1380
tttatttttg aacccctgtg tccctttttgc ataagattaa aggaaggaaa agt 1433

<210> 2
<211> 2474
<212> DNA
<213> synthetic construct

<400> 2
ctcagcgccc agccgcttcc tgcctggatt ccacagcttc gcgccgtgta ctgtcgcccc 60
atccctgcgc gcccagcctg ccaagcagcg tgccccggtt gcaggcgtca tgcagcgggc 120
gcgacccacg ctctgggccg ctgcgctgac tctgctggtg ctgctccgcg ggccgccggt 180
ggcgcgggct ggcgcgagct cgggggggctt gggtcccgtg gtgcgctgcg agccgtgcga 240
cgcgcgtgca ctggcccagt gcgcgcctcc gcccgccgtg tgcgcggagc tggtgcgcga 300
gccgggctgc ggctgctgcc tgacgtgcgc actgagcgag ggccagccgt gcggcatcta 360
caccgagcgc tgtggctccg gccttcgctg ccagccgtcg cccgacgagg cgcgaccgct 420
gcaggcgctg ctggacggcc gcgggctctg cgtcaacgct agtgccgtca gccgcctgcg 480
cgcctacctg ctgccagcgc cgccagctcc aggaaatgct agtgagtcgg aggaagaccg 540
cagcgccggc agtgtggaga gcccgtccgt ctccagcacg caccgggtgt ctgatcccaa 600
gttccacccc ctccattcaa agataatcat catcaagaaa gggcatgcta aagacagcca 660
gcgctacaaa gttgactacg agtctcagag cacagatacc cagaacttct cctccgagtc 720

caagcgggag acagaatatg gtccctgccg tagagaaatg gaagacacac tgaatcacct 780
gaagttcctc aatgtgctga gtcccagggg tgtacacatt cccaactgtg acaagaaggg 840
attttataag aaaaagcagt gtcgcccttc caaaggcagg aagcggggct tctgctggtg 900
tgtggataag tatgggcagc ctctcccagg ctacaccacc aaggggaagg aggacgtgca 960
ctgctacagc atgcagagca agtagacgcc tgccgcaagt taatgtggag ctcaaatatg 1020
ccttattttg cacaaaagac tgccaaggac atgaccagca gctggctaca gcctcgattt 1080
atatttctgt ttgtggtgaa ctgatttttt ttaaaccaaa gtttagaaag aggtttttga 1140
aatgcctatg gtttctttga atggtaaact tgagcatctt ttcactttcc agtagtcagc 1200
aaagagcagt ttgaattttc ttgtcgcttc ctatcaaaat attcagagac tcgagcacag 1260
cacccagact tcatgcgccc gtggaatgct caccacatgt tggtcgaagc ggccgaccac 1320
tgactttgtg acttaggcgg ctgtgttgcc tatgtagaga acacgcttca cccccactcc 1380
ccgtacagtg cgcacaggct ttatcgagaa taggaaaacc tttaaacccc ggtcatccgg 1440
acatcccaac gcatgctcct ggagctcaca gccttctgtg gtgtcatttc tgaaacaagg 1500
gcgtggatcc ctcaaccaag aagaatgttt atgtcttcaa gtgacctgta ctgcttgggg 1560
actattggag aaaataaggt ggagtcctac ttgtttaaaa aatatgtatc taagaatgtt 1620
ctagggcact ctgggaacct ataaaggcag gtatttcggg ccctcctctt caggaatctt 1680
cctgaagaca tggcccagtc gaaggcccag gatggctttt gctgcggccc cgtggggtag 1740
gagggacaga gagacgggag agtcagcctc cacattcaga ggcatcacaa gtaatggcac 1800
aattcttcgg atgactgcag aaaatagtgt tttgtagttc aacaactcaa gacgaagctt 1860
atttctgagg ataagctctt taaaggcaaa gctttatttt catctctcat cttttgtcct 1920
ccttagcaca atgtaaaaaa gaatagtaat atcagaacag gaaggaggaa tggcttgctg 1980
gggagcccat ccaggacact gggagcacat agagattcac ccatgtttgt tgaacttaga 2040
gtcattctca tgcttttctt tataattcac acatatatgc agagaagata tgttcttgtt 2100
aacattgtat acaacatagc cccaaatata gtaagatcta tactagataa tcctagatga 2160
aatgttagag atgctatatg atacaactgt ggccatgact gaggaaagga gctcacgccc 2220
agagactggg ctgctctccc ggaggccaaa cccaagaagg tctggcaaag tcaggctcag 2280
ggagactctg ccctgctgca gacctcggtg tggacacacg ctgcatagag ctctccttga 2340
aaacagaggg gtctcaagac attctgccta cctattagct tttctttatt tttttaactt 2400
tttgggggga aaagtatttt tgagaagttt gtcttgcaat gtatttataa atagtaaata 2460
aagtttttac catt 2474

<210> 3
<211> 4989
<212> DNA

<213> synthetic construct

<400> 3

```
ttttttttttt ttttgagaaa gggaatttca tcccaaataa aaggaatgaa gtctggctcc 60
ggaggagggt ccccgacctc gctgtggggg ctcctgtttc tctccgccgc gctctcgctc 120
tggccgacga gtggagaaat ctgcgggcca ggcatcgaca tccgcaacga ctatcagcag 180
ctgaagcgcc tggagaactg cacggtgatc gagggctacc tccacatcct gctcatctcc 240
aaggccgagg actaccgcag ctaccgcttc cccaagctca cggtcattac cgagtacttg 300
ctgctgttcc gagtggctgg cctcgagagc ctcggagacc tcttccccaa cctcacggtc 360
atccgcggct ggaaactctt ctacaactac gccctggtca tcttcgagat gaccaatctc 420
aaggatattg ggctttacaa cctgaggaac attactcggg gggccatcag gattgagaaa 480
aatgctgacc tctgttacct ctccactgtg gactggtccc tgatcctgga tgcggtgtcc 540
aataactaca ttgtggggaa taagccccca aaggaatgtg gggacctgtg tccagggacc 600
atggaggaga agccgatgtg tgagaagacc accatcaaca atgagtacaa ctaccgctgc 660
tggaccacaa accgctgcca gaaaatgtgc ccaagcacgt gtgggaagcg ggcgtgcacc 720
gagaacaatg agtgctgcca ccccgagtgc ctgggcagct gcagcgcgcc tgacaacgac 780
acggcctgtg tagcttgccg ccactactac tatgccggtg tctgtgtgcc tgcctgcccg 840
cccaacacct acaggtttga gggctggcgc tgtgtggacc gtgacttctg cgccaacatc 900
ctcagcgccg agagcagcga ctccgagggg tttgtgatcc acgacggcga gtgcatgcag 960
gagtgccccc cgggcttcat ccgcaacggc agccagagca tgtactgcat cccttgtgaa 1020
ggtccttgcc cgaaggtctg tgaggaagaa aagaaaacaa agaccattga ttctgttact 1080
tctgctcaga tgctccaagg atgcaccatc ttcaagggca atttgctcat taacatccga 1140
cgggggaata acattgcttc agagctggag aacttcatgg ggctcatcga ggtggtgacg 1200
ggctacgtga agatccgcca ttctcatgcc ttggtctcct tgtccttcct aaaaaacctt 1260
cgcctcatcc taggagagga gcagctagaa gggaattact ccttctacgt cctcgacaac 1320
cagaacttgc agcaactgtg ggactgggac caccgcaacc tgaccatcaa agcagggaaa 1380
atgtactttg ctttcaatcc caaattatgt gtttccgaaa tttaccgcat ggaggaagtg 1440
acggggacta aagggcgcca aagcaaaggg gacataaaca ccaggaacaa cggggagaga 1500
gcctcctgtg aaagtgacgt cctgcatttc acctccacca ccacgtcgaa gaatcgcatc 1560
atcataacct ggcaccggta ccggcccccc gactacaggg atctcatcag cttcaccgtt 1620
tactacaagg aagcaccctt taagaatgtc acagagtatg atgggcagga tgcctgcggc 1680
tccaacagct ggaacatggt ggacgtggac ctcccgccca acaaggacgt ggagcccggc 1740
atcttactac atgggctgaa gccctggact cagtacgccg tttacgtcaa ggctgtgacc 1800
ctcaccatgg tggagaacga ccatatccgt ggggccaaga gtgagatctt gtacattcgc 1860
accaatgctt cagttccttc cattcccttg gacgttcttt cagcatcgaa ctcctcttct 1920
```

cagttaatcg tgaagtggaa ccctccctct ctgcccaacg gcaacctgag ttactacatt 1980
gtgcgctggc agcggcagcc tcaggacggc tacctttacc ggcacaatta ctgctccaaa 2040
gacaaaatcc ccatcaggaa gtatgccgac ggcaccatcg acattgagga ggtcacagag 2100
aaccccaaga ctgaggtgtg tggtggggag aaagggcctt gctgcgcctg ccccaaaact 2160
gaagccgaga agcaggccga gaaggaggag gctgaatacc gcaaagtctt tgagaatttc 2220
ctgcacaact ccatcttcgt gcccagacct gaaaggaagc ggagagatgt catgcaagtg 2280
gccaacacca ccatgtccag ccgaagcagg aacaccacgg ccgcagacac ctacaacatc 2340
accgacccgg aagagctgga gacagagtac cctttctttg agagcagagt ggataacaag 2400
gagagaactg tcatttctaa ccttcggcct ttcacattgt accgcatcga tatccacagc 2460
tgcaaccacg aggctgagaa gctgggctgc agcgcctcca acttcgtctt tgcaaggact 2520
atgcccgcag aaggagcaga tgacattcct gggccagtga cctgggagcc aaggcctgaa 2580
aactccatct ttttaaagtg gccggaacct gagaatccca atggattgat tctaatgtat 2640
gaaataaaat acggatcaca agttgaggat cagcgagaat gtgtgtccag acaggaatac 2700
aggaagtatg gaggggccaa gctaaaccgg ctaaacccgg ggaactacac agcccggatt 2760
caggccacat ctctctctgg gaatgggtcg tggacagatc ctgtgttctt ctatgtccag 2820
gccaaaacag gatatgaaaa cttcatccat ctgatcatcg ctctgcccgt cgctgtcctg 2880
ttgatcgtgg gagggttggt gattatgctg tacgtcttcc atagaaagag aaataacagc 2940
aggctgggga atggagtgct gtatgcctct gtgaacccgg agtacttcag cgctgctgat 3000
gtgtacgttc ctgatgagtg ggaggtggct cgggagaaga tcaccatgag ccgggaactt 3060
gggcaggggt cgtttgggat ggtctatgaa ggagttgcca agggtgtggt gaaagatgaa 3120
cctgaaacca gagtggccat taaaacagtg aacgaggccg caagcatgcg tgagaggatt 3180
gagtttctca acgaagcttc tgtgatgaag gagttcaatt gtcaccatgt ggtgcgattg 3240
ctgggtgtgg tgtcccaagg ccagccaaca ctggtcatca tggaactgat gacacggggc 3300
gatctcaaaa gttatctccg gtctctgagg ccagaaatgg agaataatcc agtcctagca 3360
cctccaagcc tgagcaagat gattcagatg gccggagaga ttgcagacgg catggcatac 3420
ctcaacgcca ataagttcgt ccacagagac cttgctgccc ggaattgcat ggtagccgaa 3480
gatttcacag tcaaaatcgg agattttggt atgacgcgag atatctatga gacagactat 3540
taccggaaag gaggcaaagg gctgctgccc gtgcgctgga tgtctcctga gtccctcaag 3600
gatggagtct tcaccactta ctcggacgtc tggtccttcg gggtcgtcct ctgggagatc 3660
gccacactgg ccgagcagcc ctaccagggc ttgtccaacg agcaagtcct tcgcttcgtc 3720
atggagggcg gccttctgga caagccagac aactgtcctg acatgctgtt tgaactgatg 3780
cgcatgtgct ggcagtataa ccccaagatg aggccttcct tcctggagat catcagcagc 3840
atcaaagagg agatggagcc tggcttccgg gaggtctcct tctactacag cgaggagaac 3900
aagctgcccg agccggagga gctggacctg gagccagaga acatggagag cgtccccctg 3960
gacccctcgg cctcctcgtc ctccctgcca ctgcccgaca gacactcagg acacaaggcc 4020

gagaacggcc ccggccctgg ggtgctggtc ctccgcgcca gcttcgacga gagacagcct 4080
tacgcccaca tgaacggggg ccgcaagaac gagcgggcct tgccgctgcc ccagtcttcg 4140
acctgctgat ccttggatcc tgaatctgtg caaacagtaa cgtgtgcgca cgcgcagcgg 4200
ggtgggggggg gagagagagt tttaacaatc cattcacaag cctcctgtac ctcagtggat 4260
cttcagttct gcccttgctg cccgcgggag acagcttctc tgcagtaaaa cacatttggg 4320
atgttccttt tttcaatatg caagcagctt tttattccct gcccaaaccc ttaactgaca 4380
tgggccttta agaaccttaa tgacaacact taatagcaac agagcacttg agaaccagtc 4440
tcctcactct gtccctgtcc ttccctgttc tccctttctc tctcctctct gcttcataac 4500
ggaaaaataa ttgccacaag tccagctggg aagccctttt tatcagtttg aggaagtggc 4560
tgtccctgtg gccccatcca accactgtac acacccgcct gacaccgtgg gtcattacaa 4620
aaaaacacgt ggagatggaa atttttacct ttatctttca cctttctagg gacatgaaat 4680
ttacaaaggg ccatcgttca tccaaggctg ttaccatttt aacgctgcct aattttgcca 4740
aaatcctgaa ctttctccct catcggcccg gcgctgattc ctcgtgtccg gaggcatggg 4800
tgagcatggc agctggttgc tccatttgag agacacgctg gcgacacact ccgtccatcc 4860
gactgccccc gctgtgctgc tcaaggccac aggcacacag gtctcattgc ttctgactag 4920
attattattt gggggaactg gacacaatag gtctttctct cagtgaaggt ggggagaagc 4980
tgaaccggc 4989

<210> 4
<211> 25
<212> DNA
<213> synthetic construct

<400> 4
gcgcccgctg catgacgcct gcaac 25

<210> 5
<211> 24
<212> DNA
<213> synthetic construct

<400> 5
cgggcggctc acctggagct ggcg 24

<210> 6

<211> 18

<212> DNA

<213> synthetic construct

<400> 6

aggcggctga cggcacta 18

<210> 7

<211> 19

<212> DNA

<213> synthetic construct

<400> 7

caggcgtcat gcagcgggc 19

<210> 8

<211> 25

<212> DNA

<213> synthetic construct

<400> 8

cggagatgcc gcatgccagc gcagg 25

<210> 9

<211> 18

<212> DNA

<213> synthetic construct

<400> 9

gacagcgtcg gagcgatc 18

<210> 10

<211> 18

<212> DNA

<213> synthetic construct

<400> 10

atctctccgc ttcctttc 18

<210> 11

<211> 18

<212> DNA

<213> synthetic construct

<400> 11

gaaaggaagc ggagagat 18

<210> 12

<211> 12

<212> DNA

<213> synthetic construct

<400> 12

ccggagccag ac 12

<210> 13

<211> 12

<212> DNA

<213> synthetic construct

<400> 13

cacaggcgca ag 12

<210> 14

<211> 8

<212> DNA

<213> synthetic construct

<400> 14

cccgcccc 8

<210> 15

<211> 15

<212> DNA

<213> synthetic construct

<400> 15

agcccccaca gcgag 15

<210> 16

<211> 12

<212> DNA

<213> synthetic construct

<400> 16

gccggagaga gc 12

<210> 17

<211> 13

<212> DNA

<213> synthetic construct

<400> 17

aacagaggca gca 13

<210> 18

<211> 13

<212> DNA

<213> synthetic construct

<400> 18

ggacagggac cag 13

<210> 19

<211> 14

<212> DNA

<213> synthetic construct

<400> 19

cggcaagcac acag 14

<210> 20

<211> 15

<212> DNA

<213> synthetic construct

<400> 20

ggcaggcagg cacac 15

<210> 21

<211> 328

<212> PRT

<213> human

<400> 21

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro

1		5			10					15			
Leu	Leu	Pro	Leu	Leu	Pro	Leu	Leu	Leu	Leu	Leu	Gly	Ala	Ser	Gly
			20					25				30		
Gly	Gly	Gly	Gly	Ala	Arg	Ala	Glu	Val	Leu	Phe	Arg	Cys	Pro	Pro	Cys
		35					40					45			
Thr	Pro	Glu	Arg	Leu	Ala	Ala	Cys	Gly	Pro	Pro	Pro	Val	Ala	Pro	Pro
	50					55					60				
Ala	Ala	Val	Ala	Ala	Val	Ala	Gly	Gly	Ala	Arg	Met	Pro	Cys	Ala	Glu
65					70					75					80
Leu	Val	Arg	Glu	Pro	Gly	Cys	Gly	Cys	Cys	Ser	Val	Cys	Ala	Arg	Leu
				85					90					95	
Glu	Gly	Glu	Ala	Cys	Gly	Val	Tyr	Thr	Pro	Arg	Cys	Gly	Gln	Gly	Leu
			100					105					110		
Arg	Cys	Tyr	Pro	His	Pro	Gly	Ser	Glu	Leu	Pro	Leu	Gln	Ala	Leu	Val
		115					120					125			
Met	Gly	Glu	Gly	Thr	Cys	Glu	Lys	Arg	Arg	Asp	Ala	Glu	Tyr	Gly	Ala
	130					135					140				
Ser	Pro	Glu	Gln	Val	Ala	Asp	Asn	Gly	Asp	Asp	His	Ser	Glu	Gly	Gly
145					150					155					160
Leu	Val	Glu	Asn	His	Val	Asp	Ser	Thr	Met	Asn	Met	Leu	Gly	Gly	Gly
				165					170					175	
Gly	Ser	Ala	Gly	Arg	Lys	Pro	Leu	Lys	Ser	Gly	Met	Lys	Glu	Leu	Ala
			180					185					190		

Val Phe Arg Glu Lys Val Thr Glu Gln His Arg Gln Met Gly Lys Gly
195 200 205

Gly Lys His His Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro
210 215 220

Pro Ala Arg Thr Pro Cys Gln Gln Glu Leu Asp Gln Val Leu Glu Arg
225 230 235 240

Ile Ser Thr Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu
245 250 255

Tyr Ser Leu His Ile Pro Asn Cys Asp Lys His Gly Leu Tyr Asn Leu
260 265 270

Lys Gln Cys Lys Met Ser Leu Asn Gly Gln Arg Gly Glu Cys Trp Cys
275 280 285

Val Asn Pro Asn Thr Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg
290 295 300

Gly Asp Pro Glu Cys His Leu Phe Tyr Asn Glu Gln Gln Glu Ala Cys
305 310 315 320

Gly Val His Thr Gln Arg Met Gln
325

<210> 22
<211> 39
<212> PRT
<213> human

<400> 22
Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro

1 5 10 15

Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Leu Gly Ala Ser Gly
20 25 30

Gly Gly Gly Gly Ala Arg Ala
35

<210> 23
<211> 289
<212> PRT
<213> human

<400> 23
Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu Arg Leu Ala Ala
1 5 10 15

Cys Gly Pro Pro Pro Val Ala Pro Pro Ala Ala Val Ala Ala Val Ala
20 25 30

Gly Gly Ala Arg Met Pro Cys Ala Glu Leu Val Arg Glu Pro Gly Cys
35 40 45

Gly Cys Cys Ser Val Cys Ala Arg Leu Glu Gly Glu Ala Cys Gly Val
50 55 60

Tyr Thr Pro Arg Cys Gly Gln Gly Leu Arg Cys Tyr Pro His Pro Gly
65 70 75 80

Ser Glu Leu Pro Leu Gln Ala Leu Val Met Gly Glu Gly Thr Cys Glu
85 90 95

Lys Arg Arg Asp Ala Glu Tyr Gly Ala Ser Pro Glu Gln Val Ala Asp
100 105 110

Asn Gly Asp Asp His Ser Glu Gly Gly Leu Val Glu Asn His Val Asp
115 120 125

Ser Thr Met Asn Met Leu Gly Gly Gly Gly Ser Ala Gly Arg Lys Pro
130 135 140

Leu Lys Ser Gly Met Lys Glu Leu Ala Val Phe Arg Glu Lys Val Thr
145 150 155 160

Glu Gln His Arg Gln Met Gly Lys Gly Gly Lys His His Leu Gly Leu
165 170 175

Glu Glu Pro Lys Lys Leu Arg Pro Pro Pro Ala Arg Thr Pro Cys Gln
180 185 190

Gln Glu Leu Asp Gln Val Leu Glu Arg Ile Ser Thr Met Arg Leu Pro
195 200 205

Asp Glu Arg Gly Pro Leu Glu His Leu Tyr Ser Leu His Ile Pro Asn
210 215 220

Cys Asp Lys His Gly Leu Tyr Asn Leu Lys Gln Cys Lys Met Ser Leu
225 230 235 240

Asn Gly Gln Arg Gly Glu Cys Trp Cys Val Asn Pro Asn Thr Gly Lys
245 250 255

Leu Ile Gln Gly Ala Pro Thr Ile Arg Gly Asp Pro Glu Cys His Leu
260 265 270

Phe Tyr Asn Glu Gln Gln Glu Ala Cys Gly Val His Thr Gln Arg Met
275 280 285

Gln

<210> 24

<211> 291

<212> PRT

<213> human

<400> 24

Met Gln Arg Ala Arg Pro Thr Leu Trp Ala Ala Ala Leu Thr Leu Leu
1 5 10 15

Val Leu Leu Arg Gly Pro Pro Val Ala Arg Ala Gly Ala Ser Ser Gly
20 25 30

Gly Leu Gly Pro Val Val Arg Cys Glu Pro Cys Asp Ala Arg Ala Leu
35 40 45

Ala Gln Cys Ala Pro Pro Pro Ala Val Cys Ala Glu Leu Val Arg Glu
50 55 60

Pro Gly Cys Gly Cys Cys Leu Thr Cys Ala Leu Ser Glu Gly Gln Pro
65 70 75 80

Cys Gly Ile Tyr Thr Glu Arg Cys Gly Ser Gly Leu Arg Cys Gln Pro
85 90 95

Ser Pro Asp Glu Ala Arg Pro Leu Gln Ala Leu Leu Asp Gly Arg Gly
100 105 110

Leu Cys Val Asn Ala Ser Ala Val Ser Arg Leu Arg Ala Tyr Leu Leu
115 120 125

Pro Ala Pro Pro Ala Pro Gly Asn Ala Ser Glu Ser Glu Glu Asp Arg
130 135 140

Ser Ala Gly Ser Val Glu Ser Pro Ser Val Ser Ser Thr His Arg Val

```
145                 150                 155                 160

Ser Asp Pro Lys Phe His Pro Leu His Ser Lys Ile Ile Ile Ile Lys
                165                 170                 175

Lys Gly His Ala Lys Asp Ser Gln Arg Tyr Lys Val Asp Tyr Glu Ser
            180                 185                 190

Gln Ser Thr Asp Thr Gln Asn Phe Ser Ser Glu Ser Lys Arg Glu Thr
        195                 200                 205

Glu Tyr Gly Pro Cys Arg Arg Glu Met Glu Asp Thr Leu Asn His Leu
    210                 215                 220

Lys Phe Leu Asn Val Leu Ser Pro Arg Gly Val His Ile Pro Asn Cys
225                 230                 235                 240

Asp Lys Lys Gly Phe Tyr Lys Lys Lys Gln Cys Arg Pro Ser Lys Gly
                245                 250                 255

Arg Lys Arg Gly Phe Cys Trp Cys Val Asp Lys Tyr Gly Gln Pro Leu
            260                 265                 270

Pro Gly Tyr Thr Thr Lys Gly Lys Glu Asp Val His Cys Tyr Ser Met
        275                 280                 285

Gln Ser Lys
    290
```